U.S. patent application number 14/593260 was filed with the patent office on 2015-07-16 for aryl sultam derivatives as rorc modulators.
This patent application is currently assigned to Genentech, Inc.. The applicant listed for this patent is Genentech, Inc.. Invention is credited to Monique Bodil van Niel, Benjamin Fauber, Simon Gaines, Emanuela Gancia, Alberto Gobbi, Tammy Laddywahetty, Olivier Rene, David Vesey, Stuart Ward, Paul Winship.
Application Number | 20150197529 14/593260 |
Document ID | / |
Family ID | 52339138 |
Filed Date | 2015-07-16 |
United States Patent
Application |
20150197529 |
Kind Code |
A1 |
Fauber; Benjamin ; et
al. |
July 16, 2015 |
ARYL SULTAM DERIVATIVES AS RORc MODULATORS
Abstract
Compounds of the formula I: ##STR00001## or pharmaceutically
acceptable salts thereof, wherein m, n, p, q, r, A, W, X.sup.1,
X.sup.2, X.sup.3, X.sup.4, Y, Z, R.sup.1, R.sup.2, R.sup.3,
R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10,
R.sup.11 and R.sup.12 are as defined herein. Also disclosed are
methods of making the compounds and using the compounds for
treatment of inflammatory diseases such as arthritis.
Inventors: |
Fauber; Benjamin; (San
Francisco, CA) ; Gobbi; Alberto; (San Francisco,
CA) ; Rene; Olivier; (San Francisco, CA) ;
Bodil van Niel; Monique; (Harlow, GB) ; Gancia;
Emanuela; (Harlow, GB) ; Gaines; Simon;
(Harlow, GB) ; Laddywahetty; Tammy; (Harlow,
GB) ; Vesey; David; (Harlow, GB) ; Ward;
Stuart; (Harlow, GB) ; Winship; Paul; (Harlow,
GB) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Genentech, Inc. |
South San Francisco |
CA |
US |
|
|
Assignee: |
Genentech, Inc.
South San Francisco
CA
|
Family ID: |
52339138 |
Appl. No.: |
14/593260 |
Filed: |
January 9, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61925845 |
Jan 10, 2014 |
|
|
|
62091063 |
Dec 12, 2014 |
|
|
|
Current U.S.
Class: |
514/210.2 ;
514/211.15; 514/222.2; 540/544; 544/3; 544/6 |
Current CPC
Class: |
A61P 37/00 20180101;
A61P 11/06 20180101; C07D 417/14 20130101; A61P 19/02 20180101;
A61P 43/00 20180101; C07D 487/08 20130101; A61P 11/00 20180101;
C07D 417/10 20130101; A61P 17/00 20180101; C07D 491/107 20130101;
A61P 17/06 20180101; C07D 417/12 20130101; C07D 279/02 20130101;
C07D 491/113 20130101; A61P 21/00 20180101; A61P 1/04 20180101 |
International
Class: |
C07D 491/113 20060101
C07D491/113; C07D 491/107 20060101 C07D491/107; C07D 417/12
20060101 C07D417/12; C07D 417/14 20060101 C07D417/14; C07D 279/02
20060101 C07D279/02 |
Claims
1. A compound of formula I: ##STR00280## or a pharmaceutically
acceptable salt thereof, wherein: m is 0 or 1; n is 0 or 1; p is
from 0 to 3; q is 0, 1 or 2; r is from 1 to 3; A is: a bond;
--(CR.sub.jR.sub.k).sub.t--; --C(O)--(CR.sub.jR.sub.k).sub.t--;
--(CR.sub.jR.sub.k).sub.t--C(O)--;
--NR.sup.a--(CR.sub.jR.sub.k).sub.t--;
--(CR.sub.jR.sub.k).sub.t--NR.sup.a--;
--C(O)NR.sup.a--(CR.sub.jR.sub.k).sub.t--;
--(CR.sub.jR.sub.k).sub.t--NR.sup.aC(O)--;
--O--(CR.sub.jR.sub.k).sub.t--; --(CR.sub.jR.sub.k).sub.t--O--;
--S--(CR.sub.jR.sub.k).sub.t--; --(CR.sub.jR.sub.k).sub.t--S--;
--SO.sub.2--(CR.sub.jR.sub.k).sub.t--; or
--(CR.sub.jR.sub.k)--SO.sub.2--; t is from 0 to 4; W is:
--CR.sup.bR.sup.c--; --O--; --S--; --SO.sub.2--; or --NR.sup.d--;
one of X.sup.1, X.sup.2, X.sup.3 and X.sup.4 is N and the others
are CR.sup.e; or two of X.sup.1, X.sup.2, X.sup.3 and X.sup.4 are N
and the others are CR.sup.e; or three of X.sup.1, X.sup.2, X.sup.3
and X.sup.4 are N and the other is CR.sup.e; or each of X.sup.1,
X.sup.2, X.sup.3 and X.sup.4 is CR.sup.e; Y is: --O--; --S--;
SO.sub.2--; --CR.sup.fR.sup.g--; or --NR.sup.h--; Z is: CH; or N
wherein N may be oxidized; R.sup.1, R.sup.2, R.sup.3, R.sup.4,
R.sup.5, R.sup.6, R.sup.7 and R.sup.8 each independently is:
hydrogen; or C.sub.1-6alkyl which may be unsubstituted or
substituted one or more times with halo; or R.sup.3 and R.sup.4
together with the atom to which they are attached may form an
ethylene group; or R.sup.3 and R.sup.4 together with the atoms to
which they are attached may form a three, four, five, six or seven
membered saturated or partially saturated ring that may optionally
include one or two heteroatoms selected from --O--, --NR.sup.a-- or
--S--, and which may be optionally substituted one or more times
with R.sup.i; or R.sup.5 and R.sup.6 together with the atoms to
which they are attached may form a three, four, five, six or seven
membered saturated or partially saturated ring that may optionally
include one or two heteroatoms selected from --O--, --NR.sup.a-- or
--S--, and which may be optionally substituted one or more times
with R.sup.i; or R.sup.7 and R.sup.8 together with the atoms to
which they are attached may form a three, four, five, six or seven
membered saturated or partially saturated ring that may optionally
include one or two heteroatoms selected from --O--, --NR.sup.a-- or
--S--, and which may be optionally substituted one or more times
with R.sup.i; or one of R.sup.3 and R.sup.4 together with one of
R.sup.5 and R.sup.6 and the atoms to which they are attached may
form a three, four, five, six or seven membered saturated or
partially saturated ring that may optionally include one or two
heteroatoms selected from --O--, --NR.sup.a-- or --S--, and which
may be optionally substituted one or more times with R.sup.i; or
one of R.sup.5 and R.sup.6 together with one of R.sup.7 and R.sup.8
and the atoms to which they are attached may form a three, four,
five, six or seven membered saturated or partially saturated ring
that may optionally include one or two heteroatoms selected from
--O--, --NR.sup.a-- or --S--, and which may be optionally
substituted one or more times with R.sup.i; each R.sup.9 is
independently: C.sub.1-6alkyl; halo; C.sub.1-6alkoxy; or cyano;
wherein the C.sub.1-6alkyl moieties may be unsubstituted or
substituted one or more times with halo; R.sup.10 is: hydrogen;
carboxy; C.sub.1-6alkyl-carbonyl; C.sub.1-6alkoxy-carbonyl; oxo;
hydroxy; aminocarbonyl; N--C.sub.1-6alkyl-aminocarbonyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl; cyano; hydroxy-C.sub.1-6alkyl;
N--C.sub.1-6alkoxy-C.sub.1-6alkyl-aminocarbonyl;
N-hydroxy-C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkoxy-aminocarbonyl; halo; or C.sub.1-6alkyl which may
be unsubstituted or substituted one or more times with halo or oxo;
R.sup.11 is: hydrogen; halo; carboxy; C.sub.1-6alkyl-carbonyl;
C.sub.1-6alkoxy-carbonyl; oxo; hydroxy; aminocarbonyl;
N--C.sub.1-6alkyl-aminocarbonyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl; C.sub.1-6alkyl-sulfonylamino;
C.sub.1-6alkyl-sulfonylamino-C.sub.1-6alkyl; cyano;
hydroxy-C.sub.1-6alkyl;
N--C.sub.1-6alkoxy-C.sub.1-6alkyl-aminocarbonyl;
N-hydroxy-C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkoxy-aminocarbonyl; or C.sub.1-6 alkyl which may be
unsubstituted or substituted one or more times with halo or oxo; or
R.sup.10 and R.sup.11 together with the atoms to which they are
attached may form a three, four, five, six or seven membered
saturated or partially saturated ring that may optionally include
one or two heteroatoms selected from --O--, --NR.sup.a-- or --S--,
and which may be optionally substituted one or more times with
R.sup.i; or R.sup.10 and R.sup.11 together with the atoms to which
they are attached may form a double bond; R.sup.12 is: hydrogen;
halo; carboxy; C.sub.1-6alkyl-carbonyl; C.sub.1-6alkoxy-carbonyl;
oxo; hydroxy; aminocarbonyl; N--C.sub.1-6alkyl-aminocarbonyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl; cyano; hydroxy-C.sub.1-6alkyl;
N--C.sub.1-6alkoxy-C.sub.1-6alkyl-aminocarbonyl;
N-hydroxy-C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkoxy-aminocarbonyl; or C.sub.1-6alkyl which may be
unsubstituted or substituted one or more times with halo or oxo;
R.sup.13 is: hydrogen; or C.sub.1-6alkyl which may be unsubstituted
or substituted one or more times with halo; R.sup.a, R.sup.b,
R.sup.c and R.sup.d each independent is: hydrogen; or
C.sub.1-6alkyl which may be unsubstituted or substituted one or
more times with halo; or R.sup.b and R.sup.c together with the
atoms to which they are attached may form a three, four, five, six
or seven membered saturated or partially saturated ring that may
optionally include one or two heteroatoms selected from --O--,
--NR.sup.a-- or --S--, and which may be optionally substituted one
or more times with R.sup.i; or one of R.sup.b and R.sup.c together
with one of R.sup.7 and R.sup.8 and the atoms to which they are
attached may form a three, four, five, six or seven membered
saturated or partially saturated ring that may optionally include
one or two heteroatoms selected from --O--, --NR.sup.a-- or --S--,
and which may be optionally substituted one or more times with
R.sup.i; or one of R.sup.b and R.sup.c together with one of R.sup.5
and R.sup.6 and the atoms to which they are attached may form a
three, four, five, six or seven membered saturated or partially
saturated ring that may optionally include one or two heteroatoms
selected from --O--, --NR.sup.a-- or --S--, and which may be
optionally substituted one or more times with R.sup.i; each R.sup.e
is independently: hydrogen; C.sub.1-6alkyl; halo; C.sub.1-6alkoxy;
or cyano; wherein the C.sub.1-6alkyl moieties may be unsubstituted
or substituted one or more times with halo, hydroxy or
C.sub.1-6alkoxy; R.sup.f is: hydrogen; halo; or C.sub.1-6alkyl
which may be unsubstituted or substituted one or more times with
halo, hydroxy, or C.sub.1-6alkoxy; R.sup.g is: hydrogen;
C.sub.1-6alkyl; C.sub.3-6cycloalkyl; C.sub.3-6cycloalkenyl;
C.sub.3-6cycloalkyl-C.sub.1-6alkyl; halo; C.sub.1-6 alkyl-carbonyl;
C.sub.1-6cycloalkyl-carbonyl;
C.sub.3-6cycloalkyl-C.sub.1-6alkyl-carbonyl;
cyano-C.sub.1-6alkyl-carbonyl; hydroxy-C.sub.1-6alkyl-carbonyl;
C.sub.1-6alkoxy-C.sub.1-6alkyl-carbonyl; carboxy;
N-cyano-aminocarbonyl; N-cyano-N--C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkyl-acetimidamidyl;
N,N'-di-C.sub.1-6alkyl-acetimidamidyl;
N'-cyano-N--C.sub.1-6alkyl-acetimidamidyl;
N'-hydroxy-acetimidamidyl; N'--C.sub.1-6alkoxy-acetimidamidyl;
N'-hydroxy-N--C.sub.1-6alkyl-acetimidamidyl;
N'--C.sub.1-6alkoxy-N--C.sub.1-6alkyl-acetimidamidyl;
2-nitro-1-N--C.sub.1-6alkylamino-vinyl; formyl;
C.sub.1-6alkyl-sulfonyl; C.sub.3-6cycloalkyl-sulfonyl;
C.sub.3-6cycloalkyl-C.sub.1-6alkyl-sulfonyl;
C.sub.1-6alkyl-sulfonyl-C.sub.1-6alkyl; aminocarbonyl;
N-hydroxy-aminocarbonyl; N--C.sub.1-6alkoxy-aminocarbonyl;
N--C.sub.1-6alkyl-aminocarbonyl; aminocarbonyl-C.sub.1-6alkyl;
N--C.sub.1-6alkyl-aminocarbonyl-C.sub.1-6alkyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl-C.sub.1-6alkyl;
C.sub.1-6alkoxy-carbonyl;
N-hydroxy-N--C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkoxy-N--C.sub.1-6alkyl-aminocarbonyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl; aminosulfonyl;
N--C.sub.1-6alkyl-aminosulfonyl;
N,N-di-C.sub.1-6alkyl-aminosulfonyl; cyano; C.sub.1-6alkoxy;
C.sub.1-6alkyl-sulfonylamino;
N--C.sub.1-6alkyl-sulfonylaminocarbonyl;
N--(C.sub.1-6alkyl-sulfonyl)-N--C.sub.1-6alkyl-aminocarbonyl;
N--(C.sub.1-6alkyl-sulfonyl)-amino-C.sub.1-6alkyl; amino;
N--C.sub.1-6alkyl-amino; N,N-di-C.sub.1-6alkyl-amino;
halo-C.sub.1-6alkyl; phenyl; heterocyclyl; heteroaryl;
C.sub.1-6alkyl-carbonylamino; carbonylamino; or hydroxyl; wherein
the C.sub.1-6alkyl moieties may be unsubstituted or substituted one
or more times with halo; and wherein the phenyl, heterocyclyl,
heteroaryl, C.sub.3-6cycloalkyl, C.sub.1-6cycloalkenyl and
C.sub.3-6cycloalkyl-C.sub.1-6alkyl moieties may be unsubstituted or
substituted one or more times with R.sup.i; or R.sup.f and R.sup.g
together with the atoms to which they are attached may form a four,
five, six or seven membered saturated or partially saturated ring
that may optionally include one or two heteroatoms selected from
--O--, --NR.sup.a-- or --S--, and which may be optionally
substituted one or more times with R.sup.i; R.sup.h is: hydrogen;
C.sub.1-6alkyl; C.sub.3-6cycloalkyl; C.sub.3-6cycloalkenyl;
C.sub.3-6cycloalkyl-C.sub.1-6alkyl; C.sub.1-6alkyl-carbonyl;
C.sub.3-6cycloalkyl-carbonyl;
C.sub.3-6cycloalkyl-C.sub.1-6alkyl-carbonyl;
cyano-C.sub.1-6alkyl-carbonyl; hydroxy-C.sub.1-6alkyl-carbonyl;
C.sub.1-6alkoxy-C.sub.1-6alkyl-carbonyl; N-cyano-aminocarbonyl;
N-cyano-N--C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkyl-acetimidamidyl;
N,N'-di-C.sub.1-6alkyl-acetimidamidyl;
N'-cyano-N--C.sub.1-6alkyl-acetimidamidyl;
N'-hydroxy-acetimidamidyl; N'--C.sub.1-6alkoxy-acetimidamidyl;
N'-hydroxy-N--C.sub.1-6alkyl-acetimidamidyl;
N'--C.sub.1-6alkoxy-N--C.sub.1-6alkyl-acetimidamidyl;
2-nitro-1-N--C.sub.1-6alkylamino-vinyl; formyl;
C.sub.1-6alkyl-sulfonyl; C.sub.3-6cycloalkyl-sulfonyl;
C.sub.3-6cycloalkyl-C.sub.1-6alkyl-sulfonyl;
C.sub.1-6alkyl-sulfonyl-C.sub.1-6alkyl; aminocarbonyl;
N-hydroxy-aminocarbonyl; N--C.sub.1-6alkoxy-aminocarbonyl;
N--C.sub.1-6alkyl-aminocarbonyl;
N-hydroxy-N--C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkoxy-N--C.sub.1-6alkyl-aminocarbonyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl; aminosulfonyl;
N--C.sub.1-6alkyl-aminosulfonyl;
N,N-di-C.sub.1-6alkyl-aminosulfonyl; cyano; C.sub.1-6
alkyl-sulfonylamino; C.sub.1-6alkyl-sulfonylamino-C.sub.1-6alkyl;
N--(C.sub.1-6alkyl-sulfonyl)aminocarbonyl;
N--(C.sub.1-6alkyl-sulfonyl)-N--C.sub.1-6alkyl-aminocarbonyl;
N--(C.sub.1-6alkyl-sulfonyl)-amino-C.sub.1-6alkyl;
aminocarbonyl-C.sub.1-6alkyl;
N--C.sub.1-6alkyl-aminocarbonyl-C.sub.1-6alkyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl-C.sub.1-6alkyl;
C.sub.1-6alkoxy-carbonyl; halo-C.sub.1-6alkyl; phenyl;
heterocyclyl; or heteroaryl; wherein the C.sub.1-6alkyl moieties
may be unsubstituted or substituted one or more times with halo;
and wherein the phenyl, heterocyclyl, heteroaryl,
C.sub.3-6cycloalkyl, C.sub.1-6cycloalkenyl and
C.sub.3-6cycloalkyl-C.sub.1-6alkyl moieties may be unsubstituted or
substituted one or more times with R.sup.i; or R.sup.h and one of
R.sup.10 and R.sup.11 together with the atoms to which they are
attached may form a four, five, six or seven membered aromatic,
partially saturated or unsaturated ring that may optionally include
one or two additional heteroatom selected from --O--, --NR.sup.a--
or --S--, and which may be optionally substituted one or more times
with R.sup.i--; or one of R.sup.f and R.sup.g and one of R.sup.10
and R.sup.11 together with the atoms to which they are attached may
form a three, four, five, six or seven membered aromatic, partially
saturated or unsaturated ring that may optionally include an
additional heteroatom selected from --O--, --NR.sup.a-- or --S--,
and which may be optionally substituted one or more times with
R.sup.i; R.sup.i is: C.sub.1-6alkyl; halo; oxo; hydroxy; acetyl;
C.sub.1-6alkyl-carbonyl; amino-carbonyl; hydroxy-C.sub.1-6 alkyl;
cyano; heteroaryl; cyano-C.sub.1-6alkyl;
C.sub.1-6alkoxy-C.sub.1-6alkyl; carboxy; or C.sub.1-6alkoxy;
wherein the C.sub.1-6 alkyl moieties may be unsubstituted or
substituted one or more times with halo; R.sup.j and R.sup.k each
independent is: hydrogen; or C.sub.1-6alkyl which may be
unsubstituted or substituted one or more times with halo; wherein
the compound is selected from: wherein the compound is selected
from:
{1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylme-
thyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidin-4-yl}-methanol;
{1-[3-Fluoro-4-((3S,6S)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylme-
thyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidin-4-yl}-methanol;
(3S,6R)-2-[2-Fluoro-4-(tetrahydro-pyran-4-ylmethoxy)-benzyl]-3-methyl-6-p-
henyl-[1,2]thiazinane 1,1-dioxide;
(3S,6S)-2-[2-Fluoro-4-(4-[1,2,4]triazol-4-yl-piperidin-1-yl)-benzyl]-3,6--
dimethyl-6-phenyl-[1,2]thiazinane 1,1-dioxide;
(3S,6S)-2-{2-Fluoro-4-[4-(3-methyl-[1,2,4]triazol-4-yl)-piperidin-1-yl]-b-
enzyl}-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide;
(3S,6R)-2-[2-Fluoro-4-((2S,4R)-2-methyl-4-[1,2,4]triazol-4-yl-piperidin-1-
-yl)-benzyl]-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide;
1-{(R)-4-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan--
2-ylmethyl)-phenyl]-3-hydroxymethyl-piperazin-1-yl}-ethanone;
(3S,6R)-2-{2-Fluoro-4-[4-(3-methyl-[1,2,4]triazol-4-yl)-piperidin-1-yl]-b-
enzyl}-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide;
(3S,6R)-2-[2-Fluoro-4-((2S,4S)-2-methyl-4-[1,2,4]triazol-4-yl-piperidin-1-
-yl)-benzyl]-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide;
(4-{1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-y-
lmethyl)-phenyl]-piperidin-4-yl}-4H-[1,2,4]triazol-3-yl)-acetonitrile;
(3R,4R)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-
-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidine-3-carboxylic
acid methyl ester;
(3S,6R)-2-[2,5-Difluoro-4-(4-[1,2,4]triazol-4-yl-piperidin-1-yl)-benzyl]--
3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide;
(3S,6R)-2-{2-Fluoro-4-[4-(3-methoxymethyl-[1,2,4]triazol-4-yl)-piperidin--
1-yl]-benzyl}-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide;
(3S,4R)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-
-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidine-3-carboxylic
acid methyl ester;
(3S,6R)-2-[2-Fluoro-4-((3S,4R)-3-methyl-4-[1,2,4]triazol-4-yl-piperidin-1-
-yl)-benzyl]-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide;
(3S,6R)-2-[2-Fluoro-4-((3R,4S)-3-methyl-4-[1,2,4]triazol-4-yl-piperidin-1-
-yl)-benzyl]-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide;
(1S,5R,6S)-3-[2,3-Difluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]th-
iazinan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.1.0]hexa-
ne;
(1S,5R,6S)-3-[2,3-Difluoro-4-((3S,6S)-3-methyl-1,1-dioxo-6-phenyl-[1,2-
]thiazinan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.1.0]h-
exane;
(3S,6R)-2-[2,3-Difluoro-4-(4-[1,2,4]triazol-4-yl-piperidin-1-yl)-be-
nzyl]-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide;
(1R,5S,6S)-3-[2,5-Difluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]th-
iazinan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.1.0]hexa-
ne;
(1S,5R,6S)-3-[2,5-Difluoro-4-((3S,6S)-3-methyl-1,1-dioxo-6-phenyl-[1,2-
]thiazinan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.1.0]h-
exane;
(1R,5S,6S)-3-[2,6-Difluoro-4-((3S,6S)-3-methyl-1,1-dioxo-6-phenyl-[-
1,2]thiazinan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.1.-
0]hexane;
(1R,5S,6S)-3-[2,6-Difluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-pheny-
l-[1,2]thiazinan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3-
.1.0]hexane;
(3S,6R)-2-[2-Fluoro-4-((3R,4R)-3-methyl-4-[1,2,4]triazol-4-yl-piperidin-1-
-yl)-benzyl]-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide;
(3S,6R)-2-[2-Fluoro-4-((3S,4S)-3-methyl-4-[1,2,4]triazol-4-yl-piperidin-1-
-yl)-benzyl]-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide;
3-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmet-
hyl)-phenyl]-5-[1,2,4]triazol-4-yl-3-aza-bicyclo[4.1.0]heptane;
3-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmet-
hyl)-phenyl]-5-[1,2,4]triazol-4-yl-3-aza-bicyclo[4.1.0]heptane;
3-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmet-
hyl)-phenyl]-5-[1,2,4]triazol-4-yl-3-aza-bicyclo[4.1.0]heptane;
3-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmet-
hyl)-phenyl]-5-[1,2,4]triazol-4-yl-3-aza-bicyclo[4.1.0]heptane;
(3S,6R)-2-[3-Fluoro-4-(4-[1,2,4]triazol-4-yl-piperidin-1-yl)-benzyl]-3-me-
thyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; Carbamic acid
1-acetyl-4-[3-fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazina-
n-2-ylmethyl)-phenyl]-piperidin-4-yl ester,
(3S,6S)-2-[3-Fluoro-4-(4-[1,2,4]triazol-4-yl-piperidin-1-yl)-benzyl]-3-me-
thyl-6-phenyl-[1,2]thiazinane 1,1-dioxide;
(1R,3S,5S)-8-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazi-
nan-2-ylmethyl)-phenyl]-3-[1,2,4]triazol-4-yl-8-aza-bicyclo[3.2.1]octane;
(1R,5S,8R)-3-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazi-
nan-2-ylmethyl)-phenyl]-8-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.2.1]octane;
(1R,5S,8R)-3-[3-Fluoro-4-((3S,6S)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazi-
nan-2-ylmethyl)-phenyl]-8-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.2.1]octane;
(2S,4R)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-
-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidine-2-carboxylic
acid methyl ester;
(3S,6R)-2-(2-fluoro-4-((1-(S-methylsulfonimidoyl)piperidin-4-yl)oxy)benzy-
l)-3-methyl-6-phenyl-1,2-thiazinane 1,1-dioxide;
(3S,6R)-2-(2-fluoro-4-((1-(S-methylsulfonimidoyl)piperidin-4-yl)oxy)benzy-
l)-3-methyl-6-phenyl-1,2-thiazinane 1,1-dioxide;
(1S,5R,6S)-3-[2-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazi-
nan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.1.0]hexane;
(1S,5R,6S)-3-[2-Fluoro-4-((3S,6S)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazi-
nan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.1.0]hexane;
{(3R,4R)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazina-
n-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidin-3-yl}-methanol;
4-[4-((S)-3-Methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmethyl)-phenyl]--
2-aza-bicyclo[2.2.2]octan-3-one;
(1S,5R,6S)-3-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazi-
nan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.1.1]heptane;
{(3S,4R)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazina-
n-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidin-3-yl}-methanol;
(2R,4R)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-
-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidine-2-carboxylic
acid methyl ester;
(4-{1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1,1-dioxo-6-phenyl-[1,2]thiazinan-2-
-ylmethyl)-phenyl]-piperidin-4-yl}-4H-[1,2,4]triazol-3-yl)-methanol;
(4-{1-[3-Fluoro-4-((3S,6S)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-y-
lmethyl)-phenyl]-piperidin-4-yl}-4H-[1,2,4]triazol-3-yl)-methanol;
(2S,4S)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-
-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidine-2-carboxylic
acid methyl ester;
4-{4-[3-Fluoro-4-((3S,6R)-3-methyl-1,1,1-dioxo-6-phenyl-[1,2]thiazinan-2--
ylmethyl)-phenyl]-piperazin-1-yl}-benzoic acid;
(3S,6R)-2-[2-Fluoro-4-(1-oxy-4-[1,2,4]triazol-4-yl-piperidin-1-yl)-benzyl-
]-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide;
8-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmet-
hyl)-phenyl]-1,4-dioxa-8-aza-spiro[4.5]decane;
1-{4-[2-Hydroxymethyl-4-((3S,6R)-3-methyl-1-dioxo-6-phenyl-[1,2]thiazinan-
-2-ylmethyl)-phenyl]-piperazin-1-yl}-ethanone;
{(3S,4R)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazina-
n-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidin-3-yl}-methanol;
{(3R,4S)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazina-
n-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidin-3-yl}-methanol;
{(3S,4S)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazina-
n-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidin-3-yl}-methanol;
(3S,6R)-2-[4-(3,6-Dihydro-2H-pyran-4-yl)-2-fluoro-benzyl]-3-methyl-6-phen-
yl-[1,2]thiazinane 1,1-dioxide;
(3S,6R)-2-[2-Fluoro-4-(tetrahydro-pyran-4-yl)-benzyl]-3-methyl-6-phenyl-[-
1,2]thiazinane 1,1-dioxide;
{(3S,4S)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazina-
n-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidin-3-yl}-methanol;
(3S,6R)-2-[2-Fluoro-4-((R)-3-[1,2,4]triazol-4-yl-piperidin-1-yl)-benzyl]--
3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide
8-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmet-
hyl)-phenyl]-1-oxa-8-aza-spiro[4.5]decane;
9-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmet-
hyl)-phenyl]-1,5-dioxa-9-aza-spiro[5.5]undecane;
7-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmet-
hyl)-phenyl]-1-oxa-7-aza-spiro[3,5]nonane;
(S)-8-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-y-
lmethyl)-phenyl]-1,4-dioxa-8-aza-spiro[4.5]decane-7-carboxylic acid
methyl ester,
4-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan--
2-ylmethyl)-phenyl]-morpholine;
(R)-8-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-y-
lmethyl)-phenyl]-1,4-dioxa-8-aza-spiro[4.5]decane-7-carboxylic acid
methyl ester,
(3S,6R)-2-[2-Fluoro-4-((S)-3-[1,2,4]triazol-4-yl-piperidin-1-yl)-b-
enzyl]-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide;
(3R,6R)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2-fluorobenzyl)-3--
(difluoromethyl)-6-phenyl-1,2-thiazinane 1,1-dioxide
(3R,6S)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2-fluorobenzyl)-3--
(difluoromethyl)-6-phenyl-1,2-thiazinane 1,1-dioxide;
(3R,6S)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2,5-difluorobenzyl-
)-3-(difluoromethyl)-6-phenyl-1,2-thiazinane 1,1-dioxide;
(3R,6R)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2,5-difluorobenzyl-
)-3-(difluoromethyl)-6-phenyl-1,2-thiazinane 1,1-dioxide;
(3R,6S)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2,5-difluorobenzyl-
)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane 1,1-dioxide;
(3R,6R)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2,5-difluorobenzyl-
)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane 1,1-dioxide;
(3R,6R)-2-(4-((1R,5S,6S)-6-(4H-1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]hex-
an-3-yl)-2,5-difluorobenzyl)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane
1,1-dioxide;
(3R,6S)-2-(4-((1R,5S,6S)-6-(4H-1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]hex-
an-3-yl)-2,5-difluorobenzyl)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane
1,1-dioxide;
(3R,6R)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2-fluorobenzyl)-6--
phenyl-3-(trifluoromethyl)-1,2-thiazinane 1,1-dioxide;
(3R,6S)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2-fluorobenzyl)-6--
phenyl-3-(trifluoromethyl)-1,2-thiazinane 1,1-dioxide;
(3R,6R)-2-(4-((1R,5S,6S)-6-(4H-1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]hex-
an-3-yl)-2-fluorobenzyl)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane
1,1-dioxide;
(3R,6S)-2-(4-((1R,5S,6S)-6-(4H-1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]hex-
an-3-yl)-2-fluorobenzyl)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane
1,1-dioxide; (4R)-methyl
1-(2,5-difluoro-4-((3-methyl-1,1-dioxido-6-phenyl-1,2-thiazinan-2-yl)meth-
yl)phenyl)-4-(4H-1,2,4-triazol-4-yl)piperidine-3-carboxylate;
2-(2-fluoro-4-((4R)-3-methoxy-4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)ben-
zyl)-3-methyl-6-phenyl-1,2-thiazinane 1,1-dioxide;
2-(4-((5R)-5-(4H-1,2,4-triazol-4-yl)-2-azabicyclo[2.2.1]heptan-2-yl)-2,5--
difluorobenzyl)-3-methyl-6-phenyl-1,2-thiazinane 1,1-dioxide
2-(4-((5R)-5-(4H-1,2,4-triazol-4-yl)-2-azabicyclo[2.2.1]heptan-2-yl)-2,5--
difluorobenzyl)-3-methyl-6-phenyl-1,2-thiazinane 1,1-dioxide;
2-(2-fluoro-4-((4R)-3-fluoro-4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)benz-
yl)-3-methyl-6-phenyl-1,2-thiazinane 1,1-dioxide; and
8-(3-fluoro-4-(((3S,6R)-3-methyl-1,1-dioxido-6-phenyl-1,2-thiazinan-2-yl)-
methyl)phenyl)-3-methyl-1-oxa-8-azaspiro[4.5]decan-2-one.
2. The compound of claim 1, wherein the compound is selected from:
(1R,5S,6S)-3-[2,5-Difluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]th-
iazinan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.1.0]hexa-
ne;
(3R,6R)-2-(4-((1R,5S,6S)-6-(4H-1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]-
hexan-3-yl)-2,5-difluorobenzyl)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinan-
e 1,1-dioxide;
(3S,6R)-2-[2,5-Difluoro-4-(4-[1,2,4]triazol-4-yl-piperidin-1-yl)-benzyl]--
3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide;
(3R,6R)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2,5-difluorobenzyl-
)-3-(difluoromethyl)-6-phenyl-1,2-thiazinane 1,1-dioxide; and
(3R,6R)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2,5-difluorobenzyl-
)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane 1,1-dioxide.
3. A compound of formula XXIXa or XXIXb: ##STR00281## or a
pharmaceutically acceptable salt thereof, wherein: p is from 0 to
3; s is from 0 to 3; R.sup.1, R.sup.2 and R.sup.3 each
independently is: hydrogen; or C.sub.1-6alkyl which may be
unsubstituted or substituted one or more times with halo; each
R.sup.9 is independently: C.sub.1-6alkyl; halo; C.sub.1-6alkoxy; or
cyano; wherein the C.sub.1-6alkyl moieties may be unsubstituted or
substituted one or more times with halo; and each R.sup.e is
independently: hydrogen; C.sub.1-6alkyl; halo; C.sub.1-6alkoxy; or
cyano; wherein the C.sub.1-6alkyl moieties may be unsubstituted or
substituted one or more times with halo, hydroxy or
C.sub.1-6alkoxy; provided that the compound is not
(1R,5S,6S)-3-[3-fluoro-4-((3S)-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-
-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.1.0]hexane.
4. A compound of formula XXXa or XXXb: ##STR00282## or a
pharmaceutically acceptable salt thereof, wherein: p is from 0 to
3; q is 0, 1 or 2; r is from 1 to 3; A is: a bond;
--(CR.sub.jR.sub.k)--; --C(O)--(CR.sub.jR.sub.k).sub.t--;
--(CR.sub.jR.sub.k), --C(O)--;
--NR.sup.a--(CR.sub.jR.sub.k).sub.t--;
--(CR.sub.jR.sub.k).sub.t--NR.sup.a--;
--C(O)NR.sup.a--(CR.sub.jR.sub.k).sub.t--;
--(CR.sub.jR.sub.k).sub.t--NR.sup.aC(O)--;
--O--(CR.sub.jR.sub.k).sub.t--; --(CR.sub.jR.sub.k).sub.t--O--;
--S--(CR.sub.jR.sub.k).sub.t--; --(CR.sub.jR.sub.k).sub.t--S--;
--SO.sub.2--(CR.sub.jR.sub.k).sub.t--; or
--(CR.sub.jR.sub.k).sub.t--SO.sub.2--; t is from 0 to 4; Y is:
--O--; --S--; SO.sub.2--; --CR.sup.fR.sup.g--; or --NR.sup.h--; Z
is: CR.sup.m; or N wherein N may be oxidized; R.sup.1, R.sup.2, and
R.sup.3 each independently is: hydrogen; or C.sub.1-6alkyl which
may be unsubstituted or substituted one or more times with halo;
each R.sup.9 is independently: C.sub.1-6alkyl; halo;
C.sub.1-6alkoxy; or cyano; wherein the C.sub.1-6alkyl moieties may
be unsubstituted or substituted one or more times with halo;
R.sup.10 is: hydrogen; carboxy; C.sub.1-6alkyl-carbonyl;
C.sub.1-6alkoxy-carbonyl; oxo; hydroxy; aminocarbonyl;
N--C.sub.1-6alkyl-aminocarbonyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl; cyano; hydroxy-C.sub.1-6alkyl;
N--C.sub.1-6alkoxy-C.sub.1-6alkyl-aminocarbonyl;
N-hydroxy-C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkoxy-aminocarbonyl; halo; or C.sub.1-6alkyl which may
be unsubstituted or substituted one or more times with halo or oxo;
R.sup.11 is: hydrogen; halo; carboxy; C.sub.1-6alkyl-carbonyl;
C.sub.1-6alkoxy-carbonyl; oxo; hydroxy; aminocarbonyl;
N--C.sub.1-6alkyl-aminocarbonyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl; C.sub.1-6alkyl-sulfonylamino;
C.sub.1-6alkyl-sulfonylamino-C.sub.1-6alkyl; cyano;
hydroxy-C.sub.1-6alkyl;
N--C.sub.1-6alkoxy-C.sub.1-6alkyl-aminocarbonyl;
N-hydroxy-C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkoxy-aminocarbonyl; or C.sub.1-6alkyl which may be
unsubstituted or substituted one or more times with halo or oxo; or
R.sup.10 and R.sup.11 together with the atoms to which they are
attached may form a three, four, five, six or seven membered
saturated or partially saturated ring that may optionally include
one or two heteroatoms selected from --O--, --NR.sup.a-- or --S--,
and which may be optionally substituted one or more times with
R.sup.i; or R.sup.10 and R.sup.11 together with the atoms to which
they are attached may form a double bond; R.sup.a is: hydrogen; or
C.sub.1-6alkyl which may be unsubstituted or substituted one or
more times with halo; R.sup.f is: hydrogen; halo; or C.sub.1-6alkyl
which may be unsubstituted or substituted one or more times with
halo, hydroxy, or C.sub.1-6alkoxy; R.sup.g is: hydrogen;
C.sub.1-6alkyl; C.sub.3-6cycloalkyl; C.sub.3-6cycloalkenyl;
C.sub.3-6cycloalkyl-C.sub.1-6alkyl; halo; C.sub.1-6 alkyl-carbonyl;
C.sub.1-6cycloalkyl-carbonyl;
C.sub.3-6cycloalkyl-C.sub.1-6alkyl-carbonyl;
cyano-C.sub.1-6alkyl-carbonyl; hydroxy-C.sub.1-6alkyl-carbonyl;
C.sub.1-6alkoxy-C.sub.1-6alkyl-carbonyl; carboxy;
N-cyano-aminocarbonyl; N-cyano-N--C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkyl-acetimidamidyl;
N,N'-di-C.sub.1-6alkyl-acetimidamidyl;
N'-cyano-N--C.sub.1-6alkyl-acetimidamidyl;
N'-hydroxy-acetimidamidyl; N'--C.sub.1-6alkoxy-acetimidamidyl;
N'-hydroxy-N--C.sub.1-6alkyl-acetimidamidyl;
N'--C.sub.1-6alkoxy-N--C.sub.1-6alkyl-acetimidamidyl;
2-nitro-1-N--C.sub.1-6alkylamino-vinyl; formyl;
C.sub.1-6alkyl-sulfonyl; C.sub.3-6cycloalkyl-sulfonyl;
C.sub.3-6cycloalkyl-C.sub.1-6alkyl-sulfonyl;
C.sub.1-6alkyl-sulfonyl-C.sub.1-6alkyl; aminocarbonyl;
N-hydroxy-aminocarbonyl; N--C.sub.1-6alkoxy-aminocarbonyl;
N--C.sub.1-6alkyl-aminocarbonyl; aminocarbonyl-C.sub.1-6alkyl;
N--C.sub.1-6alkyl-aminocarbonyl-C.sub.1-6alkyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl-C.sub.1-6alkyl;
C.sub.1-6alkoxy-carbonyl;
N-hydroxy-N--C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkoxy-N--C.sub.1-6alkyl-aminocarbonyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl; aminosulfonyl;
N--C.sub.1-6alkyl-aminosulfonyl;
N,N-di-C.sub.1-6alkyl-aminosulfonyl; cyano; C.sub.1-6alkoxy;
C.sub.1-6alkyl-sulfonylamino;
N--C.sub.1-6alkyl-sulfonylaminocarbonyl;
N--(C.sub.1-6alkyl-sulfonyl)-N--C.sub.1-6alkyl-aminocarbonyl;
N--(C.sub.1-6alkyl-sulfonyl)-amino-C.sub.1-6alkyl; amino;
N--C.sub.1-6alkyl-amino; N,N-di-C.sub.1-6alkyl-amino;
halo-C.sub.1-6alkyl; phenyl; heterocyclyl; heteroaryl;
C.sub.1-6alkyl-carbonylamino; carbonylamino; or hydroxyl; wherein
the C.sub.1-6alkyl moieties may be unsubstituted or substituted one
or more times with halo; and wherein the phenyl, heterocyclyl,
heteroaryl, C.sub.3-6cycloalkyl, C.sub.1-6cycloalkenyl and
C.sub.3-6cycloalkyl-C.sub.1-6alkyl moieties may be unsubstituted or
substituted one or more times with R.sup.i; or R.sup.f and R.sup.g
together with the atoms to which they are attached may form a four,
five, six or seven membered saturated or partially saturated ring
that may optionally include one or two heteroatoms selected from
--O--, --NR.sup.a-- or --S--, and which may be optionally
substituted one or more times with R.sup.i; R.sup.h is: hydrogen;
C.sub.1-6alkyl; C.sub.3-6cycloalkyl; C.sub.3-6cycloalkenyl;
C.sub.3-6cycloalkyl-C.sub.1-6alkyl; C.sub.1-6alkyl-carbonyl;
C.sub.3-6cycloalkyl-carbonyl;
C.sub.3-6cycloalkyl-C.sub.1-6alkyl-carbonyl;
cyano-C.sub.1-6alkyl-carbonyl; hydroxy-C.sub.1-6alkyl-carbonyl;
C.sub.1-6alkoxy-C.sub.1-6alkyl-carbonyl; N-cyano-aminocarbonyl;
N-cyano-N--C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkyl-acetimidamidyl;
N,N'-di-C.sub.1-6alkyl-acetimidamidyl;
N'-cyano-N--C.sub.1-6alkyl-acetimidamidyl;
N'-hydroxy-acetimidamidyl; N'--C.sub.1-6alkoxy-acetimidamidyl;
N'-hydroxy-N--C.sub.1-6alkyl-acetimidamidyl;
N'--C.sub.1-6alkoxy-N--C.sub.1-6alkyl-acetimidamidyl;
2-nitro-1-N--C.sub.1-6alkylamino-vinyl; formyl;
C.sub.1-6alkyl-sulfonyl; C.sub.3-6cycloalkyl-sulfonyl;
C.sub.1-6cycloalkyl-C.sub.1-6alkyl-sulfonyl;
C.sub.1-6alkyl-sulfonyl-C.sub.1-6alkyl; aminocarbonyl;
N-hydroxy-aminocarbonyl; N--C.sub.1-6alkoxy-aminocarbonyl;
N--C.sub.1-6alkyl-aminocarbonyl;
N-hydroxy-N--C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkoxy-N--C.sub.1-6alkyl-aminocarbonyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl; aminosulfonyl;
N--C.sub.1-6alkyl-aminosulfonyl;
N,N-di-C.sub.1-6alkyl-aminosulfonyl; cyano; C.sub.1-6
alkyl-sulfonylamino; C.sub.1-6alkyl-sulfonylamino-C.sub.1-6alkyl;
N--(C.sub.1-6alkyl-sulfonyl)aminocarbonyl; N--(C.sub.1-6
alkyl-sulfonyl)-N--C.sub.1-6alkyl-aminocarbonyl;
N--(C.sub.1-6alkyl-sulfonyl)-amino-C.sub.1-6alkyl;
aminocarbonyl-C.sub.1-6alkyl;
N--C.sub.1-6alkyl-aminocarbonyl-C.sub.1-6alkyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl-C.sub.1-6alkyl;
C.sub.1-6alkoxy-carbonyl; halo-C.sub.1-6alkyl; phenyl;
heterocyclyl; or heteroaryl; wherein the C.sub.1-6alkyl moieties
may be unsubstituted or substituted one or more times with halo;
and wherein the phenyl, heterocyclyl, heteroaryl,
C.sub.3-6cycloalkyl, C.sub.1-6cycloalkenyl and
C.sub.3-6cycloalkyl-C.sub.1-6alkyl moieties may be unsubstituted or
substituted one or more times with R.sup.i; or R.sup.h and one of
R.sup.10 and R.sup.11 together with the atoms to which they are
attached may form a four, five, six or seven membered aromatic,
partially saturated or unsaturated ring that may optionally include
one or two additional heteroatom selected from --O--, --NR.sup.a--
or --S--, and which may be optionally substituted one or more times
with R.sup.i--; or one of R.sup.f and R.sup.g and one of R.sup.10
and R.sup.11 together with the atoms to which they are attached may
form a three, four, five, six or seven membered aromatic, partially
saturated or unsaturated ring that may optionally include an
additional heteroatom selected from --O--, --NR.sup.a-- or --S--,
and which may be optionally substituted one or more times with
R.sup.i; R.sup.f is: C.sub.1-6alkyl; halo; oxo; hydroxy; acetyl;
C.sub.1-6alkyl-carbonyl; amino-carbonyl; hydroxy-C.sub.1-6 alkyl;
cyano; heteroaryl; cyano-C.sub.1-6alkyl;
C.sub.1-6alkoxy-C.sub.1-6alkyl; carboxy; or C.sub.1-6alkoxy;
wherein the C.sub.1-6 alkyl moieties may be unsubstituted or
substituted one or more times with halo; and R.sup.j and R.sup.k
each independent is: hydrogen; or C.sub.1-6alkyl which may be
unsubstituted or substituted one or more times with halo.
5. A compound of formula XXXIIa or XXXIIb: ##STR00283## or a
pharmaceutically acceptable salt thereof, wherein: p is from 0 to
3; s is from 0 to 3; R.sup.1, R.sup.2 and R.sup.3 each
independently is: hydrogen; or C.sub.1-6alkyl which may be
unsubstituted or substituted one or more times with halo; each
R.sup.9 is independently: C.sub.1-6alkyl; halo; C.sub.1-6alkoxy; or
cyano; wherein the C.sub.1-6alkyl moieties may be unsubstituted or
substituted one or more times with halo; and each R.sup.e is
independently: hydrogen; C.sub.1-6alkyl; halo; C.sub.1-6alkoxy; or
cyano; wherein the C.sub.1-6alkyl moieties may be unsubstituted or
substituted one or more times with halo, hydroxy or
C.sub.1-6alkoxy;
6. A compound selected from:
(3S,6R)-2-[[2-fluoro-4-[(3R,4R)-3-fluoro-4-(1,2,4-triazol-4-yl)-1-piperid-
yl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide;
4-[4-[3-fluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]met-
hyl]phenyl]piperazin-1-yl]benzoic acid;
(3S,6R)-2-[[2-fluoro-4-(1-oxa-6-azaspiro[3.3]heptan-6-yl)phenyl]methyl]-3-
-methyl-6-phenyl-thiazinane 1,1-dioxide;
8-[3-fluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]methyl-
]phenyl]-1,3-dimethyl-1,3,8-triazaspiro[4.5]decane-2,4-dione;
1-[4-[[3-fluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-hydroxy-methyl]-1-piperidyl]ethanone;
(3S,6R)-2-[[2-fluoro-4-[(3S,4R)-3-fluoro-4-(1,2,4-triazol-4-yl)-1-piperid-
yl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide;
(3S,6R)-2-[[2-fluoro-4-[(3R,4S)-3-fluoro-4-(1,2,4-triazol-4-yl)-1-piperid-
yl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide;
(3S,6R)-2-[[2-fluoro-4-[(3S,4R)-3-methoxy-4-(1,2,4-triazol-4-yl)-1-piperi-
dyl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide;
(3S,6R)-2-[[2-fluoro-4-[(3R,4S)-3-methoxy-4-(1,2,4-triazol-4-yl)-1-piperi-
dyl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide;
(3S,6R)-2-[[2-fluoro-4-[(3R,4R)-3-fluoro-4-(1,2,4-triazol-4-yl)-1-piperid-
yl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide
(3S,6R)-2-[[2-fluoro-4-[(3S,4S)-3-fluoro-4-(1,2,4-triazol-4-yl)-1-piperid-
yl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide;
4-[4-[3-fluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]met-
hyl]phenyl]piperazin-1-yl]-2-hydroxy-benzoic acid;
4-[4-[3-fluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]met-
hyl]phenyl]piperazin-1-yl]-2-hydroxy-benzoic acid;
(3S,6R)-2-[[2,5-difluoro-4-[(1S,4S,5S)-5-(1,2,4-triazol-4-yl)-2-azabicycl-
o[2.2.1]heptan-2-yl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane
1,1-dioxide;
(3S,6R)-2-[[2,5-difluoro-4-[(1R,4R,5R)-5-(1,2,4-triazol-4-yl)-2-azabicycl-
o[2.2.1]heptan-2-yl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane
1,1-dioxide;
(3S,6R)-2-[[4-(3,6-dihydro-2H-pyran-4-ylmethyl)-2-fluoro-phenyl]methyl]-3-
-methyl-6-phenyl-thiazinane 1,1-dioxide;
(3S,6R)-2-[[2-fluoro-4-(tetrahydropyran-4-ylidenemethyl)phenyl]methyl]-3--
methyl-6-phenyl-thiazinane 1,1-dioxide; methyl
4-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1-dioxo-6-phenyl-thiazinan-2-yl]meth-
yl]phenyl]tetrahydropyran-4-carboxylate;
methyl(3S,4S)-3-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thi-
azinan-2-yl]methyl]phenyl]tetrahydropyran-4-carboxylate;
(3R,4R)-1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-
-2-yl]methyl]phenyl]-4-(1,2,4-triazol-4-yl)piperidin-3-ol;
(3S,4S)-1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-
-2-yl]methyl]phenyl]-4-(1,2,4-triazol-4-yl)piperidin-3-ol; methyl
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1-dioxo-6-phenyl-thiazinan-2-yl]meth-
yl]phenyl]acetate; methyl
4-[2,5-difluoro-4-[[(3S,6S)-3-methyl-1-dioxo-6-phenyl-thiazinan-2-yl]meth-
yl]phenyl]tetrahydropyran-4-carboxylate;
(3R,4R)-3-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-
-2-yl]methyl]phenyl]tetrahydropyran-4-carboxylic acid,
methyl(3S,4S)-3-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thi-
azinan-2-yl]methyl]phenyl]tetrahydropyran-4-carboxylate;
methyl(3R,4R)-3-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thi-
azinan-2-yl]methyl]phenyl]tetrahydropyran-4-carboxylate;
(3S,6R)-2-[[2,5-difluoro-4-[(3S,4R)-3-fluoro-4-(1,2,4-triazol-4-yl)-1-pip-
eridyl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide;
(3S,6R)-2-[[2,5-difluoro-4-[(3R,4S)-3-fluoro-4-(1,2,4-triazol-4-yl)-1-pip-
eridyl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide
2-[2,5-difluoro-4-[[(3S,6R)-3-methy;
1,1,1-dioxo-6-phenyl-thiazinan-2-yl]methyl]phenyl]ethanol;
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-N-(3-hydroxycyclobutyl)acetamide;
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]acetamide;
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]propan-1-ol;
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]propan-1-ol; diethyl
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1-dioxo-6-phenyl-thiazinan-2-yl]meth-
yl]phenyl]propanedioate;
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]propane-1,3-diol; tert-butyl
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]acetate;
4-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-5-hydroxy-pentanenitrile;
1-[4-[4-[[(6S)-5,5-dioxo-6-phenyl-5$1
{6}-thia-4-azaspiro[2,5]octan-4-yl]methyl]-3-fluoro-phenyl]piperazin-1-yl-
]ethanone; 1-[4-[4-[[(6S)-5,5-dioxo-6-phenyl-5$1
{6}-thia-4-azaspiro[2,5]octan-4-yl]methyl]-3-fluoro-phenyl]piperazin-1-yl-
]ethanone;
2-[1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thia-
zinan-2-yl]methyl]phenyl]-1-methyl-ethoxy]acetic acid;
2-[1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl-
]methyl]phenyl]-1-methyl-ethoxy]acetamide;
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-3-(oxetan-3-yl)propan-1-ol;
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-3-(oxetan-3-yl)propan-1-ol;
3-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-4-hydroxy-butanenitrile;
3-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-4-hydroxy-butanenitrile;
3-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-4-hydroxy-butanamide;
3-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-4-hydroxy-butanamide;
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-2-(oxetan-3-yl)ethanol;
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-2-(oxetan-3-yl)ethanol;
3-[1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl-
]methyl]phenyl]-1-methyl-ethoxy]propane-1,2-diol;
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-2-phenyl-ethanol;
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-2-phenyl-ethanol;
(2S)-3-[1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-
-2-yl]methyl]phenyl]-1-methyl-ethoxy]propane-1,2-diol;
(2R)-3-[1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-
-2-yl]methyl]phenyl]-1-methyl-ethoxy]propane-1,2-diol;
3-[1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl-
]methyl]phenyl]-2-hydroxy-ethyl]-1-methyl-pyrrolidin-2-one;
3-[1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl-
]methyl]phenyl]-2-hydroxy-ethyl]-1-methyl-pyrrolidin-2-one;
3-[1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl-
]methyl]phenyl]-2-hydroxy-ethyl]-1-methyl-pyrrolidin-2-one;
3-[1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl-
]methyl]phenyl]-2-hydroxy-ethyl]-1-methyl-pyrrolidin-2-one;
4-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-5-hydroxy-pentanamide;
4-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-5-hydroxy-pentanamide;
(3S,6R)-2-[[2,5-difluoro-4-[4-(1,2,4-triazol-4-yl)-1-piperidyl]phenyl]met-
hyl]-3-ethyl-6-phenyl-thiazinane 1,1-dioxide;
(3S,6S)-2-[[2,5-difluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3-
.1.0]hexan-3-yl]phenyl]methyl]-3-ethyl-6-phenyl-thiazinane
1,1-dioxide;
(3S,6R)-2-[[2,5-difluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3-
.1.0]hexan-3-yl]phenyl]methyl]-3-ethyl-6-phenyl-thiazinane
1,1-dioxide;
(3S,6S)-2-[[2,5-difluoro-4-[4-(1,2,4-triazol-4-yl)-1-piperidyl]phenyl]met-
hyl]-3-ethyl-6-phenyl-thiazinane 1,1-dioxide;
(3S,6R)-3-ethyl-2-[[2-fluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyc-
lo[3.1.0]hexan-3-yl]phenyl]methyl]-6-phenyl-thiazinane 1,1-dioxide;
(3S,6S)-3-ethyl-2-[[2-fluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyc-
lo[3.1.0]hexan-3-yl]phenyl]methyl]-6-phenyl-thiazinane 1,1-dioxide;
(7S)-2-[[2,5-difluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.-
0]hexan-3-yl]phenyl]methyl]-7-phenyl-thiazepane 1,1-dioxide;
(7S)-2-[[2,5-difluoro-4-[4-(1,2,4-triazol-4-yl)-1-piperidyl]phenyl]methyl-
]-7-phenyl-thiazepane 1,1-dioxide;
(7R)-2-[[2,5-difluoro-4-[4-(1,2,4-triazol-4-yl)-1-piperidyl]phenyl]methyl-
]-7-phenyl-thiazepane 1,1-dioxide;
(7R)-2-[[2,5-difluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.-
0]hexan-3-yl]phenyl]methyl]-7-phenyl-thiazepane 1,1-dioxide;
(7S)-2-[[2-fluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]he-
xan-3-yl]phenyl]methyl]-7-phenyl-thiazepane 1,1-dioxide;
(7R)-2-[[2-fluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]he-
xan-3-yl]phenyl]methyl]-7-phenyl-thiazepane 1,1-dioxide;
(7S)-2-[[2,5-difluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.-
0]hexan-3-yl]phenyl]methyl]-7-phenyl-thiazepane 1,1-dioxide;
(7S)-2-[[2,5-difluoro-4-[4-(1,2,4-triazol-4-yl)-1-piperidyl]phenyl]methyl-
]-7-phenyl-thiazepane 1,1-dioxide;
(3S,4S)-3-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-
-2-yl]methyl]phenyl]tetrahydropyran-4-carboxylic acid;
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-N-(3-hydroxycyclobutyl)acetamide;
4-[4-[3-fluoro-4-[[(3S,6S)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]met-
hyl]phenyl]piperazin-1-yl]benzoic acid; and
4-[4-[3-fluoro-4-[[(3S,6S)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]met-
hyl]phenyl]piperazin-1-yl]-2-hydroxy-benzoic acid.
7. The compound
(1R,5S,6S)-3-[2,5-Difluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]th-
iazinan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.1.0]hexa-
ne; or a pharmaceutically acceptable salt thereof.
8. The compound
(3R,6R)-2-(4-((R,5S,6S)-6-(4H-1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]hexa-
n-3-yl)-2,5-difluorobenzyl)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane
1,1-dioxide; or a pharmaceutically acceptable salt thereof.
9. A composition comprising: (a) a pharmaceutically acceptable
carrier; and (b) a compound of claim 1.
10. A method for treating arthritis, asthma, COPD, psoriasis, lupus
(Lupus erythematosus), Sjogren's disease, irritable bowel disease,
idiopathic pulmonary fibrosis or muscular sclerosis, said method
comprising administering to a subject in need thereof an effective
amount of a compound of claim 1.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of priority of U.S.
Provisional Patent Application Ser. No. 61/925,845 filed Jan. 10,
2014, and U.S. Provisional Patent Application Ser. No. 62/091,063
filed Dec. 12, 2014, the disclosures of which are incorporated
herein by reference in their entirety.
FIELD OF THE INVENTION
[0002] The invention pertains to compounds that modulate the
function of retinoid-receptor related orphan receptor RORc
(ROR.gamma.) and use of such compounds for treatment of autoimmune
diseases
BACKGROUND OF THE INVENTION
[0003] T helper 17 cells (Th17) are interleukin (IL)-17 secreting
CD4+ T cells involved in pathogenesis of autoimmune diseases such
as rheumatoid arthritis, irritable bowel disease, psoriasis,
psoriatic arthritis and spondyloarthridities. The retinoic
acid-related orphan receptor .gamma. (ROR.gamma. or RORc) is
recognized as a transcription factor necessary for Th17 cell
differentiation. RORc is an orphan member of the nuclear hormone
receptor subfamily that includes ROR.alpha. (RORa) and ROR.beta.
(RORb). RORc controls gene transcription by binding to DNA as a
monomer. Selective modulation of RORc has been proposed as a route
to discovery and development of Th17 cell-associated autoimmune
diseases.
[0004] There is accordingly a need for compounds that inhibit RORc
for use in treatment of autoimmune diseases such as rheumatoid
arthritis, irritable bowel disease, psoriasis, psoriatic arthritis
and spondyloarthridities.
SUMMARY OF THE INVENTION
[0005] The invention provides compounds of the formula I:
##STR00002##
or a pharmaceutically acceptable salt thereof, wherein: [0006] m is
0 or 1; [0007] n is 0 or 1; [0008] p is from 0 to 3; [0009] q is 0,
1 or 2; [0010] r is from 1 to 3; [0011] A is: a bond;
--(CR.sub.jR.sub.k).sub.t--; --C(O)--(CR.sub.jR.sub.k).sub.t--;
--(CR.sub.jR.sub.k).sub.t--C(O)--;
--NR.sup.a--(CR.sub.jR.sub.k).sub.t--;
--(CR.sub.jR.sub.k).sub.t--NR.sup.a--;
--C(O)NR.sup.a--(CR.sub.jR.sub.k).sub.t--;
--(CR.sub.jR.sub.k).sub.t--NR.sup.aC(O)--;
--O--(CR.sub.jR.sub.k).sub.t--; --(CR.sub.jR.sub.k).sub.t--O--;
--S--(CR.sub.jR.sub.k).sub.t--; --(CR.sub.jR.sub.k).sub.t--S--;
--SO.sub.2--(CR.sub.jR.sub.k).sub.t--; or
--(CR.sub.jR.sub.k)--SO.sub.2--; [0012] t is from 0 to 4; [0013] W
is: --CR.sup.bR.sup.c--; --O--; --S--; --SO.sub.2--; or
--NR.sup.d--; [0014] one of X.sup.1, X.sup.2, X.sup.3 and X.sup.4
is N and the others are CR.sup.e; or two of X.sup.1, X.sup.2,
X.sup.3 and X.sup.4 are N and the others are CR.sup.e; or three of
X.sup.1, X.sup.2, X.sup.3 and X.sup.4 are N and the other is
CR.sup.e; or each of X.sup.1, X.sup.2, X.sup.3 and X.sup.4 is
CR.sup.e; [0015] Y is: --O--; --S--; SO.sub.2--;
--CR.sup.fR.sup.g--; or --NR.sup.h--; [0016] Z is: CH; or N wherein
N may be oxidized; [0017] R.sup.1, R.sup.2, R.sup.3, R.sup.4,
R.sup.5, R.sup.6, R.sup.7 and R.sup.8 each independently is:
hydrogen; or C.sub.1-6alkyl which may be unsubstituted or
substituted one or more times with halo; [0018] or R.sup.3 and
R.sup.4 together with the atom to which they are attached may form
an ethylene group; [0019] or R.sup.3 and R.sup.4 together with the
atoms to which they are attached may form a three, four, five, six
or seven membered saturated or partially saturated ring that may
optionally include one or two heteroatoms selected from --O--,
--NR.sup.a-- or --S--, and which may be optionally substituted one
or more times with R.sup.i; [0020] or R.sup.5 and R.sup.6 together
with the atoms to which they are attached may form a three, four,
five, six or seven membered saturated or partially saturated ring
that may optionally include one or two heteroatoms selected from
--O--, --NR.sup.a-- or --S--, and which may be optionally
substituted one or more times with R.sup.i; [0021] or R.sup.7 and
R.sup.8 together with the atoms to which they are attached may form
a three, four, five, six or seven membered saturated or partially
saturated ring that may optionally include one or two heteroatoms
selected from --O--, --NR.sup.a-- or --S--, and which may be
optionally substituted one or more times with R.sup.i; [0022] or
one of R.sup.3 and R.sup.4 together with one of R.sup.5 and R.sup.6
and the atoms to which they are attached may form a three, four,
five, six or seven membered saturated or partially saturated ring
that may optionally include one or two heteroatoms selected from
--O--, --NR.sup.a-- or --S--, and which may be optionally
substituted one or more times with R.sup.i; [0023] or one of
R.sup.5 and R.sup.6 together with one of R.sup.7 and R.sup.8 and
the atoms to which they are attached may form a three, four, five,
six or seven membered saturated or partially saturated ring that
may optionally include one or two heteroatoms selected from --O--,
--NR.sup.a-- or --S--, and which may be optionally substituted one
or more times with R.sup.i; [0024] each R.sup.9 is independently:
C.sub.1-6alkyl; halo; C.sub.1-6alkoxy; or cyano; wherein the
C.sub.1-6alkyl moieties may be unsubstituted or substituted one or
more times with halo; [0025] R.sup.10 is: hydrogen; carboxy;
C.sub.1-6alkyl-carbonyl; C.sub.1-6alkoxy-carbonyl; oxo; hydroxy;
aminocarbonyl; N--C.sub.1-6alkyl-aminocarbonyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl; cyano; hydroxy-C.sub.1-6alkyl;
N--C.sub.1-6alkoxy-C.sub.1-6alkyl-aminocarbonyl;
N-hydroxy-C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkoxy-aminocarbonyl; halo; or C.sub.1-6alkyl which may
be unsubstituted or substituted one or more times with halo or oxo;
[0026] R.sup.11 is: hydrogen; halo; carboxy;
C.sub.1-6alkyl-carbonyl; C.sub.1-6alkoxy-carbonyl; oxo; hydroxy;
aminocarbonyl; N--C.sub.1-6alkyl-aminocarbonyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl; C.sub.1-6alkyl-sulfonylamino;
C.sub.1-6alkyl-sulfonylamino-C.sub.1-6alkyl; cyano;
hydroxy-C.sub.1-6alkyl;
N--C.sub.1-6alkoxy-C.sub.1-6alkyl-aminocarbonyl;
N-hydroxy-C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkoxy-aminocarbonyl; or C.sub.1-6 alkyl which may be
unsubstituted or substituted one or more times with halo or oxo;
[0027] or R.sup.10 and R.sup.11 together with the atoms to which
they are attached may form a three, four, five, six or seven
membered saturated or partially saturated ring that may optionally
include one or two heteroatoms selected from --O--, --NR.sup.a-- or
--S--, and which may be optionally substituted one or more times
with R.sup.i; [0028] or R.sup.10 and R.sup.11 together with the
atoms to which they are attached may form a double bond;
[0029] R.sup.12 is: hydrogen; halo; carboxy;
C.sub.1-6alkyl-carbonyl; C.sub.1-6alkoxy-carbonyl; oxo; hydroxy;
aminocarbonyl; N--C.sub.1-6alkyl-aminocarbonyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl; cyano; hydroxy-C.sub.1-6alkyl;
N--C.sub.1-6alkoxy-C.sub.1-6alkyl-aminocarbonyl;
N-hydroxy-C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkoxy-aminocarbonyl; or C.sub.1-6alkyl which may be
unsubstituted or substituted one or more times with halo or oxo;
[0030] R.sup.13 is: hydrogen; or C.sub.1-6alkyl which may be
unsubstituted or substituted one or more times with halo; [0031]
R.sup.a, R.sup.b, R.sup.c and R.sup.d each independent is:
hydrogen; or C.sub.1-6alkyl which may be unsubstituted or
substituted one or more times with halo; [0032] or R.sup.b and
R.sup.c together with the atoms to which they are attached may form
a three, four, five, six or seven membered saturated or partially
saturated ring that may optionally include one or two heteroatoms
selected from --O--, --NR.sup.a-- or --S--, and which may be
optionally substituted one or more times with R.sup.i; [0033] or
one of R.sup.b and R.sup.c together with one of R.sup.7 and R.sup.8
and the atoms to which they are attached may form a three, four,
five, six or seven membered saturated or partially saturated ring
that may optionally include one or two heteroatoms selected from
--O--, --NR.sup.a-- or --S--, and which may be optionally
substituted one or more times with R.sup.i; [0034] or one of
R.sup.b and R.sup.c together with one of R.sup.5 and R.sup.6 and
the atoms to which they are attached may form a three, four, five,
six or seven membered saturated or partially saturated ring that
may optionally include one or two heteroatoms selected from --O--,
--NR.sup.a-- or --S--, and which may be optionally substituted one
or more times with R.sup.i; [0035] each R.sup.e is independently:
hydrogen; C.sub.1-6alkyl; halo; C.sub.1-6alkoxy; or cyano; wherein
the C.sub.1-6alkyl moieties may be unsubstituted or substituted one
or more times with halo, hydroxy or C.sub.1-6alkoxy;
[0036] R.sup.f is: hydrogen; halo; or C.sub.1-6alkyl which may be
unsubstituted or substituted one or more times with halo, hydroxy,
or C.sub.1-6alkoxy;
[0037] R.sup.g is: hydrogen; C.sub.1-6alkyl; C.sub.3-6cycloalkyl;
C.sub.3-6-cycloalkenyl; C.sub.3-6cycloalkyl-C.sub.1-6alkyl; halo;
C.sub.1-6alkyl-carbonyl; C.sub.3-6cycloalkyl-carbonyl;
C.sub.3-6cycloalkyl-C.sub.1-6alkyl-carbonyl;
cyano-C.sub.1-6alkyl-carbonyl; hydroxy-C.sub.1-6alkyl-carbonyl;
C.sub.1-6alkoxy-C.sub.1-6alkyl-carbonyl; carboxy;
N-cyano-aminocarbonyl; N-cyano-N--C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkyl-acetimidamidyl;
N,N'-di-C.sub.1-6alkyl-acetimidamidyl;
N'-cyano-N--C.sub.1-6alkyl-acetimidamidyl;
N'-hydroxy-acetimidamidyl; N'--C.sub.1-6alkoxy-acetimidamidyl;
N'-hydroxy-N--C.sub.1-6alkyl-acetimidamidyl;
N'--C.sub.1-6alkoxy-N--C.sub.1-6alkyl-acetimidamidyl;
2-nitro-1-N--C.sub.1-6alkylamino-vinyl; formyl;
C.sub.1-6alkyl-sulfonyl; C.sub.3-6cycloalkyl-sulfonyl;
C.sub.3-6cycloalkyl-C.sub.1-6alkyl-sulfonyl;
C.sub.1-6alkyl-sulfonyl-C.sub.1-6alkyl; aminocarbonyl;
N-hydroxy-aminocarbonyl; N--C.sub.1-6alkoxy-aminocarbonyl;
N--C.sub.1-6alkyl-aminocarbonyl; aminocarbonyl-C.sub.1-6alkyl;
N--C.sub.1-6alkyl-aminocarbonyl-C.sub.1-6alkyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl-C.sub.1-6alkyl;
C.sub.1-6alkoxy-carbonyl;
N-hydroxy-N--C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkoxy-N--C.sub.1-6alkyl-aminocarbonyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl; aminosulfonyl;
N--C.sub.1-6alkyl-aminosulfonyl;
N,N-di-C.sub.1-6alkyl-aminosulfonyl; cyano; C.sub.1-6alkoxy;
C.sub.1-6alkyl-sulfonylamino;
N--C.sub.1-6alkyl-sulfonylaminocarbonyl;
N--(C.sub.1-6alkyl-sulfonyl)-N--C.sub.1-6alkyl-aminocarbonyl;
N--(C.sub.1-6alkyl-sulfonyl)-amino-C.sub.1-6alkyl; amino;
N--C.sub.1-6alkyl-amino; N,N-di-C.sub.1-6alkyl-amino;
halo-C.sub.1-6alkyl; phenyl; heterocyclyl; heteroaryl;
C.sub.1-6alkyl-carbonylamino; carbonylamino; or hydroxyl; wherein
the C.sub.1-6alkyl moieties may be unsubstituted or substituted one
or more times with halo; and wherein the phenyl, heterocyclyl,
heteroaryl, C.sub.3-6cycloalkyl, C.sub.1-6cycloalkenyl and
C.sub.3-6cycloalkyl-C.sub.1-6alkyl moieties may be unsubstituted or
substituted one or more times with R.sup.i; [0038] or R.sup.f and
R.sup.g together with the atoms to which they are attached may form
a four, five, six or seven membered saturated or partially
saturated ring that may optionally include one or two heteroatoms
selected from --O--, --NR.sup.a-- or --S--, and which may be
optionally substituted one or more times with R.sup.i;
[0039] R.sup.h is: hydrogen; C.sub.1-6alkyl; C.sub.3-6cycloalkyl;
C.sub.3-6cycloalkenyl; C.sub.3-6cycloalkyl-C.sub.1-6alkyl;
C.sub.1-6alkyl-carbonyl; C.sub.3-6cycloalkyl-carbonyl;
C.sub.3-6cycloalkyl-C.sub.1-6alkyl-carbonyl;
cyano-C.sub.1-6alkyl-carbonyl; hydroxy-C.sub.1-6alkyl-carbonyl;
C.sub.1-6alkoxy-C.sub.1-6alkyl-carbonyl; N-cyano-aminocarbonyl;
N-cyano-N--C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkyl-acetimidamidyl;
N,N'-di-C.sub.1-6alkyl-acetimidamidyl;
N'-cyano-N--C.sub.1-6alkyl-acetimidamidyl;
N'-hydroxy-acetimidamidyl; N'--C.sub.1-6alkoxy-acetimidamidyl;
N'-hydroxy-N--C.sub.1-6alkyl-acetimidamidyl;
N'--C.sub.1-6alkoxy-N--C.sub.1-6alkyl-acetimidamidyl;
2-nitro-1-N--C.sub.1-6alkylamino-vinyl; formyl;
C.sub.1-6alkyl-sulfonyl; C.sub.3-6cycloalkyl-sulfonyl;
C.sub.3-6cycloalkyl-C.sub.1-6alkyl-sulfonyl;
C.sub.1-6alkyl-sulfonyl-C.sub.1-6alkyl; aminocarbonyl;
N-hydroxy-aminocarbonyl; N--C.sub.1-6alkoxy-aminocarbonyl;
N--C.sub.1-6alkyl-aminocarbonyl;
N-hydroxy-N--C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkoxy-N--C.sub.1-6alkyl-aminocarbonyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl; aminosulfonyl;
N--C.sub.1-6alkyl-aminosulfonyl;
N,N-di-C.sub.1-6alkyl-aminosulfonyl; cyano; C.sub.1-6
alkyl-sulfonylamino; C.sub.1-6alkyl-sulfonylamino-C.sub.1-6alkyl;
N--(C.sub.1-6alkyl-sulfonyl)aminocarbonyl;
N--(C.sub.1-6alkyl-sulfonyl)-N--C.sub.1-6alkyl-aminocarbonyl;
N--(C.sub.1-6alkyl-sulfonyl)-amino-C.sub.1-6alkyl;
aminocarbonyl-C.sub.1-6alkyl;
N--C.sub.1-6alkyl-aminocarbonyl-C.sub.1-6alkyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl-C.sub.1-6alkyl;
C.sub.1-6alkoxy-carbonyl; halo-C.sub.1-6alkyl; phenyl;
heterocyclyl; or heteroaryl; wherein the C.sub.1-6alkyl moieties
may be unsubstituted or substituted one or more times with halo;
and wherein the phenyl, heterocyclyl, heteroaryl,
C.sub.3-6cycloalkyl, C.sub.3-6cycloalkenyl and
C.sub.3-6cycloalkyl-C.sub.1-6alkyl moieties may be unsubstituted or
substituted one or more times with R.sup.i; [0040] or R.sup.h and
one of R.sup.10 and R.sup.11 together with the atoms to which they
are attached may form a four, five, six or seven membered aromatic,
partially saturated or unsaturated ring that may optionally include
one or two additional heteroatom selected from --O--, --NR.sup.a--
or --S--, and which may be optionally substituted one or more times
with R.sup.i--; [0041] or one of R.sup.f and R.sup.g and one of
R.sup.10 and R.sup.11 together with the atoms to which they are
attached may form a three, four, five, six or seven membered
aromatic, partially saturated or unsaturated ring that may
optionally include an additional heteroatom selected from --O--,
--NR.sup.a-- or --S--, and which may be optionally substituted one
or more times with R.sup.i;
[0042] R.sup.i is: C.sub.1-6alkyl; halo; oxo; hydroxy; acetyl;
C.sub.1-6alkyl-carbonyl; amino-carbonyl; hydroxy-C.sub.1-6alkyl;
cyano; heteroaryl; cyano-C.sub.1-6alkyl;
C.sub.1-6alkoxy-C.sub.1-6alkyl; carboxy; or C.sub.1-6alkoxy;
wherein the C.sub.1-6alkyl moieties may be unsubstituted or
substituted one or more times with halo; and [0043] R.sup.j and
R.sup.k each independent is: hydrogen; or C.sub.1-6alkyl which may
be unsubstituted or substituted one or more times with halo; [0044]
wherein the compound is selected from: [0045]
{1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylme-
thyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidin-4-yl}-methanol;
[0046]
{1-[3-Fluoro-4-((3S,6S)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylme-
thyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidin-4-yl}-methanol;
[0047]
(3S,6R)-2-[2-Fluoro-4-(tetrahydro-pyran-4-ylmethoxy)-benzyl]-3-methyl-6-p-
henyl-[1,2]thiazinane 1,1-dioxide; [0048]
(3S,6S)-2-[2-Fluoro-4-(4-[1,2,4]triazol-4-yl-piperidin-1-yl)-benzyl]-3,6--
dimethyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0049]
(3S,6S)-2-{2-Fluoro-4-[4-(3-methyl-[1,2,4]triazol-4-yl)-piperidin-1-yl]-b-
enzyl}-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0050]
(3S,6R)-2-[2-Fluoro-4-((2S,4R)-2-methyl-4-[1,2,4]triazol-4-yl-piperidin-1-
-yl)-benzyl]-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0051]
1-{(R)-4-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan--
2-ylmethyl)-phenyl]-3-hydroxymethyl-piperazin-1-yl}-ethanone;
[0052]
(3S,6R)-2-{2-Fluoro-4-[4-(3-methyl-[1,2,4]triazol-4-yl)-piperidin-1-yl]-b-
enzyl}-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0053]
(3S,6R)-2-[2-Fluoro-4-((2S,4S)-2-methyl-4-[1,2,4]triazol-4-yl-piperidin-1-
-yl)-benzyl]-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0054]
(4-{1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-y-
lmethyl)-phenyl]-piperidin-4-yl}-4H-[1,2,4]triazol-3-yl)-acetonitrile;
[0055]
(3R,4R)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]th-
iazinan-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidine-3-carboxylic
acid methyl ester; [0056]
(3S,6R)-2-[2,5-Difluoro-4-(4-[1,2,4]triazol-4-yl-piperidin-1-yl)-benzyl]--
3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0057]
(3S,6R)-2-{2-Fluoro-4-[4-(3-methoxymethyl-[1,2,4]triazol-4-yl)-piperidin--
1-yl]-benzyl}-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0058]
(3S,4R)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-
-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidine-3-carboxylic
acid methyl ester; [0059]
(3S,6R)-2-[2-Fluoro-4-((3S,4R)-3-methyl-4-[1,2,4]triazol-4-yl-piperidin-1-
-yl)-benzyl]-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0060]
(3S,6R)-2-[2-Fluoro-4-((3R,4S)-3-methyl-4-[1,2,4]triazol-4-yl-piperidin-1-
-yl)-benzyl]-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0061]
(1S,5R,6S)-3-[2,3-Difluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]th-
iazinan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.1.0]hexa-
ne; [0062]
(1S,5R,6S)-3-[2,3-Difluoro-4-((3S,6S)-3-methyl-1,1-dioxo-6-phen-
yl-[1,2]thiazinan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[-
3.1.0]hexane; [0063]
(3S,6R)-2-[2,3-Difluoro-4-(4-[1,2,4]triazol-4-yl-piperidin-1-yl)-benzyl]--
3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0064]
(1R,5S,6S)-3-[2,5-Difluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]th-
iazinan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.1.0]hexa-
ne; [0065]
(1S,5R,6S)-3-[2,5-Difluoro-4-((3S,6S)-3-methyl-1,1-dioxo-6-phen-
yl-[1,2]thiazinan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[-
3.1.0]hexane; [0066]
(1R,5S,6S)-3-[2,6-Difluoro-4-((3S,6S)-3-methyl-1,1-dioxo-6-phenyl-[1,2]th-
iazinan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.1.0]hexa-
ne; [0067]
(1R,5S,6S)-3-[2,6-Difluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phen-
yl-[1,2]thiazinan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[-
3.1.0]hexane; [0068]
(3S,6R)-2-[2-Fluoro-4-((3R,4R)-3-methyl-4-[1,2,4]triazol-4-yl-piperidin-1-
-yl)-benzyl]-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0069]
(3S,6R)-2-[2-Fluoro-4-((3S,4S)-3-methyl-4-[1,2,4]triazol-4-yl-piperidin-1-
-yl)-benzyl]-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0070]
3-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmet-
hyl)-phenyl]-5-[1,2,4]triazol-4-yl-3-aza-bicyclo[4.1.0]heptane;
[0071]
3-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmet-
hyl)-phenyl]-5-[1,2,4]triazol-4-yl-3-aza-bicyclo[4.1.0]heptane;
[0072]
3-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmet-
hyl)-phenyl]-5-[1,2,4]triazol-4-yl-3-aza-bicyclo[4.1.0]heptane;
[0073]
3-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmet-
hyl)-phenyl]-5-[1,2,4]triazol-4-yl-3-aza-bicyclo[4.1.0]heptane;
[0074]
(3S,6R)-2-[3-Fluoro-4-(4-[1,2,4]triazol-4-yl-piperidin-1-yl)-benzyl]-3-me-
thyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0075] Carbamic acid
1-acetyl-4-[3-fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazina-
n-2-ylmethyl)-phenyl]-piperidin-4-yl ester, [0076]
(3S,6S)-2-[3-Fluoro-4-(4-[1,2,4]triazol-4-yl-piperidin-1-yl)-benzyl]-3-me-
thyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0077]
(1R,3S,5S)-8-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazi-
nan-2-ylmethyl)-phenyl]-3-[1,2,4]triazol-4-yl-8-aza-bicyclo[3.2.1]octane;
[0078]
(1R,5S,8R)-3-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2-
]thiazinan-2-ylmethyl)-phenyl]-8-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.2.1]o-
ctane; [0079]
(1R,5S,8R)-3-[3-Fluoro-4-((3S,6S)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazi-
nan-2-ylmethyl)-phenyl]-8-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.2.1]octane;
[0080]
(2S,4R)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]th-
iazinan-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidine-2-carboxylic
acid methyl ester; [0081]
(3S,6R)-2-(2-fluoro-4-((1-(S-methylsulfonimidoyl)piperidin-4-yl)oxy)benzy-
l)-3-methyl-6-phenyl-1,2-thiazinane 1,1-dioxide; [0082]
(3S,6R)-2-(2-fluoro-4-((1-(S-methylsulfonimidoyl)piperidin-4-yl)oxy)benzy-
l)-3-methyl-6-phenyl-1,2-thiazinane 1,1-dioxide; [0083]
(1S,5R,6S)-3-[2-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazi-
nan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.1.0]hexane;
[0084]
(1S,5R,6S)-3-[2-Fluoro-4-((3S,6S)-3-methyl-1,1-dioxo-6-phenyl-[1,2-
]thiazinan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.1.0]h-
exane; [0085]
{(3R,4R)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazina-
n-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidin-3-yl}-methanol;
[0086]
4-[4-((S)-3-Methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmethyl)-p-
henyl]-2-aza-bicyclo[2.2.2]octan-3-one; [0087]
(1S,5R,6S)-3-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazi-
nan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.1.1]heptane;
[0088]
{(3S,4R)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]t-
hiazinan-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidin-3-yl}-methano-
l; [0089]
(2R,4R)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]-
thiazinan-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidine-2-carboxyli-
c acid methyl ester; [0090]
(4-{1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-y-
lmethyl)-phenyl]-piperidin-4-yl}-4H-[1,2,4]triazol-3-yl)-methanol;
[0091]
(4-{1-[3-Fluoro-4-((3S,6S)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-y-
lmethyl)-phenyl]-piperidin-4-yl}-4H-[1,2,4]triazol-3-yl)-methanol;
[0092]
(2S,4S)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-
-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidine-2-carboxylic
acid methyl ester; [0093]
4-{4-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-yl-
methyl)-phenyl]-piperazin-1-yl}-benzoic acid; [0094]
(3S,6R)-2-[2-Fluoro-4-(1-oxy-4-[1,2,4]triazol-4-yl-piperidin-1-yl)-benzyl-
]-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0095]
8-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmet-
hyl)-phenyl]-1,4-dioxa-8-aza-spiro[4.5]decane; [0096]
1-{4-[2-Hydroxymethyl-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazin-
an-2-ylmethyl)-phenyl]-piperazin-1-yl}-ethanone; [0097]
{(3S,4R)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazina-
n-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidin-3-yl}-methanol;
[0098]
{(3R,4S)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]t-
hiazinan-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidin-3-yl}-methano-
l; [0099]
{(3S,4S)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2-
]thiazinan-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidin-3-yl}-metha-
nol; [0100]
(3S,6R)-2-[4-(3,6-Dihydro-2H-pyran-4-yl)-2-fluoro-benzyl]-3-methyl-6-phen-
yl-[1,2]thiazinane 1,1-dioxide; [0101]
(3S,6R)-2-[2-Fluoro-4-(tetrahydro-pyran-4-yl)-benzyl]-3-methyl-6-phenyl-[-
1,2]thiazinane 1,1-dioxide; [0102]
{(3S,4S)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazina-
n-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidin-3-yl}-methanol;
[0103]
(3S,6R)-2-[2-Fluoro-4-((R)-3-[1,2,4]triazol-4-yl-piperidin-1-yl)-b-
enzyl]-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide [0104]
8-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmet-
hyl)-phenyl]-1-oxa-8-aza-spiro[4.5]decane; [0105]
9-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmet-
hyl)-phenyl]-1,5-dioxa-9-aza-spiro[5.5]undecane; [0106]
7-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmet-
hyl)-phenyl]-1-oxa-7-aza-spiro[3,5]nonane; [0107]
(S)-8-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-y-
lmethyl)-phenyl]-1,4-dioxa-8-aza-spiro[4.5]decane-7-carboxylic acid
methyl ester, [0108]
4-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmet-
hyl)-phenyl]-morpholine; [0109]
(R)-8-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-y-
lmethyl)-phenyl]-1,4-dioxa-8-aza-spiro[4.5]decane-7-carboxylic acid
methyl ester, [0110]
(3S,6R)-2-[2-Fluoro-4-((S)-3-[1,2,4]triazol-4-yl-piperidin-1-yl)-benzyl]--
3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0111]
(3R,6R)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2-fluorobenzyl)-3--
(difluoromethyl)-6-phenyl-1,2-thiazinane 1,1-dioxide [0112]
(3R,6S)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2-fluorobenzyl)-3--
(difluoromethyl)-6-phenyl-1,2-thiazinane 1,1-dioxide; [0113]
(3R,6S)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2,5-difluorobenzyl-
)-3-(difluoromethyl)-6-phenyl-1,2-thiazinane 1,1-dioxide; [0114]
(3R,6R)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2,5-difluorobenzyl-
)-3-(difluoromethyl)-6-phenyl-1,2-thiazinane 1,1-dioxide; [0115]
(3R,6S)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2,5-difluorobenzyl-
)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane 1,1-dioxide; [0116]
(3R,6R)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2,5-difluorobenzyl-
)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane 1,1-dioxide; [0117]
(3R,6R)-2-(4-((1R,5S,6S)-6-(4H-1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]hex-
an-3-yl)-2,5-difluorobenzyl)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane
1,1-dioxide; [0118]
(3R,6S)-2-(4-((1R,5S,6S)-6-(4H-1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]hex-
an-3-yl)-2,5-difluorobenzyl)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane
1,1-dioxide; [0119]
(3R,6R)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2-fluorobenzyl)-6--
phenyl-3-(trifluoromethyl)-1,2-thiazinane 1,1-dioxide; [0120]
(3R,6S)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2-fluorobenzyl)-6--
phenyl-3-(trifluoromethyl)-1,2-thiazinane 1,1-dioxide; [0121]
(3R,6R)-2-(4-((1R,5S,6S)-6-(4H-1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]hex-
an-3-yl)-2-fluorobenzyl)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane
1,1-dioxide; [0122]
(3R,6S)-2-(4-((1R,5S,6S)-6-(4H-1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]hex-
an-3-yl)-2-fluorobenzyl)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane
1,1-dioxide; [0123] (4R)-methyl
1-(2,5-difluoro-4-((3-methyl-1,1-dioxido-6-phenyl-1,2-thiazinan-2-yl)meth-
yl)phenyl)-4-(4H-1,2,4-triazol-4-yl)piperidine-3-carboxylate;
[0124]
2-(2-fluoro-4-((4R)-3-methoxy-4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)ben-
zyl)-3-methyl-6-phenyl-1,2-thiazinane 1,1-dioxide; [0125]
2-(4-((5R)-5-(4H-1,2,4-triazol-4-yl)-2-azabicyclo[2.2.1]heptan-2-yl)-2,5--
difluorobenzyl)-3-methyl-6-phenyl-1,2-thiazinane 1,1-dioxide [0126]
2-(4-((5R)-5-(4H-1,2,4-triazol-4-yl)-2-azabicyclo[2.2.1]heptan-2-yl)-2,5--
difluorobenzyl)-3-methyl-6-phenyl-1,2-thiazinane 1,1-dioxide;
[0127]
2-(2-fluoro-4-((4R)-3-fluoro-4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)benz-
yl)-3-methyl-6-phenyl-1,2-thiazinane 1,1-dioxide; and [0128]
8-(3-fluoro-4-(((3S,6R)-3-methyl-1,1-dioxido-6-phenyl-1,2-thiazinan-2-yl)-
methyl)phenyl)-3-methyl-1-oxa-8-azaspiro[4.5]decan-2-one.
[0129] The invention also provides and pharmaceutical compositions
comprising the compounds, methods of using the compounds, and
methods of preparing the compounds.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
[0130] Unless otherwise stated, the following terms used in this
Application, including the specification and claims, have the
definitions given below. It must be noted that, as used in the
specification and the appended claims, the singular forms "a",
"an," and "the" include plural referents unless the context clearly
dictates otherwise.
[0131] "Alkyl" means the monovalent linear or branched saturated
hydrocarbon moiety, consisting solely of carbon and hydrogen atoms,
having from one to twelve carbon atoms. "Lower alkyl" refers to an
alkyl group of one to six carbon atoms, i.e. C.sub.1-C.sub.6alkyl.
Examples of alkyl groups include, but are not limited to, methyl,
ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, pentyl,
n-hexyl, octyl, dodecyl, and the like.
[0132] "Alkenyl" means a linear monovalent hydrocarbon radical of
two to six carbon atoms or a branched monovalent hydrocarbon
radical of three to six carbon atoms, containing at least one
double bond, e.g., ethenyl, propenyl, and the like.
[0133] "Alkynyl" means a linear monovalent hydrocarbon radical of
two to six carbon atoms or a branched monovalent hydrocarbon
radical of three to six carbon atoms, containing at least one
triple bond, e.g., ethynyl, propynyl, and the like.
[0134] "Alkylene" means a linear saturated divalent hydrocarbon
radical of one to six carbon atoms or a branched saturated divalent
hydrocarbon radical of three to six carbon atoms, e.g., methylene,
ethylene, 2,2-dimethylethylene, propylene, 2-methylpropylene,
butylene, pentylene, and the like.
[0135] "Alkoxy" and "alkyloxy", which may be used interchangeably,
mean a moiety of the formula --OR, wherein R is an alkyl moiety as
defined herein. Examples of alkoxy moieties include, but are not
limited to, methoxy, ethoxy, isopropoxy, and the like.
[0136] "Alkoxyalkyl" means a moiety of the formula
R.sup.a--O--R.sup.b--, where R.sup.a is alkyl and R.sup.b is
alkylene as defined herein. Exemplary alkoxyalkyl groups include,
by way of example, 2-methoxyethyl, 3-methoxypropyl,
1-methyl-2-methoxyethyl, 1-(2-methoxyethyl)-3-methoxypropyl, and
1-(2-methoxyethyl)-3-methoxypropyl.
[0137] "Alkoxyalkoxy" means a group of the formula --O--R--R'
wherein R is alkylene and R' is alkoxy as defined herein.
[0138] "Alkylcarbonyl" means a moiety of the formula --C(O)--R,
wherein R is alkyl as defined herein.
[0139] "Alkoxycarbonyl" means a group of the formula --C(O)--R
wherein R is alkoxy as defined herein.
[0140] "Alkylcarbonylalkyl" means a group of the formula
--R--C(O)--R wherein R is alkylene and R' is alkyl as defined
herein.
[0141] "Alkoxyalkylcarbonyl" means a moiety of the formula
--C(O)--R--R', wherein R is alkylene and R' is alkoxy as defined
herein.
[0142] "Alkoxycarbonylalkyl" means a group of the formula
--R--C(O)--R wherein R is alkylene and R' is alkoxy as defined
herein.
[0143] "Alkoxycarbonylalkoxy" means a group of the formula
--O--R--C(O)--R' wherein R is alkylene and R' is alkoxy as defined
herein.
[0144] "Hydroxycarbonylalkoxy" means a group of the formula
--O--R--C(O)--OH wherein R is alkylene as defined herein.
[0145] "Alkylaminocarbonylalkoxy" means a group of the formula
--O--R--C(O)--NHR' wherein R is alkylene and R' is alkyl as defined
herein.
[0146] "Dialkylaminocarbonylalkoxy" means a group of the formula
--O--R--C(O)--NR'R'' wherein R is alkylene and R' and R'' are alkyl
as defined herein.
[0147] "Alkylaminoalkoxy" means a group of the formula --O--R--NHR'
wherein R is alkylene and R' is alkyl as defined herein.
[0148] "Dialkylaminoalkoxy" means a group of the formula
--O--R--NR'R' wherein R is alkylene and R' and R'' are alkyl as
defined herein.
[0149] "Alkylsulfonyl" means a moiety of the formula --SO.sub.2--R,
wherein R is alkyl as defined herein.
[0150] "Alkylsulfonylalkyl means a moiety of the formula
--R'--SO.sub.2--R'' where where R' is alkylene and R'' is alkyl as
defined herein.
[0151] "Alkylsulfonylalkoxy" means a group of the formula
--O--R--SO.sub.2--R' wherein R is alkylene and R' is alkyl as
defined herein.
[0152] "Amino means a moiety of the formula --NRR' wherein R and R'
each independently is hydrogen or alkyl as defined herein. "Amino
thus includes "alkylamino (where one of R and R' is alkyl and the
other is hydrogen) and "dialkylamino (where R and R' are both
alkyl.
[0153] "Aminocarbonyl" means a group of the formula --C(O)--R
wherein R is amino as defined herein.
[0154] "N-hydroxy-aminocarbonyl" means a group of the formula
--C(O)--NR--OH wherein R is hydrogen or alkyl as defined
herein.
[0155] "N-alkoxy-aminocarbonyl" means a group of the formula
--C(O)--NR--R' wherein R is hydrogen or alkyl and R' is alkoxy as
defined herein.
[0156] "N-alkyl-aminocarbonyl means a group of the formula
--C(O)--NH--R wherein R is alkyl as defined herein.
[0157] "N-hydroxy-N-alkylaminocarbonyl means a group of the formula
--C(O)--NRR' wherein R is alkyl as defined herein and R' is
hydroxy.
[0158] "N-alkoxy-N-alkylaminocarbonyl" means a group of the formula
--C(O)--NRR' wherein R is alkyl and R' is alkoxy as defined
herein.
[0159] "N,N-di-C.sub.1-6alkyl-aminocarbonyl" means a group of the
formula --C(O)--NRR' wherein R and R' are alkyl as defined
herein.
[0160] "Aminosulfonyl" means a group of the formula
--SO.sub.2--NH.sub.2.
[0161] "N-alkylaminosulfonyl" means a group of the formula
--SO.sub.2--NHR wherein R is alkyl as defined herein.
[0162] "N,N-dialkylaminosulfonyl" means a group of the formula
--SO.sub.2--NRR' wherein R and R' are alkyl as defined herein.
[0163] "Alkylsulfonylamino" means a group of the formula
--NR'--SO.sub.2--R wherein R id alkyl and R' is hydrogen or alkyl
as defined herein.
[0164] "N-(alkylsulfonyl)-aminoalkyl" means a group of the formula
--R--NH--SO.sub.2--R' wherein R is alkylene and R' is alkyl as
defined herein.
[0165] "N-(Alkylsulfonyl)aminocarbonyl" means a group of the
formula --C(O)--NH--SO.sub.2--R wherein wherein R is alkyl as
defined herein.
[0166] "N-(Alkylsulfonyl)-N-alkylaminocarbonyl" means a group of
the formula --C(O)--NR--SO.sub.2--R' wherein wherein R and R' are
alkyl as defined herein.
[0167] "N-Alkoxyalkyl-aminocarbonyl" means a group of the formula
--C(O)--NR--R'--OR'' wherein R is hydrogen or alkyl, R' is
alkylene, and R.sup.11 is alkyl as defined herein.
[0168] "N-Hydroxyalkyl-aminocarbonyl" means a group of the formula
--C(O)--NR--R'--OH'' wherein R is hydrogen or alkyl and R' is
alkylene as defined herein.
[0169] "Alkoxyamino" means a moiety of the formula --NR--OR'
wherein R is hydrogen or alkyl and R' is alkyl as defined
herein.
[0170] "Alkylsulfanyl" means a moiety of the formula --SR wherein R
is alkyl as defined herein.
[0171] "Aminoalkyl" means a group --R--R' wherein R' is amino and R
is alkylene as defined herein. "Aminoalkyl" includes aminomethyl,
aminoethyl, 1-aminopropyl, 2-aminopropyl, and the like. The amino
moiety of "aminoalkyl" may be substituted once or twice with alkyl
to provide "alkylaminoalkyl" and "dialkylaminoalkyl" respectively.
"Alkylaminoalkyl" includes methylaminomethyl, methylaminoethyl,
methylaminopropyl, ethylaminoethyl and the like.
"Dialkylaminoalkyl" includes dimethylaminomethyl,
dimethylaminoethyl, dimethylaminopropyl,
N-methyl-N-ethylaminoethyl, and the like.
[0172] "Aminoalkoxy" means a group --OR--R' wherein R' is amino and
R is alkylene as defined herein.
[0173] "Alkylsulfonylamido" means a moiety of the formula
--NR'SO.sub.2--R wherein R is alkyl and R' is hydrogen or
alkyl.
[0174] "Aminocarbonyloxyalkyl" or "carbamylalkyl" means a group of
the formula --R--O--C(O)--NR'R'' wherein R is alkylene and R', R''
each independently is hydrogen or alkyl as defined herein.
[0175] "Alkynylalkoxy" means a group of the formula --O--R--R'
wherein R is alkylene and R' is alkynyl as defined herein.
[0176] "N-Alkylacetimidamidyl" means a group of the formula
##STR00003##
wherein R is alkyl as defined herein.
[0177] "N,N'-Dialkylacetimidamidyl" means a group of the
formula
##STR00004##
wherein R and R' are both alkyl as defined herein.
[0178] "N'-Alkoxyacetimidamidyl" means a group of the formula
##STR00005##
wherein R is alkoxy as defined herein.
[0179] "N'-Alkoxy-N-alkyl-acetimidamidyl" means a group of the
formula
##STR00006##
wherein R is alkyl and R' is alkoxy as defined herein.
[0180] "Aryl" means a monovalent cyclic aromatic hydrocarbon moiety
consisting of a mono-, bi- or tricyclic aromatic ring. The aryl
group can be optionally substituted as defined herein. Examples of
aryl moieties include, but are not limited to, phenyl, naphthyl,
phenanthryl, fluorenyl, indenyl, pentalenyl, azulenyl, oxydiphenyl,
biphenyl, methylenediphenyl, aminodiphenyl, diphenylsulfidyl,
diphenylsulfonyl, diphenylisopropylidenyl, benzodioxanyl,
benzofuranyl, benzodioxylyl, benzopyranyl, benzoxazinyl,
benzoxazinonyl, benzopiperadinyl, benzopiperazinyl,
benzopyrrolidinyl, benzomorpholinyl, methylenedioxyphenyl,
ethylenedioxyphenyl, and the like, of which may be optionally
substituted as defined herein.
[0181] "Arylalkyl" and "Aralkyl", which may be used
interchangeably, mean a radical-R.sup.aR.sup.b where R.sup.a is an
alkylene group and R.sup.b is an aryl group as defined herein;
e.g., phenylalkyls such as benzyl, phenylethyl,
3-(3-chlorophenyl)-2-methylpentyl, and the like are examples of
arylalkyl.
[0182] "Arylsulfonyl means a group of the formula --SO.sub.2--R
wherein R is aryl as defined herein.
[0183] "Aryloxy" means a group of the formula --O--R wherein R is
aryl as defined herein.
[0184] "Aralkyloxy" means a group of the formula --O--R--R" wherein
R is alkylene and R' is aryl as defined herein.
[0185] "Carboxy" or "hydroxycarbonyl", which may be used
interchangeably, means a group of the formula --C(O)--OH.
[0186] "Cyanoalkyl" means a moiety of the formula --R'--R'', where
R' is alkylene as defined herein and R'' is cyano or nitrile.
[0187] "Cycloalkyl" means a monovalent saturated carbocyclic moiety
consisting of mono- or bicyclic rings. Particular cycloalkyl are
unsubstituted or substituted with alkyl. Cycloalkyl can optionally
be substituted as defined herein. Unless defined otherwise,
cycloalkyl may be optionally substituted with one or more
substituents, wherein each substituent is independently hydroxy,
alkyl, alkoxy, halo, haloalkyl, amino, monoalkylamino, or
dialkylamino. Examples of cycloalkyl moieties include, but are not
limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cycloheptyl, and the like, including partially unsaturated
(cycloalkenyl) derivatives thereof.
[0188] "Cycloalkenyl" means a cycloalkyl as defined herein that
includes at least one double bond or unsaturation. Exemplary
cycloalkenyl include cyclohexenyl, cyclopentenyl, cyclobutenyl and
the like.
[0189] "Cycloalkylalkyl" means a moiety of the formula --R'--R'',
where R' is alkylene and R'' is cycloalkyl as defined herein.
[0190] "Cycloalkylalkoxy" means a group of the formula --O--R--R'
wherein R is alkylene and R' is cycloalkyl as defined herein.
[0191] "Cycloalkylcarbonyl" means a moiety of the formula
--C(O)--R, wherein R is cycloalkyl as defined herein.
[0192] "C.sub.3-6cycloalkyl-C.sub.1-4alkyl-carbonyl" means a moiety
of the formula --C(O)--R, wherein R is cycloalkylalkyl as defined
herein.
[0193] "Cyanoalkylcarbonyl" means a moiety of the formula
--C(O)--R--R', wherein R is alkylene as defined herein and R' is
cyano or nitrile.
[0194] "N--Cyano-aminocarbonyl" means a moiety of the formula
--C(O)--NHR, wherein R is cyano or nitrile.
[0195] "N--Cyano-N-alkyl-aminocarbonyl" means a moiety of the
formula --C(O)--NRR'--R, wherein R' is alkyl as defined herein and
R is cyano or nitrile.
[0196] "Cycloalkylsulfonyl" means a group of the formula
--SO.sub.2--R wherein R is cycloalkyl as defined herein.
[0197] "Cycloalkylalkylsulfonyl" means a group of the formula
--SO.sub.2--R wherein R is cycloalkylalkyl as defined herein.
[0198] "N'--Cyanoacetimidamidyl" means a group of the formula
##STR00007##
wherein R is cyano or nitrile. "N'--Cyano-N-alkylacetimidamidyl"
means a group of the formula
##STR00008##
wherein R is alkyl as defined herein and R' is cyano or
nitrile.
[0199] "Formyl" means a moiety of the formula --C(O)--H.
[0200] "Heteroaryl" means a monocyclic or bicyclic radical of 5 to
12 ring atoms having at least one aromatic ring containing one,
two, or three ring heteroatoms selected from N, O, or S, the
remaining ring atoms being C, with the understanding that the
attachment point of the heteroaryl radical will be on an aromatic
ring. The heteroaryl ring may be optionally substituted as defined
herein. Examples of heteroaryl moieties include, but are not
limited to, optionally substituted imidazolyl, oxazolyl,
isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl,
pyrazinyl, thienyl, benzothienyl, thiophenyl, furanyl, pyranyl,
pyridyl, pyrrolyl, pyrazolyl, pyrimidyl, quinolinyl, isoquinolinyl,
benzofuryl, benzothiophenyl, benzothiopyranyl, benzimidazolyl,
benzooxazolyl, benzooxadiazolyl, benzothiazolyl, benzothiadiazolyl,
benzopyranyl, indolyl, isoindolyl, triazolyl, triazinyl,
quinoxalinyl, purinyl, quinazolinyl, quinolizinyl, naphthyridinyl,
pteridinyl, carbazolyl, azepinyl, diazepinyl, acridinyl and the
like, each of which may be optionally substituted as defined
herein.
[0201] Heteroarylalkyl" or "heteroaralkyl" means a group of the
formula --R--R' wherein R is alkylene and R' is heteroaryl as
defined herein.
[0202] "Heteroarylsulfonyl means a group of the formula
--SO.sub.2--R wherein R is heteroaryl as defined herein.
[0203] "Heteroaryloxy" means a group of the formula --O--R wherein
R is heteroaryl as defined herein.
[0204] "Heteroaralkyloxy" means a group of the formula --O--R--R''
wherein R is alkylene and R' is heteroaryl as defined herein.
[0205] The terms "halo", "halogen" and "halide", which may be used
interchangeably, refer to a substituent fluoro, chloro, bromo, or
iodo.
[0206] "Haloalkyl" means alkyl as defined herein in which one or
more hydrogen has been replaced with same or different halogen.
Exemplary haloalkyls include --CH.sub.2Cl, --CH.sub.2CF.sub.3,
--CH.sub.2CCl.sub.3, perfluoroalkyl (e.g., --CF.sub.3), and the
like.
[0207] "Haloalkoxy" means a moiety of the formula --OR, wherein R
is a haloalkyl moiety as defined herein. An exemplary haloalkoxy is
difluoromethoxy.
[0208] "Heterocycloamino" means a saturated ring wherein at least
one ring atom is N, NH or N-alkyl and the remaining ring atoms form
an alkylene group.
[0209] "Heterocyclyl" means a monovalent saturated moiety,
consisting of one to three rings, incorporating one, two, or three
or four heteroatoms (chosen from nitrogen, oxygen or sulfur). The
heterocyclyl ring may be optionally substituted as defined herein.
Examples of heterocyclyl moieties include, but are not limited to,
optionally substituted piperidinyl, piperazinyl, morpholinyl,
thiomorpholinyl, azepinyl, pyrrolidinyl, azetidinyl,
tetrahydropyranyl, tetrahydrofuranyl, oxetanyl and the like. Such
heterocyclyl may be optionally substituted as defined herein.
[0210] "Heterocyclylalkyl" means a moiety of the formula --R--R'
wherein R is alkylene and R' is heterocyclyl as defined herein.
[0211] "Heterocyclyloxy" means a moiety of the formula --OR wherein
R is heterocyclyl as defined herein.
[0212] "Heterocyclylalkoxy" means a moiety of the formula --OR--R'
wherein R is alkylene and R' is heterocyclyl as defined herein.
[0213] "Hydroxyalkoxy" means a moiety of the formula --OR wherein R
is hydroxyalkyl as defined herein.
[0214] "Hydroxyalkylamino" means a moiety of the formula --NR--R'
wherein R is hydrogen or alkyl and R' is hydroxyalkyl as defined
herein.
[0215] "Hydroxyalkylaminoalkyl" means a moiety of the formula
--R--NR'--R'' wherein R is alkylene, R' is hydrogen or alkyl, and
R'' is hydroxyalkyl as defined herein.
[0216] "Hydroxycarbonylalkyl" or "carboxyalkyl" means a group of
the formula --R--(CO)--OH where R is alkylene as defined
herein.
[0217] "Hydroxycarbonylalkoxy" means a group of the formula
--O--R--C(O)--OH wherein R is alkylene as defined herein.
[0218] "Hydroxyalkylcarbonyl" means a moiety of the formula
--C(O)--R--R', wherein R is alkylene as defined herein and R' is
hydroxy.
[0219] "N'hydroxyacetimidamidyl" means a group of the formula
##STR00009##
[0220] "N'-hydroxy-N-alkyl-acetimidamidyl" means a group of the
formula
##STR00010##
wherein R is alkyl as defined herein.
[0221] "Hydroxyalkyloxycarbonylalkyl" or
"hydroxyalkoxycarbonylalkyl" means a group of the formula
--R--C(O)--O--R--OH wherein each R is alkylene and may be the same
or different.
[0222] "Hydroxyalkyl" means an alkyl moiety as defined herein,
substituted with one or more, for example, one, two or three
hydroxy groups, provided that the same carbon atom does not carry
more than one hydroxy group. Representative examples include, but
are not limited to, hydroxymethyl, 2-hydroxyethyl, 2-hydroxypropyl,
3-hydroxypropyl, 1-(hydroxymethyl)-2-methylpropyl, 2-hydroxybutyl,
3-hydroxybutyl, 4-hydroxybutyl, 2,3-dihydroxypropyl,
2-hydroxy-1-hydroxymethylethyl, 2,3-dihydroxybutyl,
3,4-dihydroxybutyl and 2-(hydroxymethyl)-3-hydroxypropyl
[0223] "Hydroxycycloalkyl" means a cycloalkyl moiety as defined
herein wherein one, two or three hydrogen atoms in the cycloalkyl
radical have been replaced with a hydroxy substituent.
Representative examples include, but are not limited to, 2-, 3-, or
4-hydroxycyclohexyl, and the like.
[0224] "2-Nitro-1-N-alkylamino-vinyl" means a group of the
formula
##STR00011##
wherein R is alkyl as defined herein.
[0225] "Oxo" means a group of the formula .dbd.O (i.e., an oxygen
with a double bond). Thus, for example, a 1-oxo-ethyl group is an
acetyl group.
[0226] "Alkoxy hydroxyalkyl" and "hydroxy alkoxyalkyl", which may
be used interchangeably, means an alkyl as defined herein that is
substituted at least once with hydroxy and at least once with
alkoxy. "Alkoxy hydroxyalkyl" and "hydroxy alkoxyalkyl" thus
encompass, for example, 2-hydroxy-3-methoxy-propan-1-yl and the
like.
[0227] "Urea" or "ureido" means a group of the formula
--NR'--C(O)--NR''R''' wherein R', R'' and R''' each independently
is hydrogen or alkyl.
[0228] "Carbamate" means a group of the formula --O--C(O)--NR'R''
wherein R' and R'' each independently is hydrogen or alkyl.
[0229] "Carboxy" means a group of the formula --O--C(O)--OH.
[0230] "Sulfonamido" means a group of the formula
--SO.sub.2--NR'R'' wherein R', R'' and R''' each independently is
hydrogen or alkyl.
[0231] "Optionally substituted" when used in association with an
"aryl", phenyl", "heteroaryl" "cycloalkyl" or "heterocyclyl" moiety
means that such moiety may be unsubstituted (i.e., all open
valencies are occupied by a hydrogen atom) or substituted with
specific groups as related herein.
[0232] "Leaving group" means the group with the meaning
conventionally associated with it in synthetic organic chemistry,
i.e., an atom or group displaceable under substitution reaction
conditions. Examples of leaving groups include, but are not limited
to, halogen, alkane- or arylenesulfonyloxy, such as
methanesulfonyloxy, ethanesulfonyloxy, thiomethyl,
benzenesulfonyloxy, tosyloxy, and thienyloxy, dihalophosphinoyloxy,
optionally substituted benzyloxy, isopropyloxy, acyloxy, and the
like.
[0233] "Modulator" means a molecule that interacts with a target.
The interactions include, but are not limited to, agonist,
antagonist, and the like, as defined herein.
[0234] "Optional" or "optionally" means that the subsequently
described event or circumstance may but need not occur, and that
the description includes instances where the event or circumstance
occurs and instances in which it does not.
[0235] "Disease" and "Disease state" means any disease, condition,
symptom, disorder or indication.
[0236] "Inert organic solvent" or "inert solvent" means the solvent
is inert under the conditions of the reaction being described in
conjunction therewith, including for example, benzene, toluene,
acetonitrile, tetrahydrofuran, N,N-dimethylformamide, chloroform,
methylene chloride or dichloromethane, dichloroethane, diethyl
ether, ethyl acetate, acetone, methyl ethyl ketone, methanol,
ethanol, propanol, isopropanol, tert-butanol, dioxane, pyridine,
and the like. Unless specified to the contrary, the solvents used
in the reactions of the present invention are inert solvents.
[0237] "Pharmaceutically acceptable" means that which is useful in
preparing a pharmaceutical composition that is generally safe,
non-toxic, and neither biologically nor otherwise undesirable and
includes that which is acceptable for veterinary as well as human
pharmaceutical use.
[0238] "Pharmaceutically acceptable salts" of a compound means
salts that are pharmaceutically acceptable, as defined herein, and
that possess the desired pharmacological activity of the parent
compound.
[0239] It should be understood that all references to
pharmaceutically acceptable salts include solvent addition forms
(solvates) or crystal forms (polymorphs) as defined herein, of the
same acid addition salt.
[0240] "Protective group" or "protecting group" means the group
which selectively blocks one reactive site in a multifunctional
compound such that a chemical reaction can be carried out
selectively at another unprotected reactive site in the meaning
conventionally associated with it in synthetic chemistry. Certain
processes of this invention rely upon the protective groups to
block reactive nitrogen and/or oxygen atoms present in the
reactants. For example, the terms "amino-protecting group" and
"nitrogen protecting group" are used interchangeably herein and
refer to those organic groups intended to protect the nitrogen atom
against undesirable reactions during synthetic procedures.
Exemplary nitrogen protecting groups include, but are not limited
to, trifluoroacetyl, acetamido, benzyl (Bn), benzyloxycarbonyl
(carbobenzyloxy, CBZ), p-methoxybenzyloxycarbonyl,
p-nitrobenzyloxycarbonyl, tert-butoxycarbonyl (BOC), and the like.
The artisan in the art will know how to chose a group for the ease
of removal and for the ability to withstand the following
reactions.
[0241] "Solvates" means solvent additions forms that contain either
stoichiometric or non stoichiometric amounts of solvent. Some
compounds have a tendency to trap a fixed molar ratio of solvent
molecules in the crystalline solid state, thus forming a solvate.
If the solvent is water the solvate formed is a hydrate, when the
solvent is alcohol, the solvate formed is an alcoholate. Hydrates
are formed by the combination of one or more molecules of water
with one of the substances in which the water retains its molecular
state as H.sub.2O, such combination being able to form one or more
hydrate.
[0242] "Arthritis" means a disease or condition that causes damage
to joints of the body and pain associated with such joint damage.
Arthritis includes rheumatoid arthritis, osteoarthritis, psoriatic
arthritis, septic arthritis, spondyloarthropathies, gouty
arthritis, systemic lupus erythematosus and juvenile arthritis,
osteoarthritis, and other arthritic conditions.
[0243] "Respiratory disorder" refers to, without limitation,
chronic obstructive pulmonary disease (COPD), asthma, bronchospasm,
and the like.
[0244] "Gastrointestinal disorder" ("GI disorder") refers to,
without limitation, Irritable Bowel Syndrome (IBS), Inflammatory
Bowel Disease (IBD), biliary colic and other biliary disorders,
renal colic, diarrhea-dominant IBS, pain associated with GI
distension, and the like.
[0245] "Pain" includes, without limitation, inflammatory pain;
surgical pain; visceral pain; dental pain; premenstrual pain;
central pain; pain due to burns; migraine or cluster headaches;
nerve injury; neuritis; neuralgias; poisoning; ischemic injury;
interstitial cystitis; cancer pain; viral, parasitic or bacterial
infection; post-traumatic injury; or pain associated with irritable
bowel syndrome.
[0246] "Subject" means mammals and non-mammals. Mammals means any
member of the mammalia class including, but not limited to, humans;
non-human primates such as chimpanzees and other apes and monkey
species; farm animals such as cattle, horses, sheep, goats, and
swine; domestic animals such as rabbits, dogs, and cats; laboratory
animals including rodents, such as rats, mice, and guinea pigs; and
the like. Examples of non-mammals include, but are not limited to,
birds, and the like. The term "subject" does not denote a
particular age or sex.
[0247] "Therapeutically effective amount" means an amount of a
compound that, when administered to a subject for treating a
disease state, is sufficient to effect such treatment for the
disease state. The "therapeutically effective amount" will vary
depending on the compound, disease state being treated, the
severity or the disease treated, the age and relative health of the
subject, the route and form of administration, the judgment of the
attending medical or veterinary practitioner, and other
factors.
[0248] The terms "those defined above" and "those defined herein"
when referring to a variable incorporates by reference the broad
definition of the variable as well as particular definitions, if
any.
[0249] "Treating" or "treatment" of a disease state includes, inter
alia, inhibiting the disease state, i.e., arresting the development
of the disease state or its clinical symptoms, and/or relieving the
disease state, i.e., causing temporary or permanent regression of
the disease state or its clinical symptoms.
[0250] The terms "treating", "contacting" and "reacting" when
referring to a chemical reaction means adding or mixing two or more
reagents under appropriate conditions to produce the indicated
and/or the desired product. It should be appreciated that the
reaction which produces the indicated and/or the desired product
may not necessarily result directly from the combination of two
reagents which were initially added, i.e., there may be one or more
intermediates which are produced in the mixture which ultimately
leads to the formation of the indicated and/or the desired
product.
Nomenclature and Structures
[0251] In general, the nomenclature and chemical names used in this
Application are based on ChembioOffice.TM. by CambridgeSoft.TM..
Any open valency appearing on a carbon, oxygen sulfur or nitrogen
atom in the structures herein indicates the presence of a hydrogen
atom unless indicated otherwise. Where a nitrogen-containing
heteroaryl ring is shown with an open valency on a nitrogen atom,
and variables such as R.sup.a, R.sup.b or R.sup.c are shown on the
heteroaryl ring, such variables may be bound or joined to the open
valency nitrogen. Where a chiral center exists in a structure but
no specific stereochemistry is shown for the chiral center, both
enantiomers associated with the chiral center are encompassed by
the structure. Where a structure shown herein may exist in multiple
tautomeric forms, all such tautomers are encompassed by the
structure. The atoms represented in the structures herein are
intended to encompass all naturally occurring isotopes of such
atoms. Thus, for example, the hydrogen atoms represented herein are
meant to include deuterium and tritium, and the carbon atoms are
meant to include C.sup.13 and C.sup.14 isotopes. One or more carbon
atom(s) of a compound of the invention may be replaced by a silicon
atom(s), and it is contemplated that one or more oxygen atom(s) of
a compound of the invention may be replaced by a sulfur or selenium
atom(s).
Compounds of the Invention
[0252] The invention provides compounds of the formula I:
##STR00012##
or a pharmaceutically acceptable salt thereof, wherein: [0253] m is
0 or 1; [0254] n is 0 or 1; [0255] p is from 0 to 3; [0256] q is 0,
1 or 2; [0257] r is from 1 to 3; [0258] A is: a bond;
--(CR.sub.jR.sub.k).sub.t--; --C(O)--(CR.sub.jR.sub.k).sub.t--;
--(CR.sub.jR.sub.k).sub.t--C(O)--;
--NR.sup.a--(CR.sub.jR.sub.k).sub.t--;
--(CR.sub.jR.sub.k).sub.t--NR.sup.a--;
--C(O)NR.sup.a--(CR.sub.jR.sub.k).sub.t--;
--(CR.sub.jR.sub.k).sub.t--NR.sup.aC(O)--;
--O--(CR.sub.jR.sub.k).sub.t--; --(CR.sub.jR.sub.k).sub.t--O--;
--S--(CR.sub.jR.sub.k).sub.t--; --(CR.sub.jR.sub.k).sub.t--S--;
--SO.sub.2--(CR.sub.jR.sub.k).sub.t--; or
--(CR.sub.jR.sub.k).sub.t--SO.sub.2--; [0259] t is from 0 to 4;
[0260] W is: --CR.sup.bR.sup.c--; --O--; --S--; --SO.sub.2--; or
--NR.sup.d--; [0261] one of X.sup.1, X.sup.2, X.sup.3 and X.sup.4
is N and the others are CR.sup.e; or two of X.sup.1, X.sup.2,
X.sup.3 and X.sup.4 are N and the others are CR.sup.e; or three of
X.sup.1, X.sup.2, X.sup.3 and X.sup.4 are N and the other is
CR.sup.e; or each of X.sup.1, X.sup.2, X.sup.3 and X.sup.4 is
CR.sup.e; [0262] Y is: --O--; --S--; SO.sub.2--;
--CR.sup.fR.sup.g--; or --NR.sup.h--; [0263] Z is: CH; or N wherein
N may be oxidized; [0264] R.sup.1, R.sup.2, R.sup.3, R.sup.4,
R.sup.5, R.sup.6, R.sup.7 and R.sup.8 each independently is:
hydrogen; or C.sub.1-6alkyl which may be unsubstituted or
substituted one or more times with halo; [0265] or R.sup.3 and
R.sup.4 together with the atom to which they are attached may form
an ethylene group; [0266] or R.sup.3 and R.sup.4 together with the
atoms to which they are attached may form a three, four, five, six
or seven membered saturated or partially saturated ring that may
optionally include one or two heteroatoms selected from --O--,
--NR.sup.a-- or --S--, and which may be optionally substituted one
or more times with R.sup.i; [0267] or R.sup.5 and R.sup.6 together
with the atoms to which they are attached may form a three, four,
five, six or seven membered saturated or partially saturated ring
that may optionally include one or two heteroatoms selected from
--O--, --NR.sup.a-- or --S--, and which may be optionally
substituted one or more times with R.sup.i; [0268] or R.sup.7 and
R.sup.8 together with the atoms to which they are attached may form
a three, four, five, six or seven membered saturated or partially
saturated ring that may optionally include one or two heteroatoms
selected from --O--, --NR.sup.a-- or --S--, and which may be
optionally substituted one or more times with R.sup.i; [0269] or
one of R.sup.3 and R.sup.4 together with one of R.sup.5 and R.sup.6
and the atoms to which they are attached may form a three, four,
five, six or seven membered saturated or partially saturated ring
that may optionally include one or two heteroatoms selected from
--O--, --NR.sup.a-- or --S--, and which may be optionally
substituted one or more times with R.sup.i; [0270] or one of
R.sup.5 and R.sup.6 together with one of R.sup.7 and R.sup.8 and
the atoms to which they are attached may form a three, four, five,
six or seven membered saturated or partially saturated ring that
may optionally include one or two heteroatoms selected from --O--,
--NR.sup.a-- or --S--, and which may be optionally substituted one
or more times with R.sup.i; [0271] each R.sup.9 is independently:
C.sub.1-6alkyl; halo; C.sub.1-6alkoxy; or cyano; wherein the
C.sub.1-6alkyl moieties may be unsubstituted or substituted one or
more times with halo; [0272] R.sup.10 is: hydrogen; carboxy;
C.sub.1-6alkyl-carbonyl; C.sub.1-6alkoxy-carbonyl; oxo; hydroxy;
aminocarbonyl; N--C.sub.1-6alkyl-aminocarbonyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl; cyano; hydroxy-C.sub.1-6alkyl;
N--C.sub.1-6alkoxy-C.sub.1-6alkyl-aminocarbonyl;
N-hydroxy-C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkoxy-aminocarbonyl; halo; or C.sub.1-6alkyl which may
be unsubstituted or substituted one or more times with halo or oxo;
[0273] R.sup.11 is: hydrogen; halo; carboxy;
C.sub.1-6alkyl-carbonyl; C.sub.1-6alkoxy-carbonyl; oxo; hydroxy;
aminocarbonyl; N--C.sub.1-6alkyl-aminocarbonyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl; C.sub.1-6alkyl-sulfonylamino;
C.sub.1-6alkyl-sulfonylamino-C.sub.1-6alkyl; cyano;
hydroxy-C.sub.1-6alkyl;
N--C.sub.1-6alkoxy-C.sub.1-6alkyl-aminocarbonyl;
N-hydroxy-C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkoxy-aminocarbonyl; or C.sub.1-6alkyl which may be
unsubstituted or substituted one or more times with halo or oxo;
[0274] or R.sup.10 and R.sup.11 together with the atoms to which
they are attached may form a three, four, five, six or seven
membered saturated or partially saturated ring that may optionally
include one or two heteroatoms selected from --O--, --NR.sup.a-- or
--S--, and which may be optionally substituted one or more times
with R.sup.i; [0275] or R.sup.10 and R.sup.11 together with the
atoms to which they are attached may form a double bond;
[0276] R.sup.12 is: hydrogen; halo; carboxy;
C.sub.1-6alkyl-carbonyl; C.sub.1-6alkoxy-carbonyl; oxo; hydroxy;
aminocarbonyl; N--C.sub.1-6alkyl-aminocarbonyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl; cyano; hydroxy-C.sub.1-6alkyl;
N--C.sub.1-6alkoxy-C.sub.1-6alkyl-aminocarbonyl;
N-hydroxy-C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkoxy-aminocarbonyl; or C.sub.1-6alkyl which may be
unsubstituted or substituted one or more times with halo or oxo;
[0277] R.sup.13 is: hydrogen; or C.sub.1-6alkyl which may be
unsubstituted or substituted one or more times with halo; [0278]
R.sup.a, R.sup.b, R.sup.c and R.sup.d each independent is:
hydrogen; or C.sub.1-6alkyl which may be unsubstituted or
substituted one or more times with halo; [0279] or R.sup.b and
R.sup.c together with the atoms to which they are attached may form
a three, four, five, six or seven membered saturated or partially
saturated ring that may optionally include one or two heteroatoms
selected from --O--, --NR.sup.a-- or --S--, and which may be
optionally substituted one or more times with R.sup.i; [0280] or
one of R.sup.b and R.sup.c together with one of R.sup.7 and R.sup.8
and the atoms to which they are attached may form a three, four,
five, six or seven membered saturated or partially saturated ring
that may optionally include one or two heteroatoms selected from
--O--, --NR.sup.a-- or --S--, and which may be optionally
substituted one or more times with R.sup.i; [0281] or one of
R.sup.b and R.sup.c together with one of R.sup.5 and R.sup.6 and
the atoms to which they are attached may form a three, four, five,
six or seven membered saturated or partially saturated ring that
may optionally include one or two heteroatoms selected from --O--,
--NR.sup.a-- or --S--, and which may be optionally substituted one
or more times with R.sup.i; [0282] each R.sup.e is independently:
hydrogen; C.sub.1-6alkyl; halo; C.sub.1-6alkoxy; or cyano; wherein
the C.sub.1-6alkyl moieties may be unsubstituted or substituted one
or more times with halo, hydroxy or C.sub.1-6alkoxy; [0283] R.sup.f
is: hydrogen; halo; or C.sub.1-6alkyl which may be unsubstituted or
substituted one or more times with halo, hydroxy, or
C.sub.1-6alkoxy;
[0284] R.sup.g is: hydrogen; C.sub.1-6alkyl; C.sub.3-6cycloalkyl;
C.sub.3-6cycloalkenyl; C.sub.3-6cycloalkyl-C.sub.1-6alkyl; halo;
C.sub.1-6alkyl-carbonyl; C.sub.3-6cycloalkyl-carbonyl;
C.sub.3-6cycloalkyl-C.sub.1-6alkyl-carbonyl;
cyano-C.sub.1-6alkyl-carbonyl; hydroxy-C.sub.1-6alkyl-carbonyl;
C.sub.1-6alkoxy-C.sub.1-6alkyl-carbonyl; carboxy;
N-cyano-aminocarbonyl; N-cyano-N--C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkyl-acetimidamidyl;
N,N'-di-C.sub.1-6alkyl-acetimidamidyl;
N'-cyano-N--C.sub.1-6alkyl-acetimidamidyl;
N'-hydroxy-acetimidamidyl; N'--C.sub.1-6alkoxy-acetimidamidyl;
N'-hydroxy-N--C.sub.1-6alkyl-acetimidamidyl;
N'--C.sub.1-6alkoxy-N--C.sub.1-6alkyl-acetimidamidyl;
2-nitro-1-N--C.sub.1-6alkylamino-vinyl; formyl;
C.sub.1-6alkyl-sulfonyl; C.sub.3-6cycloalkyl-sulfonyl;
C.sub.3-6cycloalkyl-C.sub.1-6alkyl-sulfonyl;
C.sub.1-6alkyl-sulfonyl-C.sub.1-6alkyl; aminocarbonyl;
N-hydroxy-aminocarbonyl; N--C.sub.1-6alkoxy-aminocarbonyl;
N--C.sub.1-6alkyl-aminocarbonyl; aminocarbonyl-C.sub.1-6alkyl;
N--C.sub.1-6alkyl-aminocarbonyl-C.sub.1-6alkyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl-C.sub.1-6alkyl;
C.sub.1-6alkoxy-carbonyl;
N-hydroxy-N--C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkoxy-N--C.sub.1-6alkyl-aminocarbonyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl; aminosulfonyl;
N--C.sub.1-6alkyl-aminosulfonyl;
N,N-di-C.sub.1-6alkyl-aminosulfonyl; cyano; C.sub.1-6alkoxy;
C.sub.1-6alkyl-sulfonylamino;
N--C.sub.1-6alkyl-sulfonylaminocarbonyl;
N--(C.sub.1-6alkyl-sulfonyl)-N--C.sub.1-6alkyl-aminocarbonyl;
N--(C.sub.1-6alkyl-sulfonyl)-amino-C.sub.1-6alkyl; amino;
N--C.sub.1-6alkyl-amino; N,N-di-C.sub.1-6alkyl-amino;
halo-C.sub.1-6alkyl; phenyl; heterocyclyl; heteroaryl;
C.sub.1-6alkyl-carbonylamino; carbonylamino; or hydroxyl; wherein
the C.sub.1-6alkyl moieties may be unsubstituted or substituted one
or more times with halo; and wherein the phenyl, heterocyclyl,
heteroaryl, C.sub.3-6cycloalkyl, C.sub.3-6cycloalkenyl and
C.sub.3-6cycloalkyl-C.sub.1-6alkyl moieties may be unsubstituted or
substituted one or more times with R.sup.i; [0285] or R.sup.f and
R.sup.g together with the atoms to which they are attached may form
a four, five, six or seven membered saturated or partially
saturated ring that may optionally include one or two heteroatoms
selected from --O--, --NR.sup.a-- or --S--, and which may be
optionally substituted one or more times with R.sup.i;
[0286] R.sup.h is: hydrogen; C.sub.1-6alkyl; C.sub.3-6cycloalkyl;
C.sub.3-6cycloalkenyl; C.sub.3-6cycloalkyl-C.sub.1-6alkyl;
C.sub.1-6alkyl-carbonyl; C.sub.3-6cycloalkyl-carbonyl;
C.sub.3-6cycloalkyl-C.sub.1-6alkyl-carbonyl;
cyano-C.sub.1-6alkyl-carbonyl; hydroxy-C.sub.1-6alkyl-carbonyl;
C.sub.1-6alkoxy-C.sub.1-6alkyl-carbonyl; N-cyano-aminocarbonyl;
N-cyano-N--C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkyl-acetimidamidyl;
N,N'-di-C.sub.1-6alkyl-acetimidamidyl;
N'-cyano-N--C.sub.1-6alkyl-acetimidamidyl;
N'-hydroxy-acetimidamidyl; N'--C.sub.1-6alkoxy-acetimidamidyl;
N'-hydroxy-N--C.sub.1-6alkyl-acetimidamidyl;
N'--C.sub.1-6alkoxy-N--C.sub.1-6alkyl-acetimidamidyl;
2-nitro-1-N--C.sub.1-6alkylamino-vinyl; formyl;
C.sub.1-6alkyl-sulfonyl; C.sub.3-6cycloalkyl-sulfonyl;
C.sub.1-6cycloalkyl-C.sub.1-6alkyl-sulfonyl;
C.sub.1-6alkyl-sulfonyl-C.sub.1-6alkyl; aminocarbonyl;
N-hydroxy-aminocarbonyl; N--C.sub.1-6alkoxy-aminocarbonyl;
N--C.sub.1-6alkyl-aminocarbonyl;
N-hydroxy-N--C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkoxy-N--C.sub.1-6alkyl-aminocarbonyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl; aminosulfonyl;
N--C.sub.1-6alkyl-aminosulfonyl;
N,N-di-C.sub.1-6alkyl-aminosulfonyl; cyano;
C.sub.1-6alkyl-sulfonylamino;
C.sub.1-6alkyl-sulfonylamino-C.sub.1-6alkyl;
N--(C.sub.1-6alkyl-sulfonyl)aminocarbonyl;
N--(C.sub.1-6alkyl-sulfonyl)-N--C.sub.1-6alkyl-aminocarbonyl;
N--(C.sub.1-6alkyl-sulfonyl)-amino-C.sub.1-6alkyl;
aminocarbonyl-C.sub.1-6alkyl;
N--C.sub.1-6alkyl-aminocarbonyl-C.sub.1-6alkyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl-C.sub.1-6alkyl;
C.sub.1-6alkoxy-carbonyl; halo-C.sub.1-6alkyl; phenyl;
heterocyclyl; or heteroaryl; wherein the C.sub.1-6alkyl moieties
may be unsubstituted or substituted one or more times with halo;
and wherein the phenyl, heterocyclyl, heteroaryl,
C.sub.3-6cycloalkyl, C.sub.3-6cycloalkenyl and
C.sub.3-6cycloalkyl-C.sub.1-6alkyl moieties may be unsubstituted or
substituted one or more times with R.sup.i; [0287] or R.sup.h and
one of R.sup.10 and R.sup.11 together with the atoms to which they
are attached may form a four, five, six or seven membered aromatic,
partially saturated or unsaturated ring that may optionally include
one or two additional heteroatom selected from --O--, --NR.sup.a--
or --S--, and which may be optionally substituted one or more times
with R.sup.i--; [0288] or one of R.sup.f and R.sup.g and one of
R.sup.10 and R.sup.11 together with the atoms to which they are
attached may form a three, four, five, six or seven membered
aromatic, partially saturated or unsaturated ring that may
optionally include an additional heteroatom selected from --O--,
--NR.sup.a-- or --S--, and which may be optionally substituted one
or more times with R.sup.i; [0289] R.sup.i is: C.sub.1-6alkyl;
halo; oxo; hydroxy; acetyl; C.sub.1-6alkyl-carbonyl;
amino-carbonyl; hydroxy-C.sub.1-6alkyl; cyano; heteroaryl;
cyano-C.sub.1-6alkyl; C.sub.1-6alkoxy-C.sub.1-6alkyl; carboxy; or
C.sub.1-6alkoxy; wherein the C.sub.1-6alkyl moieties may be
unsubstituted or substituted one or more times with halo; and
[0290] R.sup.j and R.sup.k each independent is: hydrogen; or
C.sub.1-6alkyl which may be unsubstituted or substituted one or
more times with halo; [0291] wherein the compound is selected from:
[0292] wherein the compound is selected from: [0293]
{1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylme-
thyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidin-4-yl}-methanol;
[0294]
{1-[3-Fluoro-4-((3S,6S)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylme-
thyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidin-4-yl}-methanol;
[0295]
(3S,6R)-2-[2-Fluoro-4-(tetrahydro-pyran-4-ylmethoxy)-benzyl]-3-methyl-6-p-
henyl-[1,2]thiazinane 1,1-dioxide; [0296]
(3S,6S)-2-[2-Fluoro-4-(4-[1,2,4]triazol-4-yl-piperidin-1-yl)-benzyl]-3,6--
dimethyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0297]
(3S,6S)-2-{2-Fluoro-4-[4-(3-methyl-[1,2,4]triazol-4-yl)-piperidin-1-yl]-b-
enzyl}-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0298]
(3S,6R)-2-[2-Fluoro-4-((2S,4R)-2-methyl-4-[1,2,4]triazol-4-yl-piperidin-1-
-yl)-benzyl]-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0299]
1-{(R)-4-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan--
2-ylmethyl)-phenyl]-3-hydroxymethyl-piperazin-1-yl}-ethanone;
[0300]
(3S,6R)-2-{2-Fluoro-4-[4-(3-methyl-[1,2,4]triazol-4-yl)-piperidin-1-yl]be-
nzyl}-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0301]
(3S,6R)-2-[2-Fluoro-4-((2S,4S)-2-methyl-4-[1,2,4]triazol-4-yl-piperidin-1-
-yl)-benzyl]-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0302]
(4-{1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-y-
lmethyl)-phenyl]-piperidin-4-yl}-4H-[1,2,4]triazol-3-yl)-acetonitrile;
[0303]
(3R,4R)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]th-
iazinan-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidine-3-carboxylic
acid methyl ester; [0304]
(3S,6R)-2-[2,5-Difluoro-4-(4-[1,2,4]triazol-4-yl-piperidin-1-yl)-benzyl]--
3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0305]
(3S,6R)-2-{2-Fluoro-4-[4-(3-methoxymethyl-[1,2,4]triazol-4-yl)-piperidin--
1-yl]-benzyl}-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0306]
(3S,4R)-1-[3-Fluoro-4-((3S,6R)-3-methyl-dioxo-6-phenyl-[1,2]thiazinan-2-y-
lmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidine-3-carboxylic acid
methyl ester; [0307]
(3S,6R)-2-[2-Fluoro-4-((3S,4R)-3-methyl-4-[1,2,4]triazol-4-yl-piperidin-1-
-yl)-benzyl]-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0308]
(3S,6R)-2-[2-Fluoro-4-((3R,4S)-3-methyl-4-[1,2,4]triazol-4-yl-piperidin-1-
-yl)-benzyl]-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0309]
(1S,5R,6S)-3-[2,3-Difluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]th-
iazinan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.1.0]hexa-
ne; [0310]
(1S,5R,6S)-3-[2,3-Difluoro-4-((3S,6S)-3-methyl-1,1-dioxo-6-phen-
yl-[1,2]thiazinan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[-
3.1.0]hexane; [0311]
(3S,6R)-2-[2,3-Difluoro-4-(4-[1,2,4]triazol-4-yl-piperidin-1-yl)-benzyl]--
3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0312]
(1R,5S,6S)-3-[2,5-Difluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]th-
iazinan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.1.0]hexa-
ne; [0313]
(1S,5R,6S)-3-[2,5-Difluoro-4-((3S,6S)-3-methyl-1,1-dioxo-6-phen-
yl-[1,2]thiazinan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[-
3.1.0]hexane; [0314]
(1R,5S,6S)-3-[2,6-Difluoro-4-((3S,6S)-3-methyl-1,1-dioxo-6-phenyl-[1,2]th-
iazinan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.1.0]hexa-
ne; [0315]
(1R,5S,6S)-3-[2,6-Difluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phen-
yl-[1,2]thiazinan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[-
3.1.0]hexane; [0316]
(3S,6R)-2-[2-Fluoro-4-((3R,4R)-3-methyl-4-[1,2,4]triazol-4-yl-piperidin-1-
-yl)-benzyl]-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0317]
(3S,6R)-2-[2-Fluoro-4-((3S,4S)-3-methyl-4-[1,2,4]triazol-4-yl-piperidin-1-
-yl)-benzyl]-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0318]
3-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmet-
hyl)-phenyl]-5-[1,2,4]triazol-4-yl-3-aza-bicyclo[4.1.0]heptane;
[0319]
3-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmet-
hyl)-phenyl]-5-[1,2,4]triazol-4-yl-3-aza-bicyclo[4.1.0]heptane;
[0320]
3-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmet-
hyl)-phenyl]-5-[1,2,4]triazol-4-yl-3-aza-bicyclo[4.1.0]heptane;
[0321]
3-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmet-
hyl)-phenyl]-5-[1,2,4]triazol-4-yl-3-aza-bicyclo[4.1.0]heptane;
[0322]
(3S,6R)-2-[3-Fluoro-4-(4-[1,2,4]triazol-4-yl-piperidin-1-yl)-benzyl]-3-me-
thyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0323] Carbamic acid
1-acetyl-4-[3-fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazina-
n-2-ylmethyl)-phenyl]-piperidin-4-yl ester, [0324]
(3S,6S)-2-[3-Fluoro-4-(4-[1,2,4]triazol-4-yl-piperidin-1-yl)-benzyl]-3-me-
thyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0325]
(1R,3S,5S)-8-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazi-
nan-2-ylmethyl)-phenyl]-3-[1,2,4]triazol-4-yl-8-aza-bicyclo[3.2.1]octane;
[0326]
(1R,5S,8R)-3-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2-
]thiazinan-2-ylmethyl)-phenyl]-8-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.2.1]o-
ctane; [0327]
(1R,5S,8R)-3-[3-Fluoro-4-((3S,6S)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazi-
nan-2-ylmethyl)-phenyl]-8-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.2.1]octane;
[0328]
(2S,4R)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]th-
iazinan-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidine-2-carboxylic
acid methyl ester; [0329]
(3S,6R)-2-(2-fluoro-4-((1-(S-methylsulfonimidoyl)piperidin-4-yl)oxy)benzy-
l)-3-methyl-6-phenyl-1,2-thiazinane 1,1-dioxide; [0330]
(3S,6R)-2-(2-fluoro-4-((1-(S-methylsulfonimidoyl)piperidin-4-yl)oxy)benzy-
l)-3-methyl-6-phenyl-1,2-thiazinane 1,1-dioxide; [0331]
(1S,5R,6S)-3-[2-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazi-
nan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.1.0]hexane;
[0332]
(1S,5R,6S)-3-[2-Fluoro-4-((3S,6S)-3-methyl-1,1-dioxo-6-phenyl-[1,2-
]thiazinan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.1.0]h-
exane; [0333]
{(3R,4R)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazina-
n-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidin-3-yl}-methanol;
[0334]
4-[4-((S)-3-Methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmethyl)-p-
henyl]-2-aza-bicyclo[2.2.2]octan-3-one; [0335]
(1S,5R,6S)-3-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazi-
nan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.1.1]heptane;
[0336]
{(3S,4R)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]t-
hiazinan-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidin-3-yl}-methano-
l; [0337]
(2R,4R)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]-
thiazinan-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidine-2-carboxyli-
c acid methyl ester; [0338]
(4-{1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-y-
lmethyl)-phenyl]-piperidin-4-yl}-4H-[1,2,4]triazol-3-yl)-methanol;
[0339]
(4-{1-[3-Fluoro-4-((3S,6S)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-y-
lmethyl)-phenyl]-piperidin-4-yl}-4H-[1,2,4]triazol-3-yl)-methanol;
[0340]
(2S,4S)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-
-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidine-2-carboxylic
acid methyl ester; [0341]
4-{4-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-yl-
methyl)-phenyl]-piperazin-1-yl}-benzoic acid; [0342]
(3S,6R)-2-[2-Fluoro-4-(1-oxy-4-[1,2,4]triazol-4-yl-piperidin-1-yl)-benzyl-
]-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0343]
8-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmet-
hyl)-phenyl]-1,4-dioxa-8-aza-spiro[4.5]decane; [0344]
1-{4-[2-Hydroxymethyl-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazin-
an-2-ylmethyl)-phenyl]-piperazin-1-yl}-ethanone; [0345]
{(3S,4R)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazina-
n-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidin-3-yl}-methanol;
[0346]
{(3R,4S)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]t-
hiazinan-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidin-3-yl}-methano-
l; [0347]
{(3S,4S)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2-
]thiazinan-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidin-3-yl}-metha-
nol; [0348]
(3S,6R)-2-[4-(3,6-Dihydro-2H-pyran-4-yl)-2-fluoro-benzyl]-3-methyl-6-phen-
yl-[1,2]thiazinane 1,1-dioxide; [0349]
(3S,6R)-2-[2-Fluoro-4-(tetrahydro-pyran-4-yl)-benzyl]-3-methyl-6-phenyl-[-
1,2]thiazinane 1,1-dioxide; [0350]
{(3S,4S)-1-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazina-
n-2-ylmethyl)-phenyl]-4-[1,2,4]triazol-4-yl-piperidin-3-yl}-methanol;
[0351]
(3S,6R)-2-[2-Fluoro-4-((R)-3-[1,2,4]triazol-4-yl-piperidin-1-yl)-b-
enzyl]-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide [0352]
8-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmet-
hyl)-phenyl]-1-oxa-8-aza-spiro[4.5]decane; [0353]
9-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmet-
hyl)-phenyl]-1,5-dioxa-9-aza-spiro[5.5]undecane; [0354]
7-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmet-
hyl)-phenyl]-1-oxa-7-aza-spiro[3,5]nonane; [0355]
(S)-8-[3-Fluoro-4-((3S,6R)-3-methyl-1,1,1-dioxo-6-phenyl-[1,2]thiazinan-2-
-ylmethyl)-phenyl]-1,4-dioxa-8-aza-spiro[4.5]decane-7-carboxylic
acid methyl ester; [0356]
4-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmet-
hyl)-phenyl]-morpholine; [0357]
(R)-8-[3-Fluoro-4-((3S,6R)-3-methyl-1,1,1-dioxo-6-phenyl-[1,2]thiazinan-2-
-ylmethyl)-phenyl]-1,4-dioxa-8-aza-spiro[4.5]decane-7-carboxylic
acid methyl ester; [0358]
(3S,6R)-2-[2-Fluoro-4-((S)-3-[1,2,4]triazol-4-yl-piperidin-1-yl)-benzyl]--
3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0359]
(3R,6R)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2-fluorobenzyl)-3--
(difluoromethyl)-6-phenyl-1,2-thiazinane 1,1-dioxide [0360]
(3R,6S)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2-fluorobenzyl)-3--
(difluoromethyl)-6-phenyl-1,2-thiazinane 1,1-dioxide; [0361]
(3R,6S)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2,5-difluorobenzyl-
)-3-(difluoromethyl)-6-phenyl-1,2-thiazinane 1,1-dioxide; [0362]
(3R,6R)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2,5-difluorobenzyl-
)-3-(difluoromethyl)-6-phenyl-1,2-thiazinane 1,1-dioxide; [0363]
(3R,6S)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2,5-difluorobenzyl-
)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane 1,1-dioxide; [0364]
(3R,6R)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2,5-difluorobenzyl-
)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane 1,1-dioxide; [0365]
(3R,6R)-2-(4-((1R,5S,6S)-6-(4H-1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]hex-
an-3-yl)-2,5-difluorobenzyl)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane
1,1-dioxide; [0366]
(3R,6S)-2-(4-((1R,5S,6S)-6-(4H-1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]hex-
an-3-yl)-2,5-difluorobenzyl)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane
1,1-dioxide; [0367]
(3R,6R)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2-fluorobenzyl)-6--
phenyl-3-(trifluoromethyl)-1,2-thiazinane 1,1-dioxide; [0368]
(3R,6S)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2-fluorobenzyl)-6--
phenyl-3-(trifluoromethyl)-1,2-thiazinane 1,1-dioxide; [0369]
(3R,6R)-2-(4-((1R,5S,6S)-6-(4H-1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]hex-
an-3-yl)-2-fluorobenzyl)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane
1,1-dioxide; [0370]
(3R,6S)-2-(4-((1R,5S,6S)-6-(4H-1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]hex-
an-3-yl)-2-fluorobenzyl)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane
1,1-dioxide; [0371] (4R)-methyl
1-(2,5-difluoro-4-((3-methyl-1,1-dioxido-6-phenyl-1,2-thiazinan-2-yl)meth-
yl)phenyl)-4-(4H-1,2,4-triazol-4-yl)piperidine-3-carboxylate;
[0372]
2-(2-fluoro-4-((4R)-3-methoxy-4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)ben-
zyl)-3-methyl-6-phenyl-1,2-thiazinane 1,1-dioxide; [0373]
2-(4-((5R)-5-(4H-1,2,4-triazol-4-yl)-2-azabicyclo[2.2.1]heptan-2-yl)-2,5--
difluorobenzyl)-3-methyl-6-phenyl-1,2-thiazinane 1,1-dioxide [0374]
2-(4-((5R)-5-(4H-1,2,4-triazol-4-yl)-2-azabicyclo[2.2.1]heptan-2-yl)-2,5--
difluorobenzyl)-3-methyl-6-phenyl-1,2-thiazinane 1,1-dioxide;
[0375]
2-(2-fluoro-4-((4R)-3-fluoro-4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)benz-
yl)-3-methyl-6-phenyl-1,2-thiazinane 1,1-dioxide; and
[0376]
8-(3-fluoro-4-(((3S,6R)-3-methyl-1,1-dioxido-6-phenyl-1,2-thiazina-
n-2-yl)methyl)phenyl)-3-methyl-1-oxa-8-azaspiro[4.5]decan-2-one.
[0377] In another aspect, the invention provides a compound
selected from: [0378]
(3S,6R)-2-[[2-fluoro-4-[(3R,4R)-3-fluoro-4-(1,2,4-triazol-4-yl)-1--
piperidyl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide;
[0379]
4-[4-[3-fluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]met-
hyl]phenyl]piperazin-1-yl]benzoic acid; [0380]
(3S,6R)-2-[[2-fluoro-4-(1-oxa-6-azaspiro[3.3]heptan-6-yl)phenyl]methyl]-3-
-methyl-6-phenyl-thiazinane 1,1-dioxide; [0381]
8-[3-fluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]methyl-
]phenyl]-1,3-dimethyl-1,3,8-triazaspiro[4.5]decane-2,4-dione;
[0382]
1-[4-[[3-fluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-hydroxy-methyl]-1-piperidyl]ethanone; [0383]
(3S,6R)-2-[[2-fluoro-4-[(3S,4R)-3-fluoro-4-(1,2,4-triazol-4-yl)-1-piperid-
yl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide; [0384]
(3S,6R)-2-[[2-fluoro-4-[(3R,4S)-3-fluoro-4-(1,2,4-triazol-4-yl)-1-piperid-
yl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide; [0385]
(3S,6R)-2-[[2-fluoro-4-[(3S,4R)-3-methoxy-4-(1,2,4-triazol-4-yl)-1-piperi-
dyl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide; [0386]
(3S,6R)-2-[[2-fluoro-4-[(3R,4S)-3-methoxy-4-(1,2,4-triazol-4-yl)-1-piperi-
dyl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide; [0387]
(3S,6R)-2-[[2-fluoro-4-[(3R,4R)-3-fluoro-4-(1,2,4-triazol-4-yl)-1-piperid-
yl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide [0388]
(3S,6R)-2-[[2-fluoro-4-[(3S,4S)-3-fluoro-4-(1,2,4-triazol-4-yl)-1-piperid-
yl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide; [0389]
4-[4-[3-fluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]met-
hyl]phenyl]piperazin-1-yl]-2-hydroxy-benzoic acid; [0390]
4-[4-[3-fluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]met-
hyl]phenyl]piperazin-1-yl]-2-hydroxy-benzoic acid; [0391]
(3S,6R)-2-[[2,5-difluoro-4-[(1
S,4S,5S)-5-(1,2,4-triazol-4-yl)-2-azabicyclo[2.2.1]heptan-2-yl]phenyl]met-
hyl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide; [0392]
(3S,6R)-2-[[2,5-difluoro-4-[(1R,4R,5R)-5-(1,2,4-triazol-4-yl)-2-azabicycl-
o[2.2.1]heptan-2-yl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane
1,1-dioxide; [0393]
(3S,6R)-2-[[4-(3,6-dihydro-2H-pyran-4-ylmethyl)-2-fluoro-phenyl]methyl]-3-
-methyl-6-phenyl-thiazinane 1,1-dioxide; [0394]
(3S,6R)-2-[[2-fluoro-4-(tetrahydropyran-4-ylidenemethyl)phenyl]methyl]-3--
methyl-6-phenyl-thiazinane 1,1-dioxide; [0395] methyl
4-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1-dioxo-6-phenyl-thiazinan-2-yl]meth-
yl]phenyl]tetrahydropyran-4-carboxylate; [0396]
methyl(3S,4S)-3-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thi-
azinan-2-yl]methyl]phenyl]tetrahydropyran-4-carboxylate; [0397]
(3R,4R)-1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-
-2-yl]methyl]phenyl]-4-(1,2,4-triazol-4-yl)piperidin-3-ol; [0398]
(3S,4S)-1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-
-2-yl]methyl]phenyl]-4-(1,2,4-triazol-4-yl)piperidin-3-ol; [0399]
methyl
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]acetate; [0400] methyl
4-[2,5-difluoro-4-[[(3S,6S)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]tetrahydropyran-4-carboxylate; [0401]
(3R,4R)-3-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-
-2-yl]methyl]phenyl]tetrahydropyran-4-carboxylic acid, [0402]
methyl(3S,4S)-3-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thi-
azinan-2-yl]methyl]phenyl]tetrahydropyran-4-carboxylate; [0403]
methyl(3R,4R)-3-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thi-
azinan-2-yl]methyl]phenyl]tetrahydropyran-4-carboxylate; [0404]
(3S,6R)-2-[[2,5-difluoro-4-[(3S,4R)-3-fluoro-4-(1,2,4-triazol-4-yl)-1-pip-
eridyl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide;
[0405]
(3S,6R)-2-[[2,5-difluoro-4-[(3R,4S)-3-fluoro-4-(1,2,4-triazol-4-yl)-1-pip-
eridyl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide
[0406]
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]ethanol; [0407]
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-N-(3-hydroxycyclobutyl)acetamide; [0408]
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]acetamide; [0409]
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]propan-1-ol; [0410]
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]propan-1-ol; [0411] diethyl
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]propanedioate; [0412]
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]propane-1,3-diol; [0413] tert-butyl
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]acetate; [0414]
4-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-5-hydroxy-pentanenitrile; [0415]
1-[4-[4-[[(6S)-5,5-dioxo-6-phenyl-5$1
{6}-thia-4-azaspiro[2.5]octan-4-yl]methyl]-3-fluoro-phenyl]piperazin-1-yl-
]ethanone; [0416] 1-[4-[4-[[(6S)-5,5-dioxo-6-phenyl-5$1
{6}-thia-4-azaspiro[2.5]octan-4-yl]methyl]-3-fluoro-phenyl]piperazin-1-yl-
]ethanone; [0417]
2-[1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl-
]methyl]phenyl]-1-methyl-ethoxy]acetic acid; [0418]
2-[1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl-
]methyl]phenyl]-1-methyl-ethoxy]acetamide; [0419]
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-3-(oxetan-3-yl)propan-1-ol; [0420]
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-3-(oxetan-3-yl)propan-1-ol; [0421]
3-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-4-hydroxy-butanenitrile; [0422]
3-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-4-hydroxy-butanenitrile; [0423]
3-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-4-hydroxy-butanamide; [0424]
3-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-4-hydroxy-butanamide; [0425]
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-2-(oxetan-3-yl)ethanol; [0426]
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-2-(oxetan-3-yl)ethanol; [0427]
3-[1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl-
]methyl]phenyl]-1-methyl-ethoxy]propane-1,2-diol; [0428]
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-2-phenyl-ethanol; [0429]
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-2-phenyl-ethanol; [0430]
(2S)-3-[1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-
-2-yl]methyl]phenyl]-1-methyl-ethoxy]propane-1,2-diol; [0431]
(2R)-3-[1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-
-2-yl]methyl]phenyl]-1-methyl-ethoxy]propane-1,2-diol; [0432]
3-[1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl-
]methyl]phenyl]-2-hydroxy-ethyl]-1-methyl-pyrrolidin-2-one; [0433]
3-[1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl-
]methyl]phenyl]-2-hydroxy-ethyl]-1-methyl-pyrrolidin-2-one; [0434]
3-[1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl-
]methyl]phenyl]-2-hydroxy-ethyl]-1-methyl-pyrrolidin-2-one; [0435]
3-[1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl-
]methyl]phenyl]-2-hydroxy-ethyl]-1-methyl-pyrrolidin-2-one; [0436]
4-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-5-hydroxy-pentanamide; [0437]
4-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-5-hydroxy-pentanamide; [0438]
(3S,6R)-2-[[2,5-difluoro-4-[4-(1,2,4-triazol-4-yl)-1-piperidyl]phenyl]met-
hyl]-3-ethyl-6-phenyl-thiazinane 1,1-dioxide; [0439]
(3S,6S)-2-[[2,5-difluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3-
.1.0]hexan-3-yl]phenyl]methyl]-3-ethyl-6-phenyl-thiazinane
1,1-dioxide; [0440]
(3S,6R)-2-[[2,5-difluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabi-
cyclo[3.1.0]hexan-3-yl]phenyl]methyl]-3-ethyl-6-phenyl-thiazinane
1,1-dioxide; [0441]
(3S,6S)-2-[[2,5-difluoro-4-[4-(1,2,4-triazol-4-yl)-1-piperidyl]phenyl]met-
hyl]-3-ethyl-6-phenyl-thiazinane 1,1-dioxide; [0442]
(3S,6R)-3-ethyl-2-[[2-fluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyc-
lo[3.1.0]hexan-3-yl]phenyl]methyl]-6-phenyl-thiazinane 1,1-dioxide;
[0443]
(3S,6S)-3-ethyl-2-[[2-fluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyc-
lo[3.1.0]hexan-3-yl]phenyl]methyl]-6-phenyl-thiazinane 1,1-dioxide;
[0444]
(7S)-2-[[2,5-difluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.-
0]hexan-3-yl]phenyl]methyl]-7-phenyl-thiazepane 1,1-dioxide; [0445]
(7S)-2-[[2,5-difluoro-4-[4-(1,2,4-triazol-4-yl)-1-piperidyl]phenyl]methyl-
]-7-phenyl-thiazepane 1,1-dioxide; [0446]
(7R)-2-[[2,5-difluoro-4-[4-(1,2,4-triazol-4-yl)-1-piperidyl]phenyl]methyl-
]-7-phenyl-thiazepane 1,1-dioxide; [0447]
(7R)-2-[[2,5-difluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.-
0]hexan-3-yl]phenyl]methyl]-7-phenyl-thiazepane 1,1-dioxide; [0448]
(7S)-2-[[2-fluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]he-
xan-3-yl]phenyl]methyl]-7-phenyl-thiazepane 1,1-dioxide; [0449]
(7R)-2-[[2-fluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]he-
xan-3-yl]phenyl]methyl]-7-phenyl-thiazepane 1,1-dioxide; [0450]
(7S)-2-[[2,5-difluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.-
0]hexan-3-yl]phenyl]methyl]-7-phenyl-thiazepane 1,1-dioxide; [0451]
(7S)-2-[[2,5-difluoro-4-[4-(1,2,4-triazol-4-yl)-1-piperidyl]phenyl]methyl-
]-7-phenyl-thiazepane 1,1-dioxide; [0452]
(3S,4S)-3-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-
-2-yl]methyl]phenyl]tetrahydropyran-4-carboxylic acid; [0453]
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-N-(3-hydroxycyclobutyl)acetamide; [0454]
4-[4-[3-fluoro-4-[[(3S,6S)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]met-
hyl]phenyl]piperazin-1-yl]benzoic acid; and [0455]
4-[4-[3-fluoro-4-[[(3S,6S)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]met-
hyl]phenyl]piperazin-1-yl]-2-hydroxy-benzoic acid.
[0456] In another aspect, the invention provides a compound
selected from: [0457]
(3S,6R)-2-[2,5-Difluoro-4-(4-[1,2,4]triazol-4-yl-piperidin-1-yl)-b-
enzyl]-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide [0458]
(1R,5S,6S)-3-[2,5-Difluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]th-
iazinan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.1.0]hexa-
ne [0459]
(1S,5R,6S)-3-[2,5-Difluoro-4-((3S,6S)-3-methyl-1,1-dioxo-6-pheny-
l-[1,2]thiazinan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3-
.1.0]hexane [0460]
(3R,6S)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2,5-difluorobenzyl-
)-3-(difluoromethyl)-6-phenyl-1,2-thiazinane 1,1-dioxide [0461]
(3R,6R)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2,5-difluorobenzyl-
)-3-(difluoromethyl)-6-phenyl-1,2-thiazinane 1,1-dioxide [0462]
(3R,6S)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2,5-difluorobenzyl-
)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane 1,1-dioxide [0463]
(3R,6R)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2,5-difluorobenzyl-
)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane 1,1-dioxide [0464]
(3R,6R)-2-(4-((1R,5S,6S)-6-(4H-1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]hex-
an-3-yl)-2,5-difluorobenzyl)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane
1,1-dioxide [0465]
(3R,6S)-2-(4-((1R,5S,6S)-6-(4H-1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]hex-
an-3-yl)-2,5-difluorobenzyl)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane
1,1-dioxide [0466] (4R)-methyl
1-(2,5-difluoro-4-((3-methyl-1,1-dioxido-6-phenyl-1,2-thiazinan-2-yl)meth-
yl)phenyl)-4-(4H-1,2,4-triazol-4-yl)piperidine-3-carboxylate [0467]
2-(4-((5R)-5-(4H-1,2,4-triazol-4-yl)-2-azabicyclo[2.2.1]heptan-2-yl)-2,5--
difluorobenzyl)-3-methyl-6-phenyl-1,2-thiazinane 1,1-dioxide [0468]
2-(4-((5R)-5-(4H-1,2,4-triazol-4-yl)-2-azabicyclo[2.2.1]heptan-2-yl)-2,5--
difluorobenzyl)-3-methyl-6-phenyl-1,2-thiazinane 1,1-dioxide [0469]
(3S,6R)-2-[[2,5-difluoro-4-[(1S,4S,5S)-5-(1,2,4-triazol-4-yl)-2-azabicycl-
o[2.2.1]heptan-2-yl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane
1,1-dioxide [0470]
(3S,6R)-2-[[2,5-difluoro-4-[(1R,4R,5R)-5-(1,2,4-triazol-4-yl)-2-azabicycl-
o[2.2.1]heptan-2-yl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane
1,1-dioxide [0471] methyl
4-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1-dioxo-6-phenyl-thiazinan-2-yl]meth-
yl]phenyl]tetrahydropyran-4-carboxylate [0472]
methyl(3S,4S)-3-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thi-
azinan-2-yl]methyl]phenyl]tetrahydropyran-4-carboxylate [0473]
(3R,4R)-1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-
-2-yl]methyl]phenyl]-4-(1,2,4-triazol-4-yl)piperidin-3-ol [0474]
(3S,4S)-1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-
-2-yl]methyl]phenyl]-4-(1,2,4-triazol-4-yl)piperidin-3-ol [0475]
methyl
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1-dioxo-6-phenyl-thiazinan-2-yl]meth-
yl]phenyl]acetate [0476] methyl
4-[2,5-difluoro-4-[[(3S,6S)-3-methyl-1-dioxo-6-phenyl-thiazinan-2-yl]meth-
yl]phenyl]tetrahydropyran-4-carboxylate [0477]
(3R,4R)-3-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-
-2-yl]methyl]phenyl]tetrahydropyran-4-carboxylic acid [0478]
methyl(3S,4S)-3-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thi-
azinan-2-yl]methyl]phenyl]tetrahydropyran-4-carboxylate [0479]
methyl(3R,4R)-3-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thi-
azinan-2-yl]methyl]phenyl]tetrahydropyran-4-carboxylate [0480]
(3S,6R)-2-[[2,5-difluoro-4-[(3S,4R)-3-fluoro-4-(1,2,4-triazol-4-yl)-1-pip-
eridyl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide
[0481]
(3S,6R)-2-[[2,5-difluoro-4-[(3R,4S)-3-fluoro-4-(1,2,4-triazol-4-yl)-1-pip-
eridyl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide
[0482]
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]ethanol [0483]
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-N-(3-hydroxycyclobutyl)acetamide [0484]
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]acetamide [0485]
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]propan-1-ol [0486]
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]propan-1-ol [0487] diethyl
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1-dioxo-6-phenyl-thiazinan-2-yl]meth-
yl]phenyl]propanedioate [0488]
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]propane-1,3-diol [0489] tert-butyl
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]acetate [0490]
4-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-5-hydroxy-pentanenitrile [0491]
2-[1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl-
]methyl]phenyl]-1-methyl-ethoxy]acetic acid [0492]
2-[1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl-
]methyl]phenyl]-1-methyl-ethoxy]acetamide [0493]
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-3-(oxetan-3-yl)propan-1-ol [0494]
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-3-(oxetan-3-yl)propan-1-ol [0495]
3-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-4-hydroxy-butanenitrile [0496]
3-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-4-hydroxy-butanenitrile [0497]
3-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-4-hydroxy-butanamide [0498]
3-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-4-hydroxy-butanamide [0499]
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-2-(oxetan-3-yl)ethanol [0500]
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-2-(oxetan-3-yl)ethanol [0501]
3-[1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl-
]methyl]phenyl]-1-methyl-ethoxy]propane-1,2-diol [0502]
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-2-phenyl-ethanol [0503]
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-2-phenyl-ethanol [0504]
(2S)-3-[1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-
-2-yl]methyl]phenyl]-1-methyl-ethoxy]propane-1,2-diol [0505]
(2R)-3-[1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-
-2-yl]methyl]phenyl]-1-methyl-ethoxy]propane-1,2-diol [0506]
3-[1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl-
]methyl]phenyl]-2-hydroxy-ethyl]-1-methyl-pyrrolidin-2-one [0507]
3-[1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl-
]methyl]phenyl]-2-hydroxy-ethyl]-1-methyl-pyrrolidin-2-one [0508]
3-[1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl-
]methyl]phenyl]-2-hydroxy-ethyl]-1-methyl-pyrrolidin-2-one [0509]
3-[1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl-
]methyl]phenyl]-2-hydroxy-ethyl]-1-methyl-pyrrolidin-2-one [0510]
4-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-5-hydroxy-pentanamide [0511]
4-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-5-hydroxy-pentanamide [0512]
(3S,6R)-2-[[2,5-difluoro-4-[4-(1,2,4-triazol-4-yl)-1-piperidyl]phenyl]met-
hyl]-3-ethyl-6-phenyl-thiazinane 1,1-dioxide [0513]
(3S,6S)-2-[[2,5-difluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3-
.1.0]hexan-3-yl]phenyl]methyl]-3-ethyl-6-phenyl-thiazinane
1,1-dioxide [0514]
(3S,6R)-2-[[2,5-difluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabi-
cyclo[3.1.0]hexan-3-yl]phenyl]methyl]-3-ethyl-6-phenyl-thiazinane
1,1-dioxide [0515]
(3S,6S)-2-[[2,5-difluoro-4-[4-(1,2,4-triazol-4-yl)-1-piperidyl]phenyl]met-
hyl]-3-ethyl-6-phenyl-thiazinane 1,1-dioxide
yl]phenyl]methyl]-6-phenyl-thiazinane 1,1-dioxide [0516]
(7S)-2-[[2,5-difluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.-
0]hexan-3-yl]phenyl]methyl]-7-phenyl-thiazepane 1,1-dioxide [0517]
(7S)-2-[[2,5-difluoro-4-[4-(1,2,4-triazol-4-yl)-1-piperidyl]phenyl]methyl-
]-7-phenyl-thiazepane 1,1-dioxide [0518]
(7R)-2-[[2,5-difluoro-4-[4-(1,2,4-triazol-4-yl)-1-piperidyl]phenyl]methyl-
]-7-phenyl-thiazepane 1,1-dioxide [0519]
(7R)-2-[[2,5-difluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.-
0]hexan-3-yl]phenyl]methyl]-7-phenyl-thiazepane 1,1-dioxide [0520]
(7S)-2-[[2-fluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]he-
xan-3-yl]phenyl]methyl]-7-phenyl-thiazepane 1,1-dioxide [0521]
(7R)-2-[[2-fluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]he-
xan-3-yl]phenyl]methyl]-7-phenyl-thiazepane 1,1-dioxide [0522]
(7S)-2-[[2,5-difluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.-
0]hexan-3-yl]phenyl]methyl]-7-phenyl-thiazepane 1,1-dioxide [0523]
(7S)-2-[[2,5-difluoro-4-[4-(1,2,4-triazol-4-yl)-1-piperidyl]phenyl]methyl-
]-7-phenyl-thiazepane 1,1-dioxide [0524]
(3S,4S)-3-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-
-2-yl]methyl]phenyl]tetrahydropyran-4-carboxylic acid [0525]
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-N-(3-hydroxycyclobutyl)acetamide
[0526] In another aspect, the invention provides a compound
selected from: [0527]
(3S,6R)-2-[2,5-Difluoro-4-(4-[1,2,4]triazol-4-yl-piperidin-1-yl)-b-
enzyl]-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0528]
(1R,5S,6S)-3-[2,5-Difluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]th-
iazinan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.1.0]hexa-
ne; [0529]
(1S,5R,6S)-3-[2,5-Difluoro-4-((3S,6S)-3-methyl-1,1-dioxo-6-phen-
yl-[1,2]thiazinan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[-
3.1.0]hexane; [0530]
(3R,6S)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2,5-difluorobenzyl-
)-3-(difluoromethyl)-6-phenyl-1,2-thiazinane 1,1-dioxide; [0531]
(3R,6R)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2,5-difluorobenzyl-
)-3-(difluoromethyl)-6-phenyl-1,2-thiazinane 1,1-dioxide; [0532]
(3R,6S)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2,5-difluorobenzyl-
)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane 1,1-dioxide; [0533]
(3R,6R)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2,5-difluorobenzyl-
)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane 1,1-dioxide; [0534]
(3R,6R)-2-(4-((1R,5S,6S)-6-(4H-1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]hex-
an-3-yl)-2,5-difluorobenzyl)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane
1,1-dioxide; [0535]
(3R,6S)-2-(4-((1R,5S,6S)-6-(4H-1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]hex-
an-3-yl)-2,5-difluorobenzyl)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane
1,1-dioxide; [0536] (4R)-methyl
1-(2,5-difluoro-4-((3-methyl-1,1-dioxido-6-phenyl-1,2-thiazinan-2-yl)meth-
yl)phenyl)-4-(4H-1,2,4-triazol-4-yl)piperidine-3-carboxylate;
[0537]
2-(4-((5R)-5-(4H-1,2,4-triazol-4-yl)-2-azabicyclo[2.2.1]heptan-2-yl)-2,5--
difluorobenzyl)-3-methyl-6-phenyl-1,2-thiazinane 1,1-dioxide;
[0538]
2-(4-((5R)-5-(4H-1,2,4-triazol-4-yl)-2-azabicyclo[2.2.1]heptan-2-yl)-2,5--
difluorobenzyl)-3-methyl-6-phenyl-1,2-thiazinane 1,1-dioxide;
[0539]
(3S,6R)-2-[[2,5-difluoro-4-[(1S,4S,5S)-5-(1,2,4-triazol-4-yl)-2-azabicycl-
o[2.2.1]heptan-2-yl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane
1,1-dioxide; [0540]
(3S,6R)-2-[[2,5-difluoro-4-[(1R,4R,5R)-5-(1,2,4-triazol-4-yl)-2-azabicycl-
o[2.2.1]heptan-2-yl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane
1,1-dioxide; [0541]
(3R,4R)-1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-
-2-yl]methyl]phenyl]-4-(1,2,4-triazol-4-yl)piperidin-3-ol; [0542]
(3S,4S)-1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-
-2-yl]methyl]phenyl]-4-(1,2,4-triazol-4-yl)piperidin-3-01; [0543]
(3S,6R)-2-[[2,5-difluoro-4-[(3S,4R)-3-fluoro-4-(1,2,4-triazol-4-yl)-1-pip-
eridyl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide;
[0544]
(3S,6R)-2-[[2,5-difluoro-4-[(3R,4S)-3-fluoro-4-(1,2,4-triazol-4-yl)-1-pip-
eridyl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide;
[0545]
(3S,6R)-2-[[2,5-difluoro-4-[4-(1,2,4-triazol-4-yl)-1-piperidyl]phenyl]met-
hyl]-3-ethyl-6-phenyl-thiazinane 1,1-dioxide; [0546]
(3S,6S)-2-[[2,5-difluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3-
.1.0]hexan-3-yl]phenyl]methyl]-3-ethyl-6-phenyl-thiazinane
1,1-dioxide; [0547]
(3S,6R)-2-[[2,5-difluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabi-
cyclo[3.1.0]hexan-3-yl]phenyl]methyl]-3-ethyl-6-phenyl-thiazinane
1,1-dioxide; [0548]
(3S,6S)-2-[[2,5-difluoro-4-[4-(1,2,4-triazol-4-yl)-1-piperidyl]phenyl]met-
hyl]-3-ethyl-6-phenyl-thiazinane 1,1-dioxide;
yl]phenyl]methyl]-6-phenyl-thiazinane 1,1-dioxide; [0549]
(7S)-2-[[2,5-difluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.-
0]hexan-3-yl]phenyl]methyl]-7-phenyl-thiazepane 1,1-dioxide; [0550]
(7S)-2-[[2,5-difluoro-4-[4-(1,2,4-triazol-4-yl)-1-piperidyl]phenyl]methyl-
]-7-phenyl-thiazepane 1,1-dioxide; [0551]
(7R)-2-[[2,5-difluoro-4-[4-(1,2,4-triazol-4-yl)-1-piperidyl]phenyl]methyl-
]-7-phenyl-thiazepane 1,1-dioxide; [0552]
(7R)-2-[[2,5-difluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.-
0]hexan-3-yl]phenyl]methyl]-7-phenyl-thiazepane 1,1-dioxide; [0553]
(7S)-2-[[2-fluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]he-
xan-3-yl]phenyl]methyl]-7-phenyl-thiazepane 1,1-dioxide; [0554]
(7R)-2-[[2-fluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]he-
xan-3-yl]phenyl]methyl]-7-phenyl-thiazepane 1,1-dioxide; [0555]
(7S)-2-[[2,5-difluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.-
0]hexan-3-yl]phenyl]methyl]-7-phenyl-thiazepane 1,1-dioxide; and
[0556]
(7S)-2-[[2,5-difluoro-4-[4-(1,2,4-triazol-4-yl)-1-piperidyl]phenyl]methyl-
]-7-phenyl-thiazepane 1,1-dioxide.
[0557] In another aspect, the invention provides a compound
selected from: [0558]
(3S,6R)-2-[2,5-Difluoro-4-(4-[1,2,4]triazol-4-yl-piperidin-1-yl)-b-
enzyl]-3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0559]
(3R,6S)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2,5-difluorobenzyl-
)-3-(difluoromethyl)-6-phenyl-1,2-thiazinane 1,1-dioxide; [0560]
(3R,6R)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2,5-difluorobenzyl-
)-3-(difluoromethyl)-6-phenyl-1,2-thiazinane 1,1-dioxide; [0561]
(3R,6S)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2,5-difluorobenzyl-
)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane 1,1-dioxide; [0562]
(3R,6R)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2,5-difluorobenzyl-
)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane 1,1-dioxide; [0563]
(4R)-methyl
1-(2,5-difluoro-4-((3-methyl-1,1-dioxido-6-phenyl-1,2-thiazinan-2-yl)meth-
yl)phenyl)-4-(4H-1,2,4-triazol-4-yl)piperidine-3-carboxylate;
[0564]
(3R,4R)-1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-
-2-yl]methyl]phenyl]-4-(1,2,4-triazol-4-yl)piperidin-3-ol; [0565]
(3S,4S)-1-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-
-2-yl]methyl]phenyl]-4-(1,2,4-triazol-4-yl)piperidin-3-01; [0566]
(3S,6R)-2-[[2,5-difluoro-4-[(3S,4R)-3-fluoro-4-(1,2,4-triazol-4-yl)-1-pip-
eridyl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide;
[0567]
(3S,6R)-2-[[2,5-difluoro-4-[(3R,4S)-3-fluoro-4-(1,2,4-triazol-4-yl)-1-pip-
eridyl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide;
[0568]
(3S,6R)-2-[[2,5-difluoro-4-[4-(1,2,4-triazol-4-yl)-1-piperidyl]phenyl]met-
hyl]-3-ethyl-6-phenyl-thiazinane 1,1-dioxide; [0569]
(7S)-2-[[2,5-difluoro-4-[4-(1,2,4-triazol-4-yl)-1-piperidyl]phenyl]methyl-
]-7-phenyl-thiazepane 1,1-dioxide;
(7R)-2-[[2,5-difluoro-4-[4-(1,2,4-triazol-4-yl)-1-piperidyl]phenyl]methyl-
]-7-phenyl-thiazepane 1,1-dioxide; and [0570]
(7S)-2-[[2,5-difluoro-4-[4-(1,2,4-triazol-4-yl)-1-piperidyl]phenyl]methyl-
]-7-phenyl-thiazepane 1,1-dioxide.
[0571] In another aspect, the invention provides a compound
selected from: [0572]
(1R,5S,6S)-3-[2,5-Difluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl--
[1,2]thiazinan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.1-
.0]hexane; [0573]
(1S,5R,6S)-3-[2,5-Difluoro-4-((3S,6S)-3-methyl-1,1-dioxo-6-phenyl-[1,2]th-
iazinan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.1.0]hexa-
ne; [0574]
(3R,6R)-2-(4-((1R,5S,6S)-6-(4H-1,2,4-triazol-4-yl)-3-azabicyclo-
[3.1.0]hexan-3-yl)-2,5-difluorobenzyl)-6-phenyl-3-(trifluoromethyl)-1,2-th-
iazinane 1,1-dioxide; [0575]
(3R,6S)-2-(4-((1R,5S,6S)-6-(4H-1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]hex-
an-3-yl)-2,5-difluorobenzyl)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane
1,1-dioxide; [0576]
2-(4-((5R)-5-(4H-1,2,4-triazol-4-yl)-2-azabicyclo[2.2.1]heptan-2-yl)-2,5--
difluorobenzyl)-3-methyl-6-phenyl-1,2-thiazinane 1,1-dioxide;
[0577]
2-(4-((5R)-5-(4H-1,2,4-triazol-4-yl)-2-azabicyclo[2.2.1]heptan-2-yl)-2,5--
difluorobenzyl)-3-methyl-6-phenyl-1,2-thiazinane 1,1-dioxide;
[0578] (3S,6R)-2-[[2,5-difluoro-4-[(1
S,4S,5S)-5-(1,2,4-triazol-4-yl)-2-azabicyclo[2.2.1]heptan-2-yl]phenyl]met-
hyl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide; [0579]
(3S,6R)-2-[[2,5-difluoro-4-[(1R,4R,5R)-5-(1,2,4-triazol-4-yl)-2-azabicycl-
o[2.2.1]heptan-2-yl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane
1,1-dioxide; [0580]
(3S,6S)-2-[[2,5-difluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3-
.1.0]hexan-3-yl]phenyl]methyl]-3-ethyl-6-phenyl-thiazinane
1,1-dioxide; [0581]
(3S,6R)-2-[[2,5-difluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabi-
cyclo[3.1.0]hexan-3-yl]phenyl]methyl]-3-ethyl-6-phenyl-thiazinane
1,1-dioxide; [0582]
(3S,6R)-3-ethyl-2-[[2-fluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyc-
lo[3.1.0]hexan-3-yl]phenyl]methyl]-6-phenyl-thiazinane 1,1-dioxide;
[0583]
(3S,6S)-3-ethyl-2-[[2-fluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyc-
lo[3.1.0]hexan-3-yl]phenyl]methyl]-6-phenyl-thiazinane 1,1-dioxide;
[0584]
(7S)-2-[[2,5-difluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.-
0]hexan-3-yl]phenyl]methyl]-7-phenyl-thiazepane 1,1-dioxide; [0585]
(7R)-2-[[2,5-difluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.-
0]hexan-3-yl]phenyl]methyl]-7-phenyl-thiazepane 1,1-dioxide; [0586]
(7S)-2-[[2-fluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]he-
xan-3-yl]phenyl]methyl]-7-phenyl-thiazepane 1,1-dioxide; [0587]
(7R)-2-[[2-fluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]he-
xan-3-yl]phenyl]methyl]-7-phenyl-thiazepane 1,1-dioxide; and [0588]
(7S)-2-[[2,5-difluoro-4-[(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.-
0]hexan-3-yl]phenyl]methyl]-7-phenyl-thiazepane 1,1-dioxide.
[0589] In another aspect, the invention provides a compound
selected from: [0590]
(1R,5S,6S)-3-[2,5-Difluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl--
[1,2]thiazinan-2-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.1-
.0]hexane; [0591]
(3R,6R)-2-(4-((1R,5S,6S)-6-(4H-1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]hex-
an-3-yl)-2,5-difluorobenzyl)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane
1,1-dioxide; [0592]
(3S,6R)-2-[2,5-Difluoro-4-(4-[1,2,4]triazol-4-yl-piperidin-1-yl)-benzyl]--
3-methyl-6-phenyl-[1,2]thiazinane 1,1-dioxide; [0593]
(3R,6R)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2,5-difluorobenzyl-
)-3-(difluoromethyl)-6-phenyl-1,2-thiazinane 1,1-dioxide; and
[0594]
(3R,6R)-2-(4-(4-(4H-1,2,4-triazol-4-yl)piperidin-1-yl)-2,5-difluorobenzyl-
)-6-phenyl-3-(trifluoromethyl)-1,2-thiazinane 1,1-dioxide.
[0595] In certain embodiments of formula I, when A is a heteroatom,
then X is --CH--.
[0596] In certain embodiments of formula I, when Y is a heteroatom,
then q is 1 or 2.
[0597] In certain embodiments of formula I, when Y and Z are
heteroatom, then q is 2 and r is 2 or 3.
[0598] In certain embodiments of formula I, when Z is a heteroatom
and A is --(CR.sub.jR.sub.k).sub.t--;
--NR.sup.a--(CR.sub.jR.sub.k); --O--(CR.sub.jR.sub.k).sub.t;
--S--(CR.sub.jR.sub.k).sub.t; or
--SO.sub.2--(CR.sub.jR.sub.k).sub.t; then t is from 2 to 4.
[0599] In certain embodiments of formula I, m is 0.
[0600] In certain embodiments of formula I, m is 1.
[0601] In certain embodiments of formula I, n is 0.
[0602] In certain embodiments of formula I, n is 1.
[0603] In certain embodiments of formula I, p is from 0 to 2.
[0604] In certain embodiments of formula I, p is 0 or 1.
[0605] In certain embodiments of formula I, p is 0.
[0606] In certain embodiments of formula I, p is 1.
[0607] In certain embodiments of formula I, p is 2.
[0608] In certain embodiments of formula I, p is 3.
[0609] In certain embodiments of formula I, q is 0.
[0610] In certain embodiments of formula I, q is 1.
[0611] In certain embodiments of formula I, q is 2.
[0612] In certain embodiments of formula I, r is 1.
[0613] In certain embodiments of formula I, r is 2.
[0614] In certain embodiments of formula I, r is 3.
[0615] In certain embodiments of formula I, t is from 0 to 3.
[0616] In certain embodiments of formula I, t is 0.
[0617] In certain embodiments of formula I, t is 1.
[0618] In certain embodiments of formula I, t is 2.
[0619] In certain embodiments of formula I, t is 3.
[0620] In certain embodiments of formula I, A is: a bond;
--CH.sub.2--; --C(O)--; --NR.sup.a--; --O--; --S--; or
--SO.sub.2--.
[0621] In certain embodiments of formula I, A is: a bond;
--(CR.sub.jR.sub.k).sub.t--; --C(O)--(CR.sub.jR.sub.k)--;
--(CR.sup.jR.sub.k).sub.t--C(O)--;
--(CR.sup.jR.sub.k).sub.t--NR.sup.a--;
--C(O)NR.sup.a--(CR.sup.jR.sub.k).sub.t--;
--(CR.sub.jR.sub.k).sub.t--NR.sup.aC(O)--;
--(CR.sup.jR.sub.k).sub.t--O--; --(CR.sub.jR.sub.k).sub.t--S--; --
or --(CR.sub.jR.sub.k).sub.t--SO.sub.2--.
[0622] In certain embodiments of formula I, A is: a bond;
--C(O)--(CR.sub.jR.sub.k).sub.t--; --(CR.sub.jR.sub.k--C(O)--;
--(CR.sub.jR.sub.k).sub.t--NR.sup.a--;
--C(O)NR.sup.a--(CR.sub.jR.sub.k).sub.t--;
(CR.sub.jR.sub.k).sub.t--NR.sup.aC(O)--; or
--(CR.sub.jR.sub.k).sub.t--O--.
[0623] In certain embodiments of formula I, A is: a bond;
--NR.sup.a--; --O--; or --S--.
[0624] In certain embodiments of formula I, A is: a bond;
--NR.sup.a--; or --O--.
[0625] In certain embodiments of formula I, A is a bond.
[0626] In certain embodiments of formula I, A is --CH.sub.2--.
[0627] In certain embodiments of formula I, A is --C(O)--.
[0628] In certain embodiments of formula I, A is --NR.sup.a--.
[0629] In certain embodiments of formula I, A is --O--.
[0630] In certain embodiments of formula I, A is --S--.
[0631] In certain embodiments of formula I, A is --SO.sub.2--.
[0632] In certain embodiments of formula I, A is
--C(O)NR.sup.a--(CH.sub.2).sub.t.
[0633] In certain embodiments of formula I, A is
--(CH.sub.2).sub.t--NR.sup.aC(O)--.
[0634] In certain embodiments of formula I, A is
--(CR.sub.jR.sub.k)--.
[0635] In certain embodiments of formula I, A is
--CR.sub.jR.sub.k--.
[0636] In certain embodiments of formula I, A is
--C(O)--(CR.sub.jR.sub.k).sub.t--.
[0637] In certain embodiments of formula I, A is
--(CR.sub.jR.sub.k).sub.t--C(O)--.
[0638] In certain embodiments of formula I, A is
--NR.sup.a--(CR.sub.jR.sub.k).sub.t--.
[0639] In certain embodiments of formula I, A is
--(CR.sub.jR.sub.k).sub.t--NR.sup.a--.
[0640] In certain embodiments of formula I, A is
--C(O)NR.sup.a--(CR.sub.jR.sub.k)--.
[0641] In certain embodiments of formula I, A is
(CR.sub.jR.sub.k).sub.t--NR.sup.aC(O)--.
[0642] In certain embodiments of formula I, A is
--O--(CR.sub.jR.sub.k).sub.t--.
[0643] In certain embodiments of formula I, A is
--(CR.sub.jR.sub.k).sub.t--O--.
[0644] In certain embodiments of formula I, A is
--S--(CR.sub.jR.sub.k).sub.t--.
[0645] In certain embodiments of formula I, A is
--(CR.sub.jR.sub.k)--S--.
[0646] In certain embodiments of formula I, A is
--SO.sub.2--(CR.sub.jR.sub.k).sub.t--.
[0647] In certain embodiments of formula I, A is
--(CR.sub.jR.sub.k)--SO.sub.2--.
[0648] In certain embodiments of formula I, A is
--(CH.sub.2).sub.2--O--.
[0649] In certain embodiments of formula I, A is
--(CH.sub.2)--O--.
[0650] In certain embodiments of formula I, A is
--O--(CH.sub.2).sub.2--.
[0651] In certain embodiments of formula I, A is
--O--(CH.sub.2)--.
[0652] In certain embodiments of formula I, A is
--(CH.sub.2).sub.2--C(O)--.
[0653] In certain embodiments of formula I, A is
--(CH.sub.2)--C(O)--.
[0654] In certain embodiments of formula I, A is
--C(O)--(CH.sub.2).sub.2--.
[0655] In certain embodiments of formula I, A is
--C(O)--(CH.sub.2)--.
[0656] In certain embodiments of formula I, A is --C(O)--NH--.
[0657] In certain embodiments of formula I, A is
--CH.sub.2--C(O)--NH--.
[0658] In certain embodiments of formula I, A is --NH--.
[0659] In certain embodiments of formula I, A is
--(CH.sub.2).sub.2--NH--.
[0660] In certain embodiments of formula I, A is
--CH.sub.2--NH--.
[0661] In certain embodiments of formula I, A is
--NH--(CH.sub.2).sub.2--.
[0662] In certain embodiments of formula I, A is
--NH--CH.sub.2--.
[0663] In certain embodiments of formula I, A is --NH--C(O)--.
[0664] In certain embodiments of formula I, t is from 0 to 3.
[0665] In certain embodiments of formula I, t is from 1 to 3.
[0666] In certain embodiments of formula I, t is from 0 to 2.
[0667] In certain embodiments of formula I, t is 0.
[0668] In certain embodiments of formula I, t is 1.
[0669] In certain embodiments of formula I, t is 2.
[0670] In certain embodiments of formula I, t is 3.
[0671] In certain embodiments of formula I, t is 4.
[0672] In certain embodiments of formula I, W is
--CR.sup.bR.sup.c-- or --O--.
[0673] In certain embodiments of formula I, W is
--CR.sup.bR.sup.c--.
[0674] In certain embodiments of formula I, W is --O--.
[0675] In certain embodiments of formula I, W is --NR.sup.d--.
[0676] In certain embodiments of formula I, W is --S--.
[0677] In certain embodiments of formula I, W is --SO.sub.2--.
[0678] In certain embodiments of formula I, W is --CH.sub.2--.
[0679] In certain embodiments of formula I, one or two of X.sup.1,
X.sup.2, X.sup.3 and X.sup.4 is N and the others are CR.sup.e.
[0680] In certain embodiments of formula I, three of X.sup.1,
X.sup.2, X.sup.3 and X.sup.4 are CR.sup.e and the other is N.
[0681] In certain embodiments of formula I, X.sup.1, X.sup.2,
X.sup.3 and X.sup.4 are CR.sup.e.
[0682] In certain embodiments of formula I, X.sup.1 is N and
X.sup.2, X.sup.3 and X.sup.4 are CR.sup.e.
[0683] In certain embodiments of formula I, X.sup.2 is N and
X.sup.1, X.sup.3 and X.sup.4 are CR.sup.e.
[0684] In certain embodiments of formula I, X.sup.1 and X.sup.4 are
N, and X.sup.2 and X.sup.3 are CR.sup.a.
[0685] In certain embodiments of formula I, X.sup.2 and X.sup.3 are
N, and X.sup.1 and X.sup.4 are CR.sup.e.
[0686] In certain embodiments of formula I, X.sup.1 and X.sup.2 are
N, and X.sup.3 and X.sup.4 are CR.sup.e.
[0687] In certain embodiments of formula I, Y is --O--,
--CR.sup.fR.sup.g-- or --NR.sup.h--.
[0688] In certain embodiments of formula I, Y is
--CR.sup.fR.sup.g-- or --NR.sup.h--.
[0689] In certain embodiments of formula I, Y is --O--.
[0690] In certain embodiments of formula I, Y is --S--.
[0691] In certain embodiments of formula I, Y is --SO.sub.2--.
[0692] In certain embodiments of formula I, Y is
--CR.sup.fR.sup.g--.
[0693] In certain embodiments of formula I, Y is --NR.sup.h--.
[0694] In certain embodiments of formula I, Z is CH.
[0695] In certain embodiments of formula I, Z is N.
[0696] In certain embodiments of formula I, Z is N wherein the N is
oxidized.
[0697] In certain embodiments of formula I, each R.sup.1 is
independently: C.sub.1-6alkyl; halo; C.sub.1-6alkoxy; cyano;
halo-C.sub.1-6alkyl; or halo-C.sub.1-6alkoxy.
[0698] In certain embodiments of formula I, R.sup.1 is
hydrogen.
[0699] In certain embodiments of formula I, R.sup.1 is
C.sub.1-6alkyl.
[0700] In certain embodiments of formula I, R.sup.2 is
hydrogen.
[0701] In certain embodiments of formula I, R.sup.2 is
C.sub.1-6alkyl.
[0702] In certain embodiments of formula I, R.sup.3 is
hydrogen.
[0703] In certain embodiments of formula I, R.sup.3 is
C.sub.1-6alkyl.
[0704] In certain embodiments of formula I, R.sup.3 is
halo-C.sub.1-6alkyl.
[0705] In certain embodiments of formula I, R.sup.3 is
difluoromethyl.
[0706] In certain embodiments of formula I, R.sup.3 is
trifluoromethyl.
[0707] In certain embodiments of formula I, R.sup.4 is
hydrogen.
[0708] In certain embodiments of formula I, R.sup.4 is
C.sub.1-6alkyl.
[0709] In certain embodiments of formula I, R.sup.5 is
hydrogen.
[0710] In certain embodiments of formula I, R.sup.5 is
C.sub.1-6alkyl.
[0711] In certain embodiments of formula I, R.sup.6 is
hydrogen.
[0712] In certain embodiments of formula I, R.sup.6 is
C.sub.1-6alkyl.
[0713] In certain embodiments of formula I, R.sup.7 is
hydrogen.
[0714] In certain embodiments of formula I, R.sup.7 is
C.sub.1-6alkyl.
[0715] In certain embodiments of formula I, R.sup.8 is
hydrogen.
[0716] In certain embodiments of formula I, R.sup.8 is
C.sub.1-6alkyl.
[0717] In certain embodiments of formula I, R.sup.3 and R.sup.4
together with the atoms to which they are attached form a three,
four, five, six or seven membered saturated or partially saturated
ring that may optionally include one or two heteroatoms selected
from --O--, --NR.sup.a-- or --S--, and which may be optionally
substituted one or more times with R.sup.i.
[0718] In certain embodiments of formula I, R.sup.3 and R.sup.4
together with the atoms to which they are attached form a three,
four or five membered saturated ring.
[0719] In certain embodiments of formula I, R.sup.5 and R.sup.6
together with the atoms to which they are attached form a three,
four, five, six or seven membered saturated or partially saturated
ring that may optionally include one or two heteroatoms selected
from --O--, --NR.sup.a-- or --S--, and which may be optionally
substituted one or more times with R.sup.i.
[0720] In certain embodiments of formula I, R.sup.5 and R.sup.6
together with the atoms to which they are attached form a three,
four or five membered saturated ring.
[0721] In certain embodiments of formula I, R.sup.7 and R.sup.8
together with the atoms to which they are attached form a three,
four, five, six or seven membered saturated or partially saturated
ring that may optionally include one or two heteroatoms selected
from --O--, --NR.sup.a-- or --S--, and which may be optionally
substituted one or more times with R.sup.i.
[0722] In certain embodiments of formula I, R.sup.7 and R.sup.8
together with the atoms to which they are attached form a three,
four or five membered saturated ring.
[0723] In certain embodiments of formula I, one of R.sup.3 and
R.sup.4 together with one of R.sup.5 and R.sup.6 and the atoms to
which they are attached form a three, four, five, six or seven
membered ring that may optionally include one or two heteroatoms
selected from --O--, --NR.sup.a-- or --S--, and which may be
optionally substituted one or more times with R.sup.i.
[0724] In certain embodiments of formula I, one of R.sup.5 and
R.sup.6 together with one of R.sup.7 and R.sup.8 and the atoms to
which they are attached form a three, four, five, six or seven
membered saturated or partially saturated ring that may optionally
include one or two heteroatoms selected from --O--, --NR.sup.a-- or
--S--, and which may be optionally substituted one or more times
with R.sup.i.
[0725] In certain embodiments of formula I, each R.sup.9 is
independently: C.sub.1-6alkyl; halo; or halo-C.sub.1-6alkyl.
[0726] In certain embodiments of formula I, R.sup.9 is
C.sub.1-6alkyl.
[0727] In certain embodiments of formula I, R.sup.9 is halo.
[0728] In certain embodiments of formula I, R.sup.9 is
C.sub.1-6alkoxy.
[0729] In certain embodiments of formula I, R.sup.9 is cyano.
[0730] In certain embodiments of formula I, R.sup.9 is
halo-C.sub.1-6alkyl.
[0731] In certain embodiments of formula I, each R.sup.9 is
independently: fluoro; chloro; or trifluoromethyl.
[0732] In certain embodiments of formula I, R.sup.10 is: hydrogen;
halo; or C.sub.1-6alkyl which may be unsubstituted or substituted
one or more times with halo or oxo.
[0733] In certain embodiments of formula I, R.sup.10 is: hydrogen
or C.sub.1-6alkyl.
[0734] In certain embodiments of formula I, R.sup.10 is
hydrogen.
[0735] In certain embodiments of formula I, R.sup.10 is
C.sub.1-6alkyl.
[0736] In certain embodiments of formula I, R.sup.10 is methyl.
[0737] In certain embodiments of formula I, R.sup.10 is halo.
[0738] In certain embodiments of formula I, R.sup.10 is
carboxy.
[0739] In certain embodiments of formula I, R.sup.10 is
C.sub.1-6alkyl-carbonyl.
[0740] In certain embodiments of formula I, R.sup.10 is
C.sub.1-6alkoxy-carbonyl. In certain embodiments of formula I,
R.sup.10 is oxo.
[0741] In certain embodiments of formula I, R.sup.10 is
hydroxy.
[0742] In certain embodiments of formula I, R.sup.10 is
aminocarbonyl.
[0743] In certain embodiments of formula I, R.sup.10 is
N--C.sub.1-6alkyl-aminocarbonyl.
[0744] In certain embodiments of formula I, R.sup.10 is
N,N-di-C.sub.1-6alkyl-aminocarbonyl.
[0745] In certain embodiments of formula I, R.sup.10 is cyano
[0746] In certain embodiments of formula I, R.sup.10 is
hydroxy-C.sub.1-6alkyl.
[0747] In certain embodiments of formula I, R.sup.10 is
N--C.sub.1-6alkoxy-C.sub.1-6alkyl-aminocarbonyl.
[0748] In certain embodiments of formula I, R.sup.10 is
N-hydroxy-C.sub.1-6alkyl-aminocarbonyl.
[0749] In certain embodiments of formula I, R.sup.10 is
N--C.sub.1-6alkoxy-aminocarbonyl.
[0750] In certain embodiments of formula I, R.sup.11 is: hydrogen;
halo; oxo; hydroxy; or C.sub.1-6alkyl which may be unsubstituted or
substituted one or more times with halo; or oxo.
[0751] In certain embodiments of formula I, R.sup.11 is: hydrogen;
halo; carboxy; C.sub.1-6alkyl-carbonyl; C.sub.1-6alkoxy-carbonyl;
oxo; hydroxy; aminocarbonyl; N--C.sub.1-6alkyl-aminocarbonyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl; or C.sub.1-6alkyl which may be
unsubstituted or substituted one or more times with halo or
oxo.
[0752] In certain embodiments of formula I, R.sup.11 is: hydrogen;
halo; or C.sub.1-6alkyl.
[0753] In certain embodiments of formula I, R.sup.11 is: hydrogen;
C.sub.1-6alkyl; or halo.
[0754] In certain embodiments of formula I, R.sup.11 is: hydrogen;
or C.sub.1-6alkyl.
[0755] In certain embodiments of formula I, R.sup.11 is
hydrogen.
[0756] In certain embodiments of formula I, R.sup.11 is
C.sub.1-6alkyl
[0757] In certain embodiments of formula I, R.sup.101 is
methyl.
[0758] In certain embodiments of formula I, R.sup.11 is halo.
[0759] In certain embodiments of formula I, R.sup.11 is oxo.
[0760] In certain embodiments of formula I, R.sup.11 is
C.sub.1-6alkyl-sulfonylamino.
[0761] In certain embodiments of formula I, R.sup.11 is
C.sub.1-6alkyl-sulfonylamino-C.sub.1-6alkyl.
[0762] In certain embodiments of formula I, R.sup.11 is cyano.
[0763] In certain embodiments of formula I, R.sup.11 is
hydroxy-C.sub.1-6alkyl.
[0764] In certain embodiments of formula I, R.sup.11 is
N--C.sub.1-4 alkoxy-C.sub.1-6 alkyl-aminocarbonyl.
[0765] In certain embodiments of formula I, R.sup.11 is
N-hydroxy-C.sub.1-6alkyl-aminocarbonyl.
[0766] In certain embodiments of formula I, R.sup.11 is
N--C.sub.1-6alkoxy-aminocarbonyl.
[0767] In certain embodiments of formula I, R.sup.12 is: hydrogen;
or C.sub.1-6alkyl.
[0768] In certain embodiments of formula I, R.sup.12 is
hydrogen.
[0769] In certain embodiments of formula I, R.sup.12 is halo.
[0770] In certain embodiments of formula I, R.sup.12 is
carboxy.
[0771] In certain embodiments of formula I, R.sup.12 is
C.sub.1-6alkyl-carbonyl.
[0772] In certain embodiments of formula I, R.sup.12 is
C.sub.1-6alkoxy-carbonyl.
[0773] In certain embodiments of formula I, R.sup.12 is oxo.
[0774] In certain embodiments of formula I, R.sup.12 is
hydroxy.
[0775] In certain embodiments of formula I, R.sup.12 is
aminocarbonyl.
[0776] In certain embodiments of formula I, R.sup.12 is
N--C.sub.1-6alkyl-aminocarbonyl.
[0777] In certain embodiments of formula I, R.sup.12 is
N,N-di-C.sub.1-6alkyl-aminocarbonyl.
[0778] In certain embodiments of formula I, R.sup.12 is cyano.
[0779] In certain embodiments of formula I, R.sup.12 is
hydroxy-C.sub.1-6alkyl.
[0780] In certain embodiments of formula I, R.sup.12 is
N--C.sub.1-6alkoxy-C.sub.1-6alkyl-aminocarbonyl.
[0781] In certain embodiments of formula I, R.sup.12 is
N-hydroxy-C.sub.1-6alkyl-aminocarbonyl.
[0782] In certain embodiments of formula I, R.sup.12 is
N--C.sub.1-6alkoxy-aminocarbonyl.
[0783] In certain embodiments of formula I, R.sup.12 is
C.sub.1-6alkyl.
[0784] In certain embodiments of formula I, R.sup.12 is methyl.
[0785] In certain embodiments of formula I, R.sup.10 and R.sup.11
together with the atoms to which they are attached form a three,
four, five, six or seven membered saturated or partially saturated
ring that may optionally include one or two heteroatoms selected
from --O--, --NR.sup.a-- or --S--, and which may be optionally
substituted one or more times with R.sup.i.
[0786] In certain embodiments of formula I, R.sup.10 and R.sup.11
together with the atoms to which they are attached form a four,
five, six or seven membered ring.
[0787] In certain embodiments of formula I, R.sup.10 and R.sup.11
together with the atoms to which they are attached form a double
bond.
[0788] In certain embodiments of formula I, R.sup.13 is
hydrogen.
[0789] In certain embodiments of formula I, R.sup.13 is
C.sub.1-6alkyl.
[0790] In certain embodiments of formula I, R.sup.a, R.sup.b,
R.sup.c and R.sup.d each independent is: hydrogen; or
C.sub.1-6alkyl which may be unsubstituted or
[0791] In certain embodiments of formula I, R.sup.a is
hydrogen.
[0792] In certain embodiments of formula I, R.sup.a is
C.sub.1-6alkyl.
[0793] In certain embodiments of formula I, R.sup.b is
hydrogen.
[0794] In certain embodiments of formula I, R.sup.b is
C.sub.1-6alkyl.
[0795] In certain embodiments of formula I, R.sup.c is
hydrogen.
[0796] In certain embodiments of formula I, R.sup.c is
C.sub.1-6alkyl.
[0797] In certain embodiments of formula I, R.sup.b and R.sup.c
together with the atoms to which they are attached form a three,
four, five, six or seven membered saturated or partially saturated
ring that may optionally include one or two heteroatoms selected
from --O--, --NR.sup.a-- or --S--, and which may be optionally
substituted one or more times with R.sup.i.
[0798] In certain embodiments of formula I, one of R.sup.b and
R.sup.c together with one of R.sup.7 and R.sup.8 and the atoms to
which they are attached form a three, four, five, six or seven
membered saturated or partially saturated ring that may optionally
include one or two heteroatoms selected from --O--, --NR.sup.a-- or
--S--, and which may be optionally substituted one or more times
with R.sup.i.
[0799] In certain embodiments of formula I, one of R.sup.b and
R.sup.c together with one of R.sup.5 and R.sup.6 and the atoms to
which they are attached form a three, four, five, six or seven
membered saturated or partially saturated ring that may optionally
include one or two heteroatoms selected from --O--, --NR.sup.a-- or
--S--, and which may be optionally substituted one or more times
with R.sup.i.
[0800] In certain embodiments of formula I, R.sup.d is
hydrogen.
[0801] In certain embodiments of formula I, R.sup.d is
C.sub.1-6alkyl.
[0802] In certain embodiments of formula I, each R.sup.e is
independently: hydrogen; C.sub.1-6alkyl; halo; or
halo-C.sub.1-6alkyl.
[0803] In certain embodiments of formula I, each R.sup.e is
independently: hydrogen; C.sub.1-6alkyl; or halo.
[0804] In certain embodiments of formula I, each R.sup.e is
independently: hydrogen; or halo.
[0805] In certain embodiments of formula I, each R.sup.e is
independently: hydrogen; or fluoro.
[0806] In certain embodiments of formula I, R.sup.e is
hydrogen.
[0807] In certain embodiments of formula I, R.sup.e is
C.sub.1-6alkyl.
[0808] In certain embodiments of formula I, R.sup.e is halo.
[0809] In certain embodiments of formula I, R.sup.e is
C.sub.1-6alkoxy.
[0810] In certain embodiments of formula I, R.sup.e is cyano.
[0811] In certain embodiments of formula I, R.sup.e is
halo-C.sub.1-6alkyl.
[0812] In certain embodiments of formula I, each R.sup.f is
independently: hydrogen; or C.sub.1-6alkyl.
[0813] In certain embodiments of formula I, R.sup.f is
hydrogen.
[0814] In certain embodiments of formula I, R.sup.f is
C.sub.1-6alkyl.
[0815] In certain embodiments of formula I, R.sup.f is halo.
[0816] In certain embodiments of formula I, R.sup.g is:
C.sub.1-6alkyl; C.sub.3-6cycloalkyl; C.sub.3-6cycloalkenyl;
C.sub.3-6cycloalkyl-C.sub.1-6alkyl; halo; C.sub.1-6alkyl-carbonyl;
C.sub.3-6cycloalkyl-carbonyl;
C.sub.1-6cycloalkyl-C.sub.1-6alkyl-carbonyl;
cyano-C.sub.1-6alkyl-carbonyl; hydroxy-C.sub.1-6alkyl-carbonyl;
C.sub.1-6alkoxy-C.sub.1-9alkyl-carbonyl; carboxy;
N-cyano-aminocarbonyl; N-cyano-N--C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkyl-acetimidamidyl;
N,N'-di-C.sub.1-6alkyl-acetimidamidyl;
N'-cyano-N--C.sub.1-6alkyl-acetimidamidyl;
N'-hydroxy-acetimidamidyl; N'--C.sub.1-6alkoxy-acetimidamidyl;
N'-hydroxy-N--C.sub.1-6alkyl-acetimidamidyl;
N'--C.sub.1-6alkoxy-N--C.sub.1-6alkyl-acetimidamidyl;
2-nitro-1-N--C.sub.1-6alkylamino-vinyl; formyl;
C.sub.1-6alkyl-sulfonyl; C.sub.3-6cycloalkyl-sulfonyl;
C.sub.3-6cycloalkyl-C.sub.1-6alkyl-sulfonyl;
C.sub.1-6alkyl-sulfonyl-C.sub.1-6alkyl; aminocarbonyl;
N-hydroxy-aminocarbonyl; N--C.sub.1-6alkoxy-aminocarbonyl;
N--C.sub.1-6alkyl-aminocarbonyl;
N-hydroxy-N--C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkoxy-N--C.sub.1-6alkyl-aminocarbonyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl; aminosulfonyl;
N--C.sub.1-6alkyl-aminosulfonyl;
N,N-di-C.sub.1-6alkyl-aminosulfonyl; cyano; C.sub.1-6alkoxy;
C.sub.1-6alkyl-sulfonylamino;
N--C.sub.1-6alkyl-sulfonylaminocarbonyl;
N--(C.sub.1-6alkyl-sulfonyl)-N--C.sub.1-6alkyl-aminocarbonyl;
N--(C.sub.1-6alkyl-sulfonyl)-amino-C.sub.1-6alkyl; amino;
N--C.sub.1-6alkyl-amino; N,N-di-C.sub.1-6alkyl-amino;
halo-C.sub.1-6alkyl; heterocyclyl; heteroaryl; or hydroxyl; wherein
the C.sub.1-6alkyl moieties may be unsubstituted or substituted one
or more times with halo; and wherein the heterocyclyl, heteroaryl,
C.sub.3-6cycloalkyl, C.sub.3-6cycloalkenyl and
C.sub.3-6cycloalkyl-C.sub.1-6alkyl moieties may be unsubstituted or
substituted one or more times with R.sup.i.
[0817] In certain embodiments of formula I, R.sup.g is: hydrogen;
C.sub.1-6alkyl; C.sub.3-6cycloalkyl;
C.sub.3-6cycloalkyl-C.sub.1-6alkyl; halo; C.sub.1-6alkyl-carbonyl;
C.sub.3-6cycloalkyl-carbonyl;
C.sub.3-6cycloalkyl-C.sub.1-6alkyl-carbonyl;
C.sub.1-6alkyl-sulfonyl; C.sub.3-6cycloalkyl-sulfonyl;
C.sub.3-6cycloalkyl-C.sub.1-6alkyl-sulfonyl; aminocarbonyl;
N--C.sub.1-6alkyl-aminocarbonyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl; aminosulfonyl;
N--C.sub.1-6alkyl-aminosulfonyl;
N,N-di-C.sub.1-6alkyl-aminosulfonyl; cyano; C.sub.1-6alkoxy;
C.sub.1-6alkyl-sulfonylamino; amino; N--C.sub.1-6alkyl-amino;
N,N-di-C.sub.1-6alkyl-amino; halo-C.sub.1-6alkyl; or hydroxyl;
wherein the C.sub.1-6alkyl moieties may be unsubstituted or
substituted one or more times with halo; and wherein the
C.sub.3-6cycloalkyl, and C.sub.3-6cycloalkyl-C.sub.1-6alkyl
moieties may be unsubstituted or substituted one or more times with
R.sup.i.
[0818] In certain embodiments of formula I, R.sup.g is
hydrogen.
[0819] In certain embodiments of formula I, R.sup.g is
C.sub.1-6alkyl.
[0820] In certain embodiments of formula I, R.sup.g is
C.sub.1-6cycloalkyl which may be unsubstituted or substituted one
or more times with R.sup.i.
[0821] In certain embodiments of formula I, R.sup.g is
C.sub.3-6cycloalkyl-C.sub.1-6alkyl which may be unsubstituted or
substituted one or more times with R.sup.i.
[0822] In certain embodiments of formula I, R.sup.g is halo.
[0823] In certain embodiments of formula I, R.sup.g is
C.sub.1-6alkyl-carbonyl.
[0824] In certain embodiments of formula I, R.sup.g is
C.sub.3-6cycloalkyl-carbonyl wherein the C.sub.3-6cycloalkyl moeity
may be unsubstituted or substituted one or more times with
R.sup.i.
[0825] In certain embodiments of formula I, R.sup.g is
C.sub.3-6cycloalkyl-C.sub.1-6alkyl-carbonyl wherein the
C.sub.3-6cycloalkyl-C.sub.1-6alkyl moiety may be unsubstituted or
substituted one or more times with R.sup.i.
[0826] In certain embodiments of formula I, R.sup.g is
C.sub.1-6alkyl-sulfonyl.
[0827] In certain embodiments of formula I, R.sup.g is
C.sub.1-6cycloalkyl-sulfonyl.
[0828] In certain embodiments of formula I, R.sup.g is
C.sub.3-6cycloalkyl-C.sub.1-6alkyl-sulfonyl.
[0829] In certain embodiments of formula I, R.sup.g is
aminocarbonyl.
[0830] In certain embodiments of formula I, R.sup.g is
N--C.sub.1-6alkyl-aminocarbonyl.
[0831] In certain embodiments of formula I, R.sup.g is
N,N-di-C.sub.1-6alkyl-aminocarbonyl.
[0832] In certain embodiments of formula I, R.sup.g is
aminosulfonyl.
[0833] In certain embodiments of formula I, R.sup.g is
N--C.sub.1-6alkyl-aminosulfonyl.
[0834] In certain embodiments of formula I, R.sup.g is
N,N-di-C.sub.1-6alkyl-aminosulfonyl.
[0835] In certain embodiments of formula I, R.sup.g is cyano.
[0836] In certain embodiments of formula I, R.sup.g is
C.sub.1-6alkoxy.
[0837] In certain embodiments of formula I, R.sup.g is
C.sub.1-6alkyl-sulfonylamino.
[0838] In certain embodiments of formula I, R.sup.g is amino.
[0839] In certain embodiments of formula I, R.sup.g is
N--C.sub.1-6alkyl-amino.
[0840] In certain embodiments of formula I, R.sup.g is
N,N-di-C.sub.1-6alkyl-amino.
[0841] In certain embodiments of formula I, R.sup.g is
halo-C.sub.1-6alkyl.
[0842] In certain embodiments of formula I, R.sup.g is hydroxy.
[0843] In certain embodiments of formula I, R.sup.g is
C.sub.1-6cycloalkeny which may be unsubstituted or substituted one
or more times with R.sup.i.
[0844] In certain embodiments of formula I, R.sup.g is
cyano-C.sub.1-6alkyl-carbonyl.
[0845] In certain embodiments of formula I, R.sup.g is
hydroxy-C.sub.1-6alkyl-carbonyl.
[0846] In certain embodiments of formula I, R.sup.g is
C.sub.1-6alkoxy-C.sub.1-6alkyl-carbonyl.
[0847] In certain embodiments of formula I, R.sup.g is carboxy.
[0848] In certain embodiments of formula I, R.sup.g is
N-cyano-aminocarbonyl.
[0849] In certain embodiments of formula I, R.sup.g is
N-cyano-N--C.sub.1-6alkyl-aminocarbonyl.
[0850] In certain embodiments of formula I, R.sup.g is
N--C.sub.1-6alkyl-acetimidamidyl.
[0851] In certain embodiments of formula I, R.sup.g is
N,N'-di-C.sub.1-6alkyl-acetimidamidyl.
[0852] In certain embodiments of formula I, R.sup.g is
N'-cyano-N--C.sub.1-6alkyl-acetimidamidyl.
[0853] In certain embodiments of formula I, R.sup.g is
N'-hydroxy-acetimidamidyl.
[0854] In certain embodiments of formula I, R.sup.g is
N'--C.sub.1-6alkoxy-acetimidamidyl.
[0855] In certain embodiments of formula I, R.sup.g is
N'-hydroxy-N--C.sub.1-6alkyl-acetimidamide;
N'--C.sub.1-6alkoxy-N--C.sub.1-6alkyl-acetimidamidyl.
[0856] In certain embodiments of formula I, R.sup.g is
2-nitro-1-N--C.sub.1-6 alkylamino-vinyl.
[0857] In certain embodiments of formula I, R.sup.g is
C.sub.1-6alkyl-sulfonyl-C.sub.1-6alkyl.
[0858] In certain embodiments of formula I, R.sup.g is
N-hydroxy-aminocarbonyl.
[0859] In certain embodiments of formula I, R.sup.g is
N--C.sub.1-6alkoxy-aminocarbonyl.
[0860] In certain embodiments of formula I, R.sup.g is
N-hydroxy-N--C.sub.1-6alkyl-aminocarbonyl.
[0861] In certain embodiments of formula I, R.sup.g is
N--C.sub.1-6alkoxy-N--C.sub.1-6alkyl-aminocarbonyl.
[0862] In certain embodiments of formula I, R.sup.g is
N--C.sub.1-6alkyl-sulfonylaminocarbonyl.
[0863] In certain embodiments of formula I, R.sup.g is
N--(C.sub.1-6alkyl-sulfonyl)-N--C.sub.1-6alkyl-aminocarbonyl.
[0864] In certain embodiments of formula I, R.sup.g is
aminocarbonyl-C.sub.1-6alkyl.
[0865] In certain embodiments of formula I, R.sup.g is
N--C.sub.1-6alkyl-aminocarbonyl-C.sub.1-6alkyl
[0866] In certain embodiments of formula I, R.sup.g is
N,N-di-C.sub.1-6alkyl-aminocarbonyl-C.sub.1-6alkyl.
[0867] In certain embodiments of formula I, R.sup.g is
C.sub.1-6alkoxy-carbonyl.
[0868] In certain embodiments of formula I, R.sup.g is heterocyclyl
which may be unsubstituted or substituted one or more times with
R.sup.i.
[0869] In embodiments of formula I wherein R' is heterocyclyl, such
heterocyclyl may be oxetanyl, tetrahydrofuranyl, tetrahydropyranyl,
azetidinyl, pyrrolidinyl, piperidinyl, azepinyl or piperazinyl,
each of which may be unsubstituted or substituted one or more times
with R.sup.i.
[0870] In certain embodiments of formula I, R.sup.g is heteroaryl
which may be unsubstituted or substituted one or more times with
R.sup.i.
[0871] In embodiments of formula I wherein R.sup.g is heteroaryl,
such heteroaryl may be be pyridinyl, pyrimidinyl, triazinyl,
pyrrolyl, imidazolyl, pyrazoyl, triazolyl, oxazolyl, thiazolyl,
isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl or tetrazolyl,
each of which may be unsubstituted or substituted one or more times
with R.sup.g.
[0872] In embodiments of formula I wherein R.sup.g is heteroaryl,
such heteroaryl may be be imidazolyl, pyrazoyl, triazolyl,
oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, oxadiazolyl,
thiadiazolyl or tetrazolyl, each of which may be unsubstituted or
substituted one or more times with R.sup.i.
[0873] In certain embodiments of formula I, R.sup.g is
triazolyl.
[0874] In certain embodiments of formula I, R.sup.g is
[1,2,4]triazol-4-yl.
[0875] In certain embodiments of formula I, R.sup.g is
[1,2,4]triazol-3-yl.
[0876] In certain embodiments of formula I, R.sup.g is
4-methyl-[1,2,4]triazol-3-yl.
[0877] In certain embodiments of formula I, R.sup.g is
[1,2,4]triazol-1-yl.
[0878] In certain embodiments of formula I, R.sup.g is
[1,2,3]triazol-1-yl.
[0879] In certain embodiments of formula I, R.sup.g is
[1,2,3]triazol-4-yl.
[0880] In certain embodiments of formula I, R.sup.g is
4-methyl-[1,2,4]triazol-3-yl.
[0881] In certain embodiments of formula I, R.sup.g is
pyrazolyl.
[0882] In certain embodiments of formula I, R.sup.g is
pyrazol-3-yl.
[0883] In certain embodiments of formula I, R.sup.g is
pyrazol-1-yl.
[0884] In certain embodiments of formula I, R.sup.g is
pyrazol-4-yl.
[0885] In certain embodiments of formula I, R.sup.g is
imidazolyl.
[0886] In certain embodiments of formula I, R.sup.g is
imidazol-1-yl.
[0887] In certain embodiments of formula I, R.sup.g is
I-methyl-imidazol-2-yl.
[0888] In certain embodiments of formula I, R.sup.g is
isoxazolyl.
[0889] In certain embodiments of formula I, R.sup.g is
3-hydroxyisoxazol-5-yl.
[0890] In certain embodiments of formula I, R.sup.g is
oxdiazolyl.
[0891] In certain embodiments of formula I, R.sup.g is
[1,2,4]oxadiazol-5-yl.
[0892] In certain embodiments of formula I, R.sup.g is
[1,2,4]oxadiazol-3-yl.
[0893] In certain embodiments of formula I, R.sup.g is
[1,2,3]oxadiazol-2-yl.
[0894] In certain embodiments of formula I, R.sup.g is
[1,2,3]oxadiazol-2-one-5-yl.
[0895] In certain embodiments of formula I, R.sup.g is
tetrazolyl.
[0896] In certain embodiments of formula I, R.sup.g is
tetrazol-5-yl.
[0897] In certain embodiments of formula I, R.sup.g is
tetrazol-1-yl.
[0898] In certain embodiments of formula I, R.sup.g is
tetrazol-2-yl.
[0899] In certain embodiments of formula I, R.sup.g is
pyrazolyl.
[0900] In certain embodiments of formula I, R.sup.g is
pyridazinyl.
[0901] In certain embodiments of formula I, R.sup.g is
triazinyl.
[0902] In certain embodiments of formula I, R.sup.f and R.sup.g
together with the atoms to which they are attached form a three,
four, five, six or seven membered saturated or partially saturated
ring.
[0903] In certain embodiments of formula I, R.sup.f and R.sup.g
together with the atoms to which they are attached form a three
membered ring.
[0904] In certain embodiments of formula I, R.sup.f and R.sup.g
together with the atoms to which they are attached form a four
membered ring.
[0905] In certain embodiments of formula I, R.sup.f and R.sup.g
together with the atoms to which they are attached form a five
membered ring.
[0906] In certain embodiments of formula I, R.sup.f and R.sup.g
together with the atoms to which they are attached form a six
membered ring.
[0907] In certain embodiments of formula I, R.sup.f and R.sup.g
together with the atoms to which they are attached form a seven
membered ring.
[0908] In certain embodiments of formula I, R.sup.h is: hydrogen;
C.sub.1-6alkyl; C.sub.3-6cycloalkyl; C.sub.1-6cycloalkenyl;
C.sub.1-6cycloalkyl-C.sub.1-6alkyl; C.sub.1-6alkyl-carbonyl;
C.sub.3-6cycloalkyl-carbonyl;
C.sub.3-6cycloalkyl-C.sub.1-6alkyl-carbonyl;
cyano-C.sub.1-6alkyl-carbonyl; hydroxy-C.sub.1-6alkyl-carbonyl;
C.sub.1-6alkoxy-C.sub.1-6alkyl-carbonyl; N-cyano-aminocarbonyl;
N-cyano-N--C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkyl-acetimidamidyl;
N,N'-di-C.sub.1-6alkyl-acetimidamidyl;
N'-cyano-N--C.sub.1-6alkyl-acetimidamidyl;
N'-hydroxy-acetimidamidyl; N'--C.sub.1-6alkoxy-acetimidamidyl;
N'-hydroxy-N--C.sub.1-6alkyl-acetimidamidyl;
N'--C.sub.1-6alkoxy-N--C.sub.1-6alkyl-acetimidamidyl;
2-nitro-1-N--C.sub.1-6alkylamino-vinyl; formyl;
C.sub.1-6alkyl-sulfonyl; C.sub.3-6cycloalkyl-sulfonyl;
C.sub.3-6cycloalkyl-C.sub.1-6alkyl-sulfonyl;
C.sub.1-6alkyl-sulfonyl-C.sub.1-6alkyl; aminocarbonyl;
N-hydroxy-aminocarbonyl; N--C.sub.1-6alkoxy-aminocarbonyl;
N--C.sub.1-6alkyl-aminocarbonyl;
N-hydroxy-N--C.sub.1-6alkyl-aminocarbonyl;
N--C.sub.1-6alkoxy-N--C.sub.1-6alkyl-aminocarbonyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl; aminosulfonyl;
N--C.sub.1-6alkyl-aminosulfonyl;
N,N-di-C.sub.1-6alkyl-aminosulfonyl; cyano;
C.sub.1-6alkyl-sulfonylamino;
C.sub.1-6alkyl-sulfonylamino-C.sub.1-6alkyl;
N--(C.sub.1-6alkyl-sulfonyl)aminocarbonyl;
N--(C.sub.1-6alkyl-sulfonyl)-N--C.sub.1-6alkyl-aminocarbonyl;
N--(C.sub.1-6alkyl-sulfonyl)-amino-C.sub.1-6alkyl;
halo-C.sub.1-6alkyl; heterocyclyl; or heteroaryl; wherein the
C.sub.1-6alkyl moieties may be unsubstituted or substituted one or
more times with halo; and wherein the heterocyclyl, heteroaryl,
C.sub.3-6cycloalkyl, C.sub.1-6cycloalkenyl and
C.sub.1-6cycloalkyl-C.sub.1-6alkyl moieties may be unsubstituted or
substituted one or more times with R.sup.i.
[0909] In certain embodiments of formula I, R.sup.h is: hydrogen;
C.sub.1-6alkyl; C.sub.3-6cycloalkyl; C.sub.1-6
cycloalkyl-C.sub.1-6alkyl; C.sub.1-6alkyl-carbonyl;
C.sub.3-6cycloalkyl-carbonyl;
C.sub.3-6cycloalkyl-C.sub.1-6alkyl-carbonyl; C.sub.1-6
alkyl-sulfonyl; C.sub.3-6cycloalkyl-sulfonyl;
C.sub.3-6cycloalkyl-C.sub.1-6alkyl-sulfonyl; aminocarbonyl;
N--C.sub.1-6alkyl-aminocarbonyl;
N,N-di-C.sub.1-6alkyl-aminocarbonyl; aminosulfonyl;
N--C.sub.1-6alkyl-aminosulfonyl; or
N,N-di-C.sub.1-6alkyl-aminosulfonyl; wherein the C.sub.1-6alkyl
moieties may be unsubstituted or substituted one or more times with
halo; and wherein the C.sub.3-6cycloalkyl, and
C.sub.3-6cycloalkyl-C.sub.1-6alkyl moieties may be unsubstituted or
substituted one or more times with R.sup.i.
[0910] In certain embodiments of formula I, R.sup.h is:
C.sub.1-6alkyl-carbonyl; C.sub.3-6cycloalkyl-carbonyl;
C.sub.3-6cycloalkyl-C.sub.1-alkyl-carbonyl;
C.sub.1-6alkyl-sulfonyl; C.sub.3-6cycloalkyl-sulfonyl;
C.sub.3-6cycloalkyl-C.sub.1-6-alkyl-sulfonyl; aminocarbonyl;
N--C.sub.1-6alkyl-aminocarbonyl; or
N,N-di-C.sub.1-6alkyl-aminocarbonyl; aminosulfonyl;
N--C.sub.1-6alkyl-aminosulfonyl; or
N,N-di-C.sub.1-6alkyl-aminosulfonyl; wherein the
C.sub.3-6cycloalkyl, and C.sub.1-6cycloalkyl-C.sub.1-6alkyl
moieties each may be unsubstituted or substituted one or more times
with R.sup.i.
[0911] In certain embodiments of formula I, R.sup.h is:
C.sub.1-6alkyl-carbonyl; C.sub.3-6cycloalkyl-carbonyl;
C.sub.3-6cycloalkyl-C.sub.1-6alkyl-carbonyl;
C.sub.1-6alkyl-sulfonyl; C.sub.3-6cycloalkyl-sulfonyl; or
C.sub.3-6cycloalkyl-C.sub.1-6alkyl-sulfonyl; wherein the
C.sub.3-6cycloalkyl, and C.sub.3-6cycloalkyl-C.sub.1-6alkyl
moieties each may be unsubstituted or substituted one or more times
with R.sup.i.
[0912] In certain embodiments of formula I, R.sup.h is:
C.sub.1-6alkyl-carbonyl; C.sub.3-6cycloalkyl-carbonyl; or
C.sub.3-6cycloalkyl-C.sub.1-6alkyl-carbonyl; wherein the
C.sub.3-6cycloalkyl, and C.sub.3-6cycloalkyl-C.sub.1-6alkyl
moieties each may be unsubstituted or substituted one or more times
with R.sup.i.
[0913] In certain embodiments of formula I, R.sup.h is
hydrogen.
[0914] In certain embodiments of formula I, R.sup.h is
C.sub.1-6alkyl.
[0915] In certain embodiments of formula I, R.sup.h is
C.sub.3-6cycloalkyl which may be unsubstituted or substituted one
or more times with R.sup.i.
[0916] In certain embodiments of formula I, R.sup.h is
C.sub.3-6cycloalkyl-C.sub.1-6alkyl.
[0917] In certain embodiments of formula I, R.sup.h is
C.sub.1-6alkyl-carbonyl.
[0918] In certain embodiments of formula I, R.sup.h is
C.sub.3-6cycloalkyl-carbonyl.
[0919] In certain embodiments of formula I, R.sup.h is
C.sub.3-6cycloalkyl-C.sub.1-6alkyl-carbonyl.
[0920] In certain embodiments of formula I, R.sup.h is
C.sub.1-6alkyl-sulfonyl.
[0921] In certain embodiments of formula I, R.sup.h is
C.sub.3-6cycloalkyl-sulfonyl.
[0922] In certain embodiments of formula I, R.sup.h is
C.sub.3-6cycloalkyl-C.sub.1-6alkyl-sulfonyl.
[0923] In certain embodiments of formula I, R.sup.h is
aminocarbonyl.
[0924] In certain embodiments of formula I, R.sup.h is N--C.sub.1-6
alkyl-aminocarbonyl.
[0925] In certain embodiments of formula I, R.sup.h is
N,N-di-C.sub.1-6alkyl-aminocarbonyl.
[0926] In certain embodiments of formula I, R.sup.h is
aminosulfonyl.
[0927] In certain embodiments of formula I, R.sup.h is
N--C.sub.1-6alkyl-aminosulfonyl.
[0928] In certain embodiments of formula I, R.sup.h is or
N,N-di-C.sub.1-6alkyl-aminosulfonyl.
[0929] In certain embodiments of formula I, R.sup.h is
C.sub.3-6cycloalkenyl.
[0930] In certain embodiments of formula I, R.sup.h is
cyano-C.sub.1-6alkyl-carbonyl.
[0931] In certain embodiments of formula I, R.sup.h is
hydroxy-C.sub.1-6alkyl-carbonyl.
[0932] In certain embodiments of formula I, R.sup.h is
C.sub.1-6alkoxy-C.sub.1-6alkyl-carbonyl.
[0933] In certain embodiments of formula I, R.sup.h is
N-cyano-amino-aminocarbonyl.
[0934] In certain embodiments of formula I, R.sup.h is
N-cyano-N--C.sub.1-6alkyl-aminocarbonyl.
[0935] In certain embodiments of formula I, R.sup.h is
N--C.sub.1-6alkyl-acetimidamidyl.
[0936] In certain embodiments of formula I, R.sup.h is
N,N'-di-C.sub.1-6alkyl-acetimidamidyl.
[0937] In certain embodiments of formula I, R.sup.h is
N'-cyano-N--C.sub.1-6alkyl-acetimidamidyl.
[0938] In certain embodiments of formula I, R.sup.h is
N'-hydroxy-acetimidamidyl.
[0939] In certain embodiments of formula I, R.sup.h is
N'--C.sub.1-6alkoxy-acetimidamidyl.
[0940] In certain embodiments of formula I, R.sup.h is
N'-hydroxy-N--C.sub.1-64alkyl-acetimidamidyl.
[0941] In certain embodiments of formula I, R.sup.h is
N'--C.sub.1-6alkoxy-N--C.sub.1-6 alkyl-acetimidamidyl.
[0942] In certain embodiments of formula I, R.sup.h is
2-nitro-1-N--C.sub.1-64alkylamino-vinyl.
[0943] In certain embodiments of formula I, R.sup.h is
C.sub.1-6alkyl-sulfonyl-C.sub.1-6alkyl.
[0944] In certain embodiments of formula I, R.sup.h is
N-hydroxy-aminocarbonyl.
[0945] In certain embodiments of formula I, R.sup.h is
N--C.sub.1-6alkoxy-aminocarbonyl.
[0946] In certain embodiments of formula I, R.sup.h is
N-hydroxy-N--C.sub.1-6alkyl-aminocarbonyl.
[0947] In certain embodiments of formula I, R.sup.h is
N--C.sub.1-6alkoxy-N--C.sub.1-6alkyl-aminocarbonyl.
[0948] In certain embodiments of formula I, R.sup.h is
C.sub.1-6alkyl-sulfonylamino-C.sub.1-6alkyl.
[0949] In certain embodiments of formula I, R.sup.h is
N--(C.sub.1-6alkyl-sulfonyl)aminocarbonyl.
[0950] In certain embodiments of formula I, R.sup.h is
N--(C.sub.1-6alkyl-sulfonyl)-N--C.sub.1-6alkyl-aminocarbonyl.
[0951] In certain embodiments of formula I, R.sup.h is
aminocarbonyl-C.sub.1-6alkyl.
[0952] In certain embodiments of formula I, R.sup.h is
N--C.sub.1-6alkyl-aminocarbonyl-C.sub.1-6alkyl
[0953] In certain embodiments of formula I, R.sup.h is
N,N-di-C.sub.1-6alkyl-aminocarbonyl-C.sub.1-6alkyl.
[0954] In certain embodiments of formula I, R.sup.h is
C.sub.1-6alkoxy-carbonyl.
[0955] In certain embodiments of formula I, R.sup.h is heterocyclyl
which may be unsubstituted or substituted one or more times with
R.sup.i.
[0956] In certain embodiments of formula I, R.sup.h is heteroaryl
which may be unsubstituted or substituted one or more times with
R.sup.i.
[0957] In embodiments of formula I wherein R.sup.h is heteroaryl,
such heteroaryl may be be pyridinyl, pyrimidinyl, pyrolyl,
imidazolyl, pyrazoyl, triazolyl, oxazolyl, thiazolyl, isoxazolyl,
isothiazolyl, oxadiazolyl, thiadiazolyl or tetrazolyl, each of
which may be unsubstituted or substituted one or more times with
R.sup.i.
[0958] In embodiments of formula I wherein R.sup.h is heteroaryl,
such heteroaryl may be be imidazolyl, pyrazoyl, triazolyl,
oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, oxadiazolyl,
thiadiazolyl or tetrazolyl, each of which may be unsubstituted or
substituted one or more times with R.sup.i.
[0959] In certain embodiments of formula I, R.sup.h is acetyl.
[0960] In certain embodiments of formula I, R.sup.h is
methanesulfonyl.
[0961] In certain embodiments of formula I, R.sup.h is
cyclopropylcarbonyl.
[0962] In certain embodiments of formula I, R.sup.h and one of
R.sup.10 and R.sup.11 together with the atoms to which they are
attached form a four, five, six or seven membered aromatic,
partially saturated or unsaturated ring.
[0963] In certain embodiments of formula I, R.sup.h and one of
R.sup.10 and R.sup.11 together with the atoms to which they are
attached form a four membered ring.
[0964] In certain embodiments of formula I, R.sup.h and one of
R.sup.10 and R.sup.11 together with the atoms to which they are
attached form a five membered ring.
[0965] In certain embodiments of formula I, R.sup.h and one of
R.sup.10 and R.sup.11 together with the atoms to which they are
attached form a six membered ring.
[0966] In certain embodiments of formula I, R.sup.h and one of
R.sup.10 and R.sup.11 together with the atoms to which they are
attached form a seven membered ring.
[0967] In certain embodiments of formula I, one of R.sup.f and
R.sup.g and one of R.sup.10 and R.sup.11 together with the atoms to
which they are attached form a four, five, six or seven membered
aromatic, partially saturated or unsaturated ring.
[0968] In certain embodiments of formula I, one of R.sup.f and
R.sup.g and one of R.sup.10 and R.sup.11 together with the atoms to
which they are attached form a five or six membered aromatic
ring.
[0969] In certain embodiments of formula I, one of R.sup.f and
R.sup.g and one of R.sup.10 and R.sup.11 together with the atoms to
which they are attached form a five membered aromatic ring.
[0970] In certain embodiments of formula I, one of R.sup.f and
R.sup.g and one of R.sup.10 and R.sup.11 together with the atoms to
which they are attached form a six membered aromatic ring.
[0971] In certain embodiments of formula I, one of R.sup.f and
R.sup.g and one of R.sup.10 and R.sup.11 together with the atoms to
which they are attached form a five or six membered saturated
ring.
[0972] In certain embodiments of formula I, one of R.sup.f and
R.sup.g and one of R.sup.10 and R.sup.11 together with the atoms to
which they are attached form a five membered saturated ring.
[0973] In certain embodiments of formula I, one of R.sup.f and
R.sup.g and one of R.sup.10 and R.sup.11 together with the atoms to
which they are attached form a six membered saturated ring.
[0974] In certain embodiments of formula I, one of R.sup.f and
R.sup.g and one of R.sup.10 and R.sup.11 together with the atoms to
which they are attached form a four membered ring.
[0975] In certain embodiments of formula I, one of R.sup.f and
R.sup.g and one of R.sup.10 and R.sup.11 together with the atoms to
which they are attached form a five membered ring.
[0976] In certain embodiments of formula I, one of R.sup.f and
R.sup.g and one of R.sup.10 and R.sup.11 together with the atoms to
which they are attached form a six membered ring.
[0977] In certain embodiments of formula I, one of R.sup.f and
R.sup.g and one of R.sup.10 and R.sup.11 together with the atoms to
which they are attached form a seven membered ring.
[0978] In certain embodiments of formula I, R.sup.i is:
C.sub.1-6alkyl; halo; oxo; hydroxy; acetyl; or C.sub.1-6
alkoxy.
[0979] In certain embodiments of formula I, R.sup.i is
C.sub.1-6alkyl.
[0980] In certain embodiments of formula I, R.sup.i is halo.
[0981] In certain embodiments of formula I, R.sup.i is
C.sub.1-6alkoxy.
[0982] In certain embodiments of formula I, R.sup.i is
halo-C.sub.1-6alkyl.
[0983] In certain embodiments of formula I, R.sup.i is oxo.
[0984] In certain embodiments of formula I, R.sup.i is hydroxy.
[0985] In certain embodiments of formula I, R.sup.i is acetyl.
[0986] In certain embodiments of formula I, R.sup.i is
C.sub.1-6alkyl-carbonyl.
[0987] In certain embodiments of formula I, R.sup.i is
amino-carbonyl.
[0988] In certain embodiments of formula I, R.sup.i is
hydroxy-C.sub.1-6alkyl.
[0989] In certain embodiments of formula I, R.sup.i is cyano.
[0990] In certain embodiments of formula I, R.sup.i is
heteroaryl;
[0991] In certain embodiments of formula I, R.sup.j and R.sup.k
each independent is: hydrogen; or methyl.
[0992] In certain embodiments of formula I, R.sup.j is
hydrogen.
[0993] In certain embodiments of formula I, R.sup.k is
hydrogen.
[0994] In certain embodiments of the invention, the group
##STR00013##
is:
##STR00014## ##STR00015## ##STR00016## ##STR00017## ##STR00018##
##STR00019## ##STR00020## ##STR00021## ##STR00022## ##STR00023##
##STR00024## ##STR00025## ##STR00026## ##STR00027##
[0995] In certain embodiments of the invention, the group
##STR00028##
is:
##STR00029## ##STR00030## ##STR00031## ##STR00032##
[0996] In certain embodiments of the invention, the group
##STR00033##
is:
##STR00034##
[0997] In certain embodiments of the invention, the group
##STR00035##
is:
##STR00036##
[0998] In certain embodiments of formula I, the subject compounds
may be of formula Ia or Ib:
##STR00037##
wherein m, n, p, q, r, A, W, X.sup.1, X.sup.2, X.sup.3, X.sup.4, Y,
Z, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7,
R.sup.8, R.sup.9, R.sup.10 and R.sup.11, and the
##STR00038##
are as defined herein.
[0999] In certain embodiments, the subject compounds are of formula
Ia.
[1000] In certain embodiments, the subject compounds are of formula
Ib.
[1001] In certain embodiments of formula I, the subject compounds
may be of formula IIa or IIb
##STR00039##
wherein s is from 0 to 3, wherein m, n, p, q, r, A, W, Y, Z,
R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7,
R.sup.8, R.sup.9, R.sup.10, R.sup.11, and R.sup.e, and the
group
##STR00040##
are as defined herein.
[1002] In certain embodiments, the subject compounds are of formula
IIa.
[1003] In certain embodiments, the subject compounds are of formula
IIb.
[1004] In certain embodiments of formula IIa or IIb, R.sup.e is
halo.
[1005] In certain embodiments of formula IIa or IIb, R.sup.e is
fluoro.
[1006] In certain embodiments of formula IIa or IIb, s is 0 or
1.
[1007] In certain embodiments of formula IIa or IIb, s is 0.
[1008] In certain embodiments of formula IIa or IIb, s is 1.
[1009] In certain embodiments of formula IIa or IIb, s is 1 or
2.
[1010] In certain embodiments of formula IIa or IIb, s is 2.
[1011] In certain embodiments of formula IIa or IIb, s is 1, 2 or
3.
[1012] In certain embodiments of formula IIa or IIb, s is 2 or
3.
[1013] In certain embodiments of formula IIa or IIb, s is 3.
[1014] In certain embodiments of formula I, the subject compounds
may be of formula IIIa or IIIb:
##STR00041##
wherein m, n, p, q, r, s, A, W, Y, Z, R.sup.1, R.sup.2, R.sup.3,
R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10,
R.sup.11 and R.sup.e, and the group
##STR00042##
are as defined herein.
[1015] In certain embodiments, the subject compounds are of formula
IIIa.
[1016] In certain embodiments, the subject compounds are of formula
IIIb.
[1017] In certain embodiments of formula I, the subject compounds
may be of formula IVa or IVb
##STR00043##
wherein m, n, p, q, r, s, A, W, Y, Z, R.sup.1, R.sup.2, R.sup.3,
R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10,
R.sup.11 and R.sup.e, and the group
##STR00044##
are as defined herein.
[1018] In certain embodiments, the subject compounds are of formula
IVa.
[1019] In certain embodiments, the subject compounds are of formula
IVb.
[1020] In certain embodiments of formula I, the subject compounds
may be of formula Va or Vb:
##STR00045##
wherein m, n, p, q, r, s, A, W, Y, Z, R.sup.1, R.sup.2, R.sup.3,
R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10,
R.sup.11 and R.sup.e, and the group
##STR00046##
are as defined herein.
[1021] In certain embodiments, the subject compounds are of formula
Va.
[1022] In certain embodiments, the subject compounds are of formula
Vb.
[1023] In certain embodiments of formula I, the subject compounds
may be of formula VIa or VIb:
##STR00047##
wherein m, n, p, q, r, s, A, W, Y, Z, R.sup.1, R.sup.2, R.sup.3,
R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10,
R.sup.11 and R.sup.e, and the group
##STR00048##
are as defined herein.
[1024] In certain embodiments, the subject compounds are of formula
VIa.
[1025] In certain embodiments, the subject compounds are of formula
VIb.
[1026] In certain embodiments of formula I, the subject compounds
may be of formula VIIa or VIIb:
##STR00049##
wherein m, n, p, q, r, s, A, W, Y, Z, R.sup.1, R.sup.2, R.sup.3,
R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10,
R.sup.11 and R.sup.e, and the group
##STR00050##
are as defined herein.
[1027] In certain embodiments, the subject compounds are of formula
VIIa.
[1028] In certain embodiments, the subject compounds are of formula
VIIb.
[1029] In certain embodiments of formula I, the subject compounds
may be of formula Villa or VIIIb:
##STR00051##
wherein m, n, p, q, r, s, A, W, Y, Z, R.sup.1, R.sup.2, R.sup.3,
R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10,
R.sup.11 and R.sup.e, and the group
##STR00052##
are as defined herein.
[1030] In certain embodiments, the subject compounds are of formula
VIIIa.
[1031] In certain embodiments, the subject compounds are of formula
VIIIb.
[1032] In certain embodiments of formula I, the subject compounds
may be of formula IXa or IXb:
##STR00053##
wherein m, n, p, q, r, s, W, Y, Z, R.sup.1, R.sup.2, R.sup.3,
R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10,
R.sup.11 and R.sup.e, and the group
##STR00054##
are as defined herein.
[1033] In certain embodiments, the subject compounds are of formula
IXa.
[1034] In certain embodiments, the subject compounds are of formula
IXb.
[1035] In certain embodiments of formula I, the subject compounds
may be of formula Xa or Xb:
##STR00055##
wherein m, n, p, q, r, s, W, Y, Z, R.sup.1, R.sup.2, R.sup.3,
R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10,
R.sup.11, R.sup.e, and R.sup.h are as defined herein.
[1036] In certain embodiments, the subject compounds are of formula
Xa.
[1037] In certain embodiments, the subject compounds are of formula
Xb.
[1038] In certain embodiments of formula I, the subject compounds
may be of formula XIa or XIb;
##STR00056##
wherein m, n, p, s, W, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5,
R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.e and
R.sup.h are as defined herein.
[1039] In certain embodiments, the subject compounds are of formula
XIa.
[1040] In certain embodiments, the subject compounds are of formula
XIb.
[1041] In certain embodiments of formula I, the subject compounds
may be of formula XIIa or
##STR00057##
wherein m, n, p, s, W, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5,
R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.e and
R.sup.h are as defined herein.
[1042] In certain embodiments, the subject compounds are of formula
XIIa.
[1043] In certain embodiments, the subject compounds are of formula
XIIb.
[1044] In certain embodiments of formula I, the subject compounds
may be of formula XIIIa or XIIIb;
##STR00058##
wherein m, n, p, s, W, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5,
R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.a,
R.sup.e and R.sup.h are as defined herein.
[1045] In certain embodiments, the subject compounds are of formula
XIIIa.
[1046] In certain embodiments, the subject compounds are of formula
XIIIb.
[1047] In certain embodiments of formula I, the subject compounds
may be of formula XIVa or XIVb:
##STR00059##
wherein m, n, p, s, W, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5,
R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.e and
R.sup.h are as defined herein.
[1048] In certain embodiments, the subject compounds are of formula
XIVa.
[1049] In certain embodiments, the subject compounds are of formula
XIVb.
[1050] In certain embodiments of formula I, the subject compounds
may be of formula XVa or XVb:
##STR00060##
wherein m, n, p, s, W, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5,
R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.a,
R.sup.e and R.sup.h are as defined herein.
[1051] In certain embodiments, the subject compounds are of formula
XVa.
[1052] In certain embodiments, the subject compounds are of formula
XVb.
[1053] In certain embodiments of formula I, the subject compounds
may be of formula XVIa or XVIb:
##STR00061##
wherein m, n, p, s, W, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5,
R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.e and
R.sup.g are as defined herein.
[1054] In certain embodiments, the subject compounds are of formula
XVIa.
[1055] In certain embodiments, the subject compounds are of formula
XVIb.
[1056] In certain embodiments of formula I, the subject compounds
may be of formula XVIIa or XVIIb:
##STR00062##
wherein p, q, r, s, A, Y, Z, R.sup.1, R.sup.2, R.sup.3, R.sup.9,
R.sup.10, R.sup.11 and R.sup.e, and the group
##STR00063##
are as defined herein.
[1057] In certain embodiments, the subject compounds are of formula
XVIIa.
[1058] In certain embodiments, the subject compounds are of formula
XVIIb.
[1059] In certain embodiments of formula I, the subject compounds
may be of formula XVIIIa or XVIIIb:
##STR00064##
wherein p, q, r, s, Y, Z, R.sup.1, R.sup.2, R.sup.3, R.sup.9,
R.sup.10, R.sup.11 and R.sup.e, and the group
##STR00065##
are as defined herein.
[1060] In certain embodiments, the subject compounds are of formula
XVIIIa.
[1061] In certain embodiments, the subject compounds are of formula
XVIIIb.
[1062] In certain embodiments of formula I, the subject compounds
may be of formula XIXa or XIXb:
##STR00066##
wherein m, n, p, s, R.sup.1, R.sup.2, R.sup.3, R.sup.9, R.sup.10,
R.sup.11, R.sup.e and R.sup.h are as defined herein.
[1063] In certain embodiments, the subject compounds are of formula
XIXa.
[1064] In certain embodiments, the subject compounds are of formula
XIXb.
[1065] In certain embodiments of formula I, the subject compounds
may be of formula XXa or XXb:
##STR00067##
wherein m, n, p, s, R.sup.1, R.sup.2, R.sup.3, R.sup.9, R.sup.10,
R.sup.11, R.sup.8 and R.sup.h are as defined herein.
[1066] In certain embodiments, the subject compounds are of formula
XXa.
[1067] In certain embodiments, the subject compounds are of formula
XXb.
[1068] In certain embodiments of formula I, the subject compounds
may be of formula XXIa or XXIb;
##STR00068##
wherein m, n, p, s, R.sup.1, R.sup.2, R.sup.3, R.sup.9, R.sup.10,
R.sup.11, R.sup.a, R.sup.e and R.sup.h are as defined herein.
[1069] In certain embodiments, the subject compounds are of formula
XXIa.
[1070] In certain embodiments, the subject compounds are of formula
XXIb.
[1071] In certain embodiments of formula I, the subject compounds
may be of formula XXIIa or XXIIb:
##STR00069##
wherein m, n, p, s, R.sup.1, R.sup.2, R.sup.3, R.sup.9, R.sup.10,
R.sup.11, R.sup.e and R.sup.g are as defined herein.
[1072] In certain embodiments, the subject compounds are of formula
XXIIa.
[1073] In certain embodiments, the subject compounds are of formula
XXIIb.
[1074] In certain embodiments, the subject compounds may be of one
of formulas XXIIIa through XIIId:
##STR00070##
wherein R.sup.m1, R.sup.m2, R.sup.m3 and R.sup.m4 each
independently is: hydrogen; or halo; and p, q, r, A, Y, Z, R.sup.3,
R.sup.9, R.sup.10, and R.sup.11, and the group
##STR00071##
are as defined herein.
[1075] In certain embodiments, the subject compounds are of formula
XXIIIa.
[1076] In certain embodiments, the subject compounds are of formula
XXIIIb.
[1077] In certain embodiments, the subject compounds are of formula
XXIIIc.
[1078] In certain embodiments, the subject compounds are of formula
XXIIId.
[1079] In certain embodiments, R.sup.m1, R.sup.m2, R.sup.m3 and
R.sup.m4 each independently is: hydrogen; or fluoro.
[1080] In certain embodiments, R.sup.m1 is fluoro and R.sup.m2,
R.sup.m3 and R.sup.m4 are hydrogen.
[1081] In certain embodiments, R.sup.m2 is fluoro and R.sup.m1,
R.sup.m3 and R.sup.m4 are hydrogen.
[1082] In certain embodiments, R.sup.m3 is fluoro and R.sup.m1,
R.sup.m2 and R.sup.m4 are hydrogen.
[1083] In certain embodiments, R.sup.m1 and R.sup.m2 are fluoro and
R.sup.m3 and R.sup.m4 are hydrogen.
[1084] In certain embodiments, R.sup.m1 and R.sup.m3 are fluoro and
R.sup.m2 and R.sup.m4 are hydrogen.
[1085] In certain embodiments, R.sup.m1 and R.sup.m4 are fluoro and
R.sup.m2 and R.sup.m3 are hydrogen.
[1086] In certain embodiments, R.sup.m1, R.sup.m2 and R.sup.m4 are
fluoro and R.sup.m3 is hydrogen.
[1087] In certain embodiments, R.sup.m1, R.sup.m2, R.sup.m3 and
R.sup.m4 are fluoro.
[1088] In certain embodiments, the subject compounds may be of one
of formula XXIVa through XXIVd:
##STR00072##
wherein p, q, r, Y, Z, R.sup.3, R.sup.9, R.sup.10, R.sup.11,
R.sup.m1, R.sup.m2, R.sup.m3 and R.sup.m4, and the group
##STR00073##
are as defined herein.
[1089] In certain embodiments, the subject compounds are of formula
XXIXa.
[1090] In certain embodiments, the subject compounds are of formula
XXIXb.
[1091] In certain embodiments, the subject compounds are of formula
XXIXc.
[1092] In certain embodiments, the subject compounds are of formula
XXIXd.
[1093] In certain embodiments of formula I, the subject compounds
may be of one of formulas XXVa through XXVd:
##STR00074##
wherein p, R.sup.3, R.sup.9, R.sup.10, R.sup.11, R.sup.h, R.sup.m1,
R.sup.m2, R.sup.m3 and R.sup.m4 are as defined herein.
[1094] In certain embodiments, the subject compounds are of formula
XXVa.
[1095] In certain embodiments, the subject compounds are of formula
XXVb.
[1096] In certain embodiments, the subject compounds are of formula
XXVc.
[1097] In certain embodiments, the subject compounds are of formula
XXVd.
[1098] In certain embodiments of formula I, the subject compounds
may be of one of formulas XXVIa through XXVId:
##STR00075##
wherein p, R.sup.3, R.sup.9, R.sup.10, R.sup.11, R.sup.h, R.sup.m1,
R.sup.m2, R.sup.m3 and R.sup.m4 are as defined herein.
[1099] In certain embodiments, the subject compounds are of formula
XXVIa.
[1100] In certain embodiments, the subject compounds are of formula
XXVIb.
[1101] In certain embodiments, the subject compounds are of formula
XXVIc.
[1102] In certain embodiments, the subject compounds are of formula
XXVId.
[1103] In certain embodiments of formula I, the subject compounds
may be of one of formulas XXVIIa through XXVIId;
##STR00076##
wherein p, R.sup.3, R.sup.9, R.sup.10, R.sup.11, R.sup.h, R.sup.m1,
R.sup.m2, R.sup.m3 and R.sup.m4 are as defined herein.
[1104] In certain embodiments, the subject compounds are of formula
XXVIIa.
[1105] In certain embodiments, the subject compounds are of formula
XXVIIb.
[1106] In certain embodiments, the subject compounds are of formula
XXVIIc.
[1107] In certain embodiments, the subject compounds are of formula
XXVIId.
[1108] In certain embodiments of formula I, the subject compounds
may be of one of formulas XXVIIIa through XXVIIId:
##STR00077##
wherein p, R.sup.3, R.sup.9, R.sup.10, R.sup.11, R.sup.h, R.sup.m1,
R.sup.m2, R.sup.m3 and R.sup.m4 are as defined herein.
[1109] In certain embodiments, the subject compounds are of formula
XXVIIIa.
[1110] In certain embodiments, the subject compounds are of formula
XXVIIIb.
[1111] In certain embodiments, the subject compounds are of formula
XXVIIIc.
[1112] In certain embodiments, the subject compounds are of formula
XXVIIId.
[1113] In certain embodiments, the subject compounds may be of
formula XXIXa or XXIXb:
##STR00078##
wherein p, R.sup.1, R.sup.2, R.sup.3, R.sup.9 and R.sup.e are as
defined herein, provided that the compound is not
(1R,5S,6S)-3-[3-Fluoro-4-((3S)-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-
-ylmethyl)-phenyl]-6-[1,2,4]triazol-4-yl-3-aza-bicyclo[3.1.0]hexane.
[1114] In certain embodiment, the subject compounds may be of
formula XXXa or XXXb:
##STR00079##
wherein p, q, r, A, Y, Z, R.sup.1, R.sup.2, R.sup.3, R.sup.9,
R.sup.10, R.sup.11 and R.sup.e, and the group
##STR00080##
are as defined herein.
[1115] In certain embodiments, the subject compounds may be of
formula XXXIa or XXXIb:
##STR00081##
wherein R.sup.m is: C.sub.1-6alkyl; hydroxy; halo;
hydroxy-C.sub.1-6alkyl; C.sub.1-6alkylsulfonyl-C.sub.1-6alkyl;
cyano; aminocarbonyloxy; C.sub.1-6alkoxycarbonyl; carboxy;
aminocarbonyl; N--C.sub.1-6alkylaminocarbonyl; or
N,N-di-C.sub.1-6alkyl-aminocarbonyl; and p, q, r, s, A, Y, Z,
R.sup.1, R.sup.2, R.sup.3, R.sup.9, R.sup.10, R.sup.11, and R.sup.e
are as defined herein.
[1116] In certain embodiments, the subject compounds may be of
formula XXXIIa or XXXIIb:
##STR00082##
wherein p, R.sup.1, R.sup.2, R.sup.3, R.sup.9 and R.sup.e are as
defined herein.
Methods
[1117] The invention also provides a method for treating a disease
or condition mediated by or otherwise associated with the RORc
receptor, the method comprising administering to a subject in need
thereof an effective amount of a compound of the invention.
[1118] The disease may be arthritis such as rheumatoid arthritis or
osteoarthritis.
[1119] The disease may be asthma or COPD.
[1120] The disease may be psoriasis, lupus (Lupus erythematosus),
Sjogren's diseases, irritable bowel disease or idiopathic pulmonary
fibrosis.
[1121] The disease may be muscular sclerosis.
[1122] Representative compounds in accordance with the methods of
the invention are shown in the experimental examples below.
Synthesis
[1123] Compounds of the present invention can be made by a variety
of methods depicted in the illustrative synthetic reaction schemes
shown and described below.
[1124] The starting materials and reagents used in preparing these
compounds generally are either available from commercial suppliers,
such as Aldrich Chemical Co., or are prepared by methods known to
those skilled in the art following procedures set forth in
references such as Fieser and Fieser's Reagents for Organic
Synthesis; Wiley & Sons: New York, 1991, Volumes 1-15; Rodd's
Chemistry of Carbon Compounds, Elsevier Science Publishers, 1989,
Volumes 1-5 and Supplementals; and Organic Reactions, Wiley &
Sons: New York, 1991, Volumes 1-40. The following synthetic
reaction schemes are merely illustrative of some methods by which
the compounds of the present invention can be synthesized, and
various modifications to these synthetic reaction schemes can be
made and will be suggested to one skilled in the art having
referred to the disclosure contained in this Application.
[1125] The starting materials and the intermediates of the
synthetic reaction schemes can be isolated and purified if desired
using conventional techniques, including but not limited to,
filtration, distillation, crystallization, chromatography, and the
like. Such materials can be characterized using conventional means,
including physical constants and spectral data.
[1126] Unless specified to the contrary, the reactions described
herein may be conducted under an inert atmosphere at atmospheric
pressure at a reaction temperature range of from about -78.degree.
C. to about 150.degree. C., for example, from about 0.degree. C. to
about 125.degree. C., or conveniently at about room (or ambient)
temperature, e.g., about 20.degree. C.
[1127] Scheme A below illustrates one synthetic procedure usable to
prepare specific compounds of formula I, wherein LG is a leaving
group such as halo, sulfonate, or the like, and m, n, p, q, A,
X.sup.1, X.sup.2, X.sup.3, X.sup.4, Y, R.sup.1, R.sup.2, R.sup.3,
R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10,
R.sup.b and R.sup.c are as defined herein.
##STR00083##
[1128] In step 1 of Scheme A, alkyl amine a is reacted with benzyl
sulfonyl chloride b to form sulfonamide compound c. The reaction of
step 1 may be carried out in a polar aprotic solvent such as THF or
methylene chloride, and in the presence of a tertiary amine base or
weak base such as potassium carbonate. The leaving group of
compound a may be bromo in certain embodiments. Similarly, the
chloro group of compound b may in certain embodiments be replaced
by other halo or leaving group.
[1129] A cyclization reaction is carried out in step 2 to afford
thiazinane compound d. The cyclization may be achieved in the
presence of a strong base such as an alkyl lithium reagent, using
polar aprotic solvent under anhydrous conditions.
[1130] In step 3, thiazinane compound c is reacted with aryalkyl
halide compound c to yield aralkyl thiazinane f. The reaction of
step 3 may be carried out in the presence of a strong base such as
sodium hydride under anhydrous polar aprotic solvent conditions.
The bromo groups of compound g may be replaced by other suitable
leaving groups used in the art.
[1131] Thiazinane compound f may be treated with reagent g in step
4A to provide sultam compound h, which is a compound of formula I
in accordance with the invention. In embodiments wherein A is
oxygen such that reagent g is a cyclic alcohol, the reaction of
step 4A may utilize a copper catalyst with hydrophobic solvent, in
the presence of cesium carbonate or like base.
[1132] Alternatively, step 4B may be carried out wherein Thiazinane
compound f undergoes amination by reaction with cyclic amine i to
afford sultam compound j, which is a compound of formula I in
accordance with the invention. The reaction of step may utilize a
suitable palladium catalyst under Buchwald reaction conditions.
[1133] Scheme B below shows another synthetic procedure usable to
prepare specific compounds of formula I, wherein TBS is
tri-(tert-butyl)-silyl, and m, n, p, q, A, X.sup.1, X.sup.2,
X.sup.3, X.sup.4, Y, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5,
R.sup.6, R.sup.9 and R.sup.10 are as defined herein.
##STR00084##
[1134] In step 1 of Scheme B, tri-(tert-butyl)-slilyloxy amine k is
reacted with benzyl sulfonyl chloride h, as described above with
reference to Scheme A, to form sulfonamide compound m. In certain
embodiments the tri-(tert-butyl)-slilyloxy group may be replaced
with other leaving groups.
[1135] In step 2, sulfonamide compound m is reacted with
iodochloromethane to provide an alkenylsulfonamide compound n. This
reaction may be achieved in the presence of a strong base such as
an alkyl lithium reagent, using polar aprotic solvent such as THF
under anhydrous conditions. In certain embodiments
iodochloromethane may be replaced with other methylene
reagents.
[1136] In step 3, a cyclization reaction is affected to provide
oxathiazepane compound p. The cyclization may be carried out in the
presence of an amine base under polar aprotic solvent
conditions.
[1137] In step 4, oxathiazepane compound p is reacted with aryalkyl
halide compound e to yield aralkyl oxathiazepane compound q, in the
manner described above with reference to Scheme A.
[1138] Steps 5A or 5B may then be carried out by reaction of
oxathiazepane compound q with reagents g and i respectively, in the
manner described above with reference to Scheme A, to afford sultam
compounds r and s respectively, which are compounds of formula I in
accordance with the invention.
[1139] Many variations on the procedures of Scheme A and Scheme B
are possible and will suggest themselves to those skilled in the
art. Specific details for producing compounds of the invention are
described in the Examples below.
Administration and Pharmaceutical Composition
[1140] The invention includes pharmaceutical compositions
comprising at least one compound of the present invention, or an
individual isomer, racemic or non-racemic mixture of isomers or a
pharmaceutically acceptable salt or solvate thereof, together with
at least one pharmaceutically acceptable carrier, and optionally
other therapeutic and/or prophylactic ingredients.
[1141] In general, the compounds of the invention will be
administered in a therapeutically effective amount by any of the
accepted modes of administration for agents that serve similar
utilities. Suitable dosage ranges are typically 1-500 mg daily, for
example 1-100 mg daily, and most preferably 1-30 mg daily,
depending upon numerous factors such as the severity of the disease
to be treated, the age and relative health of the subject, the
potency of the compound used, the route and form of administration,
the indication towards which the administration is directed, and
the preferences and experience of the medical practitioner
involved. One of ordinary skill in the art of treating such
diseases will be able, without undue experimentation and in
reliance upon personal knowledge and the disclosure of this
Application, to ascertain a therapeutically effective amount of the
compounds of the present invention for a given disease.
[1142] Compounds of the invention may be administered as
pharmaceutical formulations including those suitable for oral
(including buccal and sub-lingual), rectal, nasal, topical,
pulmonary, vaginal, or parenteral (including intramuscular,
intraarterial, intrathecal, subcutaneous and intravenous)
administration or in a form suitable for administration by
inhalation or insufflation. A particular manner of administration
is generally oral using a convenient daily dosage regimen which can
be adjusted according to the degree of affliction.
[1143] A compound or compounds of the invention, together with one
or more conventional adjuvants, carriers, or diluents, may be
placed into the form of pharmaceutical compositions and unit
dosages. The pharmaceutical compositions and unit dosage forms may
be comprised of conventional ingredients in conventional
proportions, with or without additional active compounds or
principles, and the unit dosage forms may contain any suitable
effective amount of the active ingredient commensurate with the
intended daily dosage range to be employed. The pharmaceutical
compositions may be employed as solids, such as tablets or filled
capsules, semisolids, powders, sustained release formulations, or
liquids such as solutions, suspensions, emulsions, elixirs, or
filled capsules for oral use; or in the form of suppositories for
rectal or vaginal administration; or in the form of sterile
injectable solutions for parenteral use. Formulations containing
about one (1) milligram of active ingredient or, more broadly,
about 0.01 to about one hundred (100) milligrams, per tablet, are
accordingly suitable representative unit dosage forms.
[1144] The compounds of the invention may be formulated in a wide
variety of oral administration dosage forms. The pharmaceutical
compositions and dosage forms may comprise a compound or compounds
of the present invention or pharmaceutically acceptable salts
thereof as the active component. The pharmaceutically acceptable
carriers may be either solid or liquid. Solid form preparations
include powders, tablets, pills, capsules, cachets, suppositories,
and dispersible granules. A solid carrier may be one or more
substances which may also act as diluents, flavouring agents,
solubilizers, lubricants, suspending agents, binders,
preservatives, tablet disintegrating agents, or an encapsulating
material. In powders, the carrier generally is a finely divided
solid which is a mixture with the finely divided active component.
In tablets, the active component generally is mixed with the
carrier having the necessary binding capacity in suitable
proportions and compacted in the shape and size desired. The
powders and tablets may contain from about one (1) to about seventy
(70) percent of the active compound. Suitable carriers include but
are not limited to magnesium carbonate, magnesium stearate, talc,
sugar, lactose, pectin, dextrin, starch, gelatine, tragacanth,
methylcellulose, sodium carboxymethylcellulose, a low melting wax,
cocoa butter, and the like. The term "preparation" is intended to
include the formulation of the active compound with encapsulating
material as carrier, providing a capsule in which the active
component, with or without carriers, is surrounded by a carrier,
which is in association with it. Similarly, cachets and lozenges
are included. Tablets, powders, capsules, pills, cachets, and
lozenges may be as solid forms suitable for oral
administration.
[1145] Other forms suitable for oral administration include liquid
form preparations including emulsions, syrups, elixirs, aqueous
solutions, aqueous suspensions, or solid form preparations which
are intended to be converted shortly before use to liquid form
preparations. Emulsions may be prepared in solutions, for example,
in aqueous propylene glycol solutions or may contain emulsifying
agents, for example, such as lecithin, sorbitan monooleate, or
acacia. Aqueous solutions can be prepared by dissolving the active
component in water and adding suitable colorants, flavors,
stabilizers, and thickening agents. Aqueous suspensions can be
prepared by dispersing the finely divided active component in water
with viscous material, such as natural or synthetic gums, resins,
methylcellulose, sodium carboxymethylcellulose, and other well
known suspending agents. Solid form preparations include solutions,
suspensions, and emulsions, and may contain, in addition to the
active component, colorants, flavors, stabilizers, buffers,
artificial and natural sweeteners, dispersants, thickeners,
solubilizing agents, and the like.
[1146] The compounds of the invention may be formulated for
parenteral administration (e.g., by injection, for example bolus
injection or continuous infusion) and may be presented in unit dose
form in ampoules, pre-filled syringes, small volume infusion or in
multi-dose containers with an added preservative. The compositions
may take such forms as suspensions, solutions, or emulsions in oily
or aqueous vehicles, for example solutions in aqueous polyethylene
glycol. Examples of oily or nonaqueous carriers, diluents, solvents
or vehicles include propylene glycol, polyethylene glycol,
vegetable oils (e.g., olive oil), and injectable organic esters
(e.g., ethyl oleate), and may contain formulatory agents such as
preserving, wetting, emulsifying or suspending, stabilizing and/or
dispersing agents. Alternatively, the active ingredient may be in
powder form, obtained by aseptic isolation of sterile solid or by
lyophilization from solution for constitution before use with a
suitable vehicle, e.g., sterile, pyrogen-free water.
[1147] The compounds of the invention may be formulated for topical
administration to the epidermis as ointments, creams or lotions, or
as a transdermal patch. Ointments and creams may, for example, be
formulated with an aqueous or oily base with the addition of
suitable thickening and/or gelling agents. Lotions may be
formulated with an aqueous or oily base and will in general also
containing one or more emulsifying agents, stabilizing agents,
dispersing agents, suspending agents, thickening agents, or
coloring agents. Formulations suitable for topical administration
in the mouth include lozenges comprising active agents in a
flavored base, usually sucrose and acacia or tragacanth; pastilles
comprising the active ingredient in an inert base such as gelatine
and glycerine or sucrose and acacia; and mouthwashes comprising the
active ingredient in a suitable liquid carrier.
[1148] The compounds of the invention may be formulated for
administration as suppositories. A low melting wax, such as a
mixture of fatty acid glycerides or cocoa butter is first melted
and the active component is dispersed homogeneously, for example,
by stirring. The molten homogeneous mixture is then poured into
convenient sized molds, allowed to cool, and to solidify.
[1149] The compounds of the invention may be formulated for vaginal
administration. Pessaries, tampons, creams, gels, pastes, foams or
sprays containing in addition to the active ingredient such
carriers as are known in the art to be appropriate.
[1150] The subject compounds may be formulated for nasal
administration. The solutions or suspensions are applied directly
to the nasal cavity by conventional means, for example, with a
dropper, pipette or spray. The formulations may be provided in a
single or multidose form. In the latter case of a dropper or
pipette, this may be achieved by the patient administering an
appropriate, predetermined volume of the solution or suspension. In
the case of a spray, this may be achieved for example by means of a
metering atomizing spray pump.
[1151] The compounds of the invention may be formulated for aerosol
administration, particularly to the respiratory tract and including
intranasal administration. The compound will generally have a small
particle size for example of the order of five (5) microns or less.
Such a particle size may be obtained by means known in the art, for
example by micronization. The active ingredient is provided in a
pressurized pack with a suitable propellant such as a
chlorofluorocarbon (CFC), for example, dichlorodifluoromethane,
trichlorofluoromethane, or dichlorotetrafluoroethane, or carbon
dioxide or other suitable gas. The aerosol may conveniently also
contain a surfactant such as lecithin. The dose of drug may be
controlled by a metered valve. Alternatively the active ingredients
may be provided in a form of a dry powder, for example a powder mix
of the compound in a suitable powder base such as lactose, starch,
starch derivatives such as hydroxypropylmethyl cellulose and
polyvinylpyrrolidine (PVP). The powder carrier will form a gel in
the nasal cavity. The powder composition may be presented in unit
dose form for example in capsules or cartridges of e.g., gelatine
or blister packs from which the powder may be administered by means
of an inhaler.
[1152] When desired, formulations can be prepared with enteric
coatings adapted for sustained or controlled release administration
of the active ingredient. For example, the compounds of the present
invention can be formulated in transdermal or subcutaneous drug
delivery devices. These delivery systems are advantageous when
sustained release of the compound is necessary and when patient
compliance with a treatment regimen is crucial. Compounds in
transdermal delivery systems are frequently attached to an
skin-adhesive solid support. The compound of interest can also be
combined with a penetration enhancer, e.g., Azone
(1-dodecylazacycloheptan-2-one). Sustained release delivery systems
are inserted subcutaneously into the subdermal layer by surgery or
injection. The subdermal implants encapsulate the compound in a
lipid soluble membrane, e.g., silicone rubber, or a biodegradable
polymer, e.g., polylactic acid.
[1153] The pharmaceutical preparations may be in unit dosage forms.
In such form, the preparation is subdivided into unit doses
containing appropriate quantities of the active component. The unit
dosage form can be a packaged preparation, the package containing
discrete quantities of preparation, such as packeted tablets,
capsules, and powders in vials or ampoules. Also, the unit dosage
form can be a capsule, tablet, cachet, or lozenge itself, or it can
be the appropriate number of any of these in packaged form.
[1154] Other suitable pharmaceutical carriers and their
formulations are described in Remington: The Science and Practice
of Pharmacy 1995, edited by E. W. Martin, Mack Publishing Company,
19th edition, Easton, Pa. Representative pharmaceutical
formulations containing a compound of the present invention are
described below.
Utility
[1155] The compounds of the invention are useful for treatment of
immune disorders generally. The compounds may be used for treatment
of arthritis, including rheumatoid arthritis, osteoarthritis,
psoriatic arthritis, septic arthritis, spondyloarthropathies, gouty
arthritis, systemic lupus erythematosus and juvenile arthritis,
osteoarthritis, and other arthritic conditions.
[1156] The compounds may be used for treatment of respiratory
disorders such as chronic obstructive pulmonary disease (COPD),
asthma, bronchospasm, and the like.
[1157] The compounds may be used for treatment of gastrointestinal
disorder ("GI disorder") such as Irritable Bowel Syndrome (IBS),
Inflammatory Bowel Disease (IBD), biliary colic and other biliary
disorders, renal colic, diarrhea-dominant IBS, pain associated with
GI distension, and the like.
[1158] The compounds may be used for treatment of pain conditions
such as inflammatory pain; arthritic pain, surgical pain; visceral
pain; dental pain; premenstrual pain; central pain; pain due to
burns; migraine or cluster headaches; nerve injury; neuritis;
neuralgias; poisoning; ischemic injury; interstitial cystitis;
cancer pain; viral, parasitic or bacterial infection;
post-traumatic injury; or pain associated with irritable bowel
syndrome.
Examples
[1159] The following preparations and examples are given to enable
those skilled in the art to more clearly understand and to practice
the present invention. They should not be considered as limiting
the scope of the invention, but merely as being illustrative and
representative thereof.
[1160] Unless otherwise stated, all temperatures including melting
points (i.e., MP) are in degrees celsius (.degree. C.). It should
be appreciated that the reaction which produces the indicated
and/or the desired product may not necessarily result directly from
the combination of two reagents which were initially added, i.e.,
there may be one or more intermediates which are produced in the
mixture which ultimately leads to the formation of the indicated
and/or the desired product. The following abbreviations may be used
in the Preparations and Examples.
LIST OF ABBREVIATIONS
[1161] AcOH Acetic acid [1162] AIBN
2,2'-Azobis(2-methylpropionitrile) [1163] Atm. Atmosphere [1164]
(BOC).sub.2O di-tert-Butyl dicarbonate [1165] DCM
Dichloromethane/Methylene chloride [1166] DIAD Diisopropyl
azodicarboxylate [1167] DIPEA Diisopropylethylamine [1168] DMAP
4-Dimethylaminopyridine [1169] DME 1,2-Dimethoxyethane [1170] DMF
N,N-Dimethylformamide [1171] DMSO Dimethyl sulfoxide [1172] DPPF
1,1'-Bis(diphenylphosphino)ferrocene [1173] Et.sub.2O Diethyl ether
[1174] EtOH Ethanol/Ethyl alcohol [1175] EtOAc Ethyl acetate [1176]
HATU 2-(1H-7-Azabenzotriazol-1-yl)-4-1,1,3,3-tetramethyl uronium
hexafluorophosphate Methanaminium [1177] HBTU
O-Benzotriazol-1-yl-N,N,N',N'-tetramethyluronium
hexafluorophosphate [1178] HOBT I-Hydroxybenzotriazole [1179] HPLC
High pressure liquid chromatography [1180] RP HPLC Reverse phase
high pressure liquid chromatography [1181] i-PrOH
Isopropanol/isopropyl alcohol [1182] LCMS Liquid Chromatograph/Mass
Spectroscopy [1183] MeOH Methanol/Methyl alcohol [1184] MW
Microwaves [1185] NBS N-Bromosuccinimide [1186] NMP
1-Methyl-2-pyrrolidinone [1187] PSI Pound per square inch [1188]
r.t. Room temperature [1189] TBDMS tert-Butyldimethylsilyl [1190]
TFA Trifluoroacetic acid [1191] THF Tetrahydrofuran [1192] TLC Thin
layer chromatography
GENERAL EXPERIMENTAL
LCMS methods
[1193] High Pressure Liquid Chromatography-Mass Spectrometry (LCMS)
experiments to determine retention times (RT) and associated mass
ions were performed using one of the following methods:
[1194] Method A: Compounds were analysed using the following
conditions: Experiments were performed on a Waters ZMD single
quadrupole mass spectrometer linked to a Hewlett Packard HPI100 LC
system with UV diode array detector and 100 position autosampler.
The spectrometer has an electrospray source operating in positive
and negative ion mode. This system uses a Phenomenex Luna 3 .mu.m
C18(2) 30.times.4.6 mm column at ambient temperature and a 2.0
mL/minute flow rate. The initial solvent system was 95% water
containing 0.1% formic acid (solvent A) and 5% acetonitrile
containing 0.1% formic acid (solvent B) for the first 0.5 minute
followed by a gradient up to 5% solvent A and 95% solvent B over
the next 4 minutes. This was maintained for 1 minute before
returning to 95% solvent A and 5% solvent B over the next 0.5
minute. Total run time was 6 minutes.
[1195] Method B: Compounds were analysed using the following
conditions: Experiments were performed on a Waters Micromass ZQ2000
quadrupole mass spectrometer linked to a Waters Acquity UPLC system
with a PDA UV detector. The spectrometer has an electrospray source
operating in positive and negative ion mode. This system uses an
Acquity BEH C18 1.7 .mu.m 100.times.2.1 mm column, maintained at
40.degree. C. or an Acquity BEH Shield RP18 1.7 .mu.m 100.times.2.1
mm column, maintained at 40.degree. C. and a 0.4 mL/minute flow
rate. The initial solvent system was 95% water containing 0.1%
formic acid (solvent A) and 5% acetonitrile containing 0.1% formic
acid (solvent B) for the first 0.4 minute followed by a gradient up
to 5% solvent A and 95% solvent B over the next 5.6 minutes. This
was maintained for 0.8 minute before returning to 95% solvent A and
5% solvent B over the next 1.2 minutes. Total run time was 8
minutes.
NMR Methods
[1196] .sup.1H NMR spectra were recorded at ambient temperature or
at 80.degree. C. where indicated using one of the following
machines: Varian Unity Inova (400 MHz) spectrometer with a triple
resonance 5 mm probe, Bruker Avance DRX 400 (400 MHz) spectrometer
with a triple resonance 5 mm probe, a Bruker Avance DPX 300 (300
MHz) equipped with a standard 5 mm dual frequency probe for
detection of 1H and 13C, Bruker Fourier 300 MHz system equipped
with a standard 5 mm 1H/13C probe, a Bruker AVIII (400 MHz) using a
BBI Broad Band Inverse 5 mm probe, or a Bruker AVIII (500 MHz)
using a QNP (Quad Nucleus detect) 5 mm probe. Chemical shifts are
expressed in ppm relative to an internal standard,
tetramethylsilane (ppm=0.00). The following abbreviations have been
used: br=broad signal, s=singlet, d=doublet, dd=double doublet,
t=triplet, td=triplet doublet, dddd=doublet doublet doublet
doublet, q=quartet, m=multiplet, or any combination of.
Microwave Reactor:
[1197] Microwave reactions were carried out using a Biotage.RTM.
Initiator.RTM. in vials appropriate to the scale of the reaction
and at the temperature and time described in the experimental
details.
Purification Equipment:
[1198] Purifications were carried out using pre-packed silica gel
cartridges either on a Teledyne ISCO CombiFlash.RTM. or
Biotage.RTM. Isolera Four.RTM. or using compressed air to apply
external pressure. Solvents and gradients shown in the experimental
details were used.
[1199] Reverse Phase High Pressure Liquid Chromatography (HPLC) was
used to purify compounds where indicated. Separation using gradient
elution on a Phenomenex Gemini C18 column (250.times.21.2 mm, 5
micron) as stationary phase and using mobile phase indicated,
operating at a 18 mL/min flow rate using a Gilson UV/Vis-155 dual
channel detector and Gilson GX-271 automated liquid handler.
[1200] Phase separator cartridges are supplied by Biotage.RTM. as
Isolute.RTM. phase separator cartridges
Preparations 1 and 2: (3R)-3-Aminobutan-1-ol and
(3S)-3-Aminobutan-1-ol
##STR00085##
[1201] Step 1 3-[[(Benzyloxy)carbonyl]amino]butanoic acid
[1202] Into a 2000-mL 4-necked round-bottom flask was placed a
solution of 3-aminobutanoic acid (100 g, 969.75 mmol, 1.00 equiv)
in water (1000 mL), followed by the addition of potassium hydroxide
(136 g, 2.42 mol, 2.50 equiv) in several batches. To this was added
benzyl chloroformate (247 g, 1.45 mol, 1.50 equiv) dropwise with
stirring at 0-5.degree. C. The resulting solution was stirred at
25.degree. C. for 5 h. The reaction progress was monitored by LCMS.
The resulting solution was extracted with dichloromethane and the
aqueous layers were combined. The pH value of the water phase was
adjusted to 3 with hydrogen chloride (2 mol/L). The precipitates
were collected by filtration and dried to afford 102 g (44%) of
3-[[(benzyloxy)carbonyl]amino]butanoic acid as a white solid.
Step 2: Benzyl N-[(2S)-4-hydroxybutan-2-yl]carbamate and Benzyl
N-[(2R)-4-hydroxybutan-2-yl]carbamate
[1203] Into a 2000-mL 3-necked round-bottom flask purged and
maintained with an inert atmosphere of nitrogen was placed a
solution of 3-[[(benzyloxy)carbonyl]amino]butanoic acid (102 g,
429.92 mmol, 1.00 equiv) in THF (300 mL), followed by the addition
of BH.sub.3/THF (1N) (645 mL, 1.50 equiv) dropwise with stirring at
0-5.degree. C. The resulting solution was stirred at 40.degree. C.
for 2 h, quenched by the addition of 200 mL of methanol and
concentrated under vacuum. The residue was purified on a silica gel
column eluting with ethyl acetate: petroleum ether (1:2). The crude
product (70 g) was purified by Prep-SFC with the following
conditions (prep SFC): Column, Phenomenex Lux 5u Cellulose-4,
2.12*25.5 um; mobile phase, CO.sub.2 (85%), ethanol (15%);
Detector, UV 254 nm. This resulted in 30 g (31.5%) of benzyl
N-[(2R)-4-hydroxybutan-2-yl]carbamate as an off-white solid and 30
g (31.5%) of benzyl N-[(2S)-4-hydroxybutan-2-yl]carbamate as an
off-white solid.
Step 3: (3R)-3-Aminobutan-1-ol and (3S)-3-Aminobutan-1-ol
[1204] Into a 1000-mL round-bottom flask was placed a solution of
benzyl N-[(2S)-4-hydroxybutan-2-yl]carbamate (30 g, 134.4 mmol,
1.00 equiv) in methanol (500 mL) and palladium carbon (3 g, 0.10
equiv). The resulting solution was stirred at 25.degree. C. for 12
h under an atmosphere of hydrogen. The solids were filtered out and
the filtrate was concentrated under vacuum to afford 11.7 g (92%)
of (3S)-3-aminobutan-1-ol as an oil. .sup.1H NMR (300 MHz, DMSO,
ppm): .delta. 4.48 (3H, s), 3.47 (2H, s), 2.96 (1H, s), 1.47-1.41
(2H, q), 1.02-0.99 (3H, d); LCMS (ESI), m/z, 90 [M+H].sup.+;
measured [.alpha.].sub.D.sup.20.2+11.65.degree. (C=1.22 g/100 mL in
EtOH), lit. [.alpha.].sub.D.sup.20+16.3.degree. (c=4.5 in EtOH) (J.
Org. Chem. 1996, 61, 2293-2304.).
[1205] Using the above procedure, 12.0 g 12 g (94%) of
(3R)-3-aminobutan-1-ol was isolated as an oil. .sup.1H NMR (300
MHz, DMSO, ppm): .delta. 4.48 (3H, s), 3.47 (2H, s), 2.96 (1H, s),
1.47-1.41 (2H, q), 1.02-0.99 (3H, d); LCMS (ESI), m/z, 90
[M+H].sup.+; measured [.alpha.].sub.D.sup.20.2-11.1.degree. (C=0.32
g/100 mL in EtOH), lit. [.alpha.].sub.D.sup.25-25.degree. (C=1.25
in EtOH) (Tetrahedron: Asymmetry 1999, 10, 2213-2224.).
Preparation 3:
(R)--N-(4-Chlorobutan-2-yl)-1-phenylmethanesulfonamide
##STR00086##
[1206] Step 1: (R)-3-(Phenylmethylsulfonamido)butyl
phenylmethanesulfonate
[1207] To a solution of (3R)-3-aminobutan-1-ol (1.0 g, 11.2 mmol)
and triethylamine (3.3 mL, 23.6 mmol) in tetrahydrofuran (37 mL) at
0.degree. C. was slowly added phenylmethanesulfonyl chloride (4.49
g, 23.6 mmol) and the reaction was stirred at room temperature for
16 hours. MTBE (100 mL) was then added and the Et.sub.3N.HCl salt
was removed by filtration. The filtrate was then concentrated to
give crude (R)-3-(phenylmethylsulfonamido)butyl
phenylmethanesulfonate which was used without purification. LCMS
(ESI), m/z, 398 [M+H]+.
Step 2: (R)--N-(4-Chlorobutan-2-yl-1-phenylmethanesulfonamide
[1208] To the crude (R)-3-(phenylmethylsulfonamido)butyl
phenylmethanesulfonate (23.6 mmol) was added sodium chloride (984
mg, 16.8 mmol) and dimethylformamide (37 mL) and the reaction was
stirred at 80.degree. C. for 16 hours. The reaction was then
diluted with EtOAc, washed with water (.times.2) and brine, dried
with MgSO.sub.4, concentrated and purified by silica gel column
chromatography (0-50% Acetone in Heptane, 216 nM) to give
(R)--N-(4-chlorobutan-2-yl)-1-phenylmethanesulfonamide (1.71 g,
6.53 mmol, 58% yield over 2 steps). LCMS (ESI), m/z, 261
[M+H]+.
[1209] Additional compounds made using the above procedure are
shown in Table 1.
TABLE-US-00001 TABLE 1 LCMS (ESI), Structure Name m/z, [M + H]+ 4
##STR00087## (S)-N-(4-chlorobutan- 2-yl)-1-phenylmethane-
sulfonamide 261 5 ##STR00088## N-(4-chloro-2- methylbutan-2-yl)-
1-phenylmethane- sulfonamide 275 6 ##STR00089##
N-(4-chlorobutyl)-1- phenylmethane- sulfonamide 261
Preparation 7: N-(2-bromoethyl)(phenyl)methanesulfonamide
##STR00090##
[1211] K.sub.2CO.sub.3 (8.7 g, 62 mmol) was added into a mixture of
phenylmethanesulfonyl chloride (6 g, 31 mmol) and 2-bromoethanamine
hydrobromide (6.4 g, 31 mmol) in DCM (100 mL) at 0.degree. C. And
the resulting mixture was stirred at r.t. for 4 hours and left
standing overnight. Upon the completion of reaction, water (100 mL)
was added in and DCM phase was separated. The aqueous phase was
extracted with DCM. The combined organic phase was dried over
Na.sub.2SO.sub.4, filtered and concentrated in vacuo to provide a
crude which was separated with column chromatography (silica gel
with 200-300 mesh, 0 to 50% of EtOAc in petroleum ether) to provide
compound N-(2-bromoethyl)(phenyl)methanesulfonamide (7.0 g, 80%) as
a pale yellow solid. .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 7.40
(m, 5H), 4.58 (m, 1H), 4.29 (s, 2H), 3.34-3.29 (m, 4H). LCMS (ESI),
300, 302 [M+Na].sup.+, Br pattern found.
Preparation 8
N-(2-bromoethyl)(4-fluorophenyl)methanesulfonamide
##STR00091##
[1213] N-(2-bromoethyl)(4-fluorophenyl)methanesulfonamide was also
made using the above procedure, replacing phenylmethanesulfonyl
chloride with 4-fluoro-phenylmethanesulfonyl chloride. .sup.1H NMR
(300 MHz, CDCl.sub.3) .delta. 7.43-7.38 (m, 2H), 7.13-7.07 (m, 2H),
4.62 (br s, 1H), 4.26 (s, 2H), 3.41-3.32 (m, 4H).
Preparation 9: N-(3-bromopropyl)(phenyl)methanesulfonamide
##STR00092##
[1215] A solution of phenylmethanesulfonyl chloride (2.19 g, 10
mmol) was added into a suspension of 3-bromopropan-1-amine
hydrobromide (2.19 g, 10 mmol) and Et.sub.3N (2.02 g, 20 mmol) in
THF (50 mL) at 0.degree. C. The mixture was stirred at 0.degree. C.
for 5 min. TLC confirmed the completion of reaction. Solid was
filtered out with suction, and the filtrate was concentrated to
provide compound N-(3-bromopropyl)(phenyl)methanesulfonamide (2.7
g, quant.) as a pale yellow solid which was used in the next step
without further purification. .sup.1H NMR (300 MHz, CDCl.sub.3)
.delta. 7.40 (m, 5H), 4.48 (m, 1H), 4.27 (s, 2H), 3.41 (t, J=6.6
Hz, 2H), 3.16 (q, 2H), 2.01 (m, 2H). LCMS (ESI), m/z, 314 and 316
[M+Na].sup.+, Br pattern found.
Preparation 10:
N-(3-bromopropyl)(4-fluorophenyl)methanesulfonamide
##STR00093##
[1217] N-(3-bromopropyl)(4-fluorophenyl)methanesulfonamide was
prepared using the above procedure. .sup.1H NMR (300 MHz,
CDCl.sub.3) .delta. 7.42-7.37 (m, 2H), 7.13-7.07 (m, 2H), 4.26 (m,
1H), 4.24 (s, 2H), 3.46-3.42 (m, 2H), 3.20-3.16 (m, 2H), 2.05-2.00
(m, 2H).
Preparation 11: 6-Phenyl-1,2-thiazinane 1,1-dioxide
##STR00094##
[1219] To a solution of
N-(3-bromopropyl)-1-phenylmethanesulfonamide (2.3 g, 7.9 mmol),
diisopropylamine (0.28 mL, 2.0 mmol) and 1,10-phenanthroline (3.6
mg, 0.02 mmol) in tetrahydrofuran (26 mL) at -78.degree. C. was
added n-BuLi (6.8 mL, 2.5 M in hexanes) dropwise and the reaction
was stirred for 16 hours. Saturated NH.sub.4Cl was then added and
the reaction was diluted with EtOAc, washed with water and brine,
dried with MgSO.sub.4, concentrated and purified by silica gel
column chromatography (0-50% EtOAc/heptane) to
6-Phenyl-1,2-thiazinane 1,1-dioxide (1.3 g, 80% yield). .sup.1H NMR
(300 MHz, DMSO-d.sub.6) .delta. 7.40-7.35 (m, 5H), 6.98 (m, 1H),
4.12 (dd, 1H), 3.26-3.20 (m, 2H), 2.40-2.30 (m, 1H), 2.16-2.12 (m,
1H), 1.77-1.65 (m, 2H). LCMS (ESI), m/z, 234 [M+Na].sup.+.
(Reference: D. Askin, et al. Org. Lett. 2003, 4175.)
[1220] Additional compounds made using the above procedure are
shown in Table 2.
TABLE-US-00002 TABLE 2 LCMS (ESI) Structure Name m/z, [M + H].sup.+
12 ##STR00095## 6-(4-fluorophenyl)-1,2- thiazinane 1,1-dioxide 230
13 ##STR00096## 5-phenylisothiazolidine 1,1-dioxide 198 14
##STR00097## 5-(4-fluorophenyl)isothiazolidine 1,1-dioxide 216 15
##STR00098## (3R)-3-methyl-6-phenyl-1,2- thiazinane 1,1-dioxide 226
16 ##STR00099## (3S)-3-methyl-6-phenyl-1,2- thiazinane 1,1-dioxide
226 17 ##STR00100## 3,3-dimethyl-6-phenyl-1,2- thiazinane
1,1-dioxide 240 18 ##STR00101## 7-phenyl-1,2-thiazepane 1,1-dioxide
226
Preparation 19: 3-Phenyl-1,4,5-oxathiazepane 4,4-dioxide
##STR00102##
[1221] Step 1:
N-(2-((Tert-butyldimethylsilyl)oxy)ethyl)-4-phenylmethanesulfonamide
[1222] To a solution of 2-((tert-butyldimethylsilyl)oxy)ethanamine
(11.7 g, 66.6 mmol) and triethylamine (11.2 mL, 79.9 mmol) in
tetrahydrofuran (222 mL) at 0.degree. C. was slowly added
phenylmethanesulfonyl chloride (12.7 g, 66.6 mmol) portion wise and
the reaction was stirred at room temperature for 16 hours. MTBE was
then added and the Et.sub.3N.HCl salt was removed by filtration.
The filtrate was then concentrated and purified by silica gel
column chromatography (0-30% Acetone in heptane, 216 nM) to
N-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-phenylmethanesulfonamide
(17.8 g, 81% yield). LCMS (ESI), m/z, 330. [M+H]+.
Step 2:
N-(2-((Tert-butyldimethylsilyl)oxy)ethyl)-1-phenylethenesulfonamid-
e
[1223] To a solution of
N-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-1-phenyl-methanesulfonamide
(33 g, 100.2 mmol) in tetrahydrofuran (334 mL) at -78.degree. C.
was slowly added n-BuLi (2.5 M in hexanes) (100 mL, 250 mmol) via
cannula and the reaction was stirred at -78.degree. C. was 2 hours.
Chloroiodomethane (8.3 mL, 110 mmol) was then slowly added and the
reaction was stirred at -78.degree. C. for one hour, then allowed
to warm to room temperature and aged for 16 hours. The reaction was
then quenched with saturated NH.sub.4Cl and extracted with
dichloromethane, dried with MgSO.sub.4, concentrated and purified
by silica gel column chromatography (0-60% EtOAc in heptane) to
give
N-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-1-phenyl-ethenesulfonamide
(24 g, 70% yield). LCMS (ESI), m/z, 342. [M+H]+.
Step 3: 3-Phenyl-1,4,5-oxathiazepane 4,4-dioxide
[1224] To a solution of
N-(2-((Tert-butyldimethylsilyl)oxy)ethyl)-1-phenylethenesulfonamide
(717 mg, 2.1 mmol) in tetrahydrofuran (7 mL) at 0.degree. C. was
added tetrabutylammonium fluoride (1.0 M in THF) (2.2 mL, 2.2 mmol)
dropwise and the reaction was stirred at room temperature for 16
hours. Saturated NH.sub.4Cl was then added and the product was
extracted with dichloromethane (.times.2), dried with MgSO.sub.4,
concentrated and purified by silica gel column chromatography
(0-100% EtOAc in heptane) to give 3-phenyl-1,4,5-oxathiazepane
4,4-dioxide (401 mg, 84% yield). (24 g, 70% yield). LCMS (ESI),
m/z, 228. [M+H]+. (Reference: P. Hansen, et al. Org. Lett. 2008,
2951).
[1225] Additional compounds made using the above procedure are
shown in Table 3.
TABLE-US-00003 TABLE 3 LCMS (ESI), Structure Name m/z, [M +
H].sup.+ 20 ##STR00103## (6R)-6-methyl- 3-phenyl-1,4,5-
oxathiazepane 4,4-dioxide 242 21 ##STR00104## (6S)-6-methyl-
3-phenyl-1,4,5- oxathiazepane 4,4-dioxide 242 22 ##STR00105##
(7S)-7-methyl- 3-phenyl-1,4,5- oxathiazepane 4,4-dioxide 242 23
##STR00106## (7R)-7-methyl- 3-phenyl-1,4,5- oxathiazepane
4,4-dioxide 242
Preparation 24
(1R,5S)-6-(1,2,4-Triazol-4-yl)-3-azabicyclo[3.1.0]hexane
hydrochloride
##STR00107##
[1226] Step 1 Tert-butyl
(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate
[1227] A 1-liter round-bottom flask was charged with
tert-butyl(1R,5S)-6-amino-3-azabicyclo[3.1.0]hexane-3-carboxylate
(9 g, 45.4 mmol), N,N'-bis(dimethylaminomethylene)hydrazine (32.3
g, 227 mmol), and p-toluenesulfonic acid (790 mg, 4.54 mmol) and
the flask was purged with nitrogen. Toluene (225 mL) was then added
and the reaction was heated to reflux under nitrogen for 16 hours.
The reaction was then diluted with ethyl acetate (500 mL) and the
hydrazine reagent was washed away with 5% citric acid in water
(2.times.100 mL). The aqueous layer was extracted with
dichloromethane (3.times.100 mL) and all organic extracts
(CH.sub.2Cl.sub.2+EtOAc) were combined, dried with MgSO4,
concentrated and purified by silica gel column chromatography
(0-10% MeOH in CH.sub.2Cl) to give
tert-butyl(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]hexane-3-carb-
oxylate (10 g, 40 mmol, 88% yield). LCMS ES.sup.+ m/z=251.
Step 2 (1R,5S)--6-(1,2,4-Triazol-4-yl)-3-azabicyclo[3.1.0]hexane
hydrochloride
[1228] To
tert-butyl(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]hexa-
ne-3-carboxylate (10 g, 40 mmol) was added hydrochloric acid (250
mL, 4M in 1,4-dioxane) under an atmosphere of nitrogen and the
reaction was stirred at room temperature for 5 hours. Methyl
tert-butyl ether (250 mL) was then added and the solid was
collected by filtration and dried under vacuum for 16 hours to give
(1R,5S)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]hexane
hydrochloride (6.9 g, 37 mmol, 81% yield). .sup.1H NMR (400 MHz,
DMSO) 10.19-9.96 (br s, 2H), 9.46 (s, 2H), 4.08-3.98 (m, 1H),
3.58-3.36 (m, 4H), 2.66-2.58 (m, 2H); LCMS ES.sup.+ m/z=151.
Examples 1 and 2:
(R)-1-(4-(4-((1,1-Dioxido-6-phenyl-1,2-thiazinan-2-yl)methyl)-3-fluorophe-
nyl)piperazin-1-yl)ethanone and
(S)-1-(4-(4-((1,1-Dioxido-6-phenyl-1,2-thiazinan-2-yl)methyl)-3-fluorophe-
nyl)piperazin-1-yl)ethanone
##STR00108##
[1229] Step 1: 2-(4-Bromo-2-fluorobenzyl)-6-phenyl-1,2-thiazinane
1,1-dioxide
[1230] To a solution of 6-phenyl-1,2-thiazinane 1,1-dioxide (300
mg, 1.42 mmol) and 4-bromo-1-(bromomethyl)-2-fluorobenzene (456 mg,
1.7 mmol) in N,N-dimethylacetamide (5 mL) at 0.degree. C. was added
sodium hydride (60% in mineral oil) (68 mg, 1.85 mmol) and the
reaction was stirred at room temperature for 2 hours. Water was
added and the reaction was diluted with EtOAc, washed with brine,
dried with MgSO.sub.4, filtered and purified by silica gel column
chromatography (0-60% EtOAc/heptane) to give
2-(4-bromo-2-fluorobenzyl)-6-phenyl-1,2-thiazinane 1,1-dioxide (396
mg, 70% yield). LCMS (ESI), m/z, 398 [M+H]+.
Step 2:
(R)-1-(4-(4-((1,1-Dioxido-6-phenyl-1,2-thiazinan-2-yl)methyl)-3-fl-
uorophenyl)piperazin-1-yl)ethanone and
(S)-1-(4-(4-((1,1-Dioxido-6-phenyl-1,2-thiazinan-2-yl)methyl)-3-fluorophe-
nyl)piperazin-1-yl)ethanone
[1231] 2-[(4-Bromo-2-fluoro-phenyl)methyl]-6-phenyl-thiazinane
1,1-dioxide (208 mg, 0.52 mmol), Pd(OAc).sub.2 (5.8 mg, 0.026
mmol), 2-dicyclohexylphosphine-2',6'-di-iso-propoxy-1,1'-biphenyl
(24.8 mg, 0.052 mmol) and cesium carbonate (254 mg, 0.78 mmol) were
weighed out in a vial and the vial was purged with nitrogen.
1,4-Dioxane (2.5 mL) and 1-piperazin-1-ylethanone (100 mg, 0.78
mmol) were then added and the reaction was stirred at 80.degree. C.
for 2 hours. The reaction was then filtered through diatomaceous
earth, concentrated and purified by reverse-phase HPLC to give
1-(4-(4-((1,1-dioxido-6-phenyl-1,2-thiazinan-2-yl)methyl)-3-fluorophenyl)-
piperazin-1-yl)ethanone (210 mg, 89% yield).
[1232] The racemic mixture (150 mg) was separated by chiral SFC to
give
1-(4-(4-((1,1-dioxido-6-phenyl-1,2-thiazinan-2-yl)methyl)-3-fluorophenyl)-
piperazin-1-yl)ethanone as isolated stereoisomers in separate
fractions: (ISOMER A) as a first fraction (50 mg, 33% yield) and
1-(4-(4-((1,1-dioxido-6-phenyl-1,2-thiazinan-2-yl)methyl)-3-fluorophenyl)-
piperazin-1-yl)ethanone (ISOMER B) as a second fraction (77 mg, 51%
yield):
[1233]
1-(4-(4-((1,1-dioxido-6-phenyl-1,2-thiazinan-2-yl)methyl)-3-fluorop-
henyl)piperazin-1-yl)ethanone (Stereoisomer A): .sup.1H NMR (400
MHz, DMSO) .delta. 7.49-7.31 (m, 5H), 7.26 (t, J=8.8 Hz, 1H),
6.86-6.73 (m, 2H), 4.49 (dd, J=12.6, 3.2 Hz, 1H), 4.35 (q, J=14.4
Hz, 2H), 3.63-3.51 (m, 4H), 3.46 (t, J=12.9 Hz, 1H), 3.28-3.19 (m,
2H), 3.19-3.04 (m, 3H), 2.48-2.35 (m, 1H), 2.22-2.07 (m, 1H), 2.04
(s, 3H), 2.01-1.87 (m, 1H), 1.72-1.49 (m, 1H). LCMS (ESI), m/z,
446.1 [M+H]+.
[1234]
1-(4-(4-((1,1-dioxido-6-phenyl-1,2-thiazinan-2-yl)methyl)-3-fluorop-
henyl)piperazin-1-yl)ethanone (Stereosiomer B): .sup.1H NMR (400
MHz, DMSO) .delta. 7.49-7.31 (m, 5H), 7.26 (t, J=8.8 Hz, 1H),
6.86-6.73 (m, 2H), 4.49 (dd, J=12.6, 3.2 Hz, 1H), 4.35 (q, J=14.4
Hz, 2H), 3.63-3.51 (m, 4H), 3.46 (t, J=12.9 Hz, 1H), 3.28-3.19 (m,
2H), 3.19-3.04 (m, 3H), 2.48-2.35 (m, 1H), 2.22-2.07 (m, 1H), 2.04
(s, 3H), 2.01-1.87 (m, 1H), 1.72-1.49 (m, 1H). LCMS (ESI), m/z,
446.1 [M+H]+.
Examples 3 and 4:
(S)-2-(2-Fluoro-4-((1-(methylsulfonyl)piperidin-4-yl)oxy)benzyl)-6-phenyl-
-1,2-thiazinane 1,1-dioxide and
(R)-2-(2-Fluoro-4-((1-(methylsulfonyl)piperidin-4-yl)oxy)benzyl)-6-phenyl-
-1,2-thiazinane 1,1-dioxide
##STR00109##
[1236] 2-(4-bromo-2-fluorobenzyl)-6-phenyl-1,2-thiazinane
1,1-dioxide (100 mg, 0.25 mmol), 1-methylsulfonylpiperidin-4-ol
(67.2 mg, 0.38 mmol), copper(I) iodide (9.5 mg, 0.05 mmol),
3,4,7,8-tetramethyl-1,10-phenanthroline (24 mg, 0.1 mmol) and
cesium carbonate (123 mg, 0.38 mmol) were weighed out in a vial and
the vial was purged with nitrogen. p-Xylene (1 mL) was then added
and the reaction was stirred at 135.degree. C. for 16 hours. The
reaction was then filtered through diatomaceous earth, concentrated
and purified by reverse-phase HPLC to give
2-(2-fluoro-4-((1-(methylsulfonyl)piperidin-4-yl)oxy)benzyl)-6-phenyl-1,2-
-thiazinane 1,1-dioxide (50.1 mg, 40% yield).
[1237] The racemic mixture (40 mg) was separated by chiral SFC to
give
2-(2-fluoro-4-((1-(methylsulfonyl)piperidin-4-yl)oxy)benzyl)-6-phenyl-1,2-
-thiazinane 1,1-dioxide as isolated stereoisomers in separate
fractions: ISOMER A as a first fraction (11.4 mg, 29% yield) and
ISOMER B as a second fraction (11.6 mg, 29% yield).
[1238]
1-(4-(4-((1,1-dioxido-6-phenyl-1,2-thiazinan-2-yl)methyl)-3-fluorop-
henyl)piperazin-1-yl)ethanone (Stereoisomer A): .sup.1H NMR (400
MHz, DMSO) .delta. 7.48-7.30 (m, 6H), 6.97-6.89 (m, 1H), 6.89-6.84
(m, 1H), 4.68-4.56 (m, 1H), 4.56-4.47 (m, 1H), 4.47-4.38 (m, 1H),
4.38-4.30 (m, 1H), 3.57-3.41 (m, 1H), 3.42-3.31 (m, 2H), 3.19-3.05
(m, 3H), 2.91 (s, 3H), 2.48-2.39 (m, 1H), 2.21-2.08 (m, 1H),
2.08-1.91 (m, 3H), 1.82-1.68 (m, 2H), 1.68-1.57 (m, 1H). LCMS
(ESI), m/z, 497.1 [M+H]+.
[1239]
1-(4-(4-((1,1-dioxido-6-phenyl-1,2-thiazinan-2-yl)methyl)-3-fluorop-
henyl)piperazin-1-yl)ethanone (Stereoisomer B): .sup.1H NMR (400
MHz, DMSO) .delta. 7.48-7.30 (m, 6H), 6.97-6.89 (m, 1H), 6.89-6.84
(m, 1H), 4.68-4.56 (m, 1H), 4.56-4.47 (m, 1H), 4.47-4.38 (m, 1H),
4.38-4.30 (m, 1H), 3.57-3.41 (m, 1H), 3.42-3.31 (m, 2H), 3.19-3.05
(m, 3H), 2.91 (s, 3H), 2.48-2.39 (m, 1H), 2.21-2.08 (m, 1H),
2.08-1.91 (m, 3H), 1.82-1.68 (m, 2H), 1.68-1.57 (m, 1H). LCMS
(ESI), m/z, 497.1 [M+H]+.
Example 5
(3S)-2-[[2-Fluoro-4-[4-(1,2,4-triazol-4-yl)-1-piperidyl]phenyl]m-
ethyl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide
##STR00110##
[1240] Step 1
(3S)-2-[(4-Bromo-2-fluoro-phenyl)methyl]-3-methyl-6-phenyl-thiazinane
1,1-dioxide
[1241]
(3S)-2-(4-bromo-2-fluorobenzyl)-3-methyl-6-phenyl-1,2-thiazinane
1,1-dioxide (40 g, 97 mmol, 15:85 mixture of cis/trans isomers,
prepared as described in Step 1 of Example 1) was suspended in
heptane (750 mL) and the suspension was heated to reflux. Ethyl
acetate was slowly added until complete dissolution of the material
occurred (250 mL). The solution was then subjected to a hot
filtration, cooled to room temperature and store at 4.degree. C.
for 16 hours. Crystals were collected by filtration to give
(3S)-2-[(4-bromo-2-fluoro-phenyl)methyl]-3-methyl-6-phenyl-thiazinane
1,1-dioxide Stereoisomer A (30 g, 73 mmol, 72% yield). .sup.1H NMR
(300 MHz, DMSO) .delta. 7.55-7.31 (m, 8H), 4.61-4.43 (m, 2H),
4.41-4.29 (m, 1H), 4.23-4.00 (m, 1H), 2.48-2.34 (m, 1H), 2.18-2.03
(m, 1H), 1.92-1.72 (m, 1H), 1.72-1.58 (m, 1H), 1.12-1.03 (d, J=6.8
Hz, 3H); LCMS [M+1]+=412.1.
Step 2
(3S)-2-[[2-Fluoro-4-[4-(1,2,4-triazol-4-yl)-1-piperidyl]phenyl]meth-
yl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide
[1242] A vial was charged with
(3S)-2-[(4-bromo-2-fluoro-phenyl)methyl]-3-methyl-6-phenyl-thiazinane
1,1-dioxide (250 mg, 0.61 mmol), 4-(1,2,4-triazol-4-yl)piperidine
hydrochloride (172 mg, 0.91 mmol), cuprous iodide (35 mg, 0.18
mmol), N,N-dimethylglycine (38 mg, 0.36 mmol) and
tetrabutylphosphonium malonate (1.3 g, 1.9 mmol) and the vial was
purged with nitrogen for. Dimethyl sulfoxide (3 mL) was then added
and the vial was purged with nitrogen for an additional 2 minutes.
The reaction mixture was then sonicated for 5 minutes and stirred
at 45.degree. C. for 20 hours. The DMSO solution was then directly
purified by preparative HPLC to give
(3S)-2-[[2-fluoro-4-[4-(1,2,4-triazol-4-yl)-1-piperidyl]phenyl]methyl]-3--
methyl-6-phenyl-thiazinane 1,1-dioxide Stereoisomer A (109 mg, 0.23
mmol, 37% yield) as a white solid. .sup.1H NMR (400 MHz, DMSO)
.delta. 8.66-8.62 (s, 2H), 7.49-7.43 (m, 2H), 7.43-7.29 (m, 4H),
6.87-6.82 (m, 1H), 6.80-6.73 (m, 1H), 4.49-4.24 (m, 4H), 4.15-4.04
(m, 1H), 3.90-3.80 (m, 2H), 2.89-2.77 (m, 2H), 2.47-2.35 (m, 1H),
2.15-2.04 (m, 3H), 2.04-1.89 (m, 2H), 1.88-1.74 (m, 1H), 1.70-1.60
(m, 1H), 1.14-1.05 (d, J=6.9 Hz, 3H); LCMS [M+1]=484.2.
Example 6
(3S)-2-[[2-fluoro-4-[4-(tetrazol-1-yl)-1-piperidyl]phenyl]methyl-
]-3-methyl-6-phenyl-thiazinane 1,1-dioxide
##STR00111##
[1244] To a solution of
1-[3-fluoro-4-[[(3S)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2yl]methyl]phe-
nyl]piperidin-4-ol Stereoisomer A (200 mg, 0.46 mmol, prepared as
described in Example 5), tetrazole (36 mg, 0.51 mmol) and
triphenylphosphine (135 mg, 0.51 mmol) in dichloromethane (2.5 mL)
was added diisopropyl azodicarboxylate (103 mg, 0.51 mmol) dropwise
and the reaction was stirred at r.t. for 16 hours. The reaction was
partitioned between water and dichloromethane and the organic layer
was concentrated and purified by preparative HPLC to give
(3S)-2-[[2-fluoro-4-[4-(tetrazol-1-yl)-1-piperidyl]phenyl]methyl]-3-methy-
l-6-phenyl-thiazinane 1,1-dioxide Stereoisomer A (57.4 mg, 0.12
mmol, 26% yield) as a white solid. .sup.1H NMR (400 MHz, DMSO)
.delta. 8.99-8.96 (s, 1H), 7.49-7.43 (m, 2H), 7.43-7.29 (m, 4H),
6.89-6.82 (m, 1H), 6.82-6.75 (m, 1H), 5.18-5.07 (m, 1H), 4.50-4.36
(m, 2H), 4.33-4.25 (m, 1H), 4.16-4.03 (m, 1H), 3.87-3.76 (m, 2H),
3.10-2.98 (m, 2H), 2.47-2.37 (m, 1H), 2.31-2.23 (m, 2H), 2.19-2.04
(m, 3H), 1.89-1.73 (m, 1H), 1.70-1.59 (m, 1H), 1.13-1.06 (d, J=6.8
Hz, 3H); LCMS [M+1]=485.2.
Example 7
(3S)-2-[[2-Fluoro-4-[4-(1,2,4-oxadiazol-3-yl)-1-piperidyl]phenyl-
]methyl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide
##STR00112##
[1245] Step 1
1-[3-fluoro-4-[[(3S)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]methyl]ph-
enyl]-N'-hydroxy-piperidine-4-carboxamidine
[1246] To s solution of
1-[3-fluoro-4-[[(3S)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]methyl]ph-
enyl]-piperidine-4-carbonitrile Stereoisomer A (1.37 g, 3.12 mmol,
prepared as described in Example 5) in ethanol (15 mL) was added
hydroxylamine (50 mass % in water, 0.29 mL, 9.4 mmol) and the
reaction was stirred at 60.degree. C. for 2 hours. The solution was
concentrated and purified by preparative HPLC to give
1-[3-fluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]methyl-
]phenyl]-N'-hydroxy-piperidine-4-carboxamidine Stereoisomer A (1.1
g, 75% yield) as a white solid. .sup.1H NMR (400 MHz, DMSO) .delta.
8.82-8.76 (s, 1H), 7.48-7.43 (m, 2H), 7.42-7.33 (m, 3H), 7.32-7.26
(m, 1H), 6.82-6.76 (m, 1H), 6.72-6.65 (m, 1H), 5.36-5.26 (s, 2H),
4.49-4.42 (m, 1H), 4.42-4.36 (m, 1H), 4.31-4.23 (m, 1H), 4.15-4.01
(m, 1H), 3.80-3.67 (m, 2H), 2.72-2.59 (m, 2H), 2.46-2.36 (m, 1H),
2.21-2.04 (m, 2H), 1.84-1.74 (m, 3H), 1.73-1.57 (m, 3H), 1.12-1.04
(d, J=6.8 Hz, 3H); LCMS [M+1].sup.+=475.2.
Step 2
(3S)-2-[[2-Fluoro-4-[4-(1,2,4-oxadiazol-3-yl-1-piperidyl]phenyl]met-
hyl]-3-methyl-6-phenyl-thiazinane 1,1-dioxide
[1247] A solution of
1-[3-fluoro-4-[[(3S)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]methyl]ph-
enyl]-N'-hydroxy-piperidine-4-carboxamidine Stereoisomer A (150 mg,
0.32 mmol) in triethyl orthoformate (2 mL) was heated to
100.degree. C. for 1 hour. 2 drops of trifluoroacetic acid were
then added and the reaction was stirred at 100.degree. C. for 1
hour. The solution was then concentrated and purified by
preparative HPLC to give
(3S)-2-[[2-fluoro-4-[4-(1,2,4-oxadiazol-3-yl)-1-piperidyl]phenyl]methyl]--
3-methyl-6-phenyl-thiazinane 1,1-dioxide Stereoisomer A (31.8 mg,
21% yield). .sup.1H NMR (400 MHz, DMSO) .delta. 9.53-9.49 (s, 1H),
7.49-7.43 (m, 2H), 7.43-7.35 (m, 3H), 7.35-7.29 (m, 1H), 6.85-6.79
(m, 1H), 6.77-6.69 (m, 1H), 4.50-4.36 (m, 2H), 4.32-4.23 (m, 1H),
4.15-4.02 (m, 1H), 3.81-3.69 (m, 2H), 3.13-3.01 (m, 1H), 2.97-2.83
(m, 2H), 2.46-2.37 (m, 1H), 2.14-1.97 (m, 3H), 1.89-1.70 (m, 3H),
1.70-1.59 (m, 1H), 1.13-1.05 (d, J=6.8 Hz, 3H); LCMS
[M+1].sup.+=485.2.
Example 8
4-(((3S)-3-methyl-1,1-dioxido-6-phenyl-1,2-thiazinan-2-yl)methyl-
-N-(tetrahydro-2H-pyran-4-yl)benzamide
##STR00113##
[1248] Step 1 Methyl(S)-methyl
4-((3-methyl-1,1-dioxido-6-phenyl-1,2-thiazinan-2-yl)methyl)benzoate
[1249] To a solution of (S)-3-methyl-6-phenyl-1,2-thiazinane
1,1-dioxide (20 g, 88.9 mmol) and methyl 4-(bromomethyl)benzoate
(22.4 g, 97.6 mmol) in N,N-dimethylformamide (295 mL) at 0.degree.
C. was added sodium hydride (60% in mineral oil, 4.6 g, 115 mmol)
in small portions and the reaction was stirred at room temperature
for 3 hours. Water (500 mL) was then added and the precipitate was
collected by filtration to give crude methyl(S)-methyl
4-((3-methyl-1,1-dioxido-6-phenyl-1,2-thiazinan-2-yl)methyl)benzoate.
Step 2
(S)-4-((3-Methyl-1,1-dioxido-6-phenyl-1,2-thiazinan-2-yl)methyl)ben-
zoic acid
[1250] To a solution of crude methyl(S)-methyl
4-((3-methyl-1,1-dioxido-6-phenyl-1,2-thiazinan-2-yl)methyl)benzoate
in tetrahydrofuran (300 mL) and water (100 mL) was added lithium
hydroxide (21.3 g, 890 mmol) and the reaction was stirred at room
temperature for 16 hours. Sodium hydroxide (1N in water, 100 mL)
and water (200 mL) were then added to the reaction and the solution
was washed with ethyl acetate. The aqueous layer was then acidified
to pH=1 with concentrated hydrochloric acid and the precipitate was
collected by filtration and dried under vacuum to give 33 grams of
crude
(S)-4-((3-methyl-1,1-dioxido-6-phenyl-1,2-thiazinan-2-yl)methyl)benzoic
acid (85:15 mixture of trans:cis isomers).
Step 3
4-[[(3S)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]methyl]benzoic
acid
[1251] The crude mixture of diastereomers was dissolved in boiling
acetonitrile (500 mL), subjected to a hot filtration and then
cooled to room temperature and stored at 4.degree. C. for 16 hours.
Crystals were collected by filtration to give
4-[[(3S)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]methyl]benzoic
acid Stereoisomer A (6 g, 16.6 mmol, 19% yield). .sup.1H NMR (400
MHz, DMSO) .delta. 12.99-12.69 (s, 1H), 7.98-7.87 (m, 2H),
7.55-7.43 (m, 4H), 7.43-7.33 (m, 3H), 4.67-4.55 (m, 1H), 4.50-4.36
(m, 2H), 4.20-4.05 (m, 1H), 2.47-2.37 (m, 2H), 2.19-2.06 (m, 1H),
1.91-1.76 (m, 1H), 1.72-1.61 (m, 1H), 1.11-1.01 (d, J=6.8 Hz, 3H);
LCMS [M+1].sup.+=360.1.
Step 4
4-(((3S)-3-methyl-1,1-dioxido-6-phenyl-1,2-thiazinan-2-yl)methyl)-N-
-(tetrahydro-2H-pyran-4-yl)benzamide
[1252] To a solution of
4-[[(3S)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]methyl]benzoic
acid Stereoisomer A (75 mg, 0.21 mmol), tetrahydropyran-4-amine (64
mg, 0.63 mmol) and triethylamine (0.12 mL, 0.83 mmol) in
N,N-dimethylformamide (1.5 mL) was added
O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (121 mg, 0.31 mmol) and the reaction was
stirred at room temperature for 2 hours. The reaction was then
partitioned between dichloromethane and saturated sodium
bicarbonate in water. The organic layer was separated, concentrated
and purified by preparative HPLC to give
4-(((3S)-3-methyl-1,1-dioxido-6-phenyl-1,2-thiazinan-2-yl)methyl)-N--
(tetrahydro-2H-pyran-4-yl)benzamide Stereoisomer A (66.4 mg, 0.15
mmol, 72% yield). .sup.1H NMR (400 MHz, DMSO) .delta. 8.27-8.19 (d,
J=7.7 Hz, 1H), 7.85-7.77 (m, 2H), 7.50-7.43 (m, 4H), 7.43-7.34 (m,
3H), 4.64-4.53 (m, 1H), 4.47-4.33 (m, 2H), 4.18-4.06 (m, 1H),
4.06-3.93 (m, 1H), 3.91-3.81 (m, 2H), 3.46-3.33 (m, 2H), 2.48-2.37
(m, 1H), 2.17-2.08 (m, 1H), 1.92-1.69 (m, 3H), 1.70-1.50 (m, 3H),
1.11-1.02 (d, J=6.9 Hz, 3H); LCMS [M+1].sup.+=443.2.
Example 9
(3S,6R)-2-[[2,5-difluoro-4-[(1S,5R)-6-(1,2,4-triazol-4-yl)-3-aza-
bicyclo[3.1.0]hexan-3-yl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane
1,1-dioxide
##STR00114##
[1253] Step 1
(3S)-2-[(4-Bromo-2,5-difluoro-phenyl)methyl]-3-methyl-6-phenyl-thiazinane
1,1-dioxide
[1254] A 250-mL round-bottom flask was charged with
(3S)-3-methyl-6-phenyl-thiazinane 1,1-dioxide (2.0 g, 8.9 mmol),
(4-bromo-2,5-difluoro-phenyl)methyl methanesulfonate (2.9 g 9.8
mmol) and N,N-dimethylformamide (45 mL) under a nitrogen atmosphere
and the solution was cooled to 0.degree. C. Sodium hydride (60% in
mineral oil) (430 mg, 11 mmol) was then added in small portions and
the reaction was stirred at 0.degree. C. for 30 mins, then warmed
to room temperature. The reaction was further stirred at that
temperature for 2 hours until completion was observed by LCMS. The
reaction was quenched by addition of water and diluted with ethyl
acetate (250 mL). The organic layer was washed with water
(2.times.100 mL), brine 50 mL, dried with MgSO.sub.4, concentrated,
and purified by silica gel column chromatography (40 g HP column,
0-70% EtOAc in heptane) to give
(3S)-2-[(4-bromo-2,5-difluoro-phenyl)methyl]-3-methyl-6-phenyl-thiazinane
1,1-dioxide (3.28 g, 86% yield) as a white solid. LCMS ES.sup.+
m/z=430.28 and 432.27, di-Br pattern found, retention time=1.46
minutes.
Step 2
(S)-2-(4-((R,5S,6R)-6-(4H-1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]he-
xan-3-yl)-2,5-difluorobenzyl)-3-methyl-6-phenyl-1,2-thiazinan
1,1-dioxide
[1255] A 250-mL round-bottom flask was charged with
(3S)-2-[(4-bromo-2,5-difluoro-phenyl)methyl]-3-methyl-6-phenyl-thiazinane
1,1-dioxide (2.8 g, 6.5 mmol),
(1S,5R)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.0]hexane
hydrochloride (1.6 g, 8.4 mmol), palladium(II) acetate (148 mg 0.65
mmol), 2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl
(617 mg 1.3 mmol), and cesium carbonate (10.6 g, 32 mmol). The
flask was purged with nitrogen for 2 minutes. 1,4-Dioxane (32 mL)
was added and the reaction was stirred at 100.degree. C. for 16
hours. The mixture was then cooled and filtered through celite,
rinsing with dichloromethane (3.times.25 mL). The filtrate was
concentrated and purified by silica gel column chromatography (40 g
HP column, 0-100% EtOAc in heptane, followed by 0-30% MeOH in
CH.sub.2Cl.sub.2) to give
(3S)-2-[[2,5-difluoro-4-[(1S,5R)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.1.-
0]hexan-3-yl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane
1,1-dioxide (1.80 g, 56% yield) as a 3:2 trans:cis mixture of
diastereomers.
(3S,6R)-2-[[2,5-Difluoro-4-[(1S,5R)-6-(1,2,4-triazol-4-yl)-3-azabicyclo[3.-
1.0]hexan-3-yl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane
1,1-dioxide
[1256] The diastereomer product mix of step 2 was subjected to
chiral supercritical fluid chromatography (see conditions below) to
afford pure trans
(3S,6R)-2-[[2,5-difluoro-4-[(1S,5R)-6-(1,2,4-triazol-4-yl)-3-azabic-
yclo[3.1.0]hexan-3-yl]phenyl]methyl]-3-methyl-6-phenyl-thiazinane
1,1-dioxide (564 mg, 17% yield):
[1257] .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.58 (s, 2H),
7.49-7.43 (m, 2H), 7.43-7.34 (m, 3H), 7.10 (dd, J=14.5, 7.0 Hz,
1H), 6.65-6.57 (m, 1H), 4.51-4.45 (m, 1H), 4.42-4.35 (m, 1H),
4.30-4.23 (m, 1H), 4.14-4.03 (m, 1H), 3.87-3.80 (m, 2H), 3.54-3.51
(m, 1H), 3.40-3.34 (m, 2H), 2.47-2.36 (m, 3H), 2.14-2.07 (m, 1H),
1.85-1.74 (m, 1H), 1.69-1.61 (m, 1H), 1.10 (d, J=6.9 Hz, 3H); LCMS
ES.sup.+ m/z=500.4, retention time=1.27 minutes.
[1258] Sample: [1259] 1.8 grams was solubilized using 60 mL MeOH
and 40 mL CH.sub.2Cl.sub.2, with a final concentration of
approximately 18 mg/mL (max sample concentration likely
higher).
[1260] Column: [1261] Regis (S,S) WHELK-O1 5/100 Kromasil 25
cm.times.30.0 mm
[1262] System: [1263] Thar/Waters SFC Prep 350 setup with online
dilution
[1264] Method: [1265] Total flow rate--150 g/min [1266]
Co-solvent--50% methanol+0.1% (33% aqueous ammonia) [1267] UV--251
[1268] Cycle time--8 minutes
[1269] Water Acquity/SQ short method--2 min acid run
TABLE-US-00004 Waters Acquity UPLC Mobile phase A H.sub.2O with
0.1% formic acid Mobile Phase B Acetonitrile with 0.1% formic acid
Column Acquity UPLC BEH C18, 1.7 um, 2.1 .times. 30 mm Column
temperature 40 degree C. LC gradient 5-95% B in 1.4 min, 95% in 0.3
min LC flowrate 700 .mu.L/min UV wavelength 220 nm and 254 nm Mass
Spec - Waters SQ Detector Ionization ESI+ Scan Range 100-800
amu
Example 10
(S)-8-[3-Fluoro-4-((3S,6R)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-yl-
methyl)-phenyl]-1,4-dioxa-8-aza-spiro[4,5]decane-7-carboxylic acid
methyl ester
##STR00115##
[1271]
(3S,6R)-2-(4-bromo-2-fluorobenzyl)-3-methyl-6-phenyl-1,2-thiazinane
1,1-dioxide (0.200 g, 0.49 mmol), together with (S)-4-oxopipecolic
acid ethylene acetal (0.100 g, 0.53 mmol), K.sub.2CO.sub.3 (0.101
g, 0.74 mmol, 1.5 eq) and CuI (0.093 g, 0.49 mmol, 1.0 eq.) were
combined with DMA (3 mL), the solution degassed and heated to
140.degree. C. for 16 h. The reaction mixture was cooled, diluted
with water and the resulting solution acidified to pH 1 with HCl
(1M). The product was extracted into EtOAc and the organic layer
washed with water, brine, dried over MgSO.sub.4 and evaporated in
vacuo. LCMS RT 4.01 min, m/z 519 [M+1].sup.+. The oil obtained was
dissolved in MeOH (10 mL), cooled to 0.degree. C. and treated with
trimethylsilyl diazomethane (0.16 mL) and stirred for 1 h. Acetic
acid (5 drops) was added and the reaction diluted with water. The
product was extracted into EtOAc. The organic layer was washed with
sat. NaHCO.sub.3, brine, dried over MgSO.sub.4 and evaporated. The
residue was purified on silica, eluting with 5-60% EtOAc in
cyclohexane to give the title compound as a white solid (0.075 g).
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 7.43-7.44 (5H, m),
7.26 (1H, t, J=8.97 Hz), 6.70-6.71 (2H, m), 4.84 (1H, d, J=5.95
Hz), 4.34-4.46 (2H, m), 4.25 (1H, d, J=16.90 Hz), 4.10 (1H, m),
3.83-3.97 (3H, m), 3.78 (1H, m), 3.65 (1H, m), 3.57 (4H, s), 2.42
(1H, m), 2.33 (2H, m), 2.09 (2H, m), 1.9 (2H, m), 1.8 (2H, m), 1.7
(2H, m), 1.08 (3H, d, J=6.90 Hz). LCMS RT 5.14 min, m/z 533
[M+1].
Examples 11 and 12
(3S,6R)-2-(2,5-difluoro-4-(1-hydroxy-3-(oxetan-3-yl)propan-2-yl)benzyl)-3-
-methyl-6-phenyl-1,2-thiazinane 1,1-dioxide
##STR00116##
[1272] Step 1: tert-Butyl
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]acetate
[1273] A vial was charged with
(3S,6R)-2-[(4-bromo-2,5-difluoro-phenyl)methyl]-3-methyl-6-phenyl-thiazin-
ane 1,1-dioxide (500 mg, 1.16 mmol), bis(dibenzylidene)palladium
(0.05 equiv., 0.058 mmol) and
1,2,3,4,5-pentaphenyl-1'-(di-tert-butylphosphino)ferrocene (0.05
equiv., 0.058 mmol) and the vial was purged with nitrogen for 2
minutes. Tetrahydrofuran (2 mL) and 2-tert-butoxy-2-oxoethylzinc
chloride (0.5 M in Et.sub.2O, 3.0 mL, 1.51 mmol) were then added
and the reaction was stirred at room temperature for 4 hours. Upon
completion, the reaction was quenched with saturated aqueous
NH.sub.4Cl and extracted with dichloromethane (10.times.2 mL),
dried with MgSO.sub.4, concentrated and purified by silica gel
column chromatography (0% to 60% acetone in heptane) to give
tert-butyl
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]acetate (534 mg, 1.15 mmol, 99% yield). .sup.1H NMR
(400 MHz, Chloroform-d) 7.50-7.43 (m, 2H), 7.43-7.33 (m, 4H), 6.94
(dd, J=10.0, 5.8 Hz, 1H), 4.52 (d, J=17.0 Hz, 1H), 4.39 (d, J=17.1
Hz, 1H), 4.33-4.20 (m, 1H), 3.98 (dd, J=13.0, 3.5 Hz, 1H), 3.53 (s,
2H), 2.74-2.58 (m, 1H), 2.28-2.18 (m, 1H), 1.81-1.72 (m, 2H), 1.44
(s, 9H), 1.14 (d, J=6.9 Hz, 3H).
Step 2: tert-Butyl
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-3-(oxetan-3-yl)propanoate
[1274] A vial was charged with tert-butyl
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]acetate (150 mg, 0.32 mmol) and N,N-dimethylformamide
(1.5 mL), cooled to 0.degree. C. and sodium hydride (60% in mineral
oil, 18 mg, 0.45 mmol) was added. The solution was stirred at that
temperature for 15 minutes and 3-(bromomethyl)oxetane (61 mg, 0.40
mmol) was subsequently added. The reaction was then warmed to room
temperature and stirred at that temperature for 4 hours. Saturated
aqueous NH.sub.4Cl (15 mL) was added and the product was extracted
with EtOAc (2.times.15 mL), dried with MgSO.sub.4, concentrated and
purified by silica gel column chromatography (0% to 100% acetone in
heptane) to give tert-butyl
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-3-(oxetan-3-yl)propanoate (86 mg, 0.16 mmol, 50%
yield). LCMS (ESI), m/z, 536.5 [M+H].sup.+.
Step 3:
2-[2,5-Difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan--
2-yl]methyl]phenyl]-3-(oxetan-3-yl)propan-1-ol
[1275] A vial was charged with tert-butyl
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-3-(oxetan-3-yl)propanoate (86 mg, 0.16 mmol) and
tetrahydrofuran (1 mL), cooled to 0.degree. C. and lithium aluminum
hydride (2.0 M in THF, 0.20 mL, 0.40 mmol) was added. The reaction
was stirred at that temperature for 1 hour and then quenched with
potassium sodium tartrate (50% in water, 10 mL). After stirred in
the aqueous solution for 2 minutes, the product was extracted with
EtOAc (2.times.15 mL), dried with MgSO.sub.4, concentrated and
purified by reverse-phase HPLC. The two epimers at the
methyloxetane were subsequently separated by chiral supercritical
fluid chromatography to give
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-3-(oxetan-3-yl)propan-1-ol EPIMER A (6.7 mg, 0.014
mmol, 9% yield) and
2-[2,5-difluoro-4-[[(3S,6R)-3-methyl-1,1-dioxo-6-phenyl-thiazinan-2-yl]me-
thyl]phenyl]-3-(oxetan-3-yl)propan-1-ol EPIMER B (6.7 mg, 0.014
mmol, 9% yield).
[1276] EPIMER A: .sup.1H NMR (400 MHz, DMSO-d6) .delta. 7.49-7.44
(m, 2H), 7.43-7.34 (m, 3H), 7.22-7.14 (m, 2H), 4.75 (t, J=5.2 Hz,
1H), 4.59-4.45 (m, 3H), 4.41 (dd, J=7.8, 5.8 Hz, 1H), 4.35 (d,
J=17.7 Hz, 1H), 4.23 (t, J=6.1 Hz, 1H), 4.17-4.07 (m, 1H), 4.03 (t,
J=6.1 Hz, 1H), 3.56-3.53 (m, 1H), 3.24-3.11 (m, 1H), 2.93-2.82 (m,
1H), 2.82-2.72 (m, 1H), 2.47-2.37 (m, 1H), 2.16-2.04 (m, 2H),
1.87-1.74 (m, 2H), 1.71-1.63 (m, 1H), 1.11 (d, J=6.9 Hz, 3H).
[1277] EPIMER B: .sup.1H NMR (400 MHz, DMSO-d6) .delta. 7.52-7.44
(m, 2H), 7.44-7.34 (m, 3H), 7.24-7.13 (m, 2H), 4.75 (t, J=5.3 Hz,
1H), 4.58-4.43 (m, 3H), 4.43-4.31 (m, 2H), 4.27-4.20 (m, 1H),
4.16-4.06 (m, 1H), 4.02 (t, J=6.2 Hz, 1H), 3.78-3.61 (m, 1H), 3.54
(t, J=6.0 Hz, 1H), 2.93-2.86 (m, 1H), 2.83-2.73 (m, 1H), 2.45-2.38
(m, 1H), 2.15-2.03 (m, 2H), 1.87-1.75 (m, 2H), 1.72-1.62 (m, 1H),
1.11 (d, J=6.9 Hz, 3H).
[1278] Compounds of the invention prepared by the above procedures
are shown in Table 4 below, together with RORc IC.sub.50
(micromolar) and proton NMR data for selected compounds.
TABLE-US-00005 TABLE 4 IC.sub.50 Structure Name (um) 1 ##STR00117##
{1-[3-Fluoro-4-((3S,6R)-3-methyl-
1,1-dioxo-6-phenyl-[1,2]thiazinan-2-
ylmethyl)-phenyl]-4-[1,2,4]triazol-4- yl-piperidin-4-yl}-methanol
0.100 2 ##STR00118## {1-[3-Fluoro-4-((3S,6S)-3-methyl-
1,1-dioxo-6-phenyl-[1,2]thiazinan-2-
ylmethyl)-phenyl]-4-[1,2,4]triazol-4- yl-piperidin-4-yl}-methanol
0.210 3 ##STR00119## (3S,6R)-2-[2-Fluoro-4-(tetrahydro-
pyran-4-ylmethoxy)-benzyl]-3- methyl-6-phenyl-[1,2]thiazinane 1,1-
dioxide 0.028 4 ##STR00120## (3S,6R)-2-(4-((1,1-
dioxidotetrahydro-2H-thiopyran-4- yl)methoxy)benzyl)-3-methyl-6-
phenyl-1,2-thiazinane 1,1-dioxide 0.130 5 ##STR00121##
(3S,6S)-2-[2-Fluoro-4-(4- [1,2,4]triazol-4-yl-piperidin-1-yl)-
benzyl]-3,6-dimethyl-6-phenyl- [1,2]thiazinane 1,1-dioxide 0.500 6
##STR00122## (3S,6S)-2-{2-Fluoro-4-[4-(3-methyl-
[1,2,4]triazol-4-yl)-piperidin-1-yl]- benzyl}-3-methyl-6-phenyl-
[1,2]thiazinane 1,1-dioxide 0.360 7 ##STR00123##
(3S,6R)-2-[2-Fluoro-4-((2S,4R)-2- methyl-4-[1,2,4]triazol-4-yl-
piperidin-1-yl)-benzyl]-3-methyl-6- phenyl-[1,2]thiazinane
1,1-dioxide 0.029 8 ##STR00124## 1-{(R)-4-[3-Fluoro-4-((3S,6R)-3-
methyl-1,1-dioxo-6-phenyl- [1,2]thiazinan-2-ylmethyl)-phenyl]-
3-hydroxymethyl-piperazin-1-yl}- ethanone 0.370 9 ##STR00125##
(3S,6R)-2-{2-Fluoro-4-[4-(3-methyl-
[1,2,4]triazol-4-yl)-piperidin-1-yl]- benzyl}-3-methyl-6-phenyl-
[1,2]thiazinane 1,1-dioxide 0.180 10 ##STR00126##
(3S,6R)-2-[2-Fluoro-4-((2S,4S)-2- methyl-4-[1,2,4]triazol-4-yl-
piperidin-1-yl)-benzyl]-3-methyl-6- phenyl-[1,2]thiazinane
1,1-dioxide 0.094 11 ##STR00127## (4-{1-[3-Fluoro-4-((3S,6R)-3-
methyl-1,1-dioxo-6-phenyl- [1,2]thiazinan-2-ylmethyl)-phenyl]-
piperidin-4-yl}-4H-[1,2,4]triazol-3- yl)-acetonitrile 0.420 12
##STR00128## (3R,4R)-1-[3-Fluoro-4-((3S,6R)-3-
methyl-1,1-dioxo-6-phenyl- [1,2]thiazinan-2 -ylmethyl)-phenyl]-
4-[1,2,4]triazol-4-yl-piperidine-3- carboxylic acid methyl ester
0.350 13 ##STR00129## (3S,6R)-2-[2,5-Difluoro-4-(4-
[1,2,4]triazol-4-yl-piperidin-1-yl)- benzyl]-3-methyl-6-phenyl-
[1,2]thiazinane 1,1-dioxide 0.033 14 ##STR00130##
(3S,6R)-2-{2-Fluoro-4-[4-(3- methoxymethyl-[1,2,4]triazol-4-yl)-
piperidin-1-yl]-benzyl)-3-methyl-6- phenyl-[1,2]thiazinane
1,1-dioxide 0.210 15 ##STR00131## (3S,4R)-1-[3-Fluoro-4-((3S,6R)-3-
methyl-1,1-dioxo-6-phenyl- [1,2]thiazinan-2-ylmethyl)-phenyl]-
4-[1,2,4]triazol-4-yl-piperidine-3- carboxylic acid methyl ester
0.087 16 ##STR00132## (3S,6R)-2-[2-Fluoro-4-((3S,4R)-3-
methyl-4-[1,2,4]triazol-4-yl- piperidin-1-yl)-benzyl]-3-methyl-6-
phenyl-[1,2]thiazinane 1,1-dioxide 0.041 17 ##STR00133##
(3S,6R)-2-[2-Fluoro-4-((3R,4S)-3- methyl-4-[1,2,4]triazol-4-yl-
piperidin-1-yl)-benzyl]-3-methyl-6- phenyl-[1,2]thiazinane
1,1-dioxide 0.015 18 ##STR00134## (1S,5R,6S)-3-[2,3-Difluoro-4-
((3S,6R)-3-methyl-1,1-dioxo-6- phenyl-[1,2]thiazinan-2-ylmethyl)-
phenyl]-6-[1,2,4]triazol-4-yl-3-aza- bicyclo[3.1.0]hexane 0.044 19
##STR00135## (1S,5R,6S)-3-[2,3-Difluoro-4-
((3S,6S)-3-methyl-1,1-dioxo-6- phenyl-[1,2]thiazinan-2-ylmethyl)-
phenyl]-6-[1,2,4]triazol-4-yl-3-aza- bicyclo[3.1.0]hexane 0.120 20
##STR00136## (3S,6R)-2-[2,3-Difluoro-4-(4-
[1,2,4]triazol-4-yl-piperidin-1-yl)- benzyl]-3-methyl-6-phenyl-
[1,2]thiazinane 1,1-dioxide 0.250 21 ##STR00137##
(1R,5S,6S)-3-[2,5-Difluoro-4- ((3S,6R)-3-methyl-1,1-dioxo-6-
phenyl-[1,2]thiazinan-2-ylmethyl)-
phenyl]-6-[1,2,4]triazol-4-yl-3-aza- bicyclo[3.1.0]hexane 0.005 22
##STR00138## (1S,5R,6S)-3-[2,5-Difluoro-4-
((3S,6S)-3-methyl-1,1-dioxo-6- phenyl-[1,2]thiazinan-2-ylmethyl)-
phenyl]-6-[1,2,4]triazol-4-yl-3-aza- bicyclo[3.1.0]hexane 0.006 23
##STR00139## (1R,5S,6S)-3-[2,6-Difluoro-4-
((3S,6S)-3-methyl-1,1-dioxo-6- phenyl-[1,2]thiazinan-2-ylmethyl)-
phenyl]-6-[1,2,4]triazol-4-yl-3-aza- bicyclo[3.1.0]hexane 24
##STR00140## (1R,5S,6S)-3-[2,6-Difluoro-4-
((3S,6R)-3-methyl-1,1-dioxo-6- phenyl-[1,2]thiazinan-2-ylmethyl)-
phenyl]-6-[1,2,4]triazol-4-yl-3-aza- bicyclo[3.1.0]hexane 0.110 25
##STR00141## (3S,6R)-2-[2-Fluoro-4-((3R,4R)-3-
methyl-4-[1,2,4]triazol-4-yl- piperidin-1-yl)-benzyl]-3-methyl-6-
phenyl-[1,2]thiazinane 1,1-dioxide 0.019 26 ##STR00142##
(3S,6R)-2-[2-Fluoro-4-((3S,4S)-3- methyl-4-[1,2,4]triazol-4-yl-
piperidin-1-yl)-benzyl]-3-methyl-6- phenyl-[1,2]thiazinane
1,1-dioxide 0.013 27 ##STR00143## 3-[3-Fluoro-4-((3S,6R)-3-methyl-
1,1-dioxo-6-phenyl-[1,2]thiazinan-2-
ylmethyl)-phenyl]-5-[1,2,4]triazol-4-
yl-3-aza-bicyclo[4.1.0]heptane 0.120 28 ##STR00144##
3-[3-Fluoro-4-((3S,6R)-3-methyl-
1,1-dioxo-6-phenyl-[1,2]thiazinan-2-
ylmethyl)-phenyl]-5-[1,2,4]triazol-4-
yl-3-aza-bicyclo[4.1.0]heptane 0.037 29 ##STR00145##
3-[3-Fluoro-4-((3S,6R)-3-methyl-
1,1-dioxo-6-phenyl-[1,2]thiazinan-2-
ylmethyl)-phenyl]-5-[1,2,4]triazol-4-
yl-3-aza-bicyclo[4.1.0]heptane 0.190 30 ##STR00146##
3-[3-Fluoro-4-((3S,6R)-3-methyl-
1,1-dioxo-6-phenyl-[1,2]thiazinan-2-
ylmethyl)-phenyl]-5-[1,2,4]triazol-4-
yl-3-aza-bicyclo[4.1.0]heptane 0.140 31 ##STR00147##
(3S,6R)-2-[3-Fluoro-4-(4- [1,2,4]triazol-4-yl-piperidin-1-yl)-
benzyl]-3-methyl-6-phenyl- [1,2]thiazinane 1,1-dioxide 0.064 32
##STR00148## Carbamic acid 1-acetyl-4-[3-fluoro-
4-((3S,6R)-3-methyl-1,1-dioxo-6- phenyl-[1,2]thiazinan-2-ylmethyl)-
phenyl]-piperidin-4-yl ester 0.410 33 ##STR00149##
(3S,6S)-2-[3-Fluoro-4-(4- [1,2,4]triazol-4-yl-piperidin-l -yl)-
benzyl]-3-methyl-6-phenyl- [l,2]thiazinane 1,1-dioxide 0.220 34
##STR00150## (1R,3S,5S)-8-[3-Fluoro-4-((3S,6R)-
3-methyl-1,1-dioxo-6-phenyl- [1,2]thiazinan-2-ylmethyl)-phenyl]-
3-[1,2,4]triazol-4-yl-8-aza- bicyclo[3.2.1]octane 0.260 35
##STR00151## (1R,5S,8R)-3-[3-Fluoro-4-((3S,6R)-
3-methyl-1,1-dioxo-6-phenyl- [1,2]thiazinan-2-ylmethyl)-phenyl]-
8-[1,2,4]triazol-4-yl-3-aza- bicyclo[3.2.1]octane 0.078 36
##STR00152## (1R,5S,8R)-3-[3-Fluoro-4-((3S,6S)-
3-methyl-1,1-dioxo-6-phenyl- [1,2]thiazinan-2-ylmethyl)-phenyl]-
8-[1,2,4]triazol-4-yl-3-aza- bicyclo[3.2.1]octane 0.320 37
##STR00153## (2S,4R)-1-[3-Fluoro-4-((3S,6R)-3-
methyl-1,1-dioxo-6-phenyl- [1,2]thiazinan-2-ylmethyl)-phenyl]-
4-[1,2,4]triazol-4-yl-piperidine-2- carboxylic acid methyl ester
0.037 38 ##STR00154## (3S,6R)-2-(2-fluoro-4-((1-(S-
methylsulfonimidoyl)piperidin-4- yl)oxy)benzyl)-3-methyl-6-phenyl-
1,2-thiazinane 1,1-dioxide 0.150 39 ##STR00155##
(3S,6R)-2-(2-fluoro-4-((1-(S- methylsulfonimidoyl)piperidin-4-
yl)oxy)benzyl)-3-methyl-6-phenyl- 1,2-thiazinane 1,1-dioxide 0.017
40 ##STR00156## (1S,5R,6S)-3-[2-Fluoro-4-((3S,6R)-
3-methyl-1,1-dioxo-6-phenyl- [1,2]thiazinan-2-ylmethyl)-phenyl]-
6-[1,2,4]triazol-4-yl-3-aza- bicyclo[3.1.0]hexane 0.015 41
##STR00157## (1S,5R,6S)-3-[2-Fluoro-4-((3S,6S)-
3-methyl-1,1-dioxo-6-phenyl- [1,2]thiazinan-2-ylmethyl)-phenyl]-
6-[1,2,4]triazol-4-yl-3-aza- bicyclo[3.1.0]hexane 0.047 42
##STR00158## {(3R,4R)-1-[3-Fluoro-4-((3S,6R)-3-
methyl-1,1-dioxo-6-phenyl- [1,2]thiazinan-2-ylmethyl)-phenyl]-
4-[1,2,4]triazol-4-yl-piperidin-3-yl}- methanol 0.026 43
##STR00159## 4-[4-((S)-3-Methyl-1,1-dioxo-6-
phenyl-[1,2]thiazinan-2-ylmethyl)-
phenyl]-2-aza-bicyclo[2.2.2]octan-3- one 0.630 44 ##STR00160##
(1S,5R,6S)-3-[3-Fluoro-4-((3S,6R)- 3-methyl-1,1-dioxo-6-phenyl-
[1,2]thiazinan-2-ylmethyl)-phenyl]- 6-[1,2,4]triazol-4-yl-3-aza-
bicyclo[3.1.1]heptane 0.190 45 ##STR00161##
{(3S,4R)-1-[3-Fluoro-4-((3S,6R)-3- methyl-1,1-dioxo-6-phenyl-
[1,2]thiazinan-2-ylmethyl)-phenyl]-
4-[1,2,4]triazol-4-yl-piperidin-3-yl} methanol 0.031 46
##STR00162## (2R,4R)-1-[3-Fluoro-4-((3S,6R)-3-
methyl-1,1-dioxo-6-phenyl- [1,2]thiazinan-2-ylmethyl)-phenyl]-
4-[1,2,4]triazol-4-yl-piperidine-2- carboxylic acid methyl ester
0.120 47 ##STR00163## (4-{1-[3-Fluoro-4-((3S,6R)-3-
methyl-1,1-dioxo-6-phenyl- [1,2]thiazinan-2-ylmethyl)-phenyl]-
piperidin-4-yl}-4H-[1,2,4]triazol-3- yl)-methanol 0.460 48
##STR00164## (4-{1-[3-Fluoro-4-((3S,6S)-3-
methyl-1,1-dioxo-6-phenyl- [1,2]thiazinan-2-ylmethyl)-phenyl]-
piperidin-4-yl}-4H-[1,2,4]triazol-3- yl)-methanol 0.480 49
##STR00165## (2S,4S)-1-[3-Fluoro-4-((3S,6R)-3-
methyl-1,1-dioxo-6-phenyl- [1,2]thiazinan-2-ylmethyl)-phenyl]-
4-[1,2,4]triazol-4-yl-piperidine-2- carboxylic acid methyl ester
0.015 50 ##STR00166## 4-{4-[3-Fluoro-4-((3S,6R)-3-methyl-
1,1-dioxo-6-phenyl-[1,2]thiazinan-2-
ylmethyl)-phenyl]-piperazin-1-yl}- benzoic acid 0.250 51
##STR00167## (3S,6R)-2-[2-Fluoro-4-(1-oxy-4-
[1,2,4]triazol-4-yl-piperidin-1-yl)- benzyl]-3-methyl-6-phenyl-
[1,2]thiazinane 1,1-dioxide 0.680 52 ##STR00168##
8-[3-Fluoro-4-((3S,6R)-3-methyl-
1,1-dioxo-6-phenyl-[1,2]thiazinan-2-
ylmethyl)-phenyl]-1,4-dioxa-8-aza- spiro[4.5]decane 0.080 53
##STR00169## 1-{4-[2-Hydroxymethyl-4-((3S,6R)-
3-methyl-1,1-dioxo-6-phenyl- [1,2]thiazinan-2-ylmethyl)-phenyl]-
piperazin-1-yl}-ethanone 1.700 54 ##STR00170##
{(3S,4R)-1-[3-Fluoro-4-((3S,6R)-3- methyl-1,1-dioxo-6-phenyl-
[1,2]thiazinan-2-ylmethyl)-phenyl]-
4-[1,2,4]triazol-4-yl-piperidin-3-yl} methanol 0.140 55
##STR00171## {(3R,4S)-1-[3-Fluoro-4-((3S,6R)-3- methyl-1,1
-dioxo-6-phenyl- [l,2]thiazinan-2-ylmethyl)-phenyl]- 4-[
1,2,4]triazol-4-yl-piperidin-3-yl} methanol 0.025 56 ##STR00172##
{(3S,4S)-1-[3-Fluoro-4-((3S,6R)-3- methyl-1,1-dioxo-6-phenyl-
[1,2]thiazinan-2-ylmethyl)-phenyl]- 4-
[1,2,4]triazol-4-yl-piperidin-3-yl}- methanol 0.650 56 ##STR00173##
(3S,6R)-2-[4-(3,6-Dihydro-2H- pyran-4-yl)-2-fluoro-benzyl]-3-
methyl-6-phenyl-[1 ,2]thiazinane 1,1- dioxide 0.200 57 ##STR00174##
(3S,6R)-2-[2-Fluoro-4-(tetrahydro- pyran-4-yl)-benzyl]-3-methyl-6-
phenyl-[1,2]thiazinane 1,1-dioxide 0.190 58 ##STR00175##
{(3S,4S)-1-[3-Fluoro-4-((3S,6R)-3- methyl-1,1-dioxo-6-phenyl-
[1,2]thiazinan-2-ylmethyl)-phenyl]-
4-[1,2,4]triazol-4-yl-piperidin-3-yl}- methanol 0.034 59
##STR00176## (3S,6R)-2-[2-Fluoro-4-((R)-3-
[1,2,4]triazol-4-yl-piperidin-1-yl)- benzyl]-3-methyl-6-phenyl-
[1,2]thiazinane 1,1-dioxide 60 ##STR00177##
8-[3-Fluoro-4-((3S,6R)-3-methyl-
1,1-dioxo-6-phenyl-[1,2]thiazinan-2-
ylmethyl)-phenyl]-1-oxa-8-aza-
spiro[4.5]decane 0.120 61 ##STR00178##
9-[3-Fluoro-4-((3S,6R)-3-methyl-
1,1-dioxo-6-phenyl-[1,2]thiazinan-2-
ylmethyl)-phenyl]-1,5-dioxa-9-aza- spiro[5.5]undecane 0.032 62
##STR00179## 7-[3-Fluoro-4-((3S,6R)-3-methyl-
1,1-dioxo-6-phenyl-[1,2]thiazinan-2- ylmethyl)-phenyl]-1-oxa-7-aza-
spiro[3.5]nonane 0.051 63 ##STR00180##
(S)-8-[3-Fluoro-4-((3S,6R)-3- methyl-1,1-dioxo-6-phenyl-
[1,2]thiazinan-2-ylmethyl)-phenyl]-
1,4-dioxa-8-aza-spiro[4.5]decane-7- carboxylic acid methyl ester
0.049 64 ##STR00181## 4-[3-Fluoro-4-((3S,6R)-3-methyl-
1,1-dioxo-6-phenyl-[1,2]thiazinan-2- ylmethyl)-phenyl]-morpholine
0.250 65 ##STR00182## (R)-8-[3-Fluoro-4-((3S,6R)-3-
methyl-1,1-dioxo-6-phenyl- [1,2]thiazinan-2-ylmethyl)-phenyl]-
1,4-dioxa-8-aza-spiro[4.5]decane-7- carboxylic acid methyl ester
0.260 66 ##STR00183## (3S,6R)-2-[2-Fluoro-4-((S)-3-
[1,2,4]triazol-4-yl-piperidin-1-yl)- benzyl]-3-methyl-6-phenyl-
[1,2]thiazinane 1,1-dioxide 0.450 67 ##STR00184##
(3R,6R)-2-(4-(4-(4H-1,2,4-triazol-4-
yl)piperidin-1-yl)-2-fluorobenzyl)-3-
(difluoromethyl)-6-phenyl-1,2- thiazinane 1,1-dioxide 0.026 68
##STR00185## (3R,6S)-2-(4-(4-(4H-1,2,4-triazol-4-
yl)piperidin-1-yl)-2-fluorobenzyl)-3-
(difluoromethyl)-6-phenyl-1,2- thiazinane 1,1-dioxide 0.077 69
##STR00186## (3R,6S)-2-(4-(4-(4H-1,2,4-triazol-4-
yl)piperidin-1-yl)-2,5- difluorobenzyl)-3-(difluoromethyl)-
6-phenyl-1,2-thiazinane 1,1 -dioxide 0.084 70 ##STR00187##
(3R,6R)-2-(4-(4-(4H-1,2,4-triazol-4- yl)piperidin-1-yl)-2,5-
difluorobenzyl)-3-(difluoromethyl)- 6-phenyl-1,2-thiazinane
1,1-dioxide 0.036 71 ##STR00188##
(3R,6S)-2-(4-(4-(4H-1,2,4-triazol-4- yl)piperidin-1-yl)-2,5-
difluorobenzyl)-6-phenyl-3- (trifluoromethyl)-1,2-thiazinane 1,1-
dioxide 0.148 72 ##STR00189## (3R,6R)-2-(4-(4-(4H-1,2,4-triazol-4-
yl)piperidin-1-yl)-2,5- difluorobenzyl)-6-phenyl-3-
(trifluoromethyl)-1,2-thiazinane 1,1- dioxide 0.376 73 ##STR00190##
(3R,6R)-2-(4-((1R,5S,6S)-6-(4H- 1,2,4-triazol-4-yl)-3-
azabicyclo[3.1.0]hexan-3-yl)-2,5- difluorobenzyl)-6-phenyl-3-
(trifluoromethyl)-1,2-thiazinane 1,1- dioxide 0.015 74 ##STR00191##
(3R,6R)-2-(4-((1R,5S,6S)-6-(4H- 1,2,4-triazol-4-yl)-3-
azabicyclo[3.1.0]hexan-3-yl)-2,5- difluorobenzyl)-6-phenyl-3-
(trifluoromethyl)-1,2-thiazinane 1,1- dioxide 0.018 75 ##STR00192##
(3R,6R)-2-(4-(4-(4H-1,2,4- triazol-4-yl)piperidin-1-yl)-2-
fluorobenzyl)-6-phenyl-3- (trifluoromethyl)-1,2-thiazinane
1,1-dioxide 0.122 76 ##STR00193## (3R,6S)-2-(4-(4-(4H-1,2,4-
triazol-4-yl)piperidin-1-yl)-2- fluorobenzyl)-6-phenyl-3-
(trifluoromethyl)-1,2-thiazinane 1,1-dioxide 0.049 77 ##STR00194##
(3R,6R)-2-(4-((1R,5S,6S)-6-(4H- 1,2,4-triazol-4-yl)-3-
azabicyclo[3.1.0]hexan-3-yl)-2- fluorobenzyl)-6-phenyl-S-
(trifluoromethyl)-1,2-thiazinane 1,1-dioxide 0.027 78 ##STR00195##
(3R,6S)-2-(4-((1R,5S,6S)-6-(4H- 1,2,4-triazol-4-yl)-3-
azabicyclo[3.1.0]hexan-3-yl)-2- fluorobenzyl)-6-phenyl-S-
(trifluoromethyl)-1,2-thiazinane 1,1-dioxide 0.060 79 ##STR00196##
(4R)-methyl 1-(2,5-difluoro-4- ((3-methyl-1,1-dioxido-6-phenyl-
1,2-thiazinan-2- yl)methyl)phenyl)-4-(4H-1,2,4-
triazol-4-yl)piperidine-3- carboxylate 0.037 80 ##STR00197##
2-(2-fluoro-4-((4R)-3-methoxy-4- (4H-1,2,4-triazol-4-yl)piperidin-
1-yl)benzyl)-3-methyl-6-phenyl- 1,2-thiazinane 1,1-dioxide 0.075 81
##STR00198## 2-(4-((5R)-5-(4H-1,2,4-triazol-4-
yl)-2-azabicyclo[2.2.1]heptan-2- yl)-2,5-difluorobenzyl)-3-methyl-
6-phenyl-1,2-thiazinane 1,1- dioxide 0.015 82 ##STR00199##
2-(4-((5R)-5-(4H-1,2,4-triazol-4- yl)-2-azabicyclo[2.2.1]heptan-2-
yl)-2,5-difluorobenzyl)-3-methyl- 6-phenyl-1,2-thiazinane 1,1-
dioxide 0.011 83 ##STR00200## 2-(2-fluoro-4-((4R)-3-fluoro-4-
(4H-1,2,4-triazol-4-yl)piperidin- 1-yl)benzyl)-3-methyl-6-phenyl-
1,2-thiazinane 1,1-dioxide 0.069 84 ##STR00201##
8-(3-fluoro-4-(((3S,6R)-3-methyl-
1,1-dioxido-6-phenyl-1,2-thiazinan- 2-yl)methyl)phenyl)-3-methyl-1-
oxa-8-azaspiro[4.5]decan-2-one 0.276 85 ##STR00202##
(3S,6R)-2-[[2-fluoro-4-[(3R,4R)-3- fluoro-4-(1,2,4-triazol-4-yl)-1-
piperidyl]phenyl]methyl]-3-methyl- 6-phenyl-thiazinane 1,1-dioxide
0.0139 86 ##STR00203## 4-[4-[3-fluoro-4-[[(3S,6R)-3-methyl-
1,1-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]piperazin-1-
yl]benzoic acid 0.558 87 ##STR00204##
(3S,6R)-2-[[2-fluoro-4-(1-oxa-6- azaspiro[3.3]heptan-6-
yl)phenyl]methyl]-3-methyl-6- phenyl-thiazinane 1,1-dioxide 0.0351
88 ##STR00205## 8-[3-fluoro-4-[[(3S,6R)-3-methyl-
1,1-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]-1,3-dimethyl-
1,3,8-triazaspiro[4.5]decane-2,4- dione 0.0069 89 ##STR00206##
1-[4-[[3-fluoro-4-[[(3S,6R)-3- methyl-1,1-dioxo-6-phenyl-
thiazinan-2-yl]methyl]phenyl]- hydroxy-methyl]-1-
piperidyl]ethanone 0.37 90 ##STR00207## (3S,6R)-2-
[[2-fluoro-4-[(3S,4R)-3- fluoro-4-(1,2,4-triazol-4-yl)-1-
piperidyl]phenyl]methyl]-3-methyl- 6-phenyl-thiazinane 1,1-dioxide
0.0185 91 ##STR00208## (3S,6R)-2-[[2-fluoro-4-[(3S,4R)-3-
fluoro-4-(1,2,4-triazol-4-yl)-1- piperidyl]phenyl]methyl]-3-methyl-
6-phenyl-thiazinane 1,1-dioxide 0.0297 92 ##STR00209##
(3S,6R)-2-[[2-fluoro-4-[(3S,4R)-3-
methoxy-4-(1,2,4-triazol-4-yl)-1-
piperidyl]phenyl]methyl]-3-methyl- 6-phenyl-thiazinane 1,1-dioxide
0.0096 93 ##STR00210## (3S,6R)-2-[[2-fluoro-4-[(3R,4S)-3-
methoxy-4-(1,2,4-triazol-4-yl)-1-
piperidyl]phenyl]methyl]-3-methyl- 6-phenyl-thiazinane 1,1-dioxide
0.0413 94 ##STR00211## (3S,6R)-2-[[2-fluoro-4-[(3S,4S)-3-
fluoro-4-(1,2,4-triazol-4-yl)-1- piperidyl]phenyl]methyl]-3-methyl-
6-phenyl-thiazinane 1,1-dioxide 0.014 95 ##STR00212##
(3S,6R)-2-[[2-fluoro-4-[(3S,4S)-3- fluoro-4-(1,2,4-triazol-4-yl)-1-
piperidyl]phenyl]methyl]-3-methyl- 6-phenyl-thiazinane 1,1-dioxide
0.0094 96 ##STR00213## 4-[4-[3-fluoro-4-[[(3S,6R)-3-methyl-
1,1-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]piperazin-1-yl]-2-
hydroxy-benzoic acid 0.264 97 ##STR00214##
4-[4-[3-fluoro-4-[[(3S,6R)-3-methyl-
1,1-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]piperazin-1-yl]-2-
hydroxy-benzoic acid 0.15 98 ##STR00215##
(3S,6R)-2-[[2,5-difluoro-4- [(1S,4S,5S)-5-(1,2,4-triazol-4-yl)-2-
azabicyclo[2.2.1]heptan-2- yl]phenyl]methyl]-3-methyl-6-
phenyl-thiazinane 1,1-dioxide 0.118 99 ##STR00216##
(3S,6R)-2-[[2,5-difluoro-4- [(1S,4S,5S)-5-(1,2,4-triazol-4-yl)-2-
azabicyclo[2.2.1]heptan-2- yl]phenyl]methyl]-3-methyl-6-
phenyl-thiazinane 1,1-dioxide 0.016 100 ##STR00217##
(3S,6R)-2-[[4-(3,6-dihydro-2H- pyran-4-ylmethyl)-2-fluoro-
phenyl]methyl]-3-methyl-6-phenyl- thiazinane 1,1-dioxide 0.058 101
##STR00218## (3S,6R)-2-[[2-fluoro-4- (tetrahydropyran-4-
ylidenemethyl)phenyl]methyl]-3- methyl-6-phenyl-thiazinane 1,1-
dioxide 0.050 102 ##STR00219## methyl 4-[2,5-difluoro-4-[[(3S,6R)-
3-methyl-1,1-dioxo-6-phenyl- thiazinan-2-
yl]methyl]phenyl]tetrahydropyran-4- carboxylate 0.011 103
##STR00220## methyl (3S,4S)-3-[2,5-difluoro-4-
[[(3S,6R)-3-methyl-1,1-dioxo-6- phenyl-thiazinan-2-
yl]methyl]phenyl]tetrahydropyran-4- carboxylate 0.054 104
##STR00221## (3R,4R)-1-[2,5-difluoro-4-[[(3S,6R)-
3-methyl-1,1-dioxo-6-phenyl- thiazinan-2-yl]methyl]phenyl]-4-
(1,2,4-triazol-4-yl)piperidin-3-ol 0.028 105 ##STR00222##
(3R,4R)-1-[2,5-difluoro-4-[[(3S,6R)- 3-methyl-1,1-dioxo-6-phenyl-
thiazinan-2-yl]methyl]phenyl]-4- (1,2,4-triazol-4-yl)piperidin-3-ol
0.015 106 ##STR00223## methyl 2-[2,5-difluoro-4-[[(3S,6R)-
3-methyl-1,1-dioxo-6-phenyl- thiazinan-2-yl]methyl]phenyl]acetate
0.058 107 ##STR00224## methyl 4-[2,5-difluoro-4-[[(3S,6S)-
3-methyl-1,1-dioxo-6-phenyl- thiazinan-2-
yl]methyl]phenyl]tetrahydropyran-4- carboxylate 0.282 108
##STR00225## (3R,4R)-3-[2,5-difluoro-4-[[(3S,6R)-
3-methyl-1,1-dioxo-6-phenyl- thiazinan-2-
yl]methyl]phenyl]tetrahydropyran-4- carboxylic acid 0.079 109
##STR00226## methyl (3S,4S)-3-[2,5-difluoro-4-
[[(3S,6R)-3-methyl-1,1-dioxo-6- phenyl-thiazinan-2-
yl]methyl]phenyl]tetrahydropyran-4- carboxylate 0.050 110
##STR00227## methyl (3S,4R)-3-[2,5-difluoro-4-
[[(3S,6R)-3-methyl-1,1-dioxo-6- phenyl-thiazinan-2-
yl]methyl]phenyl]tetrahydropyran-4- carboxylate 0.076 111
##STR00228## (3S,6R)-2-[[2,5-difluoro-4-[(3S,4R)-
3-fluoro-4-(1,2,4-triazol-4-yl)-1-
piperidyl]phenyl]methyl]-3-methyl- 6-phenyl-thiazinane 1,1-dioxide
0.013 112 ##STR00229## (3S,6R)-2-[[2,5-difluoro-4-[(3R,4S)-
3-fluoro-4-(1,2,4-triazol-4-yl)-1-
piperidyl]phenyl]methyl]-3-methyl- 6-phenyl-thiazinane 1,1-dioxide
0.033 113 ##STR00230## 2-[2,5-difluoro-4-[[(3S,6R)-3-
methyl-1,1-dioxo-6-phenyl- thiazinan-2- yl]methyl]phenyl]ethanol
0.171 114 ##STR00231## 2-[2,5-difluoro-4-[[(3S,6R)-3-
methyl-1,1-dioxo-6-phenyl- thiazinan-2-yl]methyl]phenyl]-N-(3-
hydroxycyclobutyl)acetamide 0.337 115 ##STR00232##
2-[2,5-difluoro-4-[[(3S,6R)-3- methyl-1,1-dioxo-6-phenyl-
thiazinan-2- yl]methyl]phenyl]acetamide 0.406 116 ##STR00233##
2-[2,5-difluoro-4-[[(3S,6R)-3- methyl-1,1-dioxo-6-phenyl-
thiazinan-2- yl]methyl]phenyl]propan-1-ol 0.090 117 ##STR00234##
2-[2,5-difluoro-4-[[(3S,6R)-3- methyl-1,1-dioxo-6-phenyl-
thiazinan-2- y]]methyl]phenyl]propan-1-ol 0.044 118 ##STR00235##
diethyl 2-[2,5-difluoro-4-[[(3S,6R)- 3-methyl-1,1-dioxo-6-phenyl-
thiazinan-2- yl]methyl]phenyl]propanedioate 0.061 119 ##STR00236##
2-[2,5-difluoro-4-[[(3S,6R)-3- methyl-1,1-dioxo-6-phenyl-
thiazinan-2- yl]methyl]phenyl]propane-1,3-diol 0.129 120
##STR00237## tert-butyl 2-[2,5-difluoro-4-
[[(3S,6R)-3-methyl-1,1-dioxo-6- phenyl-thiazinan-2-
yl]methyl]phenyl]acetate 0.079 121 ##STR00238##
4-[2,5-difluoro-4-[[(3S,6R)-3- methyl-1,1-dioxo-6-phenyl-
thiazinan-2-yl]methyl]phenyl]-5- hydroxy-pentanenitrile 0.0859 122
##STR00239## 1-[4-[4-[[(6S)-5,5-dioxo-6-phenyl- 5$l{circumflex over
( )}{6}-thia-4-azaspiro[2.5]octan-4- yl]methyl]-3-fluoro-
phenyl]piperazin-1-yl]ethanone 0.421 123 ##STR00240##
1-[4-[4-[[(6R)-5,5-dioxo-6-phenyl- 5$l{circumflex over (
)}{6}-thia-4-azaspiro[2.5]octan-4- yl]methyl]-3-fluoro-
phenyl]piperazin-1-yl]ethanone 0.007 124 ##STR00241##
2-[1-[2,5-difluoro-4-[[(3S,6R)-3-
methyl-1,1-dioxo-6-phenyl- thiazinan-2-yl]methyl]phenyl]-1-
methyl-ethoxy] acetic acid 0.42 125 ##STR00242##
2-[1-[2,5-difluoro-4-[[(3S,6R)-3- methyl-1,1-dioxo-6-phenyl-
thiazinan-2-yl]methyl]phenyl]-1- methyl-ethoxy] acetamide 0.014 126
##STR00243## 2-[2,5-difluoro-4-[[(3S,6R)-3-
methyl-1,1-dioxo-6-phenyl- thiazinan-2-yl]methyl]phenyl]-3-
(oxetan-3-yl)propan-1-ol 0.004 127 ##STR00244##
2-[2,5-difluoro-4-[[(3S,6R)-3- methyl-1,1-dioxo-6-phenyl-
thiazinan-2-yl]methyl]phenyl]-3- (oxetan-3-yl)propan-1-ol 0.007 128
##STR00245## 2-[2,5-difluoro-4-[[(3S,6R)-3-
methyl-1,1-dioxo-6-phenyl- thiazinan-2-yl]methyl]phenyl]-3-
(oxetan-3-yl)propan-1-ol 0.043 129 ##STR00246##
3-[2,5-difluoro-4-[[(3S,6R)-3- methyl-1,1-dioxo-6-phenyl-
thiazinan-2-yl]methyl]phenyl]-4- hydroxy-butanenitrile 0.037 130
##STR00247## 3-[2,5-difluoro-4-[[(3S,6R)-3-
methyl-1,1-dioxo-6-phenyl- thiazinan-2-yl]methyl]phenyl]-4-
hydroxy-butanamide 0.288 131 ##STR00248##
3-[2,5-difluoro-4-[[(3S,6R)-3- methyl-1,1-dioxo-6-phenyl-
thiazinan-2-yl]methyl]phenyl]-4- hydroxy-butanamide 0.289 132
##STR00249## 2-[2,5-difluoro-4-[[(3S,6R)-3-
methyl-1,1-dioxo-6-phenyl- thiazinan-2-yl]methyl]phenyl]-2-
(oxetan-3-yl)ethanol 0.051 133 ##STR00250##
2-[2,5-difluoro-4-[[(3S,6R)-3- methyl-1,1-dioxo-6-phenyl-
thiazinan-2-yl]methyl]phenyl]-2- (oxetan-3-yl)ethanol 0.025 134
##STR00251## 3-[1-[2,5-difluoro-4-[[(3S,6R)-3-
methyl-1,1-dioxo-6-phenyl- thiazinan-2-yl]methyl]phenyl]-1-
methyl-ethoxy]propane-1,2-diol 0.018 135 ##STR00252##
2-[2,5-difluoro-4-[[(3S,6R)-3- methyl-1,1-dioxo-6-phenyl-
thiazinan-2-yl]methyl]phenyl]-2- phenyl-ethanol 0.019 136
##STR00253## 2-[2,5-difluoro-4-[[(3S,6R)-3-
methyl-1,1-dioxo-6-phenyl- thiazinan-2-yl]methyl]phenyl]-2-
phenyl-ethanol 0.003 137 ##STR00254##
(2S)-3-[1-[2,5-difluoro-4-[[(3S,6R)- 3-methyl-1,1-dioxo-6-phenyl-
thiazinan-2-yl]methyl]phenyl]-1- methyl-ethoxy]propane-1,2-diol
0.019 138 ##STR00255## (2R)-3-[1-[2,5-difluoro-4-[[(3S,6R)-
3-methyl-1,1-dioxo-6-phenyl- thiazinan-2-yl]methyl]phenyl]-1-
methyl-ethoxy]propane-1,2-diol 0.049 139 ##STR00256##
3-[1-[2,5-difluoro-4-[[(3S,6R)-3- methyl-1,1-dioxo-6-phenyl-
thiazinan-2-yl]methyl]phenyl]-2-
hydroxy-ethyl]-1-methyl-pyrrolidin- 2-one 0.032 140 ##STR00257##
3-[1-[2,5-difluoro-4-[[(3S,6R)-3- methyl-1,1-dioxo-6-phenyl-
thiazinan-2-yl]methyl]phenyl]-2-
hydroxy-ethyl]-1-methyl-pyrrolidin- 2-one 0.044 141 ##STR00258##
3-[1-[2,5-difluoro-4-[[(3S,6R)-3- methyl-1,1-dioxo-6-phenyl-
thiazinan-2-yl]methyl]phenyl]-2-
hydroxy-ethyl]-1-methyl-pyrrolidin- 2-one 0.118 142 ##STR00259##
3-[1-[2,5-difluoro-4-[[(3S,6R)-3- methyl-1,1-dioxo-6-phenyl-
thiazinan-2-yl]methyl]phenyl]-2-
hydroxy-ethyl]-1-methyl-pyrrolidin- 2-one 0.084 143 ##STR00260##
4-[2,5-difluoro-4-[[(3S,6R)-3- methyl-1,1-dioxo-6-phenyl-
thiazinan-2-yl]methyl]phenyl]-5- hydroxy-pentanamide 0.084 144
##STR00261## 4-[2,5-difluoro-4-[[(3S,6R)-3-
methyl-1,1-dioxo-6-phenyl- thiazinan-2-yl]methyl]phenyl]-5-
hydroxy-pentanamide 0.029 145 ##STR00262##
(3S,6R)-2-[[2,5-difluoro-4-[4-(1,2,4- triazol-4-yl)-1-
piperidyl]phenyl]methyl]-3-ethyl-6- phenyl-thiazinane 1,1-dioxide
0.003 146 ##STR00263## (3S,6S)-2-[[2,5-difluoro-4-[(1R,5S)-
6-(1,2,4-triazol-4-yl)-3- azabicyclo[3.1.0]hexan-3-
yl]phenyl]methyl]-3-ethyl-6-phenyl- thiazinane 1,1-dioxide 0.007
147 ##STR00264## (3S,6R)-2-[[2,5-difluoro-4-[(1R,5S)-
6-(1,2,4-triazol-4-yl)-3- azabicyclo[3.1.0]hexan-3-
yl]phenyl]methyl]-3-ethyl-6-phenyl- thiazinane 1,1-dioxide 0.001
148 ##STR00265## (3S,6S)-2-[[2,5-difluoro-4-[4-(1,2,4-
triazol-4-yl)-1- piperidyl]phenyl]methyl]-3-ethyl-6-
phenyl-thiazinane 1,1-dioxide 0.14 149 ##STR00266##
(3S,6R)-3-ethyl-2-[[2-fluoro-4- [(1R,5S)-6-(1,2,4-triazol-4-yl)-3-
azabicyclo[3.1.0]hexan-3- yl]phenyl]methyl]-6-phenyl- thiazinane
1,1-dioxide 0.002 150 ##STR00267## (3S,6R)-3-ethyl-2-[[2-fluoro-4-
[(1R,5S)-6-(1,2,4-triazol-4-yl)-3- azabicyclo[3.1.0]hexan-3-
yl]phenyl]methyl]-6-phenyl- thiazinane 1,1-dioxide 0.051 151
##STR00268## (7S)-2-[[2,5-difluoro-4-[(1R,5S)-6-
(1,2,4-triazol-4-yl)-3- azabicyclo[3.1.0]hexan-3-
yl]phenyl]methyl]-7-phenyl- thiazepane 1,1-dioxide 0.005 152
##STR00269## (7S)-2-[[2,5-difluoro-4-[4-(1,2,4- triazol-4-yl)-1-
piperidyl]phenyl]methyl]-7-phenyl- thiazepane 1,1-dioxide 0.050 153
##STR00270## (7R)-2-[[2,5-difluoro-4-[4-(1,2,4- triazol-4-yl)-1-
piperidyl]phenyl]methyl]-7-phenyl- thiazepane 1,1-dioxide 0.004 154
##STR00271## (7R)-2-[[2,5-difluoro-4-[(1R,5S)-6-
(1,2,4-triazol-4-yl)-3- azabicyclo[3.1.0]hexan-3-
yl]phenyl]methyl]-7-phenyl- thiazepane 1,1-dioxide 0.001 155
##STR00272## (7S)-2-[[2-fluoro-4-[(1R,5S)-6-
(1,2,4-triazol-4-yl)-3- azabicyclo[3.1.0]hexan-3-
yl]phenyl]methyl]-7-phenyl- thiazepane 1,1-dioxide 0.047 156
##STR00273## (7R)-2-[[2-fluoro-4-[(1R,5S)-6-
(1,2,4-triazol-4-yl)-3- azabicyclo[3.1.0]hexan-3-
yl]phenyl]methyl]-7-phenyl- thiazepane 1,1-dioxide 0.002 157
##STR00274## (7S)-2-[[2,5-difluoro-4-[(1R,5S)-6-
(1,2,4-triazol-4-yl)-3- azabicyclo[3.1.0]hexan-3-
yl]phenyl]methyl]-7-phenyl- thiazepane 1,1-dioxide 0.005 158
##STR00275## (7S)-2-[[2,5-difluoro-4-[4-(1,2,4- triazol-4-yl)-1-
piperidyl]phenyl]methyl]-7-phenyl- thiazepane 1,1-dioxide 0.050 159
##STR00276## (3S,4S)-3-[2,5-difluoro-4-[[(3S,6R)-
3-methyl-1,1-dioxo-6-phenyl- thiazinan-2-
yl]methyl]phenyl]tetrahydropyran-4- carboxylic acid 1.12 160
##STR00277## 2-[2,5-difluoro-4-[[(3S,6R)-3-
methyl-1,1-dioxo-6-phenyl- thiazinan-2-yl]methyl]phenyl]-N-(3-
hydroxycyclobutyl)acetamide 1.0 161 ##STR00278##
4-[4-[3-fluoro-4-[[(3S,6S)-3-methyl-
1,1-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]piperazin-1-
yl]benzoic acid 3.02 162 ##STR00279##
4-[4-[3-fluoro-4-[[(3S,6R)-3-methyl-
1,1-dioxo-6-phenyl-thiazinan-2- yl]methyl]phenyl]piperazin-1-yl]-2-
hydroxy-benzoic acid 2.01
[1279] Proton NMR for selected compounds of Table 4 are shown
below, with compound numbers corresponding to the numbering in
Table 4.
[1280] Compound 1 .sup.1H NMR (400 MHz, DMSO) .delta. 8.67-8.61 (s,
2H), 7.48-7.42 (m, 2H), 7.42-7.33 (m, 3H), 7.33-7.27 (m, 1H),
6.82-6.77 (m, 1H), 6.75-6.68 (m, 1H), 5.19-5.12 (m, 1H), 4.48-4.35
(m, 2H), 4.31-4.22 (m, 1H), 4.14-4.01 (m, 1H), 3.54-3.48 (m, 2H),
3.48-3.40 (m, 2H), 2.88-2.76 (m, 2H), 2.45-2.37 (m, 1H), 2.37-2.27
(m, 2H), 2.13-2.01 (m, 3H), 1.87-1.72 (m, 1H), 1.70-1.59 (m, 1H),
1.11-1.02 (d, J=6.9 Hz, 3H).
[1281] Compound 3 .sup.1H NMR (400 MHz, DMSO) .delta. 7.49-7.43 (m,
2H), 7.43-7.33 (m, 4H), 6.84-6.75 (m, 2H), 4.51-4.39 (m, 2H),
4.34-4.27 (m, 1H), 4.16-4.04 (m, 1H), 3.91-3.80 (m, 4H), 3.37-3.31
(m, 2H), 2.46-2.38 (m, 1H), 2.15-2.05 (m, 1H), 2.05-1.93 (m, 1H),
1.88-1.74 (m, 1H), 1.71-1.60 (m, 3H), 1.39-1.25 (m, 2H), 1.12-1.04
(d, J=6.9 Hz, 3H).
[1282] Compound 18 .sup.1H NMR (400 MHz, DMSO) .delta. 8.62-8.57
(s, 2H), 7.49-7.43 (m, 2H), 7.43-7.33 (m, 3H), 7.15-7.07 (m, 1H),
6.68-6.60 (m, 1H), 4.54-4.40 (m, 2H), 4.35-4.25 (m, 1H), 4.15-4.03
(m, 1H), 3.89-3.80 (m, 2H), 3.57-3.51 (m, 1H), 3.45-3.37 (m, 2H),
2.46-2.34 (m, 3H), 2.15-2.05 (m, 1H), 1.89-1.73 (m, 1H), 1.70-1.60
(m, 1H), 1.14-1.05 (d, J=6.9 Hz, 3H).
[1283] Compound 21 .sup.1H NMR (400 MHz, DMSO) .delta. 8.60-8.57
(s, 2H), 7.49-7.43 (m, 2H), 7.43-7.34 (m, 3H), 7.14-7.06 (dd,
J=14.5, 7.0 Hz, 1H), 6.65-6.57 (m, 1H), 4.51-4.45 (m, 1H),
4.42-4.35 (m, 1H), 4.30-4.23 (m, 1H), 4.14-4.03 (m, 1H), 3.87-3.80
(m, 2H), 3.54-3.51 (m, 1H), 3.40-3.34 (m, 2H), 2.47-2.36 (m, 3H),
2.14-2.07 (m, 1H), 1.85-1.74 (m, 1H), 1.69-1.61 (m, 1H), 1.13-1.07
(d, J=6.9 Hz, 3H).
[1284] Compound 22 .sup.1H NMR (400 MHz, DMSO) .delta. 8.60-8.58
(s, 2H), 7.49-7.43 (m, 2H), 7.43-7.35 (m, 3H), 7.17-7.09 (m, 1H),
6.69-6.60 (dd, J=12.3, 7.4 Hz, 1H), 4.46-4.38 (m, 1H), 4.37-4.31
(s, 2H), 3.90-3.81 (m, 2H), 3.63-3.54 (m, 1H), 3.54-3.50 (m, 1H),
3.44-3.37 (m, 2H), 2.79-2.63 (m, 1H), 2.42-2.36 (m, 2H), 2.16-2.09
(m, 1H), 2.06-2.00 (m, 1H), 1.68-1.58 (m, 1H), 1.39-1.31 (d, J=7.1
Hz, 3H).
[1285] Compound 28 .sup.1H NMR (400 MHz, DMSO) .delta. 8.69-8.66
(s, 2H), 7.49-7.43 (m, 2H), 7.43-7.35 (m, 3H), 7.35-7.28 (m, 1H),
6.82-6.71 (m, 2H), 5.03-4.92 (m, 1H), 4.48-4.35 (m, 2H), 4.31-4.23
(m, 1H), 4.15-4.01 (m, 1H), 3.89-3.79 (m, 1H), 3.79-3.71 (m, 1H),
3.17-3.08 (m, 1H), 3.00-2.90 (m, 1H), 2.45-2.35 (m, 1H), 2.13-2.06
(m, 1H), 1.87-1.72 (m, 1H), 1.70-1.50 (m, 3H), 1.12-1.07 (d, J=7.0
Hz, 3H), 0.95-0.85 (m, 1H), 0.86-0.76 (m, 1H).
[1286] Compound 35 .sup.1H NMR (400 MHz, DMSO) .delta. 8.74-8.69
(s, 2H), 7.47-7.42 (m, 2H), 7.42-7.34 (m, 3H), 7.30-7.22 (m, 1H),
6.66-6.59 (m, 1H), 6.57-6.48 (m, 1H), 4.46-4.39 (m, 1H), 4.39-4.32
(m, 1H), 4.28-4.17 (m, 2H), 4.12-3.98 (m, 1H), 3.45-3.36 (m, 2H),
3.04-2.95 (s, 2H), 2.74-2.64 (m, 2H), 2.47-2.30 (m, 1H), 2.13-2.03
(m, 1H), 1.95-1.87 (m, 2H), 1.86-1.71 (m, 3H), 1.66-1.58 (m, 1H),
1.09-1.00 (d, J=6.9 Hz, 3H).
[1287] Compound 39 .sup.1H NMR (400 MHz, DMSO) .delta. 7.49-7.43
(m, 2H), 7.43-7.33 (m, 4H), 6.88-6.85 (m, 1H), 6.85-6.82 (m, 1H),
4.61-4.39 (m, 3H), 4.36-4.25 (m, 1H), 4.18-4.03 (m, 1H), 3.60-3.50
(m, 1H), 3.47-3.32 (m, 2H), 3.17-3.02 (m, 2H), 2.81-2.70 (d, J=1.6
Hz, 3H), 2.48-2.34 (m, 1H), 2.16-2.05 (m, 1H), 2.05-1.89 (m, 2H),
1.89-1.75 (m, 1H), 1.75-1.60 (m, 3H), 1.12-1.05 (d, J=6.9 Hz,
3H).
[1288] Compound 40 .sup.1H NMR (400 MHz, DMSO) .delta. 8.60-8.58
(s, 2H), 7.49-7.43 (m, 2H), 7.43-7.33 (m, 3H), 7.11-7.04 (m, 2H),
6.82-6.74 (m, 1H), 4.48-4.34 (m, 2H), 4.26-4.16 (m, 1H), 4.12-4.01
(m, 1H), 3.87-3.79 (m, 2H), 3.59-3.54 (m, 1H), 3.35-3.32 (m, 2H),
2.45-2.29 (m, 3H), 2.15-2.06 (m, 1H), 1.85-1.71 (m, 1H), 1.71-1.61
(m, 1H), 1.12-1.04 (d, J=6.9 Hz, 3H).
[1289] Compound 41 .sup.1H NMR (400 MHz, DMSO) .delta. 8.61-8.59
(s, 2H), 7.50-7.44 (m, 2H), 7.44-7.35 (m, 3H), 7.13-7.05 (m, 2H),
6.85-6.78 (m, 1H), 4.41-4.24 (m, 3H), 3.89-3.81 (m, 2H), 3.59-3.48
(m, 2H), 3.38-3.33 (m, 2H), 2.77-2.65 (m, 1H), 2.40-2.35 (m, 2H),
2.13-2.00 (m, 2H), 1.66-1.56 (m, 1H), 1.36-1.30 (d, J=7.1 Hz,
3H).
[1290] Compound 63 .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
7.43-7.44 (5H, m), 7.26 (1H, t, J=8.97 Hz), 6.70-6.71 (2H, m), 4.84
(1H, d, J=5.95 Hz), 4.34-4.46 (2H, m), 4.25 (1H, d, J=16.90 Hz),
4.10 (1H, m), 3.83-3.97 (3H, m), 3.78 (1H, m), 3.65 (1H, m), 3.57
(4H, s), 2.42 (1H, m), 2.33 (2H, m), 2.09 (2H, m), 1.9 (2H, m), 1.8
(2H, m), 1.7 (2H, m), 1.08 (3H, d, J=6.90 Hz)
[1291] Compound 68 .sup.1H NMR (400 MHz, DMSO) .delta. 8.67-8.62
(s, 2H), 7.51-7.37 (m, 5H), 7.35-7.26 (m, 1H), 6.89-6.81 (m, 2H),
6.71-6.38 (td, J=56.7, 7.5 Hz, 1H), 4.59-4.31 (m, 4H), 3.97-3.83
(m, 2H), 3.63-3.50 (s, 1H), 2.94-2.81 (m, 2H), 2.81-2.69 (m, 1H),
2.19-2.07 (m, 4H), 2.00-1.89 (m, 2H), 1.88-1.78 (m, 1H).
[1292] Compound 69 .sup.1H NMR (400 MHz, DMSO) .delta. 8.68-8.65
(s, 2H), 7.50-7.44 (m, 2H), 7.44-7.36 (m, 3H), 7.29-7.21 (m, 1H),
7.01-6.93 (m, 1H), 6.76-6.41 (m, 1H), 4.70-4.56 (m, 2H), 4.50-4.40
(m, 1H), 4.40-4.29 (m, 1H), 3.75-3.62 (s, 1H), 3.58-3.46 (m, 2H),
2.91-2.69 (m, 3H), 2.28-1.98 (m, 6H), 1.91-1.81 (m, 1H).
[1293] Compound 70 .sup.1H NMR (400 MHz, DMSO) .delta. 8.70-8.65
(s, 2H), 7.51-7.45 (m, 2H), 7.45-7.36 (m, 3H), 7.23-7.13 (dd,
J=13.4, 7.0 Hz, 1H), 6.96-6.88 (m, 1H), 6.38-6.04 (td, J=54.7, 4.5
Hz, 1H), 4.83-4.75 (dd, J=12.5, 3.7 Hz, 1H), 4.68-4.59 (m, 1H),
4.47-4.38 (m, 1H), 4.38-4.20 (m, 2H), 3.55-3.45 (m, 2H), 2.89-2.77
(m, 2H), 2.55-2.51 (m, OH), 2.29-2.19 (m, 1H), 2.14-2.00 (m, 5H),
1.91-1.82 (m, 1H).
[1294] Compound 73 .sup.1H NMR (400 MHz, DMSO) .delta. 8.62-8.56
(s, 2H), 7.52-7.37 (m, 5H), 7.12-7.01 (dd, J=14.6, 6.9 Hz, 1H),
6.66-6.57 (m, 1H), 4.84-4.77 (m, 1H), 4.77-4.66 (m, 1H), 4.65-4.57
(m, 1H), 4.40-4.31 (m, 1H), 3.89-3.79 (m, 2H), 3.55-3.51 (t, J=2.1
Hz, 1H), 3.43-3.36 (m, 2H), 2.64-2.55 (m, 1H), 2.41-2.34 (m, 2H),
2.30-2.10 (m, 2H), 2.05-1.93 (m, 1H).
[1295] Compound 74 .sup.1H NMR (400 MHz, DMSO) .delta. 8.61-8.57
(s, 2H), 7.46-7.37 (m, 5H), 7.24-7.15 (dd, J=14.2, 7.0 Hz, 1H),
6.69-6.61 (m, 1H), 4.65-4.55 (m, 2H), 4.51-4.43 (m, 1H), 4.36-4.23
(m, 1H), 3.90-3.81 (m, 2H), 3.55-3.50 (m, 1H), 3.46-3.38 (m, 2H),
2.79-2.64 (m, 1H), 2.43-2.36 (m, 2H), 2.29-2.18 (m, 2H), 2.12-2.01
(m, 1H).
[1296] 76 .sup.1H NMR (400 MHz, DMSO) .delta. 8.65-8.62 (s, 2H),
7.46-7.38 (m, 5H), 7.37-7.30 (m, 1H), 6.88-6.81 (m, 2H), 4.62-4.49
(m, 3H), 4.43-4.33 (m, 1H), 4.27-4.16 (m, 1H), 3.96-3.86 (m, 2H),
2.92-2.82 (m, 2H), 2.79-2.64 (m, 1H), 2.29-2.16 (m, 2H), 2.16-2.03
(m, 3H), 2.02-1.87 (m, 2H).
[1297] Compound 77 .sup.1H NMR (400 MHz, DMSO) .delta. 8.61-8.57
(s, 2H), 7.50-7.36 (m, 5H), 7.30-7.23 (m, 1H), 6.49-6.43 (dd,
J=8.6, 2.3 Hz, 1H), 6.41-6.33 (m, 1H), 4.82-4.74 (m, 1H), 4.74-4.64
(m, 1H), 4.63-4.55 (m, 1H), 4.41-4.32 (d, J=17.1 Hz, 1H), 3.74-3.66
(d, J=9.7 Hz, 2H), 3.47-3.42 (t, J=2.1 Hz, 1H), 3.35-3.31 (m, 1H),
3.28-3.23 (m, 1H), 2.63-2.54 (m, 1H), 2.45-2.38 (m, 2H), 2.30-2.11
(m, 2H), 2.04-1.94 (m, 1H).
[1298] Compound 78 .sup.1H NMR (400 MHz, DMSO) .delta. 8.61-8.58
(s, 2H), 7.46-7.37 (m, 5H), 7.33-7.27 (m, 1H), 6.49-6.42 (m, 2H),
4.58-4.48 (m, 3H), 4.20-4.08 (m, 1H), 3.76-3.69 (d, J=9.8 Hz, 2H),
3.47-3.42 (t, J=2.2 Hz, 1H), 3.37-3.32 (m, 2H), 2.79-2.62 (m, 1H),
2.47-2.42 (m, 2H), 2.26-2.14 (m, 2H), 2.13-2.00 (m, 1H).
Example 13 In Vitro RORc Ligand Binding Assay
[1299] This assay was used to determine a compound's potency in
inhibiting activity of RORc by determining, Ki.sub.app, IC.sub.50,
or percent inhibition values. Consumables used in this Example are
shown in Table 5 below.
TABLE-US-00006 TABLE 5 Consumable Supplier and product code GFB
Unifilter plates Perkin Elmer 6005177 3-[(3- Sigma C5070
Cholamidopropyl)dimethylammonio-]- 1-propanesulfonate (CHAPS)
96-well polypropylene U-bottom Nunc 267245 assay plate HEPES
buffer, 1M Sigma H3375 Magnesium chloride (MgCl.sub.2) Sigma M8266
D,L-Dithiothreitol (DTT) Sigma D0632 Sodium chloride (NaCl) Sigma
71382 Bovine serum albumin (BSA) Sigma A7030 [lyophilized powder,
.gtoreq.98% (agarose gel electrophoresis), Essentially fatty acid
free, essentially globulin free] 25-hydroxycholesterol Sigma H1015
25-[26,27-.sup.3H]hydroxycholesterol Perkin Elmer NET674250UC
American Radiolabeled Chemicals ART0766 RORc ligand binding domain
Genentech (e.g., PUR 28048), expressed in E. coli Plate seals
Perkin Elmer 6005185 Microscint 0 Perkin Elmer 6013611
Filter Plate Preparation
[1300] On day of the assay, 100 uL of 0.05% CHAPS (in deionized
H.sub.2O) was added to all wells of the GFB Unifilter plate and
allowed soak for 1 h. A wash buffer of 50 mM HEPES (pH 7.4), 150 mM
NaCl, and 5 mM MgCl.sub.2 was prepared to wash the filter plate. To
prepare an assay buffer, BSA was added to the wash buffer to reach
0.01% and DTT was added to reach 1 mM.
Compounds
[1301] For IC.sub.50 mode, 10 mM compound stocks were serially
diluted in DMSO with DMSO to give 20.times. required final
concentration in DMSO (15 uL compound+30 uL DMSO). The 20.times.
compound stocks were diluted in DMSO with Assay Buffer 4-fold to
reach 5.times. the final test concentration in 25% DMSO (10 uL
compound+30 uL Assay Buffer). Solutions were mixed by aspiration
several times with a pipette set on 50 uL volume. For the assay, 10
uL of 5.times. compound stock solutions in 25% DMSO were added to
the assay plate in duplicate.
[1302] For two point screening, 10 mM stock compound solutions were
diluted in DMSO to obtain 200 uM (20.times. the high test
concentration) and then diluted 10-fold further to reach 20 uM
(20.times. the low test concentration). The 20.times. stocks were
diluted 4-fold with Assay Buffer (10 uL compound+30 uL Assay
Buffer) to reach 5.times. the test concentrations (50 uM and 5 uM)
and 10 uL were added to two assay plates for the duplicate wells.
With each concentration tested on 2 plates, each set of 80
compounds used 4 assay plates (1 uM and 10 uM, with n=2).
Nonspecific Binding (NSB) Samples. Total Binding (TB) Samples and
No Receptor (No R) Samples
[1303] 25-hydroxycholesterol (1 uM) was used to determine the level
of NSB signal is prepared in DMSO as for compounds above, then
diluted in Assay Buffer to give a final concentration of 5 uM. For
25-hydroxycholesterol in 25% DMSO/75% Assay Buffer, 10 uL per well
was used for NSB samples. Wells for Total Binding and No Receptor
sample determination contained 10 uL of 25% DMSO/75% Assay Buffer
per well.
Radioligand 25-[.sup.3H]hydroxycholesterol) Preparation
[1304] 25-[.sup.3H]hydroxycholesterol was dilute in Assay Buffer to
obtain 15 nM and vortex to mix. Add 20 uL to all wells to reach 6
nM final in the assay.
Receptor Preparation
[1305] The optimal concentration for RORc receptor was found to be
0.6 ug/mL. Stock receptor solution was diluted in assay buffer to
obtain 1.5 ug/mL in Assay Buffer. 20 uL was added to all wells. For
No R samples, 20 uL Assay Buffer was substituted for receptor
solution.
[1306] Sample Addition to Plates and Incubation
[1307] Assay plates were 96-well polypropylene V-bottom plates. 10
uL of 5.times. compound in 25% DMSO/75% Assay Buffer was added to
Test wells. 10 uL of 25% DMSO/75% Assay Buffer was added to Total
Binding or No Receptor wells. 10 uL of 5 uM 25-hydroxycholesterol
in 25% DMSO/75% Assay Buffer was added to NSB wells. 20 uL of 15 nM
25-[.sup.3H]hydroxycholesterol prepared in Assay Buffer was added
to all wells. 20 uL of 1.5 ug/mL RORc receptor was added to wells
(or 40 uL Assay Buffer to No R wells). Following addition to the
wells, the plates were incubated 3 h at 25.degree. C.
Filtration
[1308] Using a Packard Filtermate Harvester, the filter plate were
washed 4 times following transfer of the incubated samples. Plates
were dry-filtered completely (2 h at 50.degree. C. or overnight at
room temperature). 50 uL Microscint 0 was added to all wells and
read on Topcount protocol Inverted.
Final Concentrations
[1309] Final concentrations were as follows: 50 mM HEPES buffer (pH
7.4); 150 mM NaCl; 1 mM DTT; 5 mM MgCl.sub.2; 0.01% BSA; 5% DMSO;
0.6 ug/mL RORc receptor, 6 nM 25-[.sup.3H]hydroxycholesterol. For
NSB wells, 1 uM 25-hydroxycholesterol was also present.
Example 14
RORc Coactivator Peptide Binding Assay
[1310] Assays were carried out in 16-microL reaction volumes in
black 384 Plus F Proxiplates (Perkin-Elmer 6008269). All assay
components except test ligand were mixed in coregulator buffer D
(Invitrogen PV4420) containing 5 mM DTT and added to the plate at
twice their final concentrations in a volume of 8 microL. Test
ligands at 2.times. the final concentration were then added to the
wells in 8 L of coregulator buffer D containing 5 mM DTT and 4%
DMSO. Final incubations contained 1.times. coregulator buffer D, 5
mM DTT, test ligand, 2% DMSO, 50 nM
biotinyl-CPSSHSSLTERKHKILHRLLQEGSPS (American Peptide Company;
Vista, Calif.), 2 nM Europium anti-GST (Cisbio 61GSTKLB), 12.5 nM
streptavidin-D2 (Cisbio 610SADAB), 50 mM KF, and 10 nM of
bacterially-expressed human RORc ligand binding domain protein
containing an N-terminal 6.times.His-GST-tag and residues 262-507
of Accession NP.sub.--005051. Ten test ligand concentrations were
tested in duplicate. After the reaction plates were incubated for 3
h in the dark at room temperature (22-23.degree. C.), the plate was
read on an EnVision plate reader (PerkinElmer) following the
Europium/D2 HTRF protocol (ex 320, em 615 and 665, 100 s lag time,
100 flashes, 500 .mu.s window). The time-resolved FRET signal at
665 nm was divided by that at 615 nm to generate the signal ratio
of each well. The signal ratio of wells containing RORc and peptide
but no test ligand were averaged and set to 0% Effect while the
signal ratios of the blank wells containing coactivator peptide but
no RORc were averaged and set to -100% Effect. RORc exhibits a
basal (constitutive) signal in this assay and test ligands can
increase or decrease the signal ratio relative to this basal signal
level. RORc agonists increase the signal ratio in this assay and
result in a positive % Effect value. Inverse agonists decrease the
signal ratio, and result in a negative % Effect value. The
EC.sub.50 value is the concentration of test compound that provides
half-maximal effect (increased or decreased assay signal) and is
calculated by Genedata Screener.RTM. software (Genedata; Basel,
Switzerland) using the following equation:
%
Effect=S.sub.0+{(S.sub.inf-S.sub.0)/[1+(10.sup.logEC.sub.50/10.sup.c).-
sup.n]}
where S.sub.0 equals the activity level at zero concentration of
test compound, S.sub.inf is the activity level at infinite
concentration of test compound, EC.sub.50 is the concentration at
which the activity reaches 50% of the maximal effect, c is the
concentration in logarithmic units corresponding to the values on
the x-axis of the dose-response curve plot, and n is the Hill
coefficient (the slope of the curve at the EC.sub.50).
Example 15
Arthritis Mouse Model
[1311] 8 to 10-week old male DBA/1 (DBA/lOlaHsd, Harlan
Laboratories) mice are housed in a specific pathogen free (SPF)
animal facility. Arthritis is induced by two injections of collagen
subcutaneously in the base of the tail. The initial injection (on
day 0) uses bovine type II collagen (2 mg/ml from Chondrex,
Redmond, Wash.) emulsified in equal volume of CFA containing 4
mg/ml of M. tuberculosis (Chondrex). The CII booster injection on
Day 29 is emulsified in incomplete Freund's adjuvant (IFA). Each
animal receives 0.1 ml of emulsion by subcutaneous/intradermal
injection in the tail 2 to 3 cm from the body of the mouse. The
booster injection site is in the vicinity of but different from the
initial injection site and closer to the body of the animal.
OR-1050 was formulated in HRC-6 as above. On weekdays, the animals
receive two doses (a.m. and p.m.) of HRC-6 or 50 mg/kg OR-1050 p.o.
(2.5 mls/kg). On weekends, a single dose of 100 mg/kg is
administered (5 mls/kg).
[1312] The mice are observed daily for clinical symptoms of CIA
based on the following qualitative scale. Each paw was examined
individually and scored. Grade 0, normal; grade 1, mild but
definite redness and swelling of the ankle or wrist, or apparent
redness and swelling limited to individual digits, regardless of
the number of affected digits; grade 2, moderate redness and
swelling of ankle or wrist; grade 3, severe redness and swelling of
the entire paw including digits; grade 4, maximally inflamed limb
with involvement of multiple joints. To estimate cumulative disease
severity for each animal, an area under the curve score is
calculated for each animal by totaling the sum of the daily hind
paw measurements betweens days 24 and 48.
Example 16
Muscular Sclerosis Mouse Model I
[1313] Experiments are conducted on female mice aged 4-6 weeks
belong to the C57BL/6 strain weighing 17-20 g. Experimental
autoimmune encephalomyelitis (EAE) is actively induced using 95%
pure synthetic myelin oligodendrocyte glycoprotein peptide 35-55
(MOG.sub.35-55) (Invitrogen). Each mouse is anesthetized and
receives 200 ug of MOG.sub.35-55 peptide and 15 ug of Saponin
extract from Quilija bark emulsified in 100 uL of
phosphate-buffered saline. A 25 uL volume is injected
subcutaneously over four flank areas. Mice are also
intraperitoneally injected with 200 ng of pertussis toxin in 200 uL
of PBS. A second, identical injection of pertussis toxin is given
after 48 h.
[1314] A compound of the invention is administered at selected
doses. Control animals receive 25 uL of DMSO. Daily treatment
extends from day 26 to day 36 post-immunization. Clinical scores
are obtained daily from day 0 post-immunization until day 60.
Clinical signs are scored using the following protocol: 0, no
detectable signs; 0.5, distal tail limpness, hunched appearance and
quiet demeanor, 1, completely limp tail; 1.5, limp tail and
hindlimb weakness (unsteady gait and poor grip with hind limbs); 2,
unilateral partial hind limb paralysis; 2.5, bilateral hind limb
paralysis; 3, complete bilateral hindlimb paralysis; 3.5, complete
hindlimb paralysis and unilateral forelimb paralysis; 4, total
paralysis of hind limbs and forelimbs (Eugster et al., Eur J
Immunol 2001, 31, 2302-2312).
[1315] Inflammation and demyelination may be assessed by histology
on sections from the CNS of EAE mice. Mice are sacrificed after 30
or 60 days and whole spinal cords are removed and placed in 0.32 M
sucrose solution at 4.degree. C. overnight. Tissues are prepared
and sectioned. Luxol fast blue stain is used to observe areas of
demyelination. Haematoxylin and eosin staining is used to highlight
areas of inflammation by darkly staining the nuclei of mononuclear
cells. Immune cells stained with H&E are counted in a blinded
manner under a light microscope. Sections are separated into gray
and white matter and each sector is counted manually before being
combined to give a total for the section. T cells are immunolabeled
with anti-CD3+ monoclonal antibody. After washing, sections are
incubated with goat anti-rat HRP secondary antibody. Sections are
then washed and counterstained with methyl green. Splenocytes
isolated from mice at 30 and 60 days post-immunization are treated
with lysis buffer to remove red blood cells. Cells are then
re-suspended in PBS and counted. Cells at a density of about
3.times.10.sup.6 cells/mL are incubated overnight with 20 ug/mL of
MOG peptide. Supernatants from stimulated cells are assayed for
IFNgamma protein levels using an appropriate mouse IFN-gamma
immunoassay system.
Example 17
Muscular Sclerosis Mouse Model II
[1316] In this model, female rodents are anesthetized with
isoflurane and injected with Freund's Incomplete Adjuvant
containing 1 mg/mL neuronal antigen (e.g. myelin basic protein,
myelin oligodendrocyte glycoprotein, proteolipid protein) and 4
mg/mL mycobacterium tuberculosis at two sites on the back on day 0
of this study. A compound of interest is then dosed daily in a
sub-cutaneous, intraperitoneally, or oral manner from day 0 until
the end of study at an efficacious dose. Daily observations of
degree of paralysis are taken as measures of efficacy.
Example 18
Psoriasis Mouse Model I
[1317] The severe, combined immunodeficient (SCID) mouse model can
be used to evaluate the efficacy of compounds for treating
psoriasis in humans (Boehncke, Ernst Schering Res Found Workshop
2005, 50, 213-34; and Bhagavathula et al., J Pharmacol Expt'l
Therapeutics 2008, 324(3), 938-947). Briefly, SCID mice are used as
tissue recipients. One biopsy for each normal or psoriatic
volunteer (human) is transplanted onto the dorsal surface of a
recipient mouse. Treatment is initiated 1 to 2 weeks after
transplantation. Animals with the human skin transplants are
divided into treatment groups. Animals are treated twice daily for
14 days. At the end of treatment, animals are photographed and then
euthanized. The transplanted human tissue along with the
surrounding mouse skin is surgically removed and fixed in 10%
formalin and samples obtained for microscopy. Epidermal thickness
is measured. Tissue sections are stained with an antibody to the
proliferation-associated antigen Ki-67 and with an anti-human
CD3.sup.+ monoclonal antibody to detect human T lymphocytes in the
transplanted tissue. Sections are also probed with antibodies to
c-myc and beta-catenin. A positive response to treatment is
reflected by a reduction in the average epiderma thickness of the
psoriatic skin transplants. A positive response is also associated
with reduced expression of Ki-67 in keratinocytes.
Example 19
Psoriasis Mouse Model II
[1318] Using the Imidquimod model of skin inflammation (Fits et al,
Journal of Immunology, 2009, 182: 5836-5845), 10-12 week old
BALB/c, I117c+/+ or I117c-/-, or I117re+/+ or I117re-/- mice were
administered 50 mg Aldara cream (5% Imidquimod in Graceway, 3M) in
the shaved back and right ear daily for 5 days. Clinical scoring
and ear thickness measurements were performed daily. Scoring was
based upon the manifestation of psoriatic symptoms, such as
erythema, scaling and thickness: 0, No disease. 1, Very mild
erythema with very mild thickening and scaling involving a small
area. 2, Mild erythema with mild thickening and scaling involving a
small area. 3, Moderate erythema with moderate thickening and
scaling (irregular and patchy) involving a small area (<25%). 4,
Severe erythema with marked thickening and scaling (irregular and
patchy) involving a moderate area (25-50%). 5, Severe erythema with
marked thickening and scaling (irregular and patchy) involving a
large area (>50%). Ear and back tissue were harvested on day 5
for histological evaluation. Efficacy of compounds is compared in
the imiquimod (IMQ) mouse model of psoriasis. Balb/c mice (10
males/group) received daily topical IMQ (5% cream) on shaved back
and right ear for 5 days as described above. Animals received oral
dose of a representative compound or DMF (45 or 90 mg-eq MMF/kg
twice daily) or vehicle from Day -5 to Day+5. Erythema score is the
primary outcome measure. The Erythema score values of the compounds
tested at an oral dose of 90 mg-eq MMF/kg BID for 10 days in male
Balb/C mice are set forth in Table 3, below. The data shows that
the compounds of the disclosure are equipotent to DMF.
Example 20
Irritable Bowel Disease Mouse Model I
[1319] Effectiveness in treatment of inflammatory bowel disease may
be evaluated as described by Jurjus et al., J Pharmaocol Toxicol
Methods 2004, 50, 81-92; Villegas et al., Int'l Immunopharmacol
2003, 3, 1731-1741; and Murakami et al., Biochemical Pharmacol
2003, 66, 1253-1261. Briefly, female ICR mice are divided into
treatment groups which are given either water (control), 5% DSS in
tap water is given at the beginning of the experiment to induce
colitis, or various concentrations of test compound. After
administering test compound for 1 week, 5% DSS in tap water is also
administered to the groups receiving test compound for 1 week. At
the end of the experiment, all mice are sacrificed and the large
intestine is removed. Colonic mucosa samples are obtained and
homogenized. Proinflammatory mediators (e.g., IL-1alpha, IL-1beta,
TNFalpha, PGE2, and PGF2alpha.) and protein concentrations are
quantified. Each excised large intestine is histologically examined
and the damage to the colon scored.
Example 21
Chronic Obstructive Pulmonary Disease Mouse Model
[1320] The cigarette smoke model of Martorana et al., Am J Respir
Crit Care Med 2005, 172, 848-835; and Cavarra et al., Am J Respir
Crit Care Med 2001, 164, 886-890 can be used for assessing efficacy
in treating emphysema. Briefly, six-week old C57B1/6J male mice are
exposed either to room air or to the smoke of five cigarettes for
20 minutes. For the acute study, mice are divided into three groups
of 40 animals each. These groups are then divided into four
subgroups of 10 mice each as follows: (1) no treatment/air-exposed;
(2) no treatment/smoke-exposed; (3) a first dose of test compound
plus smoke-exposed; and (4) a second dose of test compound. In the
first group, trolox equivalent antioxidant capacity is assessed at
the end of the exposure in bronchoalveolar lavage fluid. In the
second group, cytokines and chemokines are determined in
bronchoalveolar lavage fluid using a commercial cytokine panel at 4
hours; and in the third group bronchoalveolar lavage fluid cell
count is assessed at 24 hours.
[1321] In a chronic study, the mice are exposed to either room air
or to the smoke of three cigarettes/day, for 5 days/week, for 7
months. Five groups of animals are used: (1) no
treatment/air-exposed; (2) a first dose of a test compound plus
air-exposed; (3) no treatment/smoke-exposed; (4) a second dose of
the test compound plus smoke-exposed; and (5) the first dose of the
test compound plus smoke exposed. Seven months after chronic
exposure to room air or cigarette smoke, 5 to 12 animals from each
group are sacrificed and the lungs fixed intratracheally with
formalin. Lung volume is measured by water displacement. Lungs are
stained. Assessment of emphysema includes mean linear intercept and
internal surface area. The volume density of macrophages, marked
immunohistochemically with anti-mouse Mac-3 monoclonal antibodies
is determined by point counting. A mouse is considered to have
goblet cell metaplasia when at least one or more midsize
bronchi/lung showed a positive periodic acid-Schiff staining for
the determination of desmosine, fresh lungs are homogenized,
processed, and analyzed by high-pressure liquid chromatography.
Example 22
Asthma Mouse Model
[1322] A single inhaled allergen challenge can induce an acute
increase in airway responsiveness in some individuals and animal
models. However, repeated allergen inhalations have demonstrated
more pronounced, consistent, and prolonged increases in airway
responsiveness. This mouse model of long-term repeated inhalations
of allergen has been used to study the long term effect of allergic
diseases in the lung, and to delineate the cells, mechanisms,
molecules, and mediators involved in the induction of airway
hyperresponsiveness of lung in humans.
[1323] Crystalline OVA is obtained from Pierce Chem. Co. (Rockford,
Ill.) aluminum potassium sulfate (alum) from Sigma Chem. Co. (St.
Louis, Mo.), pyrogen-free distilled water from Baxter, Healthcare
Corporation (Deerfield, Ill.), 0.9% sodium chloride (normal saline)
from Lymphomed (Deerfield, Ill.) and Trappsol.TM. HPB-L 100
(aqueous hydroxypropylbeta cyclodextrin; 45 wt/vol % aqueous
solution) from Cyclodextrin Technologies Development, Inc.
(Gainesville, Fla.). The OVA (500 ug/ml in normal saline) is mixed
with equal volumes of 10% (wt/vol) alum in distilled water. The
mixture (pH 6.5 using 10 N NaOH) after incubation for 60 minutes at
room temperature is centrifuged at 750 g for 5 minutes; the pellet
resuspended to the original volume in distilled water and used
within one hour. The selective 5-lipoxtgenase inhibitor, Zileuton
(N-[1-benzo[b]thien-2-ylethyl]-N-hydroxyurea; J. Pharmacol Exp
Ther. 1991; 256: 929-937) is dissolved in Trappsol.TM. Histatek,
Inc. (Seattle, Wash.) to provide the mast cell degranulation
inhibitor, f-Met-Leu-Phe-Phe ("HK--X").
[1324] Female BALB/c Once (6-8 wk of age) receive an i.p. injection
of 0.2 ml (100 ug) of OVA with alum on the different protocols of
Standard (J. Exp Med. 1996; 184: 1483-1494). Mice are anesthetized
with 0.2 ml i.p. of ketamine (0.44 mg/ml)/xylazine (6.3 mg/ml) in
normal saline before receiving an intranasal (i.n.) dose of 100 ug
OVA in 0.05 ml normal saline and an i.n. dose of 50 ug OVA in 0.05
ml normal saline separately on different days. Two control groups
are used: the first group receives normal saline with alum i.p. and
normal saline without alum i.n.; and the second group receives OVA
with alum i.p., OVA without alum i.n., and normal saline,
alone.
[1325] The trachea and left lung (the right lung may be used for
bronchoalveolar lavage ("BAL") as described below) are obtained and
fixed in 10% neutral formaldehyde solution at room temperature for
about 15 h. After being embedded in paraffin, the tissues are cut
into 5-um sections and processed with the different staining or
immunolabling further. Discombe's eosinophil staining is used for
counting the cell numbers with the counterstain of methylene blue.
The eosinophil number per unit airway area (2,200 um.sup.2) is
determined by morphometry (J. Pathol. 1992; 166: 395-404; Am Rev
Respir Dis. 1993; 147:448-456). Fibrosis is identified with the
Masson's trichrome staining. Airway mucus iss identified by the
following staining method: methylene blue, hematoxylin and eosin,
mucicarmine, alcian blue, and alcian blue/periodic acid-Schiff
(PAS) reaction (Troyer, H., "Carbohydrates" in Principles and
Techniques of Histochemistry, Little, Brown and Company, Boston,
Mass., 1980: 89-121; Sheehan, D. C., et al., "Carbohydrates" in
Theory and Practice of Histotechnology, Battle Press, Columbus,
Ohio, 1980: 159-179) Mucin is stained with mucicarmine solution;
metanil yellow counterstain is employed. Acidic mucin and sulfated
mucosubstances are stained with alcian blue, pH 2.5; nuclear fast
red counterstain is used. Neutral and acidic mucosubstances are
identified by alcian blue, pH 2.5, and PAS reaction. The degree of
mucus plugging of the airways (0.5-0.8 mm in diameter) is also
assessed by morphometry. The percent occlusion of airway diameter
by mucus iss classified on a semiquantitative scale from 0 to 4+.
The histologic and morphometric analyses may be performed by
individuals blinded to the protocol design.
[1326] On day 28, 24 hours after the last i.n. administration of
either normal saline or OVA, pulmonary mechanics to intravenous
infusion of methacholine may be determined in mice in vivo by a
plethysmographic method as previously described (10, 1958; 192:
364-368; J. Appl. Physiol. 1988; 64: 2318-2323; J. Exp. Med. 1996;
184: 1483-1494).
[1327] After tying off the left lung at the mainstem bronchus, the
right lung may be lavaged three times with 0.4 ml of normal saline.
Bronchoalveolar lavage (BAL) fluid cells from a 0.05-ml aliquot of
the pooled sample are counted using a hemocytometer and the
remaining fluid centrifuged at 4.degree. C. for 10 minutes at 200
g. The supernatant may be stored at 70.degree. C. until eicosanoid
analysis is performed. After resuspension of the cell pellet in
normal saline containing 10% bovine serum albumin ("BSA"), BAL cell
smears are made on glass slides. To stain eosinophils, dried slides
are stained with Discombe's diluting fluid (0.05% aqueous eosin and
5% acetone (vol/vol) in distilled water; J. Exp. Med. 1970; 131:
1271-1287) for 5-8 minutes, rinsed with water for 0.5 minutes, and
counterstained with 0.07% methylene blue for 2 minutes.
[1328] While the present invention has been described with
reference to the specific embodiments thereof, it should be
understood by those skilled in the art that various changes may be
made and equivalents may be substituted without departing from the
true spirit and scope of the invention. In addition, many
modifications may be made to adapt a particular situation,
material, composition of matter, process, process step or steps, to
the objective spirit and scope of the present invention. All such
modifications are intended to be within the scope of the claims
appended hereto.
* * * * *